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Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic 
Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human 
Services. 
 
This information is distributed solely for the purpose of pre dissemination public comment under 
applicable information quality guidelines.  It has not been formally disseminated by the Agency for Toxic 
Substances and Disease Registry.  It does not represent and should not be construed to represent any 
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FOREWORD 
 
 
 
This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The 
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary. 
 
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein.  Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is 
also presented, but is described in less detail than the key studies.  The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced. 
 
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile 
begins with a public health statement that describes, in nontechnical language, a substance's relevant 
toxicological properties.  Following the public health statement is information concerning levels of 
significant human exposure and, where known, significant health effects.  The adequacy of information to 
determine a substance's health effects is described in a health effects summary.  Data needs that are of 
significance to protection of public health are identified by ATSDR and EPA. 
 
Each profile includes the following: 
 
   
   
   
 
    
 
   
 
  
  
 
  
   
  
 
 
   
 
 
     
  
    
   
 
   
  
    
   
 
 
 
 
  
vGLUTARALDEHYDE
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) A determination of whether adequate information on the health effects of each substance is 
available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels 
of exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and
local levels; interested private sector organizations and groups; and members of the public.  We plan to 
revise these documents in response to public comments and as additional data become available.
Therefore, we encourage comments that will make the toxicological profile series of the greatest use.
Electronic comments may be submitted via: www.regulations.gov.
Follow the on-line instructions for submitting comments.
Written comments may also be sent to:
Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences
Environmental Toxicology Branch
Regular Mailing Address: Physical Mailing Address:
1600 Clifton Road, N.E. 4770 Buford Highway
Mail Stop F-57 Building 106, 3rd floor, MS F-57
Atlanta, Georgia 30329-4027 Chamblee, Georgia 30341
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The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related 
authorities” of the statute.  This includes the preparation of toxicological profiles for hazardous
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the
most significant potential threat to human health, as determined by ATSDR and the EPA. Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile
for each substance on the list.  In addition, ATSDR has the authority to prepare toxicological profiles for
substances not found at sites on the National Priorities List, in an effort to “…establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA
Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise
necessary to support the site-specific response actions conducted by ATSDR. 
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been
peer-reviewed.  Staffs of the Centers for Disease Control and Prevention and other Federal scientists have 
also reviewed the profile.  In addition, this profile has been peer-reviewed by a nongovernmental panel
and is being made available for public review.  Final responsibility for the contents and views expressed
in this toxicological profile resides with ATSDR.
Patrick N. Breysse, Ph.D., CIH
 
Director, National Center for Environmental Health and
 
Agency for Toxic Substances and Disease Registry
 
Centers for Disease Control and Prevention
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating
patients potentially exposed to hazardous substances will find the following information helpful for fast
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets,
and assesses the significance of toxicity data to human health.
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical
setting.  Please refer to the Public Health Statement to identify general health effects observed
following exposure.
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues:
Chapter 1 How Can (Chemical X) Affect Children?
 
Chapter 1 How Can Families Reduce the Risk of Exposure to (Chemical X)?
 
Section 3.8 Children’s Susceptibility
 
Section 6.6 Exposures of Children
 
Other Sections of Interest:
Section 3.9 Biomarkers of Exposure and Effect
Section 3.12 Methods for Reducing Toxic Effects
ATSDR Information Center 
Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)
Internet:  http://www.atsdr.cdc.gov
The following additional material is available online at www.atsdr.cdc.gov:
Case Studies in Environmental Medicine—Case Studies are self-instructional publications designed to 
increase primary care provider’s knowledge of a hazardous substance in the environment and to
aid in the evaluation of potentially exposed patients.  
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Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident.  Volumes I and II are planning guides to assist first responders and hospital emergency
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health. Contact: NIOSH, 395 E Street, S.W., Suite 9200, 
Patriots Plaza Building, Washington, DC 20201 • Phone: (202) 245-0625 or 1-800-CDC-INFO 
(800-232-4636).
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Clinical Resources
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266.
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1.	 Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying
end points.
2.	 Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each
profile, and makes recommendations for derivation of MRLs.
3.	 Data Needs Review. The Environmental Toxicology Branch reviews data needs sections to
assure consistency across profiles and adherence to instructions in the Guidance.
4.	 Green Border Review.  Green Border review assures the consistency with ATSDR policy.
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PEER REVIEW
  
 
 
A peer review panel was assembled for glutaraldehyde.  The panel consisted of the following members:  
 
1.	  Dr. H.M. Bolt, Leibniz Research Centre for Working Environment and Human Factors, 
Ardeystraβe 67, D-44139 Dortmund; 
 
2.	  Dr. Barbara Shane, 205 Landreth Court, Durham, North Carolina; and 
 
3. 	 Dr. Errol Zeiger, Errol Zeiger Consulting, 800 Indian Springs Road, Chapel Hill, North Carolina. 
 
 
These experts collectively have knowledge of glutaraldehyde’s physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.   
 
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
content.  The responsibility for the content of this profile lies with the ATSDR. 
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1GLUTARALDEHYDE
1. PUBLIC HEALTH STATEMENT FOR GLUTARALDEHYDE 
 
This Public Health Statement summarizes the Division of Toxicology and Human Health Science’s 
findings on glutaraldehyde, tells you about it, the effects of exposure, and describes what you can do to 
limit that exposure. 
If you are exposed to glutaraldehyde, many factors determine whether you’ll be harmed.  These include
how much you are exposed to (dose), how long you are exposed (duration), and how you are exposed 
(route of exposure).  You must also consider the other chemicals you are exposed to and your age, sex, 
diet, family traits, lifestyle, and state of health.
WHAT IS GLUTARALDEHYDE?
Glutaraldehyde is a colorless, oily liquid with a sharp, pungent odor.  Other names for glutaraldehyde
include pentanedial, glutaral, and 1,5-pentanedial, as well as a variety of other chemical and trade names.  
Glutaraldehyde is not stable in its pure form, so it is usually found in a solution mixed with water.
WHERE IS GLUTARALDEHYDE FOUND?
Glutaraldehyde can get into air from its use as a disinfectant, such as in hospitals and dental clinics, and
from other commodities that may use glutaraldehyde (e.g., paints).  Industries using glutaraldehyde can 
also cause its release to air (e.g., oil and gas industry, animal facilities, and water treatment facilities).
Glutaraldehyde in air will be degraded by light within a relatively short time period; that is, half will be
gone from air in 16 hours.
Glutaraldehyde is used for industrial, laboratory, agricultural, and medical purposes, primarily for
disinfecting and sterilization of surfaces and equipment.  It may be found in medical facilities where it is 
used to disinfect equipment that cannot be subject to heat sterilization.  It is also used in industrial
cleaning supplies. The majority of the uses of glutaraldehyde are industrial as opposed to consumer
applications.  For example, it is used in oil and gas recovery, waste water treatment, as a pesticide and in
fogging and cleaning of poultry houses, as a chemical intermediate in the production of various materials,
in the paper industry, in x-ray processing, in embalming fluid, and for leather tanning.  It may be used in 
select goods, such as paint and laundry detergent.  Detailed information about the uses of glutaraldehyde 
can be found in Chapter 5.
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2GLUTARALDEHYDE
1.  PUBLIC HEALTH STATEMENT
Use of glutaraldehyde as a disinfectant can cause it to enter water, such as from hospital wastewater.
Glutaraldehyde may enter groundwater during its use as a biocide for processes such as industrial water
treatment or oil and gas recovery and pipeline operations. In water, glutaraldehyde will degrade quickly.
Depending on how much oxygen is available in the water, glutaraldehyde might turn into carbon dioxide
or 1,5-pentanediol.
Glutaraldehyde could get into soil in similar ways as it could get in to water.  Contaminated water can 
seep into nearby soils. Glutaraldehyde will most likely disappear quickly from soil due to degradation.  It
is expected to travel quickly through soil.
HOW MIGHT I BE EXPOSED TO GLUTARALDEHYDE?
You are most likely to be exposed if you use products such as disinfectants that contain glutaraldehyde or
if you are around areas that are being disinfected with glutaraldehyde-containing products. Because
glutaraldehyde is used in oil and gas recovery operations (including hydrofracturing processes), there is
potential for exposure among workers and the general population in areas surrounding such operations.
HOW CAN GLUTARALDEHYDE ENTER AND LEAVE MY BODY?
Most of the glutaraldehyde that you breathe in will react with tissue in your nose (or mouth and throat if
you breathe it in through your mouth) and cause irritation; some may enter your blood.
You are not likely to come into contact with glutaraldehyde in drinking water.  If you do, some of it
would react with tissue in your gastrointestinal tract and cause irritation.  Some might enter your blood.
You are not likely to come into contact with glutaraldehyde in soil.  If you were to get glutaraldehyde on 
your skin, a very small amount might enter your blood.
Glutaraldehyde in the blood can travel throughout the body; it appears to rapidly break down into other
substances including carbon dioxide.
Animal studies indicate that much of the glutaraldehyde that enters your blood is converted into carbon 
dioxide and leaves your body when you breathe it out.  Some of the glutaraldehyde and/or its breakdown 
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3GLUTARALDEHYDE
1.  PUBLIC HEALTH STATEMENT
products leave your body in the urine.  If you were to drink water or eat food containing glutaraldehyde, 
more of it and/or its breakdown products would leave your body in the feces than in urine or exhaled air.
HOW GLUTARALDEHYDE CAN AFFECT YOUR HEALTH?
You are not likely to be exposed to amounts of glutaraldehyde that would harm you.  If you were, the
health effects would depend on the amount of glutaraldehyde to which you were exposed.
HOW CAN GLUTARALDEHYDE AFFECT CHILDREN?
This section discusses potential health effects of glutaraldehyde exposure in humans from when they’re 
first conceived to 18 years of age.
Your skin and eyes could become irritated if glutaraldehyde were to contact your skin and eyes.  Your
nose could become irritated if you were to breathe in glutaraldehyde.  Your mouth, esophagus, and 
stomach could become irritated if glutaraldehyde were to enter your mouth.
Because glutaraldehyde causes irritation of tissues that come into contact with it, long-term effects are 
similar to those experienced by short-term exposure. Your skin might also become more sensitive to
glutaraldehyde if you come into repeated contact with it.
There is no evidence that glutaraldehyde causes cancer in people.  One study reported increases in a type 
of blood cancer in rats, but an EPA cancer assessment review committee concluded that this type of
cancer was common in older rats.  Other animal studies found no evidence that glutaraldehyde causes 
cancer.
The American Conference of Governmental Industrial Hygienists determined that glutaraldehyde is not 
classifiable as to whether it causes cancer based on available results from animal studies. Glutaraldehyde
is not on the National Toxicology Program (NTP) list of known or suspected cancer-causing substances. 
Glutaraldehyde is expected to affect children in the same manner as adults.  It is not known whether
children are more susceptible than adults to the effects of glutaraldehyde.
The few available reports for humans and animals have not shown that glutaraldehyde can cause birth 
defects.
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1.  PUBLIC HEALTH STATEMENT
HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO GLUTARALDEHYDE?
If your doctor finds that you have been exposed to significant amounts of glutaraldehyde, ask whether
your children might also be exposed.  Your doctor might need to ask your state health department to 
investigate.
ARE THERE MEDICAL TESTS TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO
GLUTARALDEHYDE?
Although methods are available to detect glutaraldehyde in biological materials, they are not useful for
estimating the magnitude of an exposure because glutaraldehyde reacts rapidly with tissues that it
contacts.  Also, absorbed glutaraldehyde leaves the body quickly as glutaraldehyde and/or its breakdown 
products.
WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT 
HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health.  Regulations
can be enforced by law.  Federal agencies that develop regulations for toxic substances include the
Environmental Protection Agency (EPA), the Occupational Safety and Health Administration (OSHA),
and the Food and Drug Administration (FDA).  Recommendations provide valuable guidelines to protect
public health but cannot be enforced by law.  Federal organizations that develop recommendations for
toxic substances include the Agency for Toxic Substances and Disease Registry (ATSDR) and the 
National Institute for Occupational Safety and Health (NIOSH).
Families are not likely to be exposed to glutaraldehyde, as it is primarily used in industrial or medical
applications. However, in the event that a worker’s clothing were to become soaked with glutaraldehyde, 
a change of clothes at the workplace would reduce the risk of exposing others outside the workplace 
environment.
Regulations and recommendations can be expressed as “not-to-exceed” levels; that is, levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value usually based on levels that affect
animals; levels are then adjusted to help protect humans.  Sometimes these not-to-exceed levels differ
among federal organizations.  Different organizations use different exposure times (an 8-hour workday or
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5GLUTARALDEHYDE
1.  PUBLIC HEALTH STATEMENT
a 24-hour day), different animal studies, or emphasize some factors over others, depending on their
mission.
Recommendations and regulations are also updated periodically as more information becomes available.
For the most current information, check with the federal agency or organization that issued the regulation 
or recommendation.
EPA has no drinking water standard for glutaraldehyde. OSHA has not established an exposure limit for
glutaraldehyde in air. NIOSH established a Recommended Exposure Limit (REL) of 0.2 ppm in air, as a
ceiling concentration.
WHERE CAN I GET MORE INFORMATION?
If you have any questions or concerns, please contact your community or state health or environmental
quality department, or contact ATSDR at the address and phone number below.  ATSDR can also provide
publically available information regarding medical specialists with expertise and experience recognizing,
evaluating, treating, and managing patients exposed to hazardous substances.
•	 Call the toll-free information and technical assistance number at

1-800-CDCINFO (1-800-232-4636) or
 
•	 Write to:
 
Agency for Toxic Substances and Disease Registry

Division of Toxicology and Human Health Sciences
 
1600 Clifton Road NE
 
Mailstop F-57
 
Atlanta, GA 30329-4027
 
Toxicological profiles and other information are available on ATSDR’s web site:
http://www.atsdr.cdc.gov.
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2. RELEVANCE TO PUBLIC HEALTH
 
2.1  	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO GLUTARALDEHYDE IN 
THE UNITED STATES
Glutaraldehyde is a commercial chemical used primarily as a disinfectant and biocide.  It has numerous
uses in industrial, agricultural, and medical settings, including:  leather tanning; chemical intermediate; 
industrial antimicrobial agent and pesticide (algaecide, bactericide, and fungicide); biological tissue 
fixative; protein and polyhydroxy material cross-linking; x-ray processing; embalming fluid; printing
industry preservative; poultry house fogging and other agricultural sanitization; as a materials 
preservative; intermediate for adhesives, sealants, and pharmaceuticals; and in the paper and textile 
industries.  One of the main uses of glutaraldehyde is in cold sterilization of medical and dental
equipment bronchoscopes.
Glutaraldehyde may be released to the environment through its production and use.  It may be released to 
the atmosphere from its uses as a disinfectant, in x-ray development, and from paints and laundry
detergents that used it as a slimicide.  It can also be released to air from oil and gas recovery and pipeline
operations, industrial water treatment processes, poultry house fogging, and vehicle emissions.  
Glutaraldehyde releases to water generally occur as a result of waste water disposal from hospitals, textile 
and paper industries, industrial water treatment processes, cooling water systems, leather tanning, and oil
and gas operations.  When glutaraldehyde solutions are disposed of as sewage, residues can be released to 
water following sewage treatment processes.  Disposal of cold disinfectant solutions from hospitals is the
major source of glutaraldehyde to surface waters.
Glutaraldehyde is not considered to be highly persistent in the environment.  It generally stays in the 
aquatic phase, where it rapidly degrades under both aerobic and anaerobic conditions.  It is also expected
to be highly mobile in soil, where it biodegrades under aerobic conditions.  Glutaraldehyde does not
bioaccumulate in aquatic organisms.
Glutaraldehyde has been identified in indoor and outdoor air as well as waste water samples.  The
majority of the atmospheric monitoring has been done in hospitals and dental clinics where
glutaraldehyde is used for sterilization, where the highest concentrations generally occur near the source 
of sterilization equipment.  Glutaraldehyde releases to indoor air are often mitigated by proper ventilation 
and handling techniques. Glutaraldehyde has been measured in waste water, primarily for waste streams 
originating from hospitals where glutaraldehyde solutions are regularly disposed of as sewage.
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8GLUTARALDEHYDE
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Exposure to glutaraldehyde is primarily through inhalation, although dermal contact and ingestion may
also occur.  The general public is generally not exposed to glutaraldehyde, as it is primarily used in 
industrial or medical applications.  People may be exposed in medical facilities or other areas where 
glutaraldehyde solutions are used for cleaning, and from paint and laundry detergents that contain 
glutaraldehyde.  Although glutaraldehyde is used as a disinfectant for poultry/livestock equipment and 
processing premises, because it degrades so rapidly, the potential for glutaraldehyde residues to
contaminate food sources is very slight. Medical and dental personnel are primarily at risk for
occupational exposure to glutaraldehyde due to its use in disinfecting products and x-ray film processing.
Occupational exposure may also occur as a result of paper manufacturing, oil and gas recovery and 
pipeline activities, animal house fogging and cleaning, metalworking, and other industrial processes
where glutaraldehyde is used or produced.
2.2  SUMMARY OF HEALTH EFFECTS 
Relevant information regarding glutaraldehyde toxicity in humans and laboratory animals subjected to 
systematic review (see Appendix B for detailed description of the systematic review process) and
summarized in Section 3.2 of this Toxicological Profile for Glutaraldehyde. A brief overview of the 
information in Section 3.2 follows.
Glutaraldehyde is a contact irritant, dermal sensitizer, and potential respiratory sensitizer. Occupational
exposure to glutaraldehyde has been commonly associated with symptoms of respiratory tract irritation,
particularly in medical facilities where glutaraldehyde is used as a disinfectant. In occupational settings
where personal or workplace air sampling was performed, self-reported respiratory tract symptoms
following short-term exposures occurred at concentrations as low as 0.05 ppm.  Single and repeated 
exposure of laboratory animals to glutaraldehyde vapor results in clinical signs (e.g., nasal discharge,
labored breathing, mouth breathing, audible respiration, rales, perinasal encrustation) and histopathologic
nasal lesions (e.g., rhinitis, epithelial changes, mild atrophy of olfactory mucosa) at airborne
concentrations as low as 0.0625–2.6 ppm.  Repeated-exposure scenarios result in exposure concentration-
related increased incidence and severity of clinical signs and histopathologic nasal lesions.
Glutaraldehyde-induced histopathologic lesions in animals are generally confined to the anterior nasal
cavity.
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Glutaraldehyde irritates eyes and skin upon direct contact.  Occupational exposure to glutaraldehyde has
been commonly associated with ocular irritation and severe dermal irritation.  Severe ocular effects were 
reported in patients undergoing eye surgical procedures; it was suspected that the effects were elicited by
glutaraldehyde residue on surgical equipment following disinfection with glutaraldehyde-containing
products.  Glutaraldehyde induces contact ocular and dermal irritation in laboratory animals as well.
Pathologic evidence of glutaraldehyde-induced gastrointestinal irritation was observed following
administration of aqueous glutaraldehyde by single gavage to rats and mice at sublethal and lethal doses.
Gross and/or histopathologic respiratory lesions have been observed in some animals that were 
administered glutaraldehyde by the oral exposure route and likely resulted from the release of
glutaraldehyde vapor from the digestive tract.
Depressed body weight gain or actual body weight loss was observed in some studies of animals 
repeatedly exposed to glutaraldehyde by inhalation, oral, or dermal routes. Increased incidences of self-
reported headaches were noted among workers exposed to glutaraldehyde during disinfection processes.  
However, glutaraldehyde-induced neurotoxicity has not been demonstrated in animals.
Numerous reports suggest that glutaraldehyde causes dermal sensitization in occupational settings where 
glutaraldehyde is used as a germicide.  The dermal sensitization potential of glutaraldehyde was not
demonstrated in limited controlled human studies. Evidence of glutaraldehyde-induced dermal
sensitization was noted in some animal studies.
There is some evidence for glutaraldehyde-induced respiratory hypersensitivity in occupationally-exposed 
individuals.  Results from single-blind placebo-controlled studies of health workers with occupational
exposure to glutaraldehyde and diagnosed with glutaraldehyde-induced occupational asthma and rhinitis
suggest an immunologic mechanism.  Other epidemiological studies revealed no evidence of
glutaraldehyde-induced respiratory sensitization.  There was no evidence of glutaraldehyde-induced 
respiratory sensitization in available animal studies.
Glutaraldehyde has been widely implicated as the cause of colitis and diarrhea following endoscopy or
sigmoidoscopy procedures, the likely result of contact irritation.
The potential carcinogenicity of inhaled glutaraldehyde was assessed in a 2-year inhalation study of
F344/N rats and B6C3F1 mice.  Based on the lack of exposure-related increased incidences of neoplastic 
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lesions in any organ or tissue from 2-year repeated exposures at up to 750 ppb (rats) and 250 ppb (mice), 
NTP concluded that there was “no evidence of carcinogenic activity” of glutaraldehyde.  In another
chronic study, increased incidences of large granular lymphocytic leukemia (LGLL) were noted in spleen 
and liver of female F344 rats administered glutaraldehyde in their drinking water at 50, 250, and 
1,000 ppm.  However, due to high background and variable incidences of LGLL in the Fischer 344 rat, 
statistical significance only in the female rats, and lack of a clear dose response, the study authors 
indicated that the biological significance of the LGLL findings was unclear and suggested that the 
statistical significance might possibly have been a result of an abnormally low incidence of LGLL in the 
control females.  Furthermore, a Cancer Assessment Review Committee for the U.S. EPA did not
consider the statistically increased incidences of LGLL to be treatment related because: (1) LGLL is a
common and highly variable spontaneous neoplasm in F344 rats; (2) incidences were within the range of
available historical control data; and (3) no significantly increased incidences of LGLL or any other
tumors were seen in the male rats of this drinking water study, in male or female F344 rats or B6C3F1 
mice exposed to glutaraldehyde vapor by inhalation for 2 years, or in Wistar rats exposed via the drinking
water for 2 years. Glutaraldehyde is not on the list of agents evaluated for carcinogenicity by the 
International Agency for Research on Cancer.
2.3  MINIMAL RISK LEVELS (MRLs)
As summarized in Table 2-1, inhalation MRLs have been derived for acute- and intermediate-duration 
exposure to glutaraldehyde and an oral MRL has been derived for chronic-duration exposure to 
glutaraldehyde.  The acute- and intermediate-duration inhalation MRLs are based on glutaraldehyde­
induced nasal lesions in laboratory animals, the most sensitive end point identified from results of studies 
that employed acute- or intermediate-duration inhalation exposure scenarios.  A chronic-duration 
inhalation MRL was not derived for glutaraldehyde because potential MRLs based on the most sensitive
nasal lesions observed following chronic-duration inhalation exposure (≥1 year) were 2–3-fold higher
than the intermediate-duration inhalation MRL.  Based on a conservative approach, this suggests that the 
intermediate-duration inhalation MRL would also be protective of chronic-duration inhalation exposure to 
glutaraldehyde.  Insufficient data precluded the derivation of acute- or intermediate-duration oral MRLs
for glutaraldehyde.  Gastric irritation in chronically exposed rats served as the basis for deriving a
chronic-duration oral MRL for glutaraldehyde.  Refer to Section 3.6.2 and Appendix A for detailed 
information regarding MRL derivation for glutaraldehyde.
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Table 2-1.  Minimal Risk Levels (MRLs) for Glutaraldehydea 
Exposure 
duration Critical effect
Point of
departure
Uncertainty
factor MRL
Inhalation exposure
Acute Nasal lesions observed in rats exposed to 
≥0.250 ppm (Gross et al. 1994; NTP 1993) 
NOAELHEC: 
0.003 ppm
3b 0.001 ppm
Intermediate Nasal lesions observed in mice exposed to 
≥0.0625 ppm (Gross et al. 1994; NTP
1993)
BMCL10HEC: 
0.00008 ppm
3b 0.00003 ppm
Chronic The intermediate-duration inhalation MRL
is considered protective of longer-term
exposure to glutaraldehyde because 
available animal data provide a less
conservative MRL for chronic-duration 
inhalation exposure (0.00007 ppm)
Oral exposure
Acute Insufficient data for derivation of an MRL
Intermediate Insufficient data for derivation of an MRL
Chronic Gastric irritation in rats exposed to
≥17 mg/kg/day in drinking water (van Miller
et al. 2002)
NOAEL:
4 mg/kg/day
30c 0.1 mg/kg/day
aThe respective exposure durations for acute, intermediate, and chronic MRLs are ≤14 days, 15–364 days, and 

≥1 year.
 
b1 for extrapolation from animals to humans using dosimetric conversion and 3 for human variability.
 
c10 for extrapolation from animals to humans and 3 for human variability.
 
BMCL = benchmark concentration lower confidence limit; HEC = human equivalent concentration; NOAEL = no-

observed-adverse-effect level
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13GLUTARALDEHYDE
3. HEALTH EFFECTS
3.1  INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of glutaraldehyde.  It
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
3.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure 
periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
ATSDR employed a systematic review of health effects data in preparation of this Toxicological Profile 
for Glutaraldehyde. The systematic review provides transparency regarding the process of identification,
synthesis, and interpretation of the scientific evidence regarding potential hazards associated with
inhalation, oral, and dermal/ocular exposure to glutaraldehyde.  Details regarding the framework and
implementation of the systematic review for glutaraldehyde-induced health effects are presented in
Appendix B. Relevant data extracted from individual studies selected for inclusion in the systematic 
review were summarized (see Table B-2 of Appendix B).  A summary of the extracted data for each study
is available in the Supplemental Document for Glutaraldehyde.  The available human and animal studies 
identified five potential health outcomes for glutaraldehyde:  respiratory, gastrointestinal, renal, dermal, 
and ocular effects.  Overviews of the results of the inhalation, oral, and dermal exposure studies are
presented in Section 3.2 of the profile and in the Levels Significant Exposure tables in Section 3.2 of the
profile (Tables 3-1, 3-7, and 3-8, respectively).
Dose response data for each route and duration are presented in tables and illustrated in figures.  The
points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-observed-adverse­
effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.
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The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
A User's Guide has been provided at the end of this profile (see Appendix C).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure 
3.2.1.1  Death 
Limited human data were located. Teta et al. (1995) found no evidence of increased mortality from any
or all causes within a group of 186 workers assigned to glutaraldehyde production or drumming from
1959 to 1992 at a West Virginia facility when compared to the general U.S. population.  Follow-up of this
cohort resulted in similar findings (Collins et al. 2006).
No exposure-related deaths occurred in studies of rats exposed for 4–8 hours to saturated atmospheres of
glutaraldehyde vapor generated under static conditions at temperatures ranging from 18 to 25°C 
(Ballantyne 1995; Union Carbide Chem & Plas Co. 1991v; Union Carbide Corp. 1992a, 1992b).  Studies
that included analytical measurements under static conditions (test material placed in test chamber and
atmosphere allowed to equilibrate) found average glutaraldehyde concentrations to measure <10 ppm. 
No deaths occurred among rats exposed for 4 or 8 hours to glutaraldehyde vapor under dynamic
conditions (capable of generating higher glutaraldehyde vapor concentrations than under static 
conditions) at temperatures in the range of 17–23°C (Ballantyne 1995; Union Carbide Chem & Plas Co. 
1991p, 1991x; Union Carbide Corp. 1992a, 1992c). Studies that included analytical measurements under
these conditions found glutaraldehyde vapor concentrations as high as 22.2 ppm. At air temperatures of
60–65°C within the vapor-generating system, glutaraldehyde vapor concentrations ranging from of
9.1 ppm to as high as 94.9 ppm were attained and resulted in 4-hour LC50 values of 23.5 and 40.1 ppm for
male and female rats, respectively in one study (Union Carbide Corp. 1992l) and 37.2 and 53.1 ppm, 
respectively, in another study (Ballantyne 1995). Repeated 6-hour exposures (5 days/week for
9 exposures) of male and female rats to glutaraldehyde vapor at 3.1 ppm resulted in ≥50% mortality in 
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each gender (Union Carbide Corp. 1992d).  Death was reported as early as day 3 in male mice exposed
daily to glutaraldehyde vapor for 5 hours/day at 2.6 ppm (Zissu et al. 1994). All rats and mice repeatedly
exposed to glutaraldehyde vapor concentrations ≥5 ppm (rats) and ≥1.6 ppm (mice) for 6 hours/day died 
between days 4 and 9 of 16-day studies (NTP 1993). In a 13-week repeated exposure study of rats and
mice, all mice exposed at 1 ppm glutaraldehyde died during the first 5 weeks and 2/10 female mice of the
0.5 ppm exposure level died at weeks 7 and 8; there were no deaths among the exposed rats at the highest
concentration (1 ppm) tested (NTP 1993). Similar effects on survival were observed in a time-course 
study designed to assess the effects of exposures to glutaraldehyde vapor for 1 or 4 days, or 6 or 13 weeks 
(Gross et al. 1994). In 2-year studies of rats, repeated exposure to glutaraldehyde vapor at 0.5 and 
0.75 ppm resulted in significantly decreased survival of female (but not male) rats (15/50 and 14/50 
0.5 and 0.75 ppm females, respectively, versus 26/50 control females); there was no significant effect on
survival of similarly-exposed mice at the highest concentration (0.25 ppm) tested (NTP 1999).
All reliable LOAEL and LC50 values for death in each species and duration category are recorded in
Table 3-1 and plotted in Figure 3-1.
3.2.1.2  Systemic Effects
The highest NOAEL values and all LOAEL values from each reliable study for each species, duration,
and end point for systemic effects are recorded in Table 3-1 and plotted in Figure 3-1.
No information was located regarding the following systemic effects in humans exposed to 
glutaraldehyde by the inhalation route:  gastrointestinal, hematological, musculoskeletal, hepatic, renal,
endocrine, body weight, and dermal effects. No information was located regarding musculoskeletal or
dermal effects in animals exposed to glutaraldehyde by the inhalation route.
Respiratory Effects. Results from controlled human studies and assessment of self-reported
symptoms among workers that included measurements of airborne glutaraldehyde concentrations are
summarized in Table 3-2.  The glutaraldehyde odor threshold in humans was determined to be in the
range of 0.0003 ppm based on multiple 5-second exposures; a similar exposure scenario resulted in a 
threshold of 0.47 ppm for the perception of an effect on nasal tissue (Cain et al. 2007).  Within a group of
50 female subjects exposed to air only or glutaraldehyde vapor at 0.035, 0.050, 0.075, or 0.100 ppm for
15-minute intervals, the cumulative proportion of subjects who achieved 50% correct detection of
glutaraldehyde (self-reported perception of nasal sensation) ranged from <5% at the glutaraldehyde
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Table 3-1. Levels of Significant Exposure to Glutaraldehyde – Inhalation 
Species Exposure
Figure (strain) parameters/ Parameters NOAEL Less serious Serious 
keya No./group concentrations monitored System (ppm) LOAEL (ppm) LOAEL (ppm) Results Reference/comments 
ACUTE EXPOSURE
Death
1 Rat (NS)
5 M, 5 F
Once (4 hr)
0, 11.0, 28.0, 
37.2, 59.7, 
94.9 ppm 
(measured)
CS LE 37.2 M 
53.1 F
LC50 values 
11.0 ppm: no deaths 
28.0 ppm: 1.5 M, 1/5 F died
37.2 ppm 2/5 M, 0/5 F died
59.7 ppm: 5/5 M, 4/5 F died
94.9 ppm 5/5 M, 4/5 F died
Ballantyne 1995
Vapors generated at elevated 
temperature (60°C)
2 Rat (F344)
6 M, 6 F
Once (4 hr)
0, 10.6, 23.0, 
42.7 ppm 
(measured)
CS FI GN HP 
LE WI 
23.5 M 
40.1 F
LC50 values 
10 ppm: no deaths 
20 ppm: 2/6 M, 2/6 F died
50 ppm: 6/6 M, 3/6 F died
Union Carbide Corp. 1992l
Analytical concentrations from GC 
technique; Tenax trapping method
resulted in slightly different
analytical concentrations 
3 Rat (F344)
5 M, 5 F
6 hr/d, 5 d/wk; up
to 12 exposures 
0, 0.16, 0.5, 1.6, 
5, 16 ppm (target) 
BW CS GN
LE OW
5 All male and female rats of the 5 and 
16 ppm exposure levels died by study
day 9; no deaths at lower exposure levels 
NTP 1993
Measured concentrations 96– 
100% of target
4 Rat (F344)
12 M, 12 F
6 hr/d, 5 d/wk; up
to 9 exposures 
0.3, 1.1, 3.1 ppm
(measured)
BC BW CS FI 
GN HE HP LE 
OP OW UR 
WI 
3.1 7/12 M, 6/12 F died; most deaths occurred 
during week 2 of exposures
Union Carbide Corp. 1992d
5 Rat (F344)
10 M, 10 F
6 hr/d, 5 d/wk; up
to 9 exposures 
0, 0.2, 0.63, 
2.09 ppm 
(measured)
BW CS FI GN 
LE OP OW
2.09 9/10 M, 7/10 F died; most deaths occurred 
during latter half of study; one male rat of 
the 0.63 ppm died on final exposure day 
Union Carbide Corp. 1992e
6 Mouse 
(B6C3F1)
5 M, 5 F
6 hr/d, 5 d/wk; up
to12 exposures 
0, 0.16, 0.5, 1.6, 
5, 16 ppm (target) 
BW CS GN
LE OW
1.6 All male and female mice of the 1.6, 5, and 
16 ppm exposure levels died by study
day 8; no deaths at lower exposure levels 
NTP 1993
Measured concentrations 94– 
101% of target
7 Mouse (Swiss 
OF1) 10 M
6 hr/d, 5d/wk; up 
to 9 exposures 
0, 0.3, 0.9, 
2.6 ppm 
(measured)
BW CS GN
HP 
2.6 4/10 died; mortalities occurred between 
days 3 and 5
Zissu et al. 1994 
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Table 3-1. Levels of Significant Exposure to Glutaraldehyde – Inhalation 
Species Exposure
Figure (strain) parameters/ Parameters NOAEL Less serious Serious 
keya No./group concentrations monitored System (ppm) LOAEL (ppm) LOAEL (ppm) Results Reference/comments 
Systemic
8 Human 
40 F
Multiple 5-sec 
exposures
0.229-0.772 ppm
(measured)
CS Resp 0.47 0.47 ppm considered threshold for 
detection of glutaraldehyde-induced nasal 
tissue sensation (25/40 subjects identified 
exposure to glutaraldehyde correctly 50% 
of the time)
Cain et al. 2007
9 Human 
5 M, 4 F
Multiple 2-min 
exposures during
3 d 
Multiple 
concentrations 
CS Resp 0.237–0.245 The threshold for nasal sensory irritation to 
activated (alkaline) glutaraldehyde solution 
was 0.237–0.245 ppm 
Union Carbide Corp 1976
Accommodation to nasal irritation 
after 1 min frequently reported
10 Human 
5 M, 4 F
Multiple 2-min 
exposures during
1 d; multiple 
concentrations 
CS Resp 0.255 The threshold for nasal sensory irritation to 
unactivated (acidic) glutaraldehyde solution 
was 0.255 ppm
Union Carbide Corp. 1976
Accommodation to nasal irritation 
after 1 min frequently reported
11 Human 
50F
Multiple 15-min 
exposures
0.035, 0.050, 
0.075, 0.1 ppm
(measured)
CS Resp 0.1 >50% of the subjects achieved 50% correct 
detection of glutaraldehyde (self-reported 
perception of nasal sensation) at 0.1 ppm
Cain et al. 2007
12 Rat (F344)
6 M, 6 F
Once (4 hr)
0, 10.6, 23.0, 
42.7 ppm 
(measured)
CS FI GN HP 
LE WI 
Resp 
BW 
10.6 
10.6 
Clinical signs of respiratory irritation at all 
exposure levels increased in severity with 
increasing exposure concentration; body
weight loss ranged from 14 to 30% of initial 
body weight and persisted for 7 days 
postexposure
Union Carbide Corp. 1992l
Analytical concentrations from GC 
technique; Tenax trapping method
resulted in slightly different
analytical concentrations 
13 Rat (F344)
5 M, 5 F
Once (6 hr)
0, 0.0625, 0.125,
0.25, 0.5, 1.0 ppm 
(target)
CS GN HP LE Resp 0.125b 0.25 Exposure concentration-related increasing 
incidence and severity of nasal lesions; 
clinical signs (bloating, gasping) were 
noted at the “higher concentrations” 
Gross et al. 1994
Statistical analysis not performed 
(only 5 animals/sex/group); 
analytical concentrations within 
99–104% of target (see Table 3-2
for quantitative nasal lesion data) 
14 Rat (F344)
5 M, 5 F
6 hr/d for 4 d
0, 0.0625, 0.125,
0.25, 0.5, 1.0 ppm 
(target)
CS GN HP LE Resp 0.25 M 
0.125 F
0.5 M 
0.25 F
Exposure concentration-related increasing 
incidence and severity of nasal lesions; 
clinical signs (bloating, gasping) were 
noted at the “higher concentrations” 
Gross et al. 1994
Statistical analysis not performed 
(only 5 animals/sex/group); 
analytical concentrations within 
99–104% of target (see Table 3-2
for quantitative nasal lesion data) 
17
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Table 3-1. Levels of Significant Exposure to Glutaraldehyde – Inhalation 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure
parameters/ 
concentrations
Parameters 
monitored System 
NOAEL 
(ppm)
Less serious 
LOAEL (ppm) 
Serious 
LOAEL (ppm) Results Reference/comments 
15 Rat (F344)
12 M, 12 F
6 hr/d, 5 d/wk; up
to 9 exposures 
0.3, 1.1, 3.1 ppm
(measured)
BC BW CS FI 
GN HE HP LE 
OP OW UR 
WI 
Resp 0.3 1.1 Clinical signs of respiratory tract irritation at 
1.1 and 3.1 ppm; histopathologic nasal 
lesions at 1.1 and 3.1 ppm included rhinitis, 
squamous metaplasia, and atrophy of 
olfactory mucosa 
Union Carbide Corp. 1992d
16 Rat (F344)
10 M, 10 F
6 hr/d, 5 d/wk; up
to 9 exposures 
0, 0.2, 0.63, 
2.09 ppm 
(measured)
BW CS FI GN 
LE OP OW
Resp 
BW 
0.2 
0.2 
Exposure concentration-related increasing 
severity of clinical signs of respiratory tract 
irritation; depressed body weight gain (33­
41% less than that of controls)
Union Carbide Corp. 1992e
17 Mouse 
(Swiss/ 
Webster 
4 M 
Once (30 min) 
1.6, 3.99, 4.65, 
5.6, 7.47, 17.7, 
36.7 ppm 
(measured)
BW CS LE Resp 
BW 36.7 
1.6 Decreased respiratory rates almost 
immediately at all exposure levels, 
persisting throughout exposure
Werley et al. 1995 
RD50=13.86 ppm (95% CI 9.86– 
23.58)
18 Mouse (OF1)
6 M 
Once (60 min) 
0.7, 1.3, 1.7, 3.2,
4.3, 4.5 ppm 
(measured)
CS Resp 0.7 Decreased respiratory rates almost
immediately at all exposure levels with 
some recovery during the 60-minute 
exposure period
Zissu et al. 1994 
RD50=2.6 ppm
19 Mouse 
(B6C3F1)
5 M, 5 F
Once (6 hr)
0, 0.0625, 0.125,
0.25, 0.5, 1.0 ppm 
(target)
CS GN HP LE Resp 0.25 M 
0.125 F
0.5 M 
0.25 F
Exposure concentration-related increasing 
incidence and severity of nasal lesions; 
clinical signs (bloating, gasping) were 
noted at the “higher concentrations” 
Gross et al. 1994
Statistical analysis not performed 
(only 5 animals/sex/group); 
analytical concentrations within 
99–104% of target (see Table 3-2
for quantitative nasal lesion data) 
20 Mouse 
(B6C3F1)
5 M, 5 F
6 hr/d for 4 d
0, 0.0625, 0.125,
0.25, 0.5, 1.0 ppm 
(target)
CS GN HP LE Resp 0.125 0.25 Exposure concentration-related increasing 
incidence and severity of nasal lesions; 
clinical signs (bloating, gasping) were 
noted at the “higher concentrations” 
Gross et al. 1994
Statistical analysis not performed 
(only 5 animals/sex/group); 
analytical concentrations within 
99–104% of target (see Table 3-2
for quantitative nasal lesion data) 
21 Mouse (Swiss 
OF1) 10 M
6 hr/d, 5 d/wk; 
4 or 9 exposures
0, 0.3, 1.0 ppm 
(measured)
BW CS GN
HP 
Resp 0.3 Nasal lesions (squamous metaplasia, 
keratin exudate, necrosis) in respiratory 
epithelium 
Zissu et al. 1994 
18
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Table 3-1. Levels of Significant Exposure to Glutaraldehyde – Inhalation 
Species Exposure
Figure (strain) parameters/ Parameters NOAEL Less serious Serious 
keya No./group concentrations monitored System (ppm) LOAEL (ppm) LOAEL (ppm) Results Reference/comments 
Immunological and Lymphoreticular Effects 
22 Guinea pig Induction: CS 13.9 No evidence of glutaraldehyde-induced Werley et al. 1995 
(Dunkin­ 1 hr/d for 5 d at respiratory sensitization
Hartley) 
4 M (control);
13.9 ppm (mean 
measured)
8 M (treated) Challenge: 
1 hr/d for 3 d at 
4.4 ppm (mean 
measured)
23 Mouse 1.5 hr/d for 3 d at BW CS HP 18 No evidence of glutaraldehyde-induced van Triel et al. 2011 
(BALB/c) 0, 6, 18 ppm respiratory sensitization
8 M (target)
Neurological Effects 
24 Rat (F344) Once (4 hr) CS FI GN HP 10.6 23 Impaired righting reflex following exposure Union Carbide Corp. 1992l
6 M, 6 F 0, 10.6, 23.0, LE WI at 42.7 ppm; decreased motor activity at Analytical concentrations from GC 
42.7 ppm 23 and 42.7 ppm persisting during 14 days technique; Tenax trapping method
(measured) of postexposure observation resulted in slightly different
analytical concentrations 
INTERMEDIATE EXPOSURE
Death
25 Rat (F344)
5 M, 5 F
6 hr/d, 5 d/wk for
6 or 13 wk
0, 0.0625, 0.125,
0.25, 0.5, 1.0 ppm 
(target)
CS GN HP LE 1.0 M, F 2/20 M, 3/10 F died; deaths of rats
scheduled for sacrifice at 6 or 13 weeks 
occurred during study week 3
Gross et al. 1994
Analytical concentrations within 
99–104% of target 
26 Mouse 
(B6C3F1)
5 M, 5 F
6 hr/d, 5 d/wk for
6 or 13 wk
0, 0.0625, 0.125,
0.25, 0.5, 1.0 ppm 
(target)
CS GN HP LE 1.0 M 
0.5 F
All 1.0 ppm male and female mice 
scheduled for sacrifice at 6 or 13 weeks 
died during study weeks 2–7; one 0.5 ppm 
female mouse died 
Gross et al. 1994
Analytical concentrations within 
99–104% of target 
27 Mouse 
(B6C3F1)
10 M, 10 F
6 hr/d, 5 d/wk for
13 wk
0, 0.0625, 0.125,
0.25, 0.5, 1.0 ppm 
(target)
BW BC CS 
GN HE HP LE 
OW
1.0 M 
0.5 F
All 1.0 ppm male and female mice died; 
most deaths occurred between 
weeks 1 and 3; deaths (2/10) in 0.5 ppm 
females occurred at weeks 7 and 8 
NTP 1993
Measured concentrations 94– 
101% of target
19
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Table 3-1. Levels of Significant Exposure to Glutaraldehyde – Inhalation 
Species Exposure
Figure (strain) parameters/ Parameters NOAEL Less serious Serious 
keya No./group concentrations monitored System (ppm) LOAEL (ppm) LOAEL (ppm) Results Reference/comments 
Systemic
28 Rat (F344) 6 hr/d, 5 d/wk, up BW CS GN Resp 0.16 0.5 	 Exposure concentration-related increasing NTP 1993
5 M, 5 F	 to 12 exposures LE OW BW 0.5 1.6 incidence and severity of respiratory tract Measured concentrations 96– 
in 16 d lesions; body weight of 1.6 ppm rats 100% of target
0, 0.16, 0.5, 1.6, approximately 40% less than that of 
5, 16 ppm (target) controls 
29 Rat (F344) 6 hr/d, 5 d/wk for CS GN HP LE Resp 0.125 0.25 Exposure concentration-related increasing Gross et al. 1994
5 M, 5 F 6 wk incidence and severity of nasal lesions Analytical concentrations within 
0, 0.0625, 0.125, 99–104% of target (see Table 3-2
0.25, 0.5, 1.0 ppm for quantitative nasal lesion data) 
(target)
30 Rat (F344) 6 hr/d, 5 d/wk for CS GN HP LE Resp 0.25 0.5 Exposure concentration-related increasing Gross et al. 1994
5 M, 5 F 13 wk incidence and severity of nasal lesions Analytical concentrations within 
0, 0.0625, 0.125, 99–104% of target (see Table 3-2
0.25, 0.5, 1.0 ppm for quantitative nasal lesion data) 
(target)
31 Rat (F344) 6 hr/d, 5 d/wk for BW BC CS Resp 
10 M, 10 F 13 wk GN HE HP LE Cardio 
0, 0.0625, 0.125, OW Hemato 
0.25, 0.5, 1.0 ppm Hepatic 
(target) Renal 
BW 
0.25 0.5 	 Exposure concentration-related increasing NTP 1993
1.0 	 incidence and severity of nasal lesions; Measured concentrations 94– 
1.0 	 body weight in 1.0 ppm males depressed 101% of target; no data regarding 
1.0 	 by 10%; no histopathological evidence of food consumption, which may
1.0 1.0M 	 cardiac lesions; increased numbers of have influenced body weight; 
0.5 M 	 segmented neutrophils at day 24; changes in neutrophils likely
1.0 F 	 decreased numbers of leukocytes and secondary to nasal inflammation; 
lymphocytes at 13 weeks 	 changes in leukocytes and 
lymphocytes of small magnitude 
and questionable toxicological 
significance
32 Rat (F344) 6 hr/d, 5 d/wk for BC BW CS FI Resp 0.1942 No evidence of exposure-related nasal or Union Carbide Corp 1992f
20 M, 20 F 14 wk GN HE HP LE Hemato 0.1942 respiratory tract lesions or hematological 
0, 0.0208, 0.0493, 
0.1942 ppm
OP OW Hepatic 0.1942 effects 
33 Mouse 6 hr/d, 5 d/wk, up BW CS GN Resp 0.5 1.6 Exposure concentration-related increasing NTP 1993
(B6C3F1) to 12 exposures LE OW BW 0.5 incidence and severity of respiratory tract Measured concentrations 94– 
5 M, 5 F in 16 d 
0, 0.16, 0.5, 1.6, 
lesions; body weights of 1.6, 5, and 16 ppm 
groups not measured due to 100% 
101% of target
5, 16 ppm (target) mortality in these groups
20
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Table 3-1. Levels of Significant Exposure to Glutaraldehyde – Inhalation 
Species Exposure
Figure (strain) parameters/ Parameters NOAEL Less serious Serious 
keya No./group concentrations monitored System (ppm) LOAEL (ppm) LOAEL (ppm) Results Reference/comments 
34 Mouse (Swiss 
OF1) 
6 hr/d, 5 d/wk, for 
14 exposures 
BW CS GN
HP 
Resp 0.3 Exposure concentration-related increasing 
severity of nasal lesions 
Zissu et al. 1994 
Nasal lesions persisted for 2 wks 
10 M 0, 0.3, 0.9 ppm in mice exposed at 0.9 ppm and
(measured) observed for up to 4 wks after 
exposures ceased
35 Mouse 6 hr/d, 5 d/wk for CS GN HP LE Resp 0.125 M 0.25 M Exposure concentration-related increasing Gross et al. 1994
(B6C3F1) 6 wk 0.0625 F 0.125 F incidence and severity of nasal lesions Analytical concentrations within 
5 M, 5 F 0, 0.0625, 0.125,
0.25, 0.5, 1.0 ppm 
99–104% of target (see Table 3-2
for quantitative nasal lesion data) 
(target)
36 Mouse 6 hr/d, 5 d/wk for CS GN HP LE Resp 0.0625 M 0.25 M Exposure concentration-related increasing Gross et al. 1994
(B6C3F1)
5 M, 5 F
13 wk
0, 0.0625, 0.125,
0.0625 F incidence and severity of nasal lesions Analytical concentrations within 
99–104% of target (see Table 3-2
0.25, 0.5, 1.0 ppm for quantitative nasal lesion data) 
(target)
37 Mouse 6 hr/d, 5 d/wk for BW BC CS Resp 0.25 M 0.5 M Exposure concentration-related increasing NTP 1993
(B6C3F1) 13 wk GN HE HP LE 0.0625 Fc incidence and severity of nasal lesions; no Measured concentrations 94– 
10 M, 10 F 0, 0.0625, 0.125, OW Cardio 0.5 histopathological evidence of cardiac, liver, 101% of target; no data regarding 
0.25, 0.5, 1.0 ppm Hepatic 0.5 or renal lesions at highest nonlethal food consumption, which may
(target) Renal 0.5 exposure level; 11–12% depressed body have influenced body weight
BW 0.25 0.5 weight at 0.5 ppm 
Neurological Effects 
38 Rat (F344) 6 hr/d, 5 d/wk for BW BC CS 1.0 No clinical signs of neurotoxicity NTP 1993
10 M, 10 F 13 wk GN HE HP LE Measured concentrations 94– 
0, 0.0625, 0.125,
0.25, 0.5, 1.0 ppm 
OW 101% of target
(target)
39 Mouse 6 hr/d, 5 d/wk for BW BC CS 1.0 No clinical signs of neurotoxicity NTP 1993
(B6C3F1) 13 wk GN HE HP LE Measured concentrations 94– 
10 M, 10 F 0, 0.0625, 0.125, OW 101% of target
0.25, 0.5, 1.0 ppm 
(target)
Reproductive Effects 
40 Rat (F344) 6 hr/d, 5 d/wk for BW BC CS 1.0 No effects on testicular weight, sperm NTP 1993
10 M, 10 F 13 wk GN HE HP LE morphology, vaginal cytology Measured concentrations 94– 
0, 0.0625, 0.125,
0.25, 0.5, 1.0 ppm 
OW 101% of target
(target)
21
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Table 3-1. Levels of Significant Exposure to Glutaraldehyde – Inhalation 
Species Exposure
Figure (strain) parameters/ Parameters NOAEL Less serious Serious 
keya No./group concentrations monitored System (ppm) LOAEL (ppm) LOAEL (ppm) Results Reference/comments 
41 Mouse 6 hr/d, 5 d/wk for BW BC CS  1.0 M No effects on testicular weight, sperm NTP 1993
(B6C3F1) 13 wk GN HE HP LE 0.5 F morphology, vaginal cytology; females of Measured concentrations 94– 
10 M, 10 F 0, 0.0625, 0.125, OW 0.25 and 0.5 ppm groups spent slightly 101% of target
0.25, 0.5, 1.0 ppm more time than controls in diestrus and 
(target) estrus and less time in metestrus 
CHRONIC EXPOSURE
Death
42 Rat (F344) 6 hr/d, 5 d/wk for BW CS GN 0.5 F Mean survival times among 0, 0.25, 0.5, NTP 1999
50 M, 50 F 104 wk
0, 0.25, 0.5, 
HP LE and 0.75 ppm groups of female rats were 
675, 671, 636, and 573 days, respectively; 
0.75 ppm (target) no significant differences in survival among 
groups of male rats 
Systemic
43 Rat (F344)
50 M, 50 F
6 hr/d, 5 d/wk for
104 wk
0, 0.25, 0.5, 
0.75 ppm (target)
BW CS GN
HP LE 
Resp 
Cardio 
Gastro
Hemato 
Hepatic 
Renal 
Endocr 
0.75 
0.75 
0.75 
0.75 
0.75 
0.75 
0.25 Hyperplasia and inflammation in nasal 
squamous epithelium at all exposure 
levels; additional nasal lesions at two 
highest exposure levels 
No histopathological evidence of cardiac, 
gastrointestinal, hepatic, or renal lesions, or 
lesions in endocrine tissues examined 
NTP 1999
No data regarding food 
consumption, which may have 
influenced body weight
BW 0.75 M 
0.5 F 0.75 F
(adrenal cortex, pancreas, pituitary, thyroid, 
parathyroid)
Body weight in 0.75 ppm females 
depressed by 14%
44 Mouse 
(B6C3F1)
50 M, 50 F
6 hr/d, 5 d/wk for
104 wk
0, 0.0625, 0.125,
0.0.25 ppm 
(target)
BW CS GN
HP LE 
Resp 
Cardio 
Gastro
Hemato 
Hepatic 
Renal 
Endocr 
0.125 M 
0.25 
0.25 
0.25 
0.25 
0.25 
0.25 
0.25 M 
0.0625 F
Squamous metaplasia in 0.25 ppm males; 
hyaline degeneration of respiratory 
epithelium in all groups of females and 
squamous metaplasia in 0.125 and 
0.25 ppm females 
No histopathological evidence of cardiac, 
gastrointestinal, hepatic, or renal lesions, or 
lesions in endocrine tissues examined 
NTP 1999
No glutaraldehyde exposure-
related histopathologic lesions in 
cardiovascular, gastrointestinal, 
hepatic, renal, or endocrine 
tissues 
BW 0.25 (adrenal cortex, pancreas, pituitary, thyroid, 
parathyroid)
Neurological Effects 
45 Rat (F344) 6 hr/d, 5 d/wk for BW CS GN 0.75 No clinical or histopathological signs of NTP 1999
50 M, 50 F 104 wk
0, 0.25, 0.5, 
HP LE glutaraldehyde-induced neurotoxicity 
0.75 ppm (target) 22
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Table 3-1. Levels of Significant Exposure to Glutaraldehyde – Inhalation 
Species Exposure
Figure (strain) parameters/ Parameters NOAEL Less serious Serious 
keya No./group concentrations monitored System (ppm) LOAEL (ppm) LOAEL (ppm) Results Reference/comments 
46 Mouse 6 hr/d, 5 d/wk for BW CS GN 0.25 No clinical or histopathological signs of NTP 1999
(B6C3F1) 104 wk HP LE glutaraldehyde-induced neurotoxicity 
50 M, 50 F 0, 0.0625, 0.125,
0.0.25 ppm 
(target)
Reproductive Effects 
47 Rat (F344) 6 hr/d, 5 d/wk for BW CS GN 0.75 No increased incidences of NTP 1999
50 M, 50 F 104 wk
0, 0.25, 0.5, 
HP LE histopathological lesions in reproductive 
organs or tissues 
0.75 ppm (target)
48 Mouse 6 hr/d, 5 d/wk for BW CS GN 0.25 No increased incidences of NTP 1999
(B6C3F1)
50 M, 50 F
104 wk
0, 0.0625, 0.125,
HP LE histopathological lesions in reproductive 
organs or tissues 
0.0.25 ppm 
(target)
aThe number corresponds to entries in Figures 3-1 and 3-2.

bUsed to derive an acute-duration inhalation MRL of 0.001 ppm for glutaraldehyde, as described in detail in Appendix A.  The concentration was adjusted from intermittent exposure (6 hours) to 

account for continuous exposure (6 hours/24 hours) and converted to a human equivalent concentration.  An uncertainty factor of 3 (1 for extrapolation from animals to humans using dosimetric 

adjustment and 3 for human variability) was applied. 

cStudy results used to derive an intermediate-duration inhalation MRL of 0.00003 ppm (3x10-5 ppm), as described in detail in Appendix A.  Benchmark dose analysis was performed on 

incidence data for inflammation in the nasal vestibule/anterior nares of B6C3F1 female mice to select a point of departure, which was adjusted from intermittent exposure (6 hours/day, 

5 days/week) to account for continuous exposure and converted to a human equivalent concentration.  An uncertainty factor of 3 (1 for extrapolation from animals to humans using dosimetric 

adjustment and 3 for human variability) was applied. 

BC = biochemistry; BW = body weight; Cardio = cardiovascular; CI = confidence interval; CS = clinical signs; d = day(s); Endocr = endocrine; F = female(s); FI = food intake; 

Gastro = gastrointestinal; GC = gas chromatography; GN = gross necropsy; HE = hematology; Hemato = hematology; HP = histopathology; hr = hour(s); LC50 = lethal concentration, 50% kill; 

LE = lethality; M = male(s); min = minute(s); MRL = Minimal Risk Level; NS = not specified; OP = ophthalmology; OW = organ weight; RD50 = concentration resulting in a 50% reduction in 

respiratory rate; Resp = respiratory; sec = second(s); UR = urinalysis; WI = water intake; wk = week(s)
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Figure 3-1. Levels of Significant Exposure to Glutaraldehyde - Inhalation 
Acute (≤ 14 days) 
Systemic 
Immuno/ 
Death Respiratory Body Weight Neurological Lymphoret
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Figure 3-1. Levels of Significant Exposure to Glutaraldehyde - Inhalation (Continued) 
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Figure 3-1. Levels of Significant Exposure to Glutaraldehyde - Inhalation (Continued) 
Chronic (≥365 days) 
Systemic 
Death Respiratory Cardio Gastro Hepatic Renal Hemato Endocrine Body Weight Neurological Reproductive 
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Table 3-2.  Reported Respiratory Responses in Humans Exposed to 

Glutaraldehyde Vapor
 
Reference/subjects Monitoring detail Airborne concentration Response 
Union Carbide Corp.
Controlled study:
four female and five
male volunteers
exposed activated 
(alkaline) glutaraldehyde 
for 2-minute intervals
over 3 days and 
unactivated (acidic)
glutaraldehyde on a 
4th day
Cain et al. 2007
Controlled study:
43 female subjects for
odor detection (multiple 
5-second exposures); 
40 female subjects for
nasal sensation 
(multiple 5-second 
exposures); 
50 subjects for exposure 
duration assessment
(multiple 15-minute
exposures)
Norbäck 1988
Manual cold sterilization
hospital workers:
39 exposed (handled
glutaraldehyde 
≥1 time/month); 
68 unexposed (handled 
glutaraldehyde 
<1 time/month)
Room air sampled 
for 30 minutes
following exposures
using air scrubber
Sampling for odor
detection:
2 L/minute over
30 minutes (limit of
sensitivity:
0.00044 ppm)
Sampling for nasal
sensation:
15-minute
measurements at
sampling rate of
1 L/minute); limit of
sensitivity:
0.0044 ppm
Personal
monitoring:
short-term
(15 minutes)
long-term (3– 
4 hours)
Not specified in available 
study summary
Multiple unspecified 
concentrations
15 minutes: 
GM=0.05 mg/m3 
(0.012 ppm)
range: <0.02–0.57 mg/m3 
(<0.0049–0.14 ppm)
3–4 hours: less than the 
detection limit of
0.04 mg/m3 
(<0.0098 ppm)
Sensory (mainly nasal) irritation 
threshold of 0.237–0.245 ppm
for alkaline glutaraldehyde,
0.255 ppm for acidic
glutaraldehyde
Odor detection threshold:
0.0003 ppm (GSD=2.5) for 50%
detection of odor
Perception of nasal sensation:
0.470 ppm (GSD=1.6) for 50%
detection of nasal sensation
Exposure duration assessment:
no convincing evidence of
duration-related increased 
ability to detect a
glutaraldehyde-induced nasal
sensation during exposure 
(15 min at 0.035, 0.050, 0.075,
or 0.100 ppm)
Nasal catarrha:
26% exposed; 10%
unexposed
OR=3.0 (p=0.04)
Nasal obstruction:
28% exposed; 12%
unexposed
OR=2.9 (p=0.03)
Smarting of throat:
26% exposed; 9% unexposed
OR=3.6 (p=0.02)
***DRAFT FOR PUBLIC COMMENT***
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Table 3-2.  Reported Respiratory Responses in Humans Exposed to 

Glutaraldehyde Vapor
 
Reference/subjects Monitoring detail Airborne concentration Response 
Vyas et al. 2000
Glutaraldehyde-exposed 
endoscopy nurses:
318 current workers; no 
comparison group
Pisaniello et al. 1997
Nurses at 26 hospitals
Exposed: 135 nurses
with ≥1 year of
experience with 
glutaraldehyde in 
endoscopy units and 
operating theaters
Comparison group: 
32 unexposed nurses at
the same hospitals
Personal monitoring 
of one nurse per
endoscopy unit
Background 
sampling
(52 endoscopy units
with 308 nurses)
Peak glutaraldehyde 
sampling
(43 endoscopy units
with 267 nurses)
Personal
monitoring:
short-term
measurements (1– 
15 minutes) during 
glutaraldehyde use
Area monitoring:
unspecified duration 
(much longer than 
personal monitoring 
periods)
Peakb: GM=0.06 mg/m3 
(0.015 ppm); range 
<0.001 (LOD) to 
1.08 mg/m3 
(<0.00024 ppm to 
0.263 ppm)
Backgroundc: 
GM=0.01 mg/m3 
(0.0024 ppm); range 
0.002–0.1 mg/m3 
(0.00049–0.024 ppm)
Short-term personal
sampling:
GM=0.032 ppm
(GSD=3.0)
Area sampling:
GM=0.008 ppm
(GSD=3.6)
Nasal irritation reported by
63/318 (19.8%) workers with 
exposure to glutaraldehyde
Significant association between 
peak glutaraldehyde 
concentration and prevalence 
of nasal irritation: RR=1.19 
(95% CI 1.012, 1.402),
adjusted for type of ventilation
At the end of a day of
glutaraldehyde monitoring,
22/63 nurses (35%) reported 
any nasal symptoms, 8/63 
(13%) reported any throat
symptoms; no clear evidence of
dose-response relationship
(e.g., no symptoms associated 
with four personal monitoring 
measurements ≥0.2 ppm); 
significantly (p<0.05) higher
prevalence of any throat
symptom (occurring ≥3 times at
work in last 12 months) in 
exposed (33/135; 24.4%)
versus controls (13/132; 9.8%); 
no significant difference 
between exposed and controls
regarding nasal symptoms
***DRAFT FOR PUBLIC COMMENT***
   
 
    
 
 
 
 
 
    
 
 
 
  
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   
  
  
 
  
  
  
 
    
 
 
  
 
 
 
 
  
 
  
 
  
 
 
    
 
  
 
   
 
   
   
   
 
    
 
 
 
 
 
 
  
 
  
  
  
  
 
 
  
   
 
 
  
 
  
   
 
 
 
   
 
  
   
  
 
     
  
 
 
 
 
 
  
29GLUTARALDEHYDE
3. HEALTH EFFECTS
Table 3-2.  Reported Respiratory Responses in Humans Exposed to 

Glutaraldehyde Vapor
 
Reference/subjects Monitoring detail Airborne concentration Response 
Waters et al. 2003
Glutaraldehyde-exposed 
subjects: 38 nurses from
nine work areas
(endoscopy units and 
operating theaters) at
five health care facilities
Comparison subjects: 
38 workers (at two
participating health care 
facilities) in areas where 
glutaraldehyde was not
used
NIOSH 1987a
44 hospital workers
exposed to 
glutaraldehyde at least
once per week during 
disinfection of
equipment
NIOSH 1987b
Unspecified number of
nurses involved in 
disinfecting equipment
and other contaminated 
surfaces at a medical
facility
Breathing zone air
samples collected
during three main 
phases of
disinfection (initial
disinfection and 
immersion, removal
and rinsing, and 
drying; mean 
duration 57, 142,
and 90 seconds, 
respectively)
Duration of
designated 
exposure events:
5 seconds– 
12.25 minutes
Five personal
breathing zone
samples and 
nine area samples
(sampling times: 7– 
30 minutes at 0.8– 
1.0 L/minute flow 
rate)
Eight personal
breathing zone
samples and 
nine area samples
(sampling times:
15–45 minute at
0.2 L/minute flow 
rate)
Peak glutaraldehyde 
concentrations up to 
0.15 ppm; lowest peak
reading of 0.08 ppm
where a washing
machine was used
Personal breathing zone
samples: two ND, one
each at 0.6 mg/m3 
(0.15 ppm), 0.8 mg/m3 
(0.20 ppm), and 
1.6 mg/m3 (0.39 ppm)
Area samples: ND– 
1.0 mg/m3 (0.24 ppm)
Personal breathing zone
samples: ND– 
1.98 mg/m3 (0.48 ppm);
50% above 0.7 mg/m3 
(0.17 ppm); LOD=0.33– 
1.0 mg/m3 (0.08– 
0.24 ppm)
Area samples: ND– 
0.74 mg/m3 (0.18 ppm)
No significant association
between exposure to 
glutaraldehyde and prevalence 
of nasal irritation, nasal
burning, throat irritation, or
cough
Nose irritation: 28/44 workers
Throat irritation: 14/44 workers
Unspecified numbers of self-
reported symptoms including 
nose and throat irritation during 
glutaraldehyde use
aInflammation of mucous membrane, accompanied by excessive secretions.

bPeriod of biocide changeover (a relatively short time period when glutaraldehyde was replaced in sterilization 

equipment; personal sampler flow rate 1 L/minute).
 
cGlutaraldehyde concentration during a given endoscopy session (personal sampler flow rate of 200 mL/minute) 

minus the biocide changeover period.
 
CI = confidence interval; GM = geometric mean; GSD = geometric standard deviation; LOD = level of detection;
 
ND = not detected; OR = odds ratio; RR = relative risk
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concentration of 0.035 ppm to slightly more than 50% at 0.1 ppm (Cain et al. 2007). Nasal irritation was 
reported by human subjects exposed to glutaraldehyde vapor concentrations as low as 0.237 ppm for
2 minutes, which was considered the threshold for nasal irritation (Union Carbide Corp. 1976).  
Occupational exposure to glutaraldehyde has been commonly associated with symptoms of respiratory
tract irritation, particularly in medical facilities where glutaraldehyde is used as a disinfectant (e.g.,
Jachuck et al. 1989; NIOSH 1987a, 1987b; Norbäck 1988; Pisaniello et al. 1997; Vyas et al. 2000;
Waldron 1992; Waters et al. 2003). In occupational settings where personal or workplace air sampling
was performed, self-reported respiratory tract symptoms following short-term exposures occurred at
concentrations as low as 0.012–0.17 ppm (NIOSH 1987a, 1987b; Norbäck 1988; Pisaniello et al. 1997;
Vyas et al. 2000).  See Table 8-1 for information regarding occupational exposure limits for
glutaraldehyde.  Information regarding occupational exposure to glutaraldehyde and respiratory
sensitization is discussed in Section 3.2.1.3 (Immunological and Lymphoreticular Effects).
Studies in animals identify the upper respiratory tract as a particularly sensitive target of glutaraldehyde 
toxicity following inhalation exposure. Single 4–8-hour exposure of rats to saturated atmospheres of
glutaraldehyde vapor (generated at 21–25°C) resulted in clinical signs of respiratory tract irritation during
exposure (Ballantyne 1995; Union Carbide Corp. 1992c, 1992d); although glutaraldehyde vapor
concentrations were not monitored in these studies, they were likely <20 ppm. Single exposures of mice 
to glutaraldehyde vapor concentrations at 1.6–36.7 ppm for 30 minutes (Werley et al. 1995) or 0.7– 
4.3 ppm for 1 hour (Zissu et al. 1994) resulted in calculated 30-minute and 1-hour RD50 values of
13.86 and 2.6 ppm, respectively (RD50 is defined as the concentration resulting in a 50% reduction in 
respiratory rate). In rodents exposed to glutaraldehyde vapor for 4–6 hours/day and 1–14 exposures
during 1–16 days, clinical signs of respiratory effects included nasal discharge, labored breathing, mouth 
breathing, audible respiration, rales, and perinasal encrustation at concentrations as low as 0.2–10.6 ppm
(Ballantyne 1995; Gross et al. 1994; NTP 1993; Union Carbide Corp. 1992d, 1992e, 1992l; Zissu et al.
1994). Histopathologic evaluation of respiratory tissues revealed nasal lesions including rhinitis, 
epithelial changes (erosion, exfoliation, metaplasia), and mild atrophy of olfactory mucosa at exposure 
concentrations as low as 0.25–2.6 ppm (Gross et al. 1994; NTP 1993; Union Carbide Corp. 1992d; Zissu
et al. 1994). Longer-term repeated exposures (6 weeks to 2 years) resulted in exposure concentration-
related increased incidence and severity of clinical signs of respiratory irritation and histopathologic nasal
lesions (exfoliation, inflammation, hyperplasia, and ulceration of nasal squamous epithelium;
granulocytes and necrosis in nasal passages; laryngeal squamous metaplasia; necrosis in nasal nares) at
exposure levels as low as 0.0625–1.0 ppm (Gross et al. 1994; NTP 1993, 1999; van Birgelen et al. 2000;
Zissu et al. 1998). For example, nasal inflammation and neutrophilic infiltrate into nasal squamous
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epithelium were observed in mice repeatedly exposed to glutaraldehyde vapor at 0.0625 ppm for
6 hours/day, 5 days/week, for 6 or 13 weeks (Gross et al. 1994; NTP 1993).  Histopathologic nasal lesions
were sometimes noted at exposure levels lower than those resulting in overt clinical signs of respiratory
tract irritation.
The time-course of glutaraldehyde-induced nasal lesions was assessed in male and female F344/N rats 
and B6C3F1 mice exposed to glutaraldehyde vapor at 0.0625, 0.125, 0.25, 0.5, or 1 ppm for 6 hours/day
for 1 or 4 days or 6 or 13 weeks (Gross et al. 1994; NTP 1993); results from the time-course study serve 
as basis for acute- and intermediate-duration inhalation MRLs for glutaraldehyde, as described in detail in
Sections 2.3 and 3.6 and Appendix A.  Groups of five animals/species/sex were evaluated at each time 
point; selected results for the rats and mice are summarized in Tables 3-3 and 3-4, respectively.  All mice
in the 1-ppm exposure group destined for evaluation at 6 and 13 weeks died or were sacrificed moribund 
prior to their scheduled sacrifice; deaths were attributed to chronic nasal obstruction and consequent
asphyxiation.  After a single exposure session, most rats and mice of the 0.5 and 1 ppm exposure levels 
exhibited layers of eosinophilic coagulated squames within the external nares that were apparently
derived from exfoliation of squamous epithelial lining of the nasal vestibule and a mild neutrophilic
infiltration in adjacent lamina propria.  After four daily exposures at 0.5 or 1 ppm, the inflammatory
response was more intense and many of the animals exhibited obstruction of the nasal passages with
intraluminal debris.  Extensive granulocytic intra- and subepithelial infiltration (principally neutrophils)
was observed in the most anterior portion of the nasal vestibule of most 0.5- and 1-ppm mice and rats;
however, interpretation of this lesion in the rats was complicated by the fact that most control and 
glutaraldehyde-exposed rats exhibited suppurative and nonsuppurative rhinitis.  In general, neutrophilic
infiltration increased in severity with time and exposure concentration in the time-course study and was
most marked in all exposure groups of female mice at 13 weeks.  The severity of neutrophilic infiltration 
in the rats appeared to peak at 6 weeks and decreased in severity at 13 weeks.  Squamous metaplasia was
observed in all 0.5- and 1-ppm male and female rats after four exposures and in most 0.5- and 1-ppm rats 
at the 6- and 13-week time points.  However, although 4/5 of the 1-ppm male mice exhibited squamous 
metaplasia after four exposures, this lesion type was not as prominent at other time points or among the
glutaraldehyde-exposed female mice. Other nasal lesions were generally confined to the higher exposure 
concentrations and included an array of degenerative and hyperplastic epithelial changes.  Olfactory
degeneration was noted in one or more 1-ppm male and female rats at all time points and in one or two 
0.5-ppm male mice at 6 and 13 weeks. There was no evidence of glutaraldehyde-induced histopathologic
lesions of lower respiratory tract regions in the rats and mice of the time-course study vapor
concentrations as high as 1 ppm (Gross et al. 1994; NTP 1993). Discolored lungs were observed in some 
***DRAFT FOR PUBLIC COMMENT***
   
 
    
 
 
Table 3-3.        Incidences of Male and Female F344/N Rats with Selected
 
   Histopathologic Lesions in the Nasal Vestibule Following Exposure 

   to Glutaraldehyde Vapor 6 Hours/Day, 5 Days/Week for up to 

     13 Weeks in the Time-Course Study  

 
  0
 Exposure level (ppm)a 
 0.0625  0.125  0.250  0.500  1.000
 
 Male rats
 1 Day
4 Days 
 6 Weeks
 13 Weeks
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils  
Epithelial erosions 
Squamous metaplasia 
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils  
Epithelial erosions 
Squamous metaplasia 
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils  
Epithelial erosions 
Squamous metaplasia 
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils  
Epithelial erosions 
Squamous metaplasia 
0/5b  
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
1/5 (0.2) 
0/5 
0/5 
0/5 
1/5 (0.2) 
2/5 (0.4) 
0/5 
0/5 
0/5 
5/5 (1.2) 
5/5 (1.0) 
1/5  
1/5 (0.2) 
1/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
3/5 (0.6) 
0/5 
0/5 
0/5 
3/5 (0.8) 
4/5 (1.0) 
1/5 
0/5 
0/4 
0/4 
0/4 
0/4 
0/4 
0/5 
0/5 
2/5 (0.4) 
0/5 
0/5 
0/5 
1/5 (0.2) 
2/5 (0.6) 
0/5 
0/5 
0/5 
5/5 (1.0) 
5/5 (1.2) 
1/5 
0/5 
1/5 
 1/5 (0.4)c 
3/5 (0.8) 
1/5 
3/5 (0.6) 
0/5 
0/5 
1/5 (0.2) 
1/5 
0/5 
0/5 
2/5 (0.4) 
4/5 (0.8) 
0/5 
0/5 
2/5 
5/5 (1.2) 
5/5 (1.6) 
1/5 
0/5 
3/5 
2/5 (0.4) 
5/5 (1.8) 
5/5 
1/5 (0.2) 
3/5 
5/5 (1.4) 
5/5 (1.6) 
2/5 
5/5 (1.2) 
3/5 
4/5 (0.8) 
5/5 (2.0) 
4/5 
4/5 (1.6) 
2/5 
4/5 (1.2) 
5/5 (1.4) 
1/5 
5/5 (2.0) 
5/5 
5/5 (1.2) 
5/5 (2.6) 
5/5 
1/5 (0.2) 
5/5 
5/5 (2.6) 
5/5 (3.4) 
5/5 
5/5 (1.2) 
3/3 
3/3 (3.0) 
3/3 (3.7) 
3/3 
3/3 (3.3) 
2/5 
5/5 (1.6) 
5/5 (2.0) 
1/5 
5/5 (3.0) 
 Female rats
 1 Day
4 Days 
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils  
Epithelial erosions 
Squamous metaplasia 
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils  
Epithelial erosions 
Squamous metaplasia 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
1/5 (0.2) 
2/5 (0.4) 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
1/5 (0.4) 
1/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
2/5 
0/5 
1/5 (0.2) 
0/5 
0/5 
3/5 
2/5 (0.4) 
4/5 (1.4) 
2/5 
1/5 (0.2) 
3/5 
2/5 (0.6) 
5/5 (2.4) 
4/5 
0/5 
5/5 
5/5 (2.2) 
5/5 (2.8) 
3/5 
5/5 (2.0) 
4/5 
4/5 (1.0) 
5/5 (2.8) 
5/5 
0/5 
5/5 
5/5 (3.4) 
5/5 (3.8) 
5/5 
5/5 (3.0) 
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Table 3-3.  Incidences of Male and Female F344/N Rats with Selected
 
Histopathologic Lesions in the Nasal Vestibule Following Exposure 

to Glutaraldehyde Vapor 6 Hours/Day, 5 Days/Week for up to 

13 Weeks in the Time-Course Study 

Exposure level (ppm)a 
0 0.0625 0.125 0.250 0.500 1.000
 
6 Weeks	 Squamous exfoliation 0/5 0/5 0/5 3/5 2/5 2/2
Intraepithelial neutrophils 0/5 1/5 (0.2) 0/5
Subepithelial neutrophils 1/5 (0.6) 2/5 (0.4) 1/5 (0.4)
Epithelial erosions 0/5 0/5 0/5
Squamous metaplasia 0/5 0/5 0/5
13 Weeks	 Squamous exfoliation 0/5 0/5 0/5
Intraepithelial neutrophils 1/5 (0.2) 0/5 1/5 (0.4)
Subepithelial neutrophils 2/5 (0.4) 0/5 1/5 (0.8)
Epithelial erosions 0/5 0/5 0/5 0/5 0/5 1/5
Squamous metaplasia 0/5 0/5 0/5 0/5 3/5 (1.2) 5/5 (2.6)
0/5 2/5 (0.6) 2/2 (3.5)
1/5 (0.4) 5/5 (2.2) 2/2 (4.5)
0/5 4/5 1/2
0/5 3/5 (0.6) 2/2 (3.5)
0/5 2/5 4/4
3/5 (1.0) 2/5 (0.8) 4/5 (1.4)
3/5 (1.0) 4/5 (1.8) 4/5 (2.0)
aGray shaded cells suggest a glutaraldehyde-induced effect (lesion incidence at least 2 greater than controls).
 
bIncidence is the number of animals with lesions.

cSeverity (in parentheses) was the mean for all animals in a group where: 0 = no lesion, 1 = minimal, 2 = mild,
 
3 = moderate, and 4 = marked.

Sources: Gross et al. 1994; NTP 1993
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Table 3-4.        Incidences of Male and Female B6C3F1 Mice with Selected
 
   Histopathologic Lesions in the Nasal Vestibule Following Exposure 

   to Glutaraldehyde Vapor 6 Hours/Day, 5 Days/Week for up to 

      13 Weeks in the Time-Course Study
 
  0
 Exposure level (ppm)a 
 0.0625  0.125  0.250  0.500  1.000
 
 Male mice
 1 Day	 
4 Days	  
 6 Weeks	 
 13 Weeks	 
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils 
Epithelial erosions 
Squamous metaplasia 
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils  
Epithelial erosions 
Squamous metaplasia 
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils  
Epithelial erosions 
Squamous metaplasia 
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils  
Epithelial erosions 
Squamous metaplasia 
0/5b  
 1/5 (0.2)c 
 1/5 (0.2) 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5  
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
1/5 (0.2) 
0/5 
0/5 
0/5 
1/5 (0.2) 
 1/5 (0.2) 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
2/5 
0/5 
0/5 
0/5 
0/5 
0/5 
1/5 (0.2) 
2/5 (0.8) 
0/5 
0/5 
0/5 
0/5 
1/5 (0.2) 
0/5 
0/5 
4/5 
1/5 (0.2) 
2/5 (0.4) 
0/5 
0/5 
0/5 
1/5 (0.2) 
1/5 (0.4) 
0/5 
0/5 
3/5 
4/5 (1.6) 
5/5 (2.2) 
1/5 
0/5 
4/5 
1/5 (0.2) 
2/5 (0.4) 
1/5 
0/5 
2/5 
4/5 (1.8) 
4/5 (1.8) 
1/5 
1/5 (0.2) 
0/4 
1/4 (0.8) 
4/4 (2.3) 
0/4 
2/4 (0.5) 
1/5 
5/5 (2.6) 
5/5 (2.8) 
3/5 
1/5 (0.2) 
5/5 
5/5 (1.0) 
5/5 (1.6) 
2/5 
0/5 
5/5 
5/5 (2.8) 
5/5 (3.2) 
2/5 
4/5 (0.8) 
–d  
–d  
–d  
–d  
–d  
–d  
–d  
–d  
–d  
–d  
 Female mice
 1 Day
4 Days 
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils  
Epithelial erosions 
Squamous metaplasia 
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils  
Epithelial erosions 
Squamous metaplasia 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
1/5 (0.2) 
0/5 
0/5 
0/5 
0/5 
0/5 
1/5 (0.2) 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
2/5 
1/5 (0.4) 
1/5 (0.4) 
0/5 
0/5 
5/5 
0/5 
2/5 (0.4) 
0/5 
0/5 
5/5 
5/5 (1.0) 
5/5 (1.6) 
0/5 
0/5 
4/5 
1/5 (0.4) 
3/5 (1.2) 
1/5 
0/5 
5/5 
4/5 (0.8) 
5/5 (2.0) 
2/5 
0/5 
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Table 3-4.        Incidences of Male and Female B6C3F1 Mice with Selected
 
   Histopathologic Lesions in the Nasal Vestibule Following Exposure 

   to Glutaraldehyde Vapor 6 Hours/Day, 5 Days/Week for up to 

      13 Weeks in the Time-Course Study
 
  0
 Exposure level (ppm)a 
 0.0625  0.125  0.250  0.500  1.000
 6 Weeks
 13 Weeks
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils  
Epithelial erosions 
Squamous metaplasia 
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils  
Epithelial erosions 
Squamous metaplasia 
0/5 
0/5 
1/5 (0.2) 
0/5 
0/5 
0/5 
0/5 
2/5 (0.4) 
0/5 
0/5 
0/5 
1/5 (0.4) 
1/5 (0.4) 
0/5 
0/5 
05 
4/5 (2.0) 
5/5 (2.0) 
0/5 
0/5 
0/5 
4/5 (1.6) 
4/5 (2.0) 
0/5 
0/5 
0/5 
5/5 (2.4) 
5/5 (2.8) 
0/5 
0/5 
0/5 
4/5 (1.8) 
5/5 (2.4) 
0/5 
0/5 
0/5 
5/5 (3.2) 
5/5 (3.2) 
0/5 
0/5 
2/5 
5/5 (2.2) 
5/5 (2.6) 
0/5 
3/5 (0.8) 
1/4 
4/4 (2.8) 
4/4 (2.8) 
0/4 
1/4 (0.5) 
–d  
–d  
–d  
–d  
–d  
–d  
–d  
–d  
–d  
–d  
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aGray shaded cells suggest a glutaraldehyde-induced effect (lesion incidence at least 2 greater than controls).
 
bIncidence is the number of animals with lesions.

cSeverity (in parentheses) was the mean for all animals within a group where: 0 = no lesion, 1 = minimal, 2 = mild,
 
3 = moderate, and 4 = marked.

dNot evaluated, all animals died.
 
Sources: Gross et al. 1994; NTP 1993
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male and female rats following 4-hour exposure to glutaraldehyde vapor at 20 or 50 ppm (Union Carbide
Corp. 1992l).  Halatek et al. (2003) reported histopathologic lung lesions that included morphological
changes in pulmonary epithelium of male rats exposed to glutaraldehyde vapor at 0.1 ppm, 6 hours/day, 
5 days/week for 4 weeks.  The study did not include evaluation of extrapulmonary respiratory tissues.  
Results from 13-week core studies of F344/N rats and B6C3F1 mice (NTP 1993) support the 13-week
findings of the time-course study (Gross et al. 1994; NTP 1993). There was no histopathologic evidence 
of glutaraldehyde-induced lesions in the trachea or lungs of mice repeatedly exposed to glutaraldehyde 
vapor at up to 2.6 ppm for up to 14 days (Zissu et al. 1994) or other mice exposed at 0.1 ppm for up to 
78 weeks (Zissu et al. 1998).
In 2-year chronic toxicity/carcinogenicity studies that employed exposure to glutaraldehyde vapor for
6 hours/day, 5 days/week, male and female F344/N rats (50/sex/group) were exposed at 0.25, 0.5, or
0.75 ppm and male and female B6C3F1 (50/sex/group) mice were exposed at 0.0625, 0.125, or 0.25 ppm
(NTP 1999). Selected results for the rats and mice are summarized in Tables 3-5 and 3-6, respectively.  
Glutaraldehyde-related histopathological lesions were limited to the nasal cavity. Statistically
significantly increased incidences of hyperplasia and inflammation within nasal squamous epithelium
were observed in all groups of glutaraldehyde-exposed male and female rats, relative to controls.
Hyperplasia and/or inflammation of the respiratory epithelium were observed in male and female rats of
the two highest exposure concentrations (0.5 and 0.75 ppm).  Other effects within the respiratory
epithelium of both sexes of rats included significantly increased incidences of squamous metaplasia at 
0.5 and 0.75 ppm and goblet cell hyperplasia at 0.75 ppm.  Significantly increased incidences of hyaline 
degeneration within olfactory epithelium were noted in the 0.75-ppm male rats and 0.5- and 0.75-ppm 
female rats. Histopathologic nasal lesions among the mice exposed for 2 years included significantly
increased incidences of squamous metaplasia of the respiratory epithelium of 0.25-ppm males and 
0.125- and 0.25-ppm females, inflammation in the nasal cavity of 0.25-ppm females, and hyaline 
degeneration of respiratory epithelium in all glutaraldehyde-exposed groups of female mice.  
Histopathologic evaluations of pulmonary tissue from the rats and mice of the 2-year inhalation study
revealed alveolar/bronchiolar adenoma in 1/50 of the 0.25- and 0.5-ppm males, 2/50 of the 0.75-ppm 
males, and 1/50 of the 0.5-ppm females (not statistically significantly different from control incidence of
0/50); the adenomas were not considered related to glutaraldehyde exposure.  Statistically significantly
increased incidences of histiocyte infiltration in 0.75-ppm females and interstitial fibrosis in 0.5- and 
0.75-ppm females were not considered a direct effect of glutaraldehyde exposure because they are 
common spontaneous lesions in rats.
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Table 3-5.  Incidences of Male and Female F344/N Rats with Selected
 
Histopathologic Lesions in the Nasal Vestibule Following 

Exposure to Glutaraldehyde Vapor 6 Hours/Day,
 
5 Days/Week for up to 2 Years

Exposure level (ppm)
0 0.25 0.5 0.75
Male rats
Squamous epithelium
Hyperplasia 3/50 (2.0)a 11/50b (1.6) 39/50c (2.2) 48/50c (2.9)
Inflammation 6/50 (2.0) 17/50b (1.5) 41/50c (2.7) 49/50c (3.6)
Respiratory epithelium
Hyperplasia 6/50 (2.0) 5/50 (2.0) 17/50c (1.9) 35/50c (1.9)
Inflammation 17/50 (2.1) 10/50 (1.5) 25/50 (2.4) 43/50c (3.2)
Squamous metaplasia 1/50 (2.0) 2/50 (1.5) 11/50c (2.0) 24/50c (2.2)
Goblet cell hyperplasia 1/50 (1.0) 0/50 6/50 (1.8) 6/50b (1.2)
Olfactory epithelium
Hyaline degeneration 4/50 (1.0) 8/50 (1.3) 9/50 (1.1) 14/50c (1.1)
Female rats
Squamous epithelium
Hyperplasia 3/50 (1.3) 15/50c (1.7) 29/50c (2.0) 45/49c (2.7)
Inflammation 6/50 (2.5) 26/50c (1.5) 42/50c (2.1) 48/49c (3.2)
Respiratory epithelium
Hyperplasia 1/50 (3.0) 6/50 (1.7) 15/50c (1.9) 29/49c (1.9)
Inflammation 5/50 (2.2) 9/50 (1.7) 26/50c (2.1) 42/49c (2.5)
Squamous metaplasia 1/50 (2.0) 1/50 (3.0) 11/50c (1.6) 16/49c (2.3)
Goblet cell hyperplasia 1/50 (2.0) 3/50 (1.3) 5/50 (1.4) 8/49c (1.6)
Olfactory epithelium
Hyaline degeneration 4/50 (1.0) 5/50 (1.0) 12/50b (1.1) 15/49c (1.1)
aSeverity (in parentheses) is the average grade of lesions in affected animals where: 1 = minimal, 2 = mild,
 
3 = moderate, and 4 = marked.

bSignificantly increased relative to chamber control group by the Poly-3 test (p≤0.05).
	
cSignificantly increased relative to chamber control group by the Poly-3 test (p≤0.01).
 
Source: NTP 1999
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Table 3-6.  Incidences of Male and Female B6C3F1 Mice with Selected
 
Histopathologic Lesions in the Nasal Vestibule Following 

Exposure to Glutaraldehyde Vapor 6 Hours/Day,
 
5 Days/Week for up to 2 Years

Exposure level (ppm)
0 0.0625 0.125 0.25
Male mice
Respiratory epithelium
Squamous metaplasia 2/48 (1.0)a 5/50 (1.0) 6/50 (1.2) 9/50b (1.1)
Turbinate
Necrosis 0/50 0/50 2/50 (2.0) 0/50
Female mice
Inflammation 6/50 (1.2) 7/49 (1.3) 13/50 (1.4) 14/50b (1.4)
Respiratory epithelium
Squamous metaplasia 7/50 (1.1) 11/49 (1.0) 16/50b (1.3) 21/50c (1.5)
Hyaline degeneration 16/50 (1.4) 35/49c (1.4) 32/50c (1.3) 30/50b (1.1)
Turbinate
Necrosis 0/50 3/49 (2.0) 1/50 (1.0) 4/50 (1.5)
aSeverity (in parentheses) is the average grade of lesions in affected animals where: 1 = minimal, 2 = mild,
 
3 = moderate, and 4 = marked.

bSignificantly increased relative to chamber control group by the Poly-3 test (p≤0.05).
	
cSignificantly increased relative to chamber control group by the Poly-3 test (p≤0.01).
 
Source: NTP 1999
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Selected results from acute-, intermediate- and chronic-duration inhalation exposure to glutaraldehyde in 
laboratory animals and controlled studies of humans are presented in Figure 3-2.  Human nasal sensory
irritation thresholds of 0.47 and 0.237 ppm for repeated 5-second or 2-minute inhalation exposures, 
respectively, are in the range of acute-duration exposure levels (0.25–0.5 ppm for 6-hour exposures
during 1 or 4 days) for male and female rats and mice that elicited histopathologic nasal lesions
(e.g., squamous exfoliation, infiltration of intra- and subepithelial neutrophils, epithelial erosions).  
Results of an NTP (1993) 13-week inhalation study (exposures of 6 hours/day, 5 days/week) of male and 
female rats  and mice suggest that mice may be somewhat more susceptible to glutaraldehyde-induced 
nasal lesions than rats and that female mice may be more susceptible than male mice, as demonstrated by
significantly increased incidence of nasal inflammation in the female mice at the lowest exposure level
tested (0.0625 ppm) compared to a NOAEL of 0.25 ppm and a LOAEL of 0.5 ppm for nasal
inflammation in the male mice.  There was no indication of glutaraldehyde-induced nasal lesions in male
or female rats exposed at 0.25 ppm; the 0.5 ppm level represented a LOAEL for male and female rats
(squamous exfoliation in males and females, hyperplasia in respiratory epithelium of males).  Multiple 
nasal lesion types (hyperplasia, squamous metaplasia, inflammation in respiratory epithelium, and 
squamous exfoliation in nasal vestibule/anterior nares of male and female rats; inflammation in
respiratory epithelium, squamous exfoliation in nasal vestibule/anterior nares, squamous metaplasia in the 
larynx of male and female mice) were observed at the highest exposure level (1 ppm).  Female mice also
appeared to be the most sensitive to glutaraldehyde-induced nasal lesions following 2 years of repeated
exposures (NTP 1999).  The lowest exposure level tested (0.0625 ppm) resulted in respiratory epithelial
hyaline degeneration in the female mice; squamous metaplasia was noted in the female mice of the next
higher exposure level (0.125 ppm).  A LOAEL of 0.25 ppm (the highest exposure level tested) was
identified for squamous metaplasia in the male mice.  In the male and female rats, the lowest exposure 
level tested (0.25 ppm) represented a LOAEL for hyperplasia and inflammation in squamous epithelium;
the next higher exposure level for the rats (0.5 ppm) caused multiple other nasal lesion types
(e.g., hyperplasia and squamous metaplasia in respiratory epithelium of male and female rats;
inflammation in respiratory epithelium and hyaline degeneration in olfactory epithelium of female rats).
The 2-year studies of rats and mice (NTP 1999) found no evidence of glutaraldehyde-induced neoplastic
nasal lesions.
Cardiovascular Effects. Available information in humans is limited to a report from an
occupational physician who had evaluated 7 separate cases of patients who presented with palpitations or
tachycardia (Connaughton 1993).  Occupational exposure was considered as a possible cause because the
effects resolved when glutaraldehyde exposure ceased.
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Figure 3-2. Exposure-Response Array of Selected Glutaraldehyde-Induced Respiratory Effects Following Acute-, 
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There were no exposure-related effects on incidences of histopathologic lesions of the cardiovascular
system of rats or mice following up to 2 years of repeated exposure to glutaraldehyde vapor
concentrations as high as 0.75 ppm (rats) and 0.25 ppm (mice) (NTP 1999; van Birgelen et al. 2000).
Gastrointestinal Effects. There were no exposure-related effects on incidences of histopathologic
lesions of the gastrointestinal system of rats or mice following up to 2 years of repeated exposure to 
glutaraldehyde vapor concentrations as high as 0.75 ppm (rats) and 0.25 ppm (mice) (NTP 1999; van 
Birgelen et al. 2000).
Hematological Effects. No exposure-related effects on hematological parameters were seen in rats 
exposed to glutaraldehyde vapor for 14 weeks (6 hours/day, 5 days/week) at 0.1942 ppm, the highest
concentration tested (Ballantyne 1995; Union Carbide Corp. 1992f). A 13-week study of rats and mice 
exposed to glutaraldehyde vapor concentrations in the range of 0.0625–1 ppm included groups assigned
for hematology and clinical chemistry evaluations at study days 4 and 24 (NTP 1993).  Male rats from
three of the four highest exposure groups and female rats from two of the three highest exposure groups
exhibited significantly increased segmented neutrophils at day 24 assessment.  Because the increase in
segmented neutrophils was not accompanied by increased lymphocytes, the mature neutrophilia was
considered the result of exposure-related inflammation in the nares and not a direct glutaraldehyde­
induced hematological effect.  Hematology results for core-study rats after 13 weeks of repeated exposure 
revealed significant changes in 0.5- and 1.0-ppm exposure groups of males that included decreased
numbers of leukocytes (14 and 8%, respectively, lower than controls) and lymphocytes (16–17% lower
than controls); however the changes in leukocyte and lymphocyte counts were apparently considered of
little toxicological significance because there was no mention of these effects in the results or discussion
sections of the study report. There were no exposure-related effects on incidences of histopathologic
lesions in hematopoietic tissues of rats or mice following up to 2 years of repeated exposure to 
glutaraldehyde vapor concentrations as high as 0.75 ppm (rats) and 0.25 ppm (mice) (NTP 1999; van 
Birgelen et al. 2000).
Hepatic Effects. No exposure-related hepatic effects were seen in rats exposed to glutaraldehyde 
vapor for 14 weeks (6 hours/day, 5 days/week) at 0.1942 ppm, the highest concentration tested
(Ballantyne 1995; Union Carbide Corp. 1992f). Varpela et al. (1971) reported toxic hepatitis in mice 
following inhalation of glutaraldehyde for 24 hours at a concentration of 0.133 mg/L (ca. 33 ppm). There
were no exposure-related effects on incidences of histopathologic lesions of the liver of rats or mice 
following repeated exposure to glutaraldehyde for 13 weeks at vapor concentrations as high as 1 ppm
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(rats) and 0.5 ppm (mice) (NTP 1993) or up to 2 years at vapor concentrations as high as 0.75 ppm (rats)
and 0.25 ppm (mice) (NTP 1999; van Birgelen et al. 2000).
Renal Effects. No exposure-related renal effects were seen in rats exposed to glutaraldehyde vapor
for 14 weeks (6 hours/day, 5 days/week) at 0.1942 ppm, the highest concentration tested (Ballantyne
1995; Union Carbide Corp. 1992f).  There were no exposure-related effects on incidences of
histopathologic renal lesions in rats or mice following repeated exposure to glutaraldehyde for 13 weeks
at vapor concentrations as high as 1 ppm (rats) and 0.5 ppm (mice) (NTP 1993) or up to 2 years at vapor
concentrations as high as 0.75 ppm (rats) and 0.25 ppm (mice) (NTP 1999; van Birgelen et al. 2000).
Endocrine Effects. There were no exposure-related effects on incidences of histopathologic lesions
in endocrine organs or tissues (adrenal cortex, pancreas, pituitary, thyroid, parathyroid) in rats or mice
following up to 2 years of repeated exposure of rats and mice to glutaraldehyde vapor concentrations as 
high as 0.75 ppm (rats) and 0.25 ppm (mice) (NTP 1999; van Birgelen et al. 2000). It should be noted 
that hormone levels were not monitored in these studies.
Ocular Effects. Occupational exposure to glutaraldehyde has been commonly associated with ocular
irritation (Calder et al. 1992; Jachuck et al. 1989; NIOSH 1987a, 1987b; Pisaniello et al. 1997; Vyas et al.
2000; Waters et al. 2003).  Refer to Section 3.2.3.2 (Ocular Effects) of this Toxicological Profile for
Glutaraldehyde for additional information because the ocular effects were considered to have occurred as 
a result of direct ocular contact with airborne glutaraldehyde vapor.
Ocular results from studies in which laboratory animals were exposed to atmospheres containing
glutaraldehyde vapor are summarized under dermal exposure because the effects resulted from direct
contact with glutaraldehyde.
Body Weight Effects. Depressed body weight gain and actual body weight loss have been observed 
in laboratory animals exposed to glutaraldehyde vapor. Single exposure of male and female rats to
glutaraldehyde vapor for 4 hours at analytical concentrations in the range of 9.1–43.5 ppm resulted in 
body weight loss ranging from 14 to 30% for up to 7 days postexposure and 35–42% depressed body
weight gain over 14 days of postexposure observation (Union Carbide Corp. 1992l).  Repeated 6-hour
exposures of male and female rats to glutaraldehyde vapor (5/days/week for 11 days) resulted in 33–41%
depressed body weight gain at 0.2 ppm glutaraldehyde and 21–22% body weight loss at 0.63 ppm (Union 
Carbide Corp. 1992e). Rats and mice repeatedly exposed to glutaraldehyde vapor at 0.9–1.6 ppm for 
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6 hours/day for periods of 12 days to 13 weeks exhibited significantly lower mean final body weights
than their respective controls (NTP 1993; Zissu et al. 1994); as much as 41–42% lower final body weights
were observed in male and female rats exposed to glutaraldehyde vapor at 1.6 ppm, 6 hours/day, for
12 exposures in a 16-day period (NTP 1993). In a 2-year repeated-exposure inhalation study, exposures
of male and female rats to glutaraldehyde vapor at 0.75 ppm resulted in approximately 9 and 14% lower
mean body weights, respectively (NTP 1999; van Birgelen et al. 2000).
3.2.1.3  Immunological and Lymphoreticular Effects 
Case reports of some workers exposed to glutaraldehyde during disinfection processes provide some
evidence of glutaraldehyde-induced respiratory hypersensitivity.  Gannon et al. (1995) reported seven 
cases of workers from endoscopy or x-ray departments with occupational asthma (as determined by peak
expiratory flow measurements and positive specific bronchial challenge tests to glutaraldehyde).  The
median airborne glutaraldehyde level at the time of challenge was 0.068 mg/m3 (0.0166 ppm); the range 
was 0.064–0.081 mg/m3 (0.0156–0.0198 ppm). To estimate occupational glutaraldehyde exposure levels, 
30 personal air samples were taken from 13 hospital endoscopy units. Median glutaraldehyde 
concentrations were 0.016 mg/m3 (95% confidence interval [CI] 0.12–0.68 mg/m3) or 0.0039 ppm for 
short-term exposure during activities likely to produce peak levels of glutaraldehyde vapor, 0.041 mg/m3 
(95% CI 0.016–0.14 mg/m3) or 0.01 ppm for long-term samples (34–120 minutes, during which time
exposure was intermittent), and 0.17 mg/m3 (95% CI 0.12–0.25 mg/m3) or 0.0415 ppm for static short-
term samples. Glutaraldehyde air concentrations in 19 air samples collected from 6 x-ray darkrooms were 
<0.009 mg/m3 (<0.0022 ppm).  The study did not include blood testing for antibodies or other signs of
glutaraldehyde-induced allergy.  Di Stefano et al. (1999) reported similar results for eight hospital
workers with occupational asthma; glutaraldehyde challenge concentrations for those workers averaged
0.075 mg/m3 (0.018 ppm).  Other cases of glutaraldehyde-induced occupational asthma have been 
reported as well (Chan-Yeung et al. 1993; Corrado et al. 1986; Cullinan et al. 1992; Ong et al. 2004;
Quirce et al. 1999; Trigg et al. 1992).
A single-blind placebo-controlled study of 11 health workers with diagnoses of glutaraldehyde-induced 
occupational asthma and rhinitis and occupational exposures to glutaraldehyde during 2–10 years, 
10 nonexposed atopic subjects with perennial asthma and rhinitis, and 10 nonexposed healthy subjects 
was performed to evaluate changes in nasal lavage fluid content before and following glutaraldehyde
challenge exposure (Palczyński et al. 2001). The mean airborne glutaraldehyde concentration during
challenge was 0.32±0.08 mg/m3 (0.077 ppm).  Upon glutaraldehyde challenge, those subjects diagnosed 
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with occupational asthma exhibited significantly increased eosinophil numbers and percentages and 
significantly increased concentrations of albumin, eosinophil cation protein, and mast-cell tryptase in the 
nasal lavage fluid. These results are suggestive of an immunologic mechanism for glutaraldehyde­
induced asthma.  A similarly-designed study evaluated bronchoalveolar lavage fluid (BALF) components
and Clara cell protein (CC16) concentration in serum and BALF before and after glutaraldehyde
inhalation challenge (Palczyński et al. 2005).  Postchallenge evaluation revealed significantly lower Clara 
cell protein levels in BALF and serum at 24 hours postchallenge and significant increases in proportions
of eosinophils, basophils, and lymphocytes in BALF of the glutaraldehyde-sensitized asthmatics.
Other studies found no evidence of glutaraldehyde-induced respiratory sensitization.  In a survey of
150 hospital workers with exposure to glutaraldehyde, symptoms of respiratory and ocular irritation were
commonly reported, but there was no indication of allergic responses (Waldron 1992).  Similar results 
were obtained in a survey of 348 nurses in endoscopy units of facilities in the United Kingdom and 
18 former workers (Vyas et al. 2000). Waters et al. (2003) reported significant cross-shift reductions in 
forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) in a group of
38 glutaraldehyde-exposed nurses following work shifts during which short term airborne glutaraldehyde
levels measuring up to 0.15 ppm were recorded; however, the mean decreases in FVC and FEV1 were of 
small magnitude (<10%) and no significant differences were found regarding prevalence of self-reported 
respiratory irritation symptoms between exposed and unexposed workers. 
There were no indications of glutaraldehyde-induced respiratory sensitization within a group of
218 workers employed at a glutaraldehyde production facility (Teta et al. 1995).  The time period of
assessment was 1959–1992.  The average time spent in the glutaraldehyde production or drumming areas
was 3.8 years and workplace time-weighted average (TWA) glutaraldehyde concentrations between 1977 
and 1992 ranged from 0.04 to 0.08 ppm, except for 1982 (TWA of 1.02 ppm).
Limited information is available regarding the potential for inhaled glutaraldehyde to cause 
immunological effects in laboratory animals.  Male Dunkin-Hartley guinea pigs were exposed to 
glutaraldehyde vapor at approximately 14 ppm for 1 hour/day for 5 consecutive days followed by 1-hour
challenge exposures at approximately 4.4 ppm at 14, 21, and 35 days following the final induction 
exposure (Werley et al. 1995). There was no evidence of glutaraldehyde-induced respiratory
sensitization. Exposure of BALB/c mice to glutaraldehyde vapor or aerosols at 6 or 18 ppm for
1.5 hours/day on 3 consecutive days resulted in clinical signs of respiratory tract irritation, but no
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evidence of glutaraldehyde-induced respiratory sensitization as assessed by the local lymph node assay
(LLNA) (van Triel et al. 2011).
3.2.1.4  Neurological Effects 
Information regarding neurological effects in humans exposed to glutaraldehyde is limited to reports of
increased incidences of self-reported headaches among occupationally-exposed workers during
disinfection processes in which glutaraldehyde was used (e.g., Guthua et al. 2001; Norbäck 1988; 
Pisaniello et al. 1997; Waters et al. 2003).
Impaired righting reflex was noted in rats exposed to glutaraldehyde vapor at 42.7 ppm for 4 hours;
decreased motor activity was observed during 14 days of postexposure observation at exposure
concentrations of 23 and 42.7 ppm (Union Carbide Corp. 1992l). There were no clinical signs of
neurotoxicity in male or female rats or mice exposed to glutaraldehyde vapor at concentrations as high as 
1 ppm for 6 hours/day, 5 days/week for 13 weeks (NTP 1993) or rats or mice similarly exposed for up to 
2 years at glutaraldehyde vapor concentrations as high as 0.75 ppm (rats) and 0.25 ppm (mice) (NTP
1999). The 2-year study found no evidence of glutaraldehyde-induced neurohistopathological effects.
Katagiri et al. (2011) measured neurotransmitter levels in various brain regions of the rat following nose-
only exposure to glutaraldehyde vapor for 1 hour/day, 5 days/week for 4 weeks at concentrations in the
range of 50–200 ppb (0.05–0.2 ppm).  In the medulla oblongata (the only region in which glutaraldehyde
exposure-related changes were found), significantly lower mean 5-hydroxyindoleacetic acid content was
observed at glutaraldehyde vapor concentrations of 0.05–0.2 ppm (20–30% lower than that of controls).
Dopamine content was significantly lower at glutaraldehyde exposure concentrations of 0.1 and 0.2 ppm
(20–38% lower than that of controls). The toxicological significance of the reported results is uncertain
in the absence of obvious clinical signs of toxicity and lack of neurological histopathology other than 
monitoring of neurotransmitter levels.  Other studies found no evidence of glutaraldehyde-induced 
neurotoxicity in laboratory animals repeatedly exposed to higher glutaraldehyde vapor concentrations for
longer periods (NTP 1993, 1999).
3.2.1.5  Reproductive Effects
Rates of spontaneous abortion for the years 1951–1960, 1961–1970, and 1971–1981 were evaluated
among sterilizing staff employed at Finnish hospitals and control workers at the same hospitals who were 
not occupationally exposed to sterilizing agents (Hemminki et al. 1982).  Evaluation of those workers
***DRAFT FOR PUBLIC COMMENT***
   
 
    
 
 
 
   
  
  
  
  
    
  
  
     
  
    
     
    
    
 
      
   
  
  
    
      
     
     
  
 
  
 
     
  
 
 
     
 
 
 
 
  
46GLUTARALDEHYDE
3. HEALTH EFFECTS
exposed to glutaraldehyde (but not other sterilizing agents) during pregnancy (n=364) and those not
exposed to glutaraldehyde or other sterilizing agents during pregnancy (n=768) revealed no significant
differences in frequency of spontaneous abortion 9.4 versus 7.8% for controls) after adjusting for age,
parity, decade of pregnancy, smoking habits, and alcohol and coffee consumption. Data obtained from
hospital discharge registers that included details of spontaneous abortions among glutaraldehyde-exposed 
sterilizing staff (n=178) and controls (n=368) during the years 1973–1979 revealed rates of spontaneous
abortions among the controls and glutaraldehyde-exposed staff of 9.2 and 12.9%, respectively (no 
statistically significant difference). Another study included nurses employed in selected departments at
Finnish hospitals between 1973 and 1979 in which 217 cases of women with spontaneous abortions were 
compared to controls consisting of nurses with normal births and matched by age and employment facility
(generally three controls per case) (Hemminki et al. 1985). The cases and controls had the potential for
exposure to anesthetic gases, cytostatic drugs, and other hazardous substances including glutaraldehyde.  
One result of the study was the observation that similar proportions of spontaneous abortion cases and 
normal birth controls were exposed to glutaraldehyde (34/164 or 20.7% for cases and 88/464; 19.0% for
controls).  However, the small numbers of study subjects precludes any definitive conclusions regarding
possible associations between exposure to glutaraldehyde and incidences of spontaneous abortions.
No animal studies specifically designed to assess the reproductive toxicity of inhaled glutaraldehyde were
located.  Evaluations of testicular weight, sperm morphology, and vaginal cytology in rats and mice 
exposed to glutaraldehyde vapor at concentrations in the range of 0.0625–1 ppm for 6 hours/day, 
5 days/week for 13 weeks revealed no evidence of exposure-related adverse effects, although female mice 
of the two highest nonlethal exposure levels (0.25 and 0.5 ppm) spent significantly more time in estrous 
stages than controls (p<0.05) (NTP 1993). The toxicological significance of this finding and its potential
human relevance are uncertain. No increased incidences of nonneoplastic lesions in reproductive organs
or tissues were observed following 2 years of repeated exposure of rats and mice to glutaraldehyde vapor
concentrations as high as 0.75 ppm (rats) and 0.25 ppm (mice) (NTP 1999; van Birgelen et al. 2000).
3.2.1.6  Developmental Effects 
Available information regarding the potential for glutaraldehyde-induced developmental effects in
humans is limited to results of a study that included nurses employed in selected departments at Finnish 
hospitals between 1973 and 1979 with 46 documented cases of mothers with a malformed child and 
controls consisting of nurses with normal births and matched by age and employment facility (generally
three controls per case) (Hemminki et al. 1985).  The cases and controls had the potential for exposure to 
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anesthetic gases, cytostatic drugs, and other hazardous substances including glutaraldehyde.  One result of
the study was the observation of similar proportions of glutaraldehyde-exposed mothers among the
malformed child cases (5/34 or 14.7%) and the controls with normal births (17/95 or 17.9%). However,
the small numbers of study subjects precludes any definitive conclusions.
No animal studies designed to assess the developmental toxicity of inhaled glutaraldehyde were located.
3.2.1.7  Cancer
Limited human data were located.  Teta et al. (1995) found no evidence of increased mortality from
cancer (total malignant neoplasms) within a group of 186 workers assigned to glutaraldehyde production 
or drumming from 1959 to 1992 at a West Virginia facility when compared to the general U.S. 
population. A total of 4 cancer deaths were observed compared to 6.1 expected (standardized mortality
ratio [SMR] = 0.065; 95% CI 0.2–1.7). The cancer SMR was lower for those who worked ≥5 years in the 
units.  Although the study authors associated the healthy worker effect with noncancer causes of death,
there was no mention of such an effect for death due to cancer.  Follow-up of this cohort resulted in no 
evidence for increased cancer rates for respiratory cancers (SMRs of 0.9 [95% CI 0.7–1.1], 1.0 [95% CI
0.2–3.0], and 0.3 [95% CI 0.0–1.5] for workers in categories of unexposed, >0–100 ppb-years, and
100+ ppb-years, respectively) or leukemia (0 cases among glutaraldehyde-exposed workers versus 
0.6 expected) (Collins et al. 2006).
NTP determined that there was no evidence of carcinogenic activity of glutaraldehyde in male or female
F344/N rats exposed to glutaraldehyde vapor at 250, 500, or 750 ppb or male or female B6C3F1 mice
exposed to 62.5, 125, or 250 ppb for up to 2 years (NTP 1999). This determination was based on the lack
of treatment-related increased incidences of neoplastic lesions in any organ or tissue from the rats or
mice. Glutaraldehyde is not included in the list of agents evaluated for carcinogenicity by IARC (2013).
3.2.2 Oral Exposure
3.2.2.1  Death 
Available human data are limited to a single case report of a 78-year-old man who deliberately ingested 
an unspecified quantity of a biocide containing glutaraldehyde and a quaternary ammonium compound 
(Simonenko et al. 2009).  The man developed acute respiratory distress syndrome and severe metabolic
acidosis 24 hours after being admitted to a hospital, and died 21 days after hospital admission.
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The acute oral lethality of glutaraldehyde has been evaluated in laboratory animals using a variety of
aqueous dilutions.  For 50% aqueous glutaraldehyde, reported single-dose LD50 values fall within a range 
of 87–734 mg glutaraldehyde/kg for rats (Ballantyne 1995; BASF Corp 1990j; Union Carbide Chem &
Plas Co. 1992; Union Carbide Corp. 1992b) and 115–151 mg glutaraldehyde/kg for mice (Ballantyne
1995; Union Carbide Corp. 1992i).  Evaluations of glutaraldehyde dilution on acute lethality in male and
female rats and mice indicate greater lethality at dilutions in the range of 1–15% compared to more
concentrated solutions.  For example, LD50 values of 734, 498, 166, 165, and 123 mg glutaraldehyde/kg 
were reported for male rats administered glutaraldehyde as 50, 25, 10, 5, or 1% aqueous glutaraldehyde,
respectively (Ballantyne 1995; Union Carbide Chem & Plas Co. 1991l). Similarly, LD50 values of 115, 
228, 28.9, 29.7, and 14.8 mg glutaraldehyde/kg were reported for female mice administered 50, 25, 5, 1, 
or 0.1% aqueous glutaraldehyde, respectively (Ballantyne 1995; Union Carbide Corp. 1992i). However,
expressed in terms of volume of glutaraldehyde per kg body weight, the LD50 values for these mice 
increased with increasing volume (e.g., 0.2, 0.81, 0.54, 2.83, and 13.5 mL/kg for 50, 25, 5, 1, and 0.1 mg
glutaraldehyde/kg, respectively).  In these studies, dosing volume varied for each concentration tested.
Although underlying principles involved in the apparent increased lethality (in terms of mg
glutaraldehyde/kg body weight) at lower glutaraldehyde concentrations have not been elucidated, these 
results indicate that administration of water following ingestion of relatively high concentrations of
glutaraldehyde might enhance its toxicity. Stock glutaraldehyde is stored at relatively low pH (3.1–4.5)
and is alkalinized to neutral pH (7.8–8.0) to optimize its biocidal activity as a disinfectant.  In a study that 
evaluated the acute oral lethality of stock and alkalinized glutaraldehyde (2.2% aqueous solution), similar
LD50 values were obtained for rats administered unbuffered or buffered solutions (Ballantyne 1995).
LD50 values were 3.34 and 3.65 mL/kg (males) and 3.49 and 4.89 (females) for unbuffered and buffered 
solutions, respectively.
Maternal deaths were reported from daily gavage administration of 50% aqueous glutaraldehyde to rats
during gestation days (GDs) 6–15 at 25 mg glutaraldehyde/kg (Ema et al. 1992) and rabbits during
GDs 7–19 at 22.5 mg glutaraldehyde/kg (BASF Corp. 1991a). No treatment-related deaths were 
observed among rats, mice, or dogs administered glutaraldehyde in the drinking water for 13 weeks at
concentrations resulting in ingested doses of glutaraldehyde as high as 120, 233, and 15 mg/kg/day, 
respectively (Union Carbide Chem & Plas Co. 1991r, 1991w, 1991ee). Continuous exposure of rats to 
glutaraldehyde in the drinking water for up to 2 years at concentrations resulting in glutaraldehyde doses
as high as 64–121 mg/kg/day did not appear to affect survival (Confidential 2002; van Miller et al. 2002).
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All reliable LOAEL and LD50 values for death in each species and duration category are recorded in
Table 3-7 and plotted in Figure 3-3.
3.2.2.2  Systemic Effects
The highest NOAEL values and all LOAEL values from each reliable study for each species, duration, 
and end point for systemic effects are recorded in Table 3-7 and plotted in Figure 3-3.
No information was located regarding the following systemic effects in humans exposed to 
glutaraldehyde by the oral route:  gastrointestinal, hematological, hepatic, renal, endocrine, body weight, 
and ocular effects.  No information was located regarding the following systemic effects in laboratory
animals exposed to glutaraldehyde by the oral route:  cardiovascular, musculoskeletal, and dermal effects.
Respiratory Effects. Available human data are limited to two separate case reports.  A 78-year-old 
male, who deliberately ingested an unspecified quantity of a biocide containing glutaraldehyde and a
quaternary ammonium compound, developed acute respiratory distress and severe metabolic acidosis and
subsequently died (Simonenko et al. 2009); the respiratory distress was likely secondary to metabolic 
acidosis.  A 19-year-old female deliberately ingested an unspecified quantity of Omnicide (a poultry
biocide containing 15% glutaraldehyde and 10% coco benzyl dimethyl ammonium chloride) (Perera et al. 
2008). This subject also developed acute respiratory distress and severe metabolic acidosis, but
subsequently recovered.
Gross pathologic evidence of glutaraldehyde-induced irritation in the lungs was observed following single 
gavage administration of aqueous glutaraldehyde to rats and mice at doses ≥100 and ≥16.9 mg/kg,
respectively (Ballantyne 1995; Union Carbide Chem & Plas Co. 1992; Union Carbide Corp. 1992i).  The
respiratory effects are likely the result of aspiration of glutaraldehyde from the stomach. There were no 
indications of glutaraldehyde-induced respiratory effects in rats or mice receiving glutaraldehyde from the 
drinking water for 16 days or 13 weeks at doses as high as 100–120 mg/kg/day (rats) and 200– 
327.6 mg/kg/day (mice) (Union Carbide Chem & Plas Co. 1991r, 1991v, 1991w).  In Wistar rats
administered glutaraldehyde in the drinking water for up to 2 years at 2,000 ppm (estimated
glutaraldehyde doses of 60 and 88 mg glutaraldehyde/kg for males and females, respectively),
significantly increased incidences of nonneoplastic lesions were noted in larynx (diffuse squamous
metaplasia in males and females and focal squamous metaplasia in females) and trachea (focal and diffuse 
squamous metaplasia in females) (BASF 2013; Confidential 2002).  In addition, significant trends for
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Table 3-7. Levels of Significant Exposure to Glutaraldehyde – Oral 
Less 
Species Exposure serious Serious 
Figure (strain) parameters/ Parameters NOAEL LOAEL LOAEL 
keya No./group dose (mg/kg/d) monitored System (mg/kg/d) (mg/kg/d) (mg/kg/d) Results Reference/comments 
ACUTE EXPOSURE
Death
1 Rat (Wistar) 
5 M, 5 F
Once (GW)
113, 170, 283, 
565, 961
BW CS GN
LE 
  181 M 
209 F
LD50=0.32 mL/kg (males), 0.37 mL/kg 
(females) for 50% aqueous 
glutaraldehyde
BASF Corp. 1990j 
Reported doses in mL/kg test substance 
(50% aqueous glutaraldehyde) converted 
to mg glutaraldehyde/kg using specific 
gravity of 1.13 g/mL 
2 Rat (Wistar) 
5 M 
Once (GW)
283, 565, 1,130
BW CS GN
LE 
734 
LD50=1.3 mL/kg for 50% aqueous 
glutaraldehyde
Union Carbide Corp. 1992b
Reported doses in mL/kg test substance 
(50% aqueous glutaraldehyde) converted 
to mg glutaraldehyde/kg using specific 
gravity of 1.13 g/mL 
3 Rat (Sprague-
Dawley) 
5 M, 5 F
Once (GW)
M: 50, 100, 200 
F: 50, 70.5, 100
BW CS GN
LE 
  139 M 
87 F
LD50=246 mg/kg (males), 154 mg/kg 
(females) for 50% aqueous 
glutaraldehyde
Union Carbide Chem & Plas Co. 1992
Reported doses in mg test substance (50% 
aqueous glutaraldehyde/kg multiplied by
0.5 for expression as mg glutaraldehyde/kg 
4 Rat (albino)
5 M 
Once (GW)
252, 504, 1,008
BW CS GN
LE 
540 
LD50=1.19 mL/kg for 45% aqueous 
glutaraldehyde
Union Carbide Corp. 1992a
Reported doses in mL/kg test substance 
(45% aqueous glutaraldehyde) converted 
to mg glutaraldehyde/kg using specific 
gravity of 1.12 g/mL 
5 Rat (Sprague-
Dawley) 
2 or 5 M, 2 or
5 F
Once (GW)
22.5, 45, 90, 180
BW CS GN
LE 
  75.6 M 
72.9 F
LD50=168 mg/kg (males), 162 mg/kg 
(females) for 45% aqueous 
glutaraldehyde (Ucarcide antimicrobial 
145LT)
Union Carbide Chem & Plas Co. 1991z 
Reported doses in mg test substance (45% 
aqueous glutaraldehyde)/kg multiplied by
0.45 for expression as mg 
glutaraldehyde/kg 
6 Rat (Sprague-
Dawley) 
5 M, 5 F
Once (GW)
M: 49, 99, 197, 
394, 788
F: 99, 197, 394
BW CS GN
LE 
  197 M 
212 F
LD50 Union Carbide Chem & Plas Co. 1991t
Doses reported as mg active ingredient/kg; 
test substance was 45% aqueous 
glutaraldehyde
7 Rat (NS)
NS 
Once (GW)
Doses NS 
LE 
410 
Reported LD50=1.54 mL/kg for 25% 
aqueous glutaraldehyde (dosed as
received) 
Union Carbide Chem & Plas Co. 1991g
LD50 converted to mg/kg using specific 
gravity of 1.065 g/mL for 25% 
glutaraldehyde
50
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Table 3-7. Levels of Significant Exposure to Glutaraldehyde – Oral 
Less 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure
parameters/ 
dose (mg/kg/d)
Parameters 
monitored System 
NOAEL 
(mg/kg/d) 
serious 
LOAEL 
(mg/kg/d) 
Serious 
LOAEL 
(mg/kg/d) Results Reference/comments 
8 Rat (Wistar) 
5 M 
Once (GW)
266, 533, 1,065
BW CS GN
LE 
499 
LD50=1.87 mL/kg for 25% aqueous 
glutaraldehyde
Union Carbide Corp. 1992c
Reported doses in mL/kg test substance 
(25% aqueous glutaraldehyde) converted 
to mg glutaraldehyde/kg using specific 
gravity of 1.065 g/mL 
9 Rat (Hilltop-
Wistar) 
5 M, 5 F
Once (GW)
51, 103, 205, 410 
BW CS GN
LE 
  166 M 
110 F
LD50=1.62 mL/kg (males), 1.07 mL/kg 
(females) for 10% aqueous 
glutaraldehyde
Union Carbide Chem & Plas Co. 1991l 
Reported doses in mL/kg test substance 
(10% aqueous glutaraldehyde) converted 
to mg glutaraldehyde/kg using specific 
gravity of 1.025 g/mL 
10 Rat (Hilltop-
Wistar) 
5 M, 5 F
Once (GW)
51, 101, 203, 406, 
811 
BW CS GN
LE 
  165 M 
66 F
LD50=3.25 mL/kg (males), 1.30 mL/kg 
(females) for 5% aqueous 
glutaraldehyde
Union Carbide Chem & Plas Co. 1991l 
Reported doses in mL/kg test substance 
(5% aqueous glutaraldehyde) converted to 
mg glutaraldehyde/kg using specific gravity
of 1.014 g/mL
11 Rat (Hilltop-
Wistar) 
5 M, 5 F
Once (GW)
40, 80, 160
BW CS GN
LE 
  123 M 
96 F
LD50=12.3 mL/kg (males), 9.85 mL/kg 
(females) for 1% aqueous 
glutaraldehyde
Union Carbide Chem & Plas Co. 1991l 
Reported doses in mL/kg test substance 
(1% aqueous glutaraldehyde); converted to 
mg glutaraldehyde/kg using specific gravity
of 1.0025 g/mL
12 Mouse (NS)
5 M, 5 F
Once (GW)
M: 70.5, 141, 282 
F: 70.5, 141, 282, 
565 
CS LE GN 151 M 
115 F
LD50 Union Carbide Corp. 1992i
Reported doses in mL/kg test substance 
(50% aqueous glutaraldehyde) converted 
to mg glutaraldehyde/kg using specific 
gravity of 1.13 g/mL 
13 Mouse (NS)
5 M, 5 F
Once (GW)
M: 74.7, 149, 299, 
598, 1,195
F: 149, 299, 598
CS LE GN 182 M 
228 F
LD50 Union Carbide Corp. 1992i
Reported doses in mL/kg test substance 
(25% aqueous glutaraldehyde) converted 
to mg glutaraldehyde/kg using specific 
gravity of 1.064 g/mL 
14 Mouse (NS)
5 M, 5 F
Once (GW)
M: 13.6, 27, 54,
109, 217, 434 
F: 13.6, 27
CS LE GN 33.2 M 
28.9 F
LD50 Union Carbide Corp. 1992i
Reported doses in mL/kg test substance 
(5% aqueous glutaraldehyde) converted to 
mg glutaraldehyde/kg using specific gravity
of 1.014 g/mL
51
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Table 3-7. Levels of Significant Exposure to Glutaraldehyde – Oral 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure
parameters/ 
dose (mg/kg/d)
Parameters 
monitored System 
NOAEL 
(mg/kg/d) 
Less 
serious 
LOAEL 
(mg/kg/d) 
Serious 
LOAEL 
(mg/kg/d) Results Reference/comments 
15 Mouse (NS)
5 M, 5 F
Once (GW)
M: 10.6, 21.2, 
42.5 
F: 5.3, 10.6, 21.2, 
42.5, 85
CS LE GN 36.0 M 
29.7 F
LD50 Union Carbide Corp. 1992i
Reported doses in mL/kg test substance 
(1% aqueous glutaraldehyde) converted to 
mg glutaraldehyde/kg using specific gravity
of 1.003 g/mL
16 Mouse (NS)
5 F
Once (GW)
F: 4, 8, 16
CS LE GN 14.8 LD50 Union Carbide Corp. 1992i
Reported doses in mL/kg test substance 
(0.1% aqueous glutaraldehyde) converted 
to mg glutaraldehyde/kg using specific 
gravity of 1.00 g/mL 
17 Rat (Wistar) 
21 or 26 F
1 x/d (GW) on 
Gd 6–15 
0, 12.5, 25, 50
BW CS DX FI 
FX LE MX TG 
25 12.5 mg/kg/d: no deaths 
25 mg/kg/d: 2/21 maternal deaths
50 mg/kg/d: 5/26 maternal deaths
Ema et al. 1992 
Reported doses in mg test substance/kg/d 
multiplied by 0.5 (proportion of 
glutaraldehyde in test substance) for 
expression as mg glutaraldehyde/kg/d 
18 Rabbit 1 x/d (GW) on BW CS DX FI 
22.5 
2.5 mg/kg/d: no deaths BASF Corp 1991a 
(Himalayan) Gd 7–19 FX GN LE MX 7.5 mg/kg/d: no deaths Reported doses in mg test substance/kg/d 
15 F 0, 2.5, 7.5, 22.5 TG 22.5 mg/kg/d: 5/15 maternal deaths multiplied by 0.5 (proportion of 
glutaraldehyde in test substance) for 
expression as mg glutaraldehyde/kg/d 
Systemic
19 Rat (Sprague-
Dawley) 
5 M, 5 F
Once (GW)
M: 50, 100, 200 
F: 50, 70.5, 100
BW CS GN
LE 
Gastro 50 M, F 100 M 
70.5 F
 Gastrointestinal irritation Union Carbide Chem & Plas Co. 1992
Reported doses in mg test substance (50% 
aqueous glutaraldehyde/kg multiplied by
0.5 for expression as mg 
glutaraldehyde/kg.  Discolored lungs at 
some dose levels were a likely result of 
aspiration. 
20 Rat (Harlan-
Wistar) 
5 M 
DW for 4 d
0, 440, 640
BW CS FI LE 
OW WI
Hepatic 
BW 
640 
640 
  Increased relative kidney weight, 
decreased urinary output at 440 and 
640 mg/kg/d; no effects on relative liver 
weight or body weight 
Union Carbide Chem & Plas Co. 1991f
Kidney effects likely result of decreased 
food and water intake 
21 Rat (Harlan-
Wistar) 
5 M 
DW for 4 d
0, 180
BW CS FI LE 
OW WI
Hepatic 
Renal 
BW 
180 
180 
180 
No effects on relative liver or kidney
weight or body weight 
Union Carbide Chem & Plas Co. 1991f
52
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Table 3-7. Levels of Significant Exposure to Glutaraldehyde – Oral 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure
parameters/ 
dose (mg/kg/d)
Parameters 
monitored System 
NOAEL 
(mg/kg/d) 
Less 
serious 
LOAEL 
(mg/kg/d) 
Serious 
LOAEL 
(mg/kg/d) Results Reference/comments 
22 Rat (Wistar) 
10 F
1 x/d (GW) on 
Gd 6–15 
0, 10, 50
BW CS DX FI 
FX LE MX TG
WI 
Gastro
Hepatic 
Renal 
BW 
10 
50 
10 
50 
50 
50 
50 mg/kg/d: thickened margo plicatus in 
forestomach of 10/10 dams, unspecified 
lesions in glandular stomach of 
3/10 dams, 9% decreased serum total 
proteins, 10% increased mean relative 
kidney weight
BASF Corp. 1991b, 1991c
Not specified whether reported doses were 
adjusted for proportion of glutaraldehyde in 
test substance (50% aqueous 
glutaraldehyde)
23 Rat (Wistar) 
10 F
DW on Gd 6–16
0, 11, 51
BI BW CS DX 
FI FX GN HP 
LE MX OW 
TG WI
Gastro
Hepatic 
Renal 
BW 
11 
51 
51 
51 
51 Foci in glandular stomach of 2/10 dams BASF Corp. 1990l, 1991b
Author-estimated glutaraldehyde doses 
24 Rat (Wistar) 
25 F
DW on Gd 6–16
0, 5, 26, 68
BI BW CS DX 
FI FX GN HP 
LE MX OW 
TG WI
BW 68 No effects on mean maternal body
weight
BASF Corp. 1991b 
Author-estimated glutaraldehyde doses 
25 Rat (Wistar) 
21 or 26 F
1 x/d (GW) on 
Gd 6–15 
0, 12.5, 25, 50
BW CS DX FI 
FX LE MX TG 
Gastro
BW 
25 
25 
50 
50 
50 mg/kg/d: hemorrhagic irritation of 
stomach noted in 12/21 dams; 57% 
depressed mean maternal body weight 
gain 
Ema et al. 1992 
Reported doses in mg test substance/kg/d 
multiplied by 0.5 (proportion of 
glutaraldehyde in test substance) for 
expression as mg glutaraldehyde/kg/d 
26 Rat (F344)
10 M, 10 F
DW for 14 d
M: 0, 12.8, 100.7
F: 0, 13.6, 105.5
BC BW CS FI 
GN HE HP LE 
WI 
Hemato 
Hepatic 
Renal 
BW 
100.7 M 
105.5 F
100.7 M 
105.5 F
100.7 M 
105.5 F
100.7 M 
105.5 F
No treatment-related effects on clinical 
signs, clinical chemistry or hematology
measurements, body weight, absolute or 
relative liver or kidney weights, or 
histopathology of liver or kidney 
Union Carbide Chem & Plas Co. 1991o
Author-estimated glutaraldehyde doses 
27 Mouse (NS)
5 M, 5 F
Once (GW)
various doses 
CS LE GN Gastro 8.4 16.9 Gastrointestinal irritation Union Carbide Corp. 1992i
Results for 0.05% aqueous glutaraldehyde 
test substance; respiratory and 
gastrointestinal effects occurred at higher 
doses among mice treated using 0.1–50% 
aqueous glutaraldehyde test substance.  
Discolored lungs at some dose levels were
a likely result of aspiration. 
28 Rabbit 
(Himalayan) 
6 F
DW on Gd 7–20
0, 7.1, 23.4
BW CS DX FI 
FX LE MX TG
WI 
Hepatic 
Renal 
BW 
23.4 
23.4 
23.4 
No effects on liver weight or gross 
lesions, kidney weight, or body weight 
BASF Corp. 1991a, 1991c
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Table 3-7. Levels of Significant Exposure to Glutaraldehyde – Oral 
Less 
Species Exposure serious Serious 
Figure (strain) parameters/ Parameters NOAEL LOAEL LOAEL 
keya No./group dose (mg/kg/d) monitored System (mg/kg/d) (mg/kg/d) (mg/kg/d) Results Reference/comments 
29 Rabbit 1 x/d (GW) on BW CS DX FI Gastro 5 25 Gastritis in fundus/pyloris of 2/6 does, no BASF 1990m
(Himalayan) 
6 F
Gd 7–19 
0, 5, 25
FX LE MX TG
WI 
Hepatic 
Renal 
25 
25 
treatment-related effects on liver, kidney, 
or body weights
BW 25 
30 Rabbit 1 x/d (GW) on BW CS DX FI Gastro 15 
45 
45 mg/kg/d: gastrointestinal irritative BASF Corp. 1991a 
(Himalayan) 
15 F
Gd 7–19 
0, 5, 15, 45
FX GN LE MX 
TG
BW 15 45 effects included reddening and 
ulceration in fundus, edema of fundus/ 
Body weight loss accompanied by 40% 
decreased food intake 
pylorus, distended cecum/colon in nearly
all does; actual body weight loss during 
treatment period
Note: 5/15 does in the 45 mg/kg/d group 
died 
31 Dog (beagle) DW for 14 d BC BW CS FI Gastro 7 M Mucosal irritation (glossitis and Union Carbide Chem & Plas Co. 1991dd
2 M, 2 F M: 0, 7, 14 GN HE HP LE 10 F esophagitis), more prominent in males Author-estimated glutaraldehyde doses 
F: 0, 10, 13 OP UR WI
Developmental
32 Rat (Wistar) 
10 F
DW on Gd 6–16
0, 11, 51
BI BW CS DX 
FI FX GN HP 
LE MX OW 
TG WI
 51 No effects on uterine weight or uterine 
contents 
BASF Corp. 1990l, 1991b
Author-estimated glutaraldehyde doses 
33 Rat (Wistar) 
10 F
1 x/d (GW) on 
Gd 6–15 
0, 10, 50
BW CS DX FI 
FX LE MX TG
WI 
50 No effects on uterine weight or uterine 
contents 
BASF Corp. 1991c 
Range-finding study for definitive study 
34 Rat (Wistar) 
25 F
DW on Gd 6–16
0, 5, 26, 68
BI BW CS DX 
FI FX GN HP 
LE MX OW 
TG WI
68 No effects on uterine weight or uterine 
contents 
BASF Corp. 1991b 
Author-estimated glutaraldehyde doses 
35 Rat (Wistar) 
21 or 26 F
1 x/d (GW) on 
Gd 6–15 
0, 12.5, 25, 50
BW CS DX FI 
FX LE MX TG 
50 No effects on uterine weight or uterine 
contents up to and including maternally-
toxic dose 
Ema et al. 1992 
Reported doses in mg test substance/kg/d 
multiplied by 0.5 (proportion of 
glutaraldehyde in test substance) for 
expression as mg glutaraldehyde/kg/d 
36 Rabbit 
(Himalayan) 
6 F
DW on Gd 7–20
0, 7.1, 23.4
BW CS DX FI 
FX LE MX TG
WI 
23.4 BASF Corp. 1991a, 1991c
37 Rabbit 
(Himalayan) 
6 F
1 x/d (GW) on 
Gd 7–19 
0, 5, 25
BW CS DX FI 
FX LE MX TG
WI 
25 No effect on fertility or fecundity BASF 1990m
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Table 3-7. Levels of Significant Exposure to Glutaraldehyde – Oral 
Less 
Species Exposure serious Serious 
Figure (strain) parameters/ Parameters NOAEL LOAEL LOAEL 
keya No./group dose (mg/kg/d) monitored System (mg/kg/d) (mg/kg/d) (mg/kg/d) Results Reference/comments 
38 Rabbit 1 x/d (GW) on BW CS DX FI 15 45 mg/kg/d: decreased gravid uterine BASF Corp. 1991a 
(Himalayan) Gd 7–19 FX GN LE MX weight, decreased number of does with 
15 F 0, 5, 15, 45 TG fetuses, 100% resorptions in 9/15 does, Note: 45 mg/kg/d dose was extremely 
increased postimplantation loss, toxic; 5/15 does in the 45 mg/kg/d group 
markedly reduced mean placental and died 
fetal body weights 
INTERMEDIATE EXPOSURE
Systemic
39 Mouse (CD-1)
10 M, 10 F
DW for 16 d
M: 0, 32.1, 69.8, 
257.4 
BC BW CS FI 
GN HE HP LE 
OW UR WI
Resp 
Hemato 
257.4 M 
327.6 F
257.4 M 
12% increased mean relative kidney
weight in high-dose females; 32–77% 
depressed mean body weight gain in 
Union Carbide Chem & Plas Co. 1991v 
Author-estimated glutaraldehyde doses 
F: 0, 37.8, 92.5, 327.6 F mid- and high-dose males No histopathological evidence of treatment-
327.6 Renal 257.4 M related effects on kidney 
95.2 F 327.6 F
BW 32.1 M 69.8 M
327.6 F
40 Rat (F344)
20 M, 20 F
DW for 13 wk
M: 0, 5, 23, 100
BC BW CS FI 
GN HE HP LE 
Resp 100 M 
120 F
Dose-related increased absolute and/or 
relative kidney weight 
Union Carbide Chem & Plas Co. 1991r
Author-estimated doses 
F: 0, 7, 35, 120 OP OW UR Hemato 100 M 
WI 
Hepatic 
120 F
100 M 
120 F
No histopathological evidence of treatment-
related effects on kidney 
Renal 5 M 23 M 
7 F 35 F
BW 100 M 
120 F
Ocular 100 M 
120 F
55
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Table 3-7. Levels of Significant Exposure to Glutaraldehyde – Oral 
Less 
Species Exposure	 serious Serious 
Figure 	 (strain) parameters/ Parameters NOAEL LOAEL LOAEL 
keya	 No./group dose (mg/kg/d) monitored System (mg/kg/d) (mg/kg/d) (mg/kg/d) Results Reference/comments 
41 	Mouse (CD-1) DW for 13 wk BC BW CS FI Resp 
20 M, 20 F M: 0, 25, 61, 200 GN HE HP LE 
F: 0, 31, 74, 233	 OP OW UR Hemato 
WI 
Hepatic 
Renal 
BW 
Ocular
200 M 
233 F
200 M 
233 F
200 M 
233 F
25 M 
74 F 
200 M 
233 F
200 M 
233 F
Renal effects included decreased urine Union Carbide Chem & Plas Co. 1991w 
volume in males at 61 and 200 mg/kg/d Author-estimated doses 
and females at 233 mg/kg/d, increased 
mean urine osmolality in males at 61 and No histopathological evidence of treatment-
200 mg/kg/d (~37% greater than related effects on kidney 
controls) and females at 233 mg/kg/d 
61 M (49% greater than controls 
233 F
42 	Rat (CD)
28 M (F0, F1) 
28 F (F0, F1)
DW during 
premating, 
mating, gestation, 
and lactation for 
2 generations
F0 M: 0, 4.25, 
17.5, 69.07
F0 F: 0, 6.68, 
28.28, 98.37
F1 M: 0, 4.53, 
21.95, 71.08
F1 F: 0, 6.72, 
29.57, 99.56
BW CS DX FI BW 69.07 F0 M 
FX GN HP LE 71.08 F1 M 
MX TG WI 98.37 F0 F 
99.56 F1 F
F0 males: reduced body weight gain in 
mid- and high-dose groups only during 
first exposure week; decreased water 
consumption in mid- and high-dose 
groups; sporadic decreased food 
consumption in mid- and high-dose 
groups 
F0 females:  reduced body weight gain
in high-dose group only at weeks 3 and 
at parturition; decreased water 
consumption in mid- and high-dose 
groups; sporadic decreased food 
consumption in high-dose group
F1 males: depressed body weight in 
high-dose group at times during 
premating only; decreased water 
consumption in mid- and high-dose 
groups; decreased food consumption in 
high-dose group
F1 females: decreased water and food 
consumption in mid- and high-dose 
groups
Neeper-Bradley and Ballantyne 2000 
Author-estimated doses 
Differences in body weight between 
controls and high-dose groups of parental 
rats were in the range of 5–6%, with the 
exception of 10 and 14% lower mean body 
weight of mid- and high-dose F0 male rats, 
respectively, at exposure week 1
No histopathological evidence of treatment-
related effects on reproductive organs or 
tissues 
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Table 3-7. Levels of Significant Exposure to Glutaraldehyde – Oral 
Less 
Species Exposure serious Serious 
Figure (strain) parameters/ Parameters NOAEL LOAEL LOAEL 
keya No./group dose (mg/kg/d) monitored System (mg/kg/d) (mg/kg/d) (mg/kg/d) Results Reference/comments 
43 Dog (beagle) DW for 13 wk BW BC BW Gastro
4 M, 4 F M: 0, 3.3, 9.6, CS FI GN HE 
14.1 HP LE OP Hemato 
F: 0, 3.2, 9.9, OW UR WI
15.1 Hepatic 
Renal 
Ocular 
BW 
3.3 M 
3.2 F 
14.1 M 
15.1 F
14.1 M 
15.1 F
14.1 M 
15.1 F
14.1 M 
15.1 F
14.1 M 
15.1 F
9.6 M 
9.9 F
Increased incidences of intermittent 
vomiting in mid- and high-dose males 
and females; reduced body weight and 
body weight gain in all dose groups of 
females (irregular intervals, small 
magnitude, and without dose-response 
characteristic); ophthalmologic 
examinations negative; increased 
relative kidney weight in high-dose 
females not considered biologically 
significant in absence of exposure-
related changes in urinalysis or renal 
histopathology; no exposure-related 
effects on hematology, serum chemistry,
or gross or histopathology 
Union Carbide Chem & Plas Co. 1991ee
Author-estimated doses 
Reproductive
44 Rat (CD) DW during BW CS DX FI 69.07 F0 M 
28 M (F0, F1) premating, FX GN HP LE 71.08 F1 M 
 28 F (F0, F1) mating, gestation, MX TG WI 98.37 F0 F 
and lactation for 99.56 F1 F
2 generations
F0 M: 0, 4.25, 
17.5, 69.07
F0 F: 0, 6.68, 
28.28, 98.37
F1 M: 0, 4.53, 
21.95, 71.08
F1 F: 0, 6.72, 
29.57, 99.56
No effects on fertility; no 
histopathological evidence of treatment-
related effects on reproductive organs or 
tissues 
Neeper-Bradley and Ballantyne 2000 
Author-estimated doses 
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Table 3-7. Levels of Significant Exposure to Glutaraldehyde – Oral 
Less 
Species Exposure serious Serious 
Figure (strain) parameters/ Parameters NOAEL LOAEL LOAEL 
keya No./group dose (mg/kg/d) monitored System (mg/kg/d) (mg/kg/d) (mg/kg/d) Results Reference/comments 
Developmental
45 Rat (CD)
28 M (F0, F1) 
 28 F (F0, F1)
DW during 
premating, 
mating, gestation, 
lactation for 2 
generations 
F0 M: 0, 4.25, 
17.5, 69.07
F0 F: 0, 6.68, 
28.28, 98.37
F1 M: 0, 4.53, 
21.95, 71.08
F1 F: 0, 6.72, 
29.57, 99.56
BW CS DX FI  98.37 F1
FX GN HP LE 99.56 F2 
MX TG WI
F1 pups: significantly depressed mean 
pup body weight in high-dose pups at 
postpartum days 21 and 28 (5–11%
lower than controls) and mean pup body
weight gain during lactation days 14–28 
(14–19% less than controls)
F2 pups: significantly depressed mean 
pup body weight in high-dose pups at 
postpartum days 21 and 28 (7–13%
lower than controls) and mean pup body
weight gain during lactation days 14–28 
(17–27% less than controls)
No treatment-related effects on other 
developmental indices 
Neeper-Bradley and Ballantyne 2000 
Author-estimated doses 
Effects on pup body weight likely due to 
taste aversion 
CHRONIC EXPOSURE
 
Systemic
46 Rat (F344)
100 M 
100 F
DW up to 104 wk
M: 0, 4, 17, 64
F: 0, 6, 25, 86
BC BW CS FI 
GN HE HP LE 
OP OW UR 
WI 
Gastro
Hemato 
Hepatic 
Renal 
BW 
4 Mb 
6 F 
64 M 
86 F 
64 M 
17 M 
25 F 
Gastric irritation (multifocal color change, 
mucosal thickening, nodules, and 
ulceration affecting primarily the 
nonglandular mucosa) in mid- and high-
dose males and females; increased 
van Miller et al. 2002 
Author-estimated doses 
Study authors considered most kidney
effects a physiological compensatory
86 F 
64 M 
F 86 
incidences of nucleated red blood cell 
and large monocytes in mid- and high-
dose males and bone marrow
adaptation to decreased water 
consumption and bone marrow
hyperplasia, renal tubular pigmentation, 
17 M 
25 F
64 M 
86 F
hyperplasia in high-dose males and low-, 
mid-, and high-dose females; increased 
incidences of renal tubular pigmentation 
in high-dose males and mid- and high-
and increased incidences of nucleated red 
blood cells and large monocytes secondary
to low-grade anemia in rats with large 
granular lymphocytic anemia 
dose females; increased kidney weight 
in high-dose females; decreased urine 
volume in high-dose males and females; 
depressed body weight and body weight 
gain in high-dose males and females (3– 
14% less than controls) 
58
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Table 3-7. Levels of Significant Exposure to Glutaraldehyde – Oral 
Less 
Species Exposure serious Serious 
Figure (strain) parameters/ Parameters NOAEL LOAEL LOAEL 
keya No./group dose (mg/kg/d) monitored System (mg/kg/d) (mg/kg/d) (mg/kg/d) Results Reference/comments 
47 Rat (Wistar) DW up to 24 mo BC BW CS FI Resp 16 M 60 M Laryngeal and tracheal metaplasia in BASF 2013; Confidential 2002 
50 M 
50 F 
M: 0, 3, 16, 60
F: 0, 5, 24, 88
GN HE HP LE 
OP OW WI Gastro
24 F 
60 M 
88 F males and females; erosion/ulceration in 
glandular stomach of females 
A detailed study report is not available to 
the general public 
24 F 88 F
aThe number corresponds to entries in Figure 3-3.

bUsed to derive a chronic-duration oral MRL of 0.1 mg/kg/day for glutaraldehyde.  The NOAEL of 4 mg/kg/day was divided by an uncertainty factor of 30 (10 for extrapolation from animals to 

humans and 3 for human variability) (see Appendix A). 

BC = biochemistry; BI = biochemical changes; BW = body weight; CS = clinical signs; d = day(s); DW = drinking water; DX = developmental toxicity; F = female(s); FI = food intake; FX = fetal 

toxicity; Gastro = gastrointestinal; Gd = gestation day(s); GN = gross necropsy; GW = gavage in water; HE = hematology; Hemato = hematological; HP = histopathology; LD50 = lethal dose, 

50% kill; LE = lethality; M = male(s); MRL = Minimal Risk Level; MX = maternal toxicity; NS = not specified; OP = ophthalmology; OW = organ weight; Resp = respiratory; sec = second(s); 

TG = teratogenicity; UR = urinalysis; WI = water intake; wk = week(s); x = time(s)
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Figure 3-3. Levels of Significant Exposure to Glutaraldehyde - Oral 
Acute (≤ 14 days) 
Systemic 
Hepatic Body Weight Hemato Developmental 
1000 
Gastrointestinal Renal Death 
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1 
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22R 
23R 
25R 29H 
32R22R 
30H 
29H 
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25R 30H10R 35R 
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9R 11R 12M 
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Human - NOAEL Animal - NOAEL 
Human - LOAEL, Less Serious Animal - LOAEL, Less Serious 
Human - LOAEL, More Serious Animal - LOAEL, More Serious 
Human - Cancer Effect Level Animal - Cancer Effect Level 
Animal - LD50/LC50 Minimal Risk Level for effects other than cancer 
C-Cat K-Monkey J-Pigeon  O-Other 
D-Dog M-Mouse E-Gerbil 
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Figure 3-3. Levels of Significant Exposure to Glutaraldehyde - Oral (Continued) 
Intermediate (15-364 days) 
Systemic 
Reproductive DevelopmentalRespiratory Gastro Hepatic HematologicalRenal OcularBody Weight 
39M 39M 39M 
39M 
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41M 
41M 
41M 
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Human -Cancer Effect Level Animal -C ancer Effect Level 
Animal -L D50/LC50 Minimal Risk Level for effects other than cancer 
C-Cat K-Monkey J-Pigeon  O-Other
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Figure 3-3. Levels of Significant Exposure to Glutaraldehyde - Oral (Continued) 
Chronic (≥365 days) 
Systemic 
1000 
Respiratory Gastrointestinal Hepatic Renal Body Weight Hematological 
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Human - Cancer Effect Level Animal - Cancer Effect Level 
Animal - LD50/LC50 Minimal Risk Level for effects other than cancer 
C-Cat K-Monkey J-Pigeon  O-Other 
D-Dog M-Mouse E-Gerbil 
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P-Pig A-Sheep G-Guinea Pig 
Q-Cow   F-Ferret N-Mink 62
   
 
    
 
 
 
    
   
 
      
  
 
     
  
     
  
   
   
  
     
       
 
  
     
   
    
  
       
   
    
  
   
 
 
      
      
  
   
   
 
 
 
 
  
63GLUTARALDEHYDE
3. HEALTH EFFECTS
increasing incidence with increasing glutaraldehyde concentration were noted for diffuse metaplasia in 
the larynx of male and female rats, focal metaplasia in the larynx of females, focal squamous metaplasia
in the trachea of males and females, and diffuse metaplasia in the trachea of females.
Gastrointestinal Effects. Pathologic evidence of glutaraldehyde-induced gastrointestinal irritation
was observed following administration of aqueous glutaraldehyde by single gavage at sublethal and lethal
doses to rats and mice (Ballantyne 1995; Union Carbide Chem & Plas Co. 1991t, 1991z, 1992; Union 
Carbide Corp. 1992a, 1992c, 1992i). Clinical signs of gastrointestinal disturbances (lack of fecal
production, diarrhea, and bleeding) were noted in pregnant rabbits administered glutaraldehyde by gavage 
at 45 mg/kg/day during GDs 7–19 (BASF Corp. 1991a).  Evidence of gastric irritation (e.g., thickened
margo plicatus in the forestomach and unspecified lesions in the glandular stomach) were observed in 
pregnant Wistar rats administered glutaraldehyde by gavage at 50 mg/kg/day during GDs 6–15 (BASF 
Corp. 1991c; Ema et al. 1992).  However, no clinical or gross pathologic signs of glutaraldehyde-induced 
gastrointestinal effects were observed in rat dams administered glutaraldehyde in the drinking water
during GDs 6–16 at concentrations resulting in glutaraldehyde doses as high as 68 mg/kg/day (BASF
Corp. 1991b). van Miller et al. (2002) reported gross and histopathological evidence of gastric irritation
in nonglandular stomach mucosa of male and female rats receiving glutaraldehyde from the drinking
water for 1–2 years at concentrations resulting in estimated glutaraldehyde doses of 17 and 64 mg/kg/day
(males) and 25 and 86 mg/kg/day (females). These effects were not observed at estimated doses of 4 and
6 mg/kg/day to the males and females, respectively. In Wistar rats administered glutaraldehyde in the
drinking water for up to 2 years at 2,000 ppm (estimated glutaraldehyde doses of 60 and 88 mg/kg for
males and females, respectively), significantly increased incidence of erosion/ulceration was noted in the
glandular stomach of the females (BASF 2013; Confidential 2002). Upper alimentary mucosal irritation
was reported for dogs receiving glutaraldehyde from the drinking water for 14 days at 7–10 mg/kg/day
(Union Carbide Chem & Plas Co. 1991dd). Vomiting was noted in male and female dogs receiving 
glutaraldehyde from the drinking water for 13 weeks at approximately 10 mg/kg/day; there was no 
indication of glutaraldehyde treatment-related vomiting in low-dose (ca. 3 mg/kg/day) dogs (Union 
Carbide Chem & Plas Co. 1991ee).
Hematological Effects. No treatment-related effects on hematology parameters were observed in
studies of rats, mice, or dogs receiving glutaraldehyde from the drinking water for 2–13 weeks at doses as 
high as 100–120, 200–328, and 13–15 mg/kg/day, respectively (Union Carbide Chem & Plas Co. 1991o, 
1991r, 1991v, 1991w, 1991ee). Significantly increased mean (±standard deviation [SD]) numbers of
large monocytes were reported in the peripheral blood of male rats receiving glutaraldehyde from the 
***DRAFT FOR PUBLIC COMMENT***
   
 
    
 
 
     
    
  
   
     
    
     
 
      
   
 
       
   
  
 
       
   
 
   
  
  
    
   
    
    
    
  
     
     
    
  
 
 
 
 
 
 
  
64GLUTARALDEHYDE
3. HEALTH EFFECTS
drinking water for up to 2 years at 17 or 64 mg/kg/day (5,761 per µL blood ± 17,648 and 6,984 per µL
blood ± 24,262, versus 1,166 per µL blood ± 5,215 for controls) (van Miller et al. 2002).  However, the
toxicological significance of the increased numbers of large monocytes in the glutaraldehyde-exposed rats 
is uncertain because SDs were >3-fold higher than the mean, and increased numbers of peripheral blood 
nucleated erythrocytes and large monocytes are likely precursors to the development of LGLL, which 
occurs at high incidence in aged Fischer 344 rats (van Miller et al. 2002). In the same 2-year study, high
incidences of bone marrow hyperplasia were observed in rats that died prior to terminal sacrifice as well
as those surviving to terminal sacrifice; however, the bone marrow hyperplasia (along with renal tubular
pigmentation) was considered most likely related to low-grade hemolytic anemia that accompanied LGLL
in these rats (Stromberg et al. 1983; van Miller et al. 2002).
Hepatic Effects. Available animal studies provide no evidence of glutaraldehyde-induced hepatic
effects following oral exposure for acute, intermediate, or chronic durations (BASF Corp. 1990l, 1990m, 
1991c; Union Carbide Chem & Plas Co. 1991o, 1991r, 1991w, 1991dd, 1991ee; van Miller et al. 2002).
Renal Effects. Most animal studies provide no evidence of glutaraldehyde-induced renal effects 
following oral exposure for acute, intermediate, or chronic durations (BASF Corp. 1990l, 1990m, 1991c; 
Union Carbide Chem & Plas Co. 1991o, 1991r, 1991w, 1991dd, 1991ee).  Increased relative kidney
weight and decreased urinary output were observed in male Harlan-Wistar rats administered
glutaraldehyde in the drinking water for 4 days at concentrations resulting in estimated doses of 440 and 
640 mg/kg/day; however, the kidney effects were likely related to decreased food and water intake (Union 
Carbide Chem & Plas Co. 1991f).  Significantly increased mean relative kidney weight (10% higher than
controls) was noted in one study of rat dams administered glutaraldehyde by daily gavage on GDs 6–15 at
50 mg/kg/day (BASF Corp. 1991c); however, there was no effect on kidney weight in rat dams receiving
glutaraldehyde from the drinking water during GDs 6–16 at 50 mg/kg/day (BASF Corp. 1990l).
Approximately 12% increased mean relative kidney weight (in the absence of histopathologic renal
lesions) was reported in female rats receiving glutaraldehyde from the drinking water for 16 days at
328 mg/kg/day; kidney weight was not affected in male rats similarly treated at up to 257 mg/kg/day
(Union Carbide Chem & Plas Co. 1991v). Dose-related increased absolute and/or relative kidney weights
were noted in F344 rats administered glutaraldehyde in the drinking water for 13 weeks at concentrations 
resulting in author-estimated glutaraldehyde doses of 23 mg/kg/day to the males and 35 mg/kg/day to the
females (Union Carbide Chem & Plas Co. 1991r).  In a study of CD-1 mice administered glutaraldehyde
in the drinking water for 13 weeks, estimated glutaraldehyde doses of 23 and 100 mg/kg/day (males) and 
120 mg/kg/day (females) resulted in decreased urine volume output and increased mean urine osmolality
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in the absence of histopathological evidence of treatment-related histopathological kidney effects (Union 
Carbide Chem & Plas Co. 1991w).  Renal tubular pigmentation was observed in glutaraldehyde-exposed 
male and female rats that died during chronic treatment in the drinking water at concentrations resulting
in glutaraldehyde doses in the range of 4–86 mg/kg/day and in rats surviving until terminal sacrifice (van 
Miller et al. 2002); however, the pigmentation was considered most likely related to low grade hemolytic 
anemia that accompanied LGLL in these rats (Stromberg et al. 1983; van Miller et al. 2002).
Endocrine Effects. Information regarding endocrine effects in animals following oral exposure to 
glutaraldehyde is limited to reports that oral exposure for intermediate or chronic durations did not affect
weights of adrenal gland, thyroid, ovaries, or testes (Union Carbide Chem & Plas Co. 1991r, 1991v, 
1991w, 1991ee; van Miller et al. 2002).
Body Weight Effects. Significantly depressed mean maternal body weight gain (57% less than 
controls) was observed in rat dams administered aqueous glutaraldehyde at 50 mg/kg/day during GDs 6– 
15 (Ema et al. 1992).  As much as 19% mean maternal body weight loss was reported in pregnant rabbits 
administered aqueous glutaraldehyde by gavage during GDs 7–19 at 45 mg/kg/day (BASF Corp. 1991a).  
No treatment-related effects on body weight were seen in male or female rats administered glutaraldehyde
in the drinking water for 14 days at concentrations resulting in doses as high as 100–105 mg
glutaraldehyde/kg/day (Union Carbide Chem & Plas Co. 1991o) or for 13 weeks at concentrations 
resulting in doses as high as 25–35 mg/kg/day (Union Carbide Chem & Plas Co. 1991r). Depressed body
weight gain in male and female rats receiving glutaraldehyde from the drinking water at 100– 
120 mg/kg/day for 13 weeks was the likely result of decreased water and food consumption (Union 
Carbide Chem & Plas Co. 1991r). There were no treatment-related effects on mean body weight among
female mice receiving glutaraldehyde from the drinking water for 16 days at doses up to 327 mg/kg/day;
however, at doses ≥69.8 mg/kg/day, the males exhibited significantly depressed mean body weight gain
(33–77% less than controls) (Union Carbide Chem & Plas Co. 1991v).  In 13-week drinking water
studies, no signs of treatment-related body weight effects were seen among male and female mice at
glutaraldehyde doses as high as 200–233 mg/kg/day (Union Carbide Chem & Plas Co. 1991w) or male or 
female dogs at doses as high as 14–15 mg/kg/day (Union Carbide Chem & Plas Co. 1991ee).  In a 2-year
study of glutaraldehyde in the drinking water of rats, slightly (significant) depressed mean body weight
and body weight gain were observed at glutaraldehyde doses of 64 mg/kg/day in males and 86 mg/kg/day
in females; however, the rats exhibited significantly decreased water consumption as well (van Miller et
al. 2002).
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Ocular Effects. Available information regarding ocular effects in animals following oral exposure to 
glutaraldehyde consists of results from ophthalmologic evaluations. No signs of ocular effects were seen
in rats, mice, or dogs receiving glutaraldehyde from the drinking water for 13 weeks at doses as high as 
100–120, 257–327, and 14–15 mg/kg/day, respectively (Union Carbide Chem & Plas Co. 1991r, 1991v, 
1991ee) or in rats receiving glutaraldehyde from the drinking water for 2 years at 64–86 mg/kg/day (van
Miller et al. 2002).
Metabolic Effects. Available information regarding metabolic effects following oral exposure to 
glutaraldehyde is limited. Severe metabolic acidosis occurred in a 19-year-old female who deliberately
ingested an unspecified quantity of Omnicide (a poultry biocide containing 15% glutaraldehyde and 10%
coco benzyl dimethyl ammonium chloride) (Perera et al. 2008). A 78-year-old male, who deliberately
ingested an unspecified quantity of a biocide containing glutaraldehyde and a quaternary ammonium
compound, developed severe metabolic acidosis and acute respiratory distress and subsequently died 
(Simonenko et al. 2009).
3.2.2.3  Immunological and Lymphoreticular Effects 
No information was located regarding immunological or lymphoreticular effects in humans or laboratory 
animals following oral exposure to glutaraldehyde.
3.2.2.4  Neurological Effects 
No information was located regarding neurological effects in humans or laboratory animals following oral
exposure to glutaraldehyde.
3.2.2.5  Reproductive Effects
No data were located regarding reproductive effects in humans following oral exposure to glutaraldehyde.  
Neeper-Bradley and Ballantyne (2000) exposed groups of parental (F0) male and female CD rats to
glutaraldehyde in the drinking water at concentrations of 0, 50, 250, or 1,000 ppm glutaraldehyde during
premating, mating, gestation, and lactation.  Selected male and female pups (F1) were similarly-exposed 
through production of F2 pups that were maintained throughout lactation.  Average glutaraldehyde doses 
for the 50, 250, and 1,000 ppm groups over the entire treatment period were 4.25, 17.5, and 
69.07 mg/kg/day, respectively, for the F0 males; 6.68, 28.28, and 98.37 mg/kg/day, respectively, for the
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F0 females; 4.53, 21.95, and 71.08 mg/kg/day, respectively for the F1 parental males; and 6.72, 29.57, 
and 99.56 mg/kg/day, respectively, for the F1 parental females. There were no significant treatment-
related effects on fertility.
Results from studies in which pregnant rats or rabbits were administered glutaraldehyde orally are 
presented in Section 3.2.2.6 (Developmental Effects).
3.2.2.6  Developmental Effects 
No data were located regarding developmental effects in humans following oral exposure to 
glutaraldehyde.
Developmental end points have been assessed in rats and rabbits following oral exposure of maternal
animals during gestation.  Study reports available to ATSDR through the Toxic Substances Control Act
(TSCAT) include a developmental toxicity study of rats administered glutaraldehyde in the drinking
water during GDs 6–15 (BASF Corp. 1991b) with summary data from range-finding studies that
employed oral exposure via the drinking water and via gavage administration, and a developmental
toxicity study of rabbits administered glutaraldehyde via gavage during GDs 7–19 (BASF Corp. 1991a)
with summary data from range-finding studies that employed oral exposure via the drinking water and via
gavage administration. TSCAT submissions (BASF1990l, 1990m, 1991c) contained summary tables for
the range-finding studies.  There was no evidence of glutaraldehyde-induced effects on numbers of
corpora lutea, implantation sites, dead implantations, early and late resorptions, or live or dead fetuses; or
gross fetal anomalies among rats administered glutaraldehyde by gavage at doses as high as 50– 
68 mg/kg/day during GDs 6–15 (BASF Corp. 1991b, 1991c; Ema et al. 1992), rats exposed via the
drinking water at doses as high as 51 mg/kg/day during GDs 6–16 (BASF Corp. 1990l, 1991b), rabbits
administered gavage doses as high as 25 mg/kg/day during GDs 7–19 (BASF Corp. 1990m, 1991a), or
rabbits exposed via the drinking water at doses as high as 23 mg/kg/day during GDs 7–20 (BASF Corp. 
1991a, 1991c). Gavage treatment of pregnant rabbits at 22.5 mg/kg/day) resulted in decreased gravid
uterine weight (93% less than controls); decreases in numbers of does with fetuses (1/15 versus 15/15 in
controls), does with 100% resorptions (9/15 versus 0/15 in controls), postimplantation loss (94% versus 
14% in controls); and markedly reduced mean placental and fetal body weights (BASF Corp. 1991a).  
However, the 22.5 mg/kg/day dose level was maternally toxic, resulting in death (5/15 does) and actual
body weight loss among survivors. Significantly lower mean live fetal body weights (6–9% less than
controls) were noted at a gavage dose level of 100 mg/kg/day, a dose that resulted in the death of
***DRAFT FOR PUBLIC COMMENT***
   
 
    
 
 
   
     
 
     
  
  
  
  
   
    
    
  
      
 
   
  
 
 
    
 
   
 
    
 
   
 
  
    
  
   
 
 
     
  
 
 
 
 
  
68GLUTARALDEHYDE
3. HEALTH EFFECTS
5/26 pregnant rats; although the next lower dose level (25 mg/kg/day) resulted in 2/21 maternal deaths, 
there was no significant effect on fetal body weights (Ema et al. 1992).
In a 2-generation oral study, groups of F0 rats were exposed to glutaraldehyde in the drinking water at
concentrations resulting in average glutaraldehyde doses of 0, 4.25, 17.5, or 69.07 mg/kg/day for the
males and 0, 6.68, 28.28, or 98.37 mg/kg/day for the females; doses to similarly-treated F1 parental rats 
were 0, 4.53, 21.95, or 71.08 mg/kg/day for the males and 0, 6.72, 29.57, and 99.56 mg/kg/day for the
females (Neeper-Bradley and Ballantyne 2000). Significantly depressed mean pup body weight per litter 
was noted for high-dose F1 pups at postpartum days 21 and 28 (5–11% lower than controls); mean pup 
body weight gain per litter was 14–19% less than that of controls during lactation days 14–28.  
Significantly depressed mean pup body weight per litter was noted for high-dose F2 pups at postpartum
days 21 and 28 (7–13% lower than controls); for lactation days 14–21 and 21–28, mean pup body weight
gain per litter was 17–27% less than that of controls. The effects on pup body weight were likely due to 
aversion to glutaraldehyde-treated drinking water during and subsequent to weaning (significantly
decreased water consumption was observed among both F0 and F1 high-dose parental rats). There were
no treatment-related effects on other developmental indices.
The highest NOAEL values and all LOAEL values from each reliable study for developmental effects in
each species and duration category are recorded in Table 3-7 and plotted in Figure 3-3.
3.2.2.7  Cancer
No data were located regarding cancer in humans following oral exposure to glutaraldehyde.
Groups of Fischer 344 rats (100/sex/group) were administered glutaraldehyde in the drinking water for up 
to 2 years at concentrations of 50, 250, or 1,000 ppm (calculated doses in the range of 4–64 mg/kg/day for
the males and 6–86 mg/kg/day for the females) (van Miller et al. 2002).  Interim sacrifices at 52 and
78 weeks revealed no evidence of treatment-related increased incidences of neoplastic lesions compared
to untreated controls.  At 104-week terminal sacrifice, significantly increased incidences of LGLL were
noted in the spleen and liver of 50, 250, and 1,000 ppm groups of female rats (spleen: 21/47, 22/52, 
33/56, respectively, compared to 13/62 controls; liver: 20/47, 22/52, and 37/56, respectively, compared to 
12/62 controls).  Incidences of LGLL in the glutaraldehyde-treated male rats were not significantly
different from that of controls, with the exception of increased LGLL in the liver (but not the spleen) of
the 50 ppm group of males at week 104 sacrifice (incidence of 32/52 versus 22/56 for controls).  Due to 
***DRAFT FOR PUBLIC COMMENT***
   
 
    
 
 
 
     
    
  
    
 
  
   
   
  
     
   
   
      
    
    
   
 
       
   
 
    
 
  
 
  
 
  
     
     
  
 
    
   
  
 
 
 
 
  
69GLUTARALDEHYDE
3. HEALTH EFFECTS
high background and variable incidences of LGLL in the Fischer 344 rat, statistical significance only in 
the female rats, and lack of a clear dose response, the study authors indicated that the biological
significance of the LGLL findings was unclear and suggested that the statistical significance among the
glutaraldehyde-treated female rats might possibly have been a result of an abnormally low incidence of
LGLL in the control females. Upon evaluation of the study results by a Cancer Assessment Review
Committee for the U.S. EPA (EPA 2006), it was determined that the incidences of LGLL were either all
within the historical range of three studies from the testing laboratory (19–35%) or the NTP historical
control database (14–52%).  The Committee did not consider the statistically increased incidences of
LGLL in the female F344 rats to be treatment related for the following reasons: (1) LGLL is a common 
and highly variable spontaneous neoplasm in F344 rats; (2) incidences were within the range of available 
historical control data; and (3) no significantly increased incidences of LGLL or any other tumors were
seen in the male rats of this drinking water study (van Miller et al. 2002), in male or female F344 rats or
B6C3F1 mice exposed to glutaraldehyde vapor by inhalation for 2 years (NTP 1999), or Wistar rats
exposed via the drinking water for 2 years (Confidential 2002). As noted earlier, high incidences of bone
marrow hyperplasia and renal tubular pigmentation observed in rats that died prior to terminal sacrifice as 
well as those surviving to terminal sacrifice were most likely related to low grade hemolytic anemia that
accompanied LGLL in these rats (Stromberg et al. 1983; van Miller et al. 2002).
As noted in Section 3.2.1.7 (Cancer), glutaraldehyde is not included in the list of agents evaluated for
carcinogenicity by IARC (IARC 2013).
3.2.3 Dermal Exposure 
3.2.3.1  Death 
No information was located regarding death in humans following dermal exposure to glutaraldehyde.
Available acute lethality studies in which rabbits received dermal application of aqueous glutaraldehyde
for 24 hours reported dermal LD50 values generally within a range of 898–3,405 mg/kg (Ballantyne 1995;
Ballantyne and Jordan 2001; Union Carbide Chem & Plas Co. 1991k, 1991q; Union Carbide Corp. 
1992b, 1992c).  Aqueous glutaraldehyde concentrations in the range of 45–50% were considered 
moderately toxic following acute dermal application; 25% glutaraldehyde was considered significantly
less toxic, and concentrations ≤10% were not considered to pose a significant acute dermal toxicity
hazard (Ballantyne 1995; Ballantyne and Jordan 2001).  However, LD50 values of 282 mg/kg (Union 
Carbide Corp. 1992a) and 9,322 mg/kg (BASF Corp. 1990i) were determined in two other studies that 
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employed 45–50% aqueous glutaraldehyde solutions.  In a repeated-dose dermal study of mice (5/dose)
administered glutaraldehyde via unoccluded dermal application at glutaraldehyde doses in the range of
0.86–1,024 mg/kg/day (5 days/week for up to 10 applications in a 12-day period), doses ≥510 mg/kg/day 
resulted in 100% mortality (Union Carbide Chem & Plas Co. 1991y).  Deaths occurred after 4– 
9 applications.  Only one death occurred among mice treated at <510 mg/kg/day; the death occurred in a 
group treated at 41 mg/kg/day and was not considered treatment related.
All reliable LOAEL and LD50 values for death in each species and duration category are recorded in
Table 3-8.
3.2.3.2  Systemic Effects
The highest NOAEL values and all LOAEL values from each reliable study for each species, duration, 
and end point for systemic effects are recorded in Table 3-8.
No information was located regarding the following effects in humans or laboratory animals exposed to
glutaraldehyde by the dermal route: respiratory, cardiovascular, gastrointestinal, hematological,
musculoskeletal, hepatic, renal, and endocrine effects.
Dermal Effects. Glutaraldehyde is widely recognized as a severe dermal irritant. Numerous reports
are available in which irritant effects have been associated with dermal exposure to glutaraldehyde; these 
results were largely obtained for individuals in a variety of occupational settings where glutaraldehyde is 
used as a germicide (e.g., Bardazzi et al. 1986; Cusano and Luciano 1993; di Prima et al. 1988; Fowler
1989; Hamann et al. 2003; Hansen 1983a, 1983b; Jordan et al. 1972; Kanerva et al. 2000; Kiec-
Swierczynska and Krecisz 2001; Kiec-Swierczynska et al. 2001; Kucenic and Belsito 2002; Maibach 
1975; Nethercott et al. 1988; Nettis et al. 2002; Ravis et al. 2003; Sanderson and Cronin 1968; Shaffer
and Belsito 2000; Stingeni et al. 1995; Tam et al. 1989).
Several human studies were designed to assess glutaraldehyde-induced dermal irritation and sensitization
potential at relatively low dermal dose levels.  In one study, a total of 109 volunteers received repeated
occlusive dermal applications of 0.1, 0.2, and 0.5% aqueous glutaraldehyde to unique sites on the back for
a total of 10 induction applications (Union Carbide Corp. 1980).  Patches remained in place for 48 hours
(72 hours on weekends), followed by removal and readings 15 minutes later for evidence of dermal
irritation.  A total of 7/109 volunteers exhibited application site erythema and 9 other volunteers exhibited 
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Table 3-8. Levels of Significant Exposure to Glutaraldehyde – Dermal 
Species 
(strain) Exposure Parameters Less serious Serious 
number/group parameters monitored System NOAEL LOAEL LOAEL Results Reference/comments 
ACUTE EXPOSURE
Death
Rabbit (albino) Once (24 hr BW CS GN 1,435 mg/kg LD50=2.54 mL/kg for 50% aqueous Union Carbide Corp. 1992b
4 M occluded) 
452, 904, 1,808, 
LE glutaraldehyde Reported doses in mL/kg test substance 
(50% aqueous glutaraldehyde) 
3,616 mg/kg converted to mg glutaraldehyde/kg using 
specific gravity of 1.13 g/mL
Rabbit (albino)
4 M 
Once (24 hr 
occluded) 
BW CS GN
LE 
898 mg/kg LD50=1.59 mL/kg for 50% aqueous 
glutaraldehyde
Union Carbide Chem & Plas Co. 1991k 
Reported doses in mL/kg test substance 
282, 565, 1,130, (50% aqueous glutaraldehyde) 
2,260 mg/kg converted to mg glutaraldehyde/kg using 
specific gravity of 1.13 g/mL
Rabbit (New Once (24 hr BW CS GN 9,322 mg/kg LD50=16.5 mL/kg (combined sexes) BASF Corp. 1990i 
Zealand) occluded) LE for 50% aqueous glutaraldehyde Reported doses in mg test substance 
5 M, 5 F 2,825, 5,650, 
11,300 mg/kg
(50% aqueous glutaraldehyde) 
converted to mg glutaraldehyde/kg using 
specific gravity of 1.13 g/mL
Rabbit (New Once (24 hr BW CS GN 1,008 mg/kg M LD50=2.00 mL/kg (males), 2.71 mL/kg Union Carbide Chem & Plas Co. 1991q
Zealand)
2 or 5 M, 5 F
occluded)
M: 504, 1,008, 2,016, 
LE 1,366 mg/kg F (females) for 45% aqueous 
glutaraldehyde
Reported doses in mg test substance 
(45% aqueous glutaraldehyde/kg 
4,032, 8,064 mg/kg converted to mg glutaraldehyde/kg using 
F: 504, 1,008, 1,411, 
2,016 mg/kg
specific gravity of 1.12 g/mL
Rabbit (New
Zealand)
Once (24 hr 
occluded)
BW CS GN
LE 
282 mg/kg LD50=0.56 mL/kg for 45% aqueous 
glutaraldehyde
Union Carbide Corp. 1992a
Reported doses in mL/kg test substance 
4 M 126, 252, 504 mg/kg (45% aqueous glutaraldehyde) 
converted to mg glutaraldehyde/kg using 
specific gravity of 1.12 g/mL
Rabbit (albino) Once (24 hr BW CS GN 2,128 mg/kg LD50=8.00 mL/kg for 25% aqueous Union Carbide Chem & Plas Co. 1991k 
4 M occluded) 
532, 1,065, 2,130, 
LE glutaraldehyde Reported doses in mL/kg test substance 
(25% aqueous glutaraldehyde) 
4,260 mg/kg converted to mg glutaraldehyde/kg using 
specific gravity of 1.064 g/mL
Rabbit (New Once (24 hr BW CS GN 3,405 mg/kg LD50=12.8 mL/kg for 25% aqueous Union Carbide Corp. 1992c
Zealand)
2 or 4 M
occluded)
213, 852, 1,704, 
3,408 mg/kg
LE glutaraldehyde Reported doses in mL/kg test substance 
(25% aqueous glutaraldehyde) 
converted to mg glutaraldehyde/kg using 
specific gravity of 1.064 g/mL
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Table 3-8. Levels of Significant Exposure to Glutaraldehyde – Dermal 
Species 
(strain) Exposure Parameters Less serious Serious 
number/group parameters monitored System NOAEL LOAEL LOAEL Results Reference/comments 
Mouse 
(C3H/HeJ) 
5 M 
12 d, 5 d/wk, 1 x/d 
(unoccluded) 
0.86, 3.9, 7.9, 41, 95, 
510, 1,024 mg/kg/d 
BW CS GN
LE 
510 mg/kg 0.086–95 mg/kg/d: no treatment-
related deaths
510 and 1,024 mg/kg/d: all mice died 
Union Carbide Chem & Plas Co. 1991y 
Mice received 0.05 mL of various 
dilutions of 50% aqueous 
glutaraldehyde; doses estimated using 
dosing volume and reported mean body
weight for each dilution and accounting 
for proportion of glutaraldehyde for each 
dilution 
Systemic
Human 
41 F (18-35 yr)
Multiple 25-sec 
exposures to 
glutaraldehyde vapor 
at 0.229–0.772 ppm 
CS Ocular 0.39 ppm Threshold of ocular detection Cain et al. 2007
Rat (various 
strains)
4–6-hr exposures to 
glutaraldehyde vapor
CS Ocular 3–78 ppm Clinical signs of ocular irritation Hoechst Celanese 1981; Union Carbide 
Chem & Plas Co. 1991p, 1991x 
Results for multiple studies
Rat (F344)
10 M, 10 F
6 hr/d for 9 exposures 
in 11 d at vapor 
concentrations of 
0.2–2.09 ppm
CS Ocular 0.2 ppm Clinical signs of ocular irritation at
0.2 ppm; dull cornea at 2.09 ppm
Union Carbide Corp. 1992e
Rabbit Single 24-hr dermal 
application 
(unoccluded)
CS Dermal 0.01–0.05 mL Signs of moderate dermal irritation at 
application site following application of 
25–50% aqueous glutaraldedyde
Union Carbide Corp. 1992a, 1992b, 
1992c 
Results for multiple studies
Rabbit Single 1–4 hr dermal 
application (occluded)
CS Dermal 0.5 mL Dose-related persistent primary skin 
irritation following application of 5– 
50% aqueous glutaraldehyde
Union Carbide Chem & Plas Co. 
1991bb, 1991m; Union Carbide Corp. 
1992h, 1992j
Results for multiple studies
Rabbit (New
Zealand)
2 or 4 M
Once (24 hr 
occluded)
213, 852, 1,704, 
3,408 mg/kg
BW CS GN
LE 
Dermal 213 mg/kg Edema and necrosis persisting for 
14 d posttreatment 
Union Carbide Corp. 1992c
Reported doses in mL/kg test substance 
(25% aqueous glutaraldehyde) 
converted to mg glutaraldehyde/kg using 
specific gravity of 1.064 g/mL
Rabbit (albino)
4 M 
Once (24 hr 
occluded) 
452, 904, 1,808, 
3,616 mg/kg
BW CS GN
LE 
Dermal 452 mg/kg Edema and necrosis persisting for 
14 d posttreatment 
Union Carbide Corp. 1992b
Reported doses in mL/kg test substance 
(50% aqueous glutaraldehyde) 
converted to mg glutaraldehyde/kg using 
specific gravity of 1.13 g/mL
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Table 3-8. Levels of Significant Exposure to Glutaraldehyde – Dermal 
Species 
(strain) Exposure Parameters Less serious Serious 
number/group parameters monitored System NOAEL LOAEL LOAEL Results Reference/comments 
Rabbit (New Once (24 hr BW CS GN Dermal 900 mg/kg Application-site erythema, edema, Union Carbide Chem & Plas Co. 1991aa 
Zealand) occluded) LE ecchymosis, necrosis, desquamation, Reported doses in mg test substance 
5 M, 5 F 900 mg/kg ulceration (2000 mg 45% aqueous 
glutaraldehyde/kg) converted to mg 
glutaraldehyde/kg 
Rabbit (New Once (24 hr BW CS GN Dermal 2,825 mg/kg Application-site eschar formation in all BASF Corp. 1990i 
Zealand) occluded) LE rabbits at all dose levels Reported doses in mg test substance 
5 M, 5 F 2,825, 5,650, (50% aqueous glutaraldehyde) 
11,300 mg/kg	 converted to mg glutaraldehyde/kg using 
specific gravity of 1.13 g/mL
Rabbit (New Single 24-hr dermal CS Dermal 0.5 mL Eschar formation in 5/6 rabbits within BASF Corp. 1990f 
Zealand) application (occluded) 24 hr following application of 50% 
6 (sex NS) aqueous glutaraldehyde; persistent 
irritation for 14 d posttreatment
Rabbit (New Single 24-hr dermal CS Dermal 0.5 mL Eschar formation in 6/6 rabbits within BASF Corp. 1990g 
Zealand) application (occluded) 24 hr following application of 25% 
6 (sex NS) aqueous glutaraldehyde; persistent 
irritation for 14 d posttreatment
Mouse 12 d, 5 d/wk, 1 x/d BW CS GN Dermal 7.9 mg/kg/d 41 mg/kg/d
(C3H/HeJ) (unoccluded) LE BW 41 mg/kg/d 95 mg/kg/d
5 M 0, 0.86, 3.9, 7.9, 41, 
95, 510, 1,024 

mg/kg/d 

0.86–41 mg/kg/d: no dermal effects; 
no body weight effects 
95 mg/kg/d: flaky skin at application 
site; 3% body weight loss 
510 mg/kg/d: stained and firm skin at 
application site; 5/5 died 
1,024 mg/kg/d: stained and firm skin, 
subcutaneous edema at application 
site; 5/5 died 
Union Carbide Chem & Plas Co. 1991y 
Mice received 0.05 mL of various 
dilutions of 50% aqueous 
glutaraldehyde; doses estimated using 
dosing volume and reported mean body
weight for each dilution and accounting 
for proportion of glutaraldehyde for each 
dilution 
BW = body weight; CS = clinical signs; d = day(s); F = female(s); GN = gross necropsy; hr = hour(s); LD50 = lethal dose, 50% kill; LE = lethality; M = male(s); NS = not specified; 
sec = second(s); wk = week(s); x = time(s); yr = years of age 
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questionable responses. In another study (Union Carbide Corp. 1966), a group of 21 volunteers were to 
receive repeated 24-hour occluded dermal applications of 5% aqueous glutaraldehyde; dermal irritation
was noted in 15 of the volunteers after two applications; subsequent applications of 1, 2, or 5% aqueous
glutaraldehyde under unoccluded conditions resulted in no signs of dermal irritation.  The study authors
suggested that the irritative effects observed following the initial two applications were attributable to the 
occlusive material rather than glutaraldehyde. However, the study lacked a group receiving occlusion 
treatment in the absence of glutaraldehyde and the lack of dermal effects following unoccluded 
application may have been related to evaporation from the application site. Another group of 40 subjects
received repeated dermal applications of 1–5% aqueous glutaraldehyde for periods of 1 or 5 days under
occluded or unoccluded conditions for a total of five applications (Union Carbide Corp. 1966).  Dermal
irritation was observed in all 40 subjects following 5-day occluded application of 5% glutaraldehyde and 
in 7/40 subjects following 5-day application of 2% aqueous glutaraldehyde, but there was no evidence of
dermal irritation following 1-day unoccluded dermal application at 5% aqueous glutaraldehyde. 
Numerous reports are available regarding glutaraldehyde-induced contact irritation following dermal
application to laboratory animals.  For example, as little as 0.01–0.05 mL of 25–50% aqueous
glutaraldehyde applied to the skin of rabbits for 24 hours resulted in signs of moderate dermal irritation at
the application site (Union Carbide Corp. 1992a, 1992b, 1992c).  A single 24-hour occluded dermal
application of 0.5 mL of 25 or 50% aqueous glutaraldehyde to the skin of rabbits resulted in signs of
severe primary dermal irritation with rapid eschar formation persisting throughout 14 days of
posttreatment observation (BASF Corp. 1990f, 1990g).  Single occluded dermal application of 0.5 mL of
5–50% aqueous glutaraldehyde to rabbit skin for as little as 1–4 hours resulted in dose-related persistent
primary skin irritation (Union Carbide Chem & Plas Co. 1991m; Union Carbide Corp. 1992h, 1992j).  In 
acute lethality studies that employed single 24-hour dermal application to rabbits followed by up to 
14 days of posttreatment observation, severe primary dermal irritation (as evidenced by necrosis and rapid
eschar formation) was observed at 213 mg glutaraldehyde/kg (Union Carbide Corp. 1992c), 452 mg/kg 
(Union Carbide Corp. 1992b), and 2,825 mg/kg (BASF Corp. 1990i), the lowest dose level tested in each
study. Application site dermal irritation was noted in mice receiving repeated 24-hour dermal
applications of glutaraldehyde at doses ≥41 mg glutaraldehyde/kg/day for a total of 10 applications in a
12-day period (Union Carbide Chem & Plas Co. 1991y). Werley et al. (1996) reported signs of
application site dermal irritation (mainly minimal erythema and edema) among rats receiving repeated
dermal applications of aqueous glutaraldehyde for 4 weeks at doses of 50–150 mg/kg/day; the irritative
effects resolved during a 4-week recovery period.
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Ocular Effects. Occupational exposure to glutaraldehyde has been commonly associated with ocular
irritation (Calder et al. 1992; Jachuck et al. 1989; NIOSH 1987a, 1987b; Pisaniello et al. 1997; Vyas et al. 
2000; Waldron 1992; Waters et al. 2003). In some occupational reports that included measurements of
personal and/or workplace airborne glutaraldehyde levels, ocular irritation was self-reported at short-term 
exposure levels as low as 0.05–0.2 ppm).  However, these reports do not provide adequate exposure-
response data for useful quantitative risk analysis. Severe ocular effects were reported in cases of patients 
undergoing eye surgical procedures; it was suspected that the effects were elicited by glutaraldehyde 
residue on surgical equipment following disinfection with glutaraldehyde-containing products (Dailey et
al. 1993; Unal et al. 2006). Cain et al. (2007) reported a threshold of ocular detection of 0.39 ppm, based 
on self-reported results from multiple 25-second exposures of 41 nonsmoking female volunteers (18– 
35 years of age) to glutaraldehyde vapor at 0.229–0.772 ppm.
Numerous reports are available regarding glutaraldehyde-induced effects following ocular instillation of
glutaraldehyde to animals.  For example, installation of as little as 0.005 mL of a 25–50% aqueous
glutaraldehyde solution into rabbit eyes caused severe ocular injury such as necrosis, severe corneal
injury, iritis, and swollen and necrosed eyelids (Union Carbide Corp. 1992a, 1992b, 1992c). Traces of
corneal injury also occurred following instillation of 0.5 mL of 1% aqueous glutaraldehyde (Union
Carbide Corp. 1992a, 1992b). Slight eyelid redness, conjunctival injection, and white discharge were 
observed in the treated eye of three of six rabbits following 0.1 mL ocular installation of 0.2% aqueous
glutaraldehyde; slightly more persistent effects were noted in eyes treated with 0.5% aqueous
glutaraldehyde (Union Carbide Chem & Plas Co. 1991k). Another study reported severe corneal injury
that persisted for 21 days postinstillation of 0.1 mL of 45% aqueous glutaraldehyde into rabbit eyes
(Union Carbide Chem & Plas Co. 1991cc).
Single 4–6-hour exposure of rats to glutaraldehyde vapor at concentrations in the range of 3–78 ppm
resulted in clinical signs of ocular irritation (Hoechst Celanese Corp. 1981; Union Carbide Chem & Plas 
Co. 1991p, 1991x).  In one study of repeated exposure to airborne glutaraldehyde, clinical signs of ocular
irritation were observed at 0.2 ppm and dull corneas were noted at 2.09 ppm (Union Carbide Corp. 
1992e). These effects were the result of direct ocular contact with glutaraldehyde vapor.
Body Weight Effects. No information was located regarding body weight effects in humans
following dermal exposure to glutaraldehyde.
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Significantly depressed mean body weight gain (20% less than that of controls) was reported in male mice
administered a 50% aqueous glutaraldehyde solution dermally via 24-hour occluded patch, 5 days/week
for a total of 10 applications in a 12-day period at a dose level of 95 mg/kg/day (Union Carbide Chem &
Plas Co. 1991y); there were no significant effects on body weight at doses ≤41 mg/kg/day.
3.2.3.3  Immunological and Lymphoreticular Effects 
Numerous reports are available in which dermal patch testing of glutaraldehyde elicited positive results;
these results were obtained for individuals in a variety of occupational settings where glutaraldehyde is 
used as a germicide (e.g., Bardazzi et al. 1986; Cusano and Luciano 1993; di Prima et al. 1988; Fowler
1989; Hamann et al. 2003; Hansen 1983a, 1983b; Jordan et al. 1972; Kanerva et al. 2000; Kiec-
Swierczynska and Krecisz 2001; Kiec-Swierczynska et al. 2001; Kucenic and Belsito 2002; Maibach 
1975; Nethercott et al. 1988; Nettis et al. 2002; Ravis et al. 2003; Sanderson and Cronin 1968; Shaffer
and Belsito 2000; Stingeni et al. 1995; Tam et al. 1989).
Controlled human studies were designed to assess the dermal sensitization potential of glutaraldehyde
(Table 3-9).  In one study of 109 volunteers that employed repeated occlusive dermal applications of 0.1, 
0.2, and 0.5% aqueous glutaraldehyde to unique sites on the back during induction and a single challenge 
application, no sensitization responses were elicited by challenge at 0.1 or 0.2% glutaraldehyde; challenge
at 0.5% glutaraldehyde resulted in one case of erythema and edema and one other case of a questionable 
reaction (Union Carbide Corp. 1980).  In another study (Union Carbide Corp. 1966), a group of
21 volunteers received repeated dermal applications of 5% aqueous glutaraldehyde during induction, 
followed by challenge application.  Based on the severity of reactions provoked by occluded patches
during the first two applications, the remaining applications were unoccluded.  There were no signs of
dermal irritation at any unoccluded site during induction or challenge.  Another group of 40 subjects
received repeated dermal applications of 1–5% aqueous glutaraldehyde for periods of 1 or 5 days under
occluded or unoccluded conditions (Union Carbide Corp. 1966).  Dermal irritation was observed in all
subjects following 5-day occluded application of 5% glutaraldehyde and in 7/40 subjects following 5-day 
occluded application of 2% aqueous glutaraldehyde, but there was no evidence of dermal irritation 
following 1-day unoccluded dermal application at 5% aqueous glutaraldehyde, 5-day occluded 
application of 1% aqueous glutaraldehyde, or in response to challenge application (2% occluded or 5%
unoccluded).
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Table 3-9. Summarized Results from Studies Designed to Evaluate 

Glutaraldehyde-Induced Dermal Hypersensitivity
 
Reference/study
type and subjects Study design Results 
Union Carbide Corp.
1980
Controlled human 
study of dermal
sensitization potential;
109 volunteers
(≥12 years of age)
Union Carbide Corp.
1966
Controlled human 
study of dermal
sensitization potential;
21 ambulatory
subjects (age 
20 months–55 years)
Induction:  ten 48- or 72-hour occlusive 
dermal applications of 0.1, 0.2, and 0.5%
aqueous glutaraldehyde to unique sites
on the back (one site per concentration 
of test material; evaluations for dermal
irritation 15 minutes following removal
Challenge:  single 48-hour application of
0.1, 0.2, and 0.5% aqueous
glutaraldehyde to unique sites;
evaluations at 15 minutes and 24 hours
following removal
Induction: 15 24-hour dermal
applications of 5% aqueous
glutaraldehyde with 24- or 48-hour rest
between applications (first 2 applications
occluded, remaining applications
unoccluded due to severity of irritation 
during occluded applications)
Challenge:  single 24-hour application of
5% aqueous glutaraldehyde to unique
sites after a 2-week rest period
0.1% glutaraldehyde:
Induction:  dermal irritation in 3/109 
Challenge:  no sensitization
0.2% glutaraldehyde:
Induction:  dermal irritation in 3/109 
Challenge:  no sensitization
0.5% glutaraldehyde:
Induction:  dermal irritation or
questionable response in 16/109 
Challenge:  one case of erythema and 
edema and one questionable 
response upon challenge
Induction:  during occluded 
applications, slight to marked erythema 
in 13/20 (one subject dropped out)
Challenge:  no sensitization
Note: these subjects also received 
seven occluded dermal applications of
1% glutaraldehyde and three occluded 
applications of 2% glutaraldehyde in the 
induction phase, followed by challenge 
with 2% glutaraldehyde; erythema was
noted in one subject after the 7th 
application of 1% glutaraldehyde; slight
erythema was noted in 6/20 subjects
following challenge at 2%
glutaraldehyde
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Table 3-9. Summarized Results from Studies Designed to Evaluate 

Glutaraldehyde-Induced Dermal Hypersensitivity
 
Reference/study
type and subjects Study design Results 
Union Carbide Corp.
Controlled human 
study of dermal
sensitization potential;
40 nursing home 
patients (≥30 years of
age)
Stern et al. 1989
Dermal contact
hypersensitivity study
in female guinea pigs
(6/group)
Induction:  one 24-hour occluded dermal
application of 5% glutaraldehyde 
(assumed to be an aqueous solution)
immediately followed by a 5-day 
occluded dermal application of 5%
glutaraldehyde, 48-hour rest, 24-hour
occluded application of 1%
glutaraldehyde to new site, 24-hour rest,
24-hour rest, 24-hour unoccluded 
application of 5% glutaraldehyde to new
site, 48-hour rest, 5-day occluded 
application of 2% glutaraldehyde to new
site, 2-week rest
Challenge:  24-hour applications of 2%
(occluded) and 5% (unoccluded)
glutaraldehyde to new sites
Induction:  dermal application of 0.3, 1,
or 3% glutaraldehyde to the shaved left
side of back on each of 14 consecutive 
days, followed by 7 days of rest
Challenge:  Dermal application of 10%
glutaraldehyde to a new site on left side 
of back, visual evaluation at 24 and 
48 hours postchallenge application,
radioassay of tissue biopsies from left
and right lumbar regions taken at
48 hours postchallenge
Study included vehicle (olive oil:acetone 
1:4) and positive control groups
Induction:  all subjects exhibited 
marked erythema from the 5-day 
occluded application of 5%
glutaraldehyde; 6/40 subjects exhibited 
marked erythema from the 5-day 
occluded application of 2%
glutaraldehyde
Challenge:  no sensitization
Results of visual inspection:  contact
hypersensitivity response at 24 and 
48 hours postchallenge in the group 
receiving 3% glutaraldehyde during 
induction
Results of radioassay:  contact
hypersensitivity response in the lumbar
tissue (but not ear tissue) in the group 
receiving 3% glutaraldehyde during 
induction
Note:  Radioassay method more 
sensitive indicator of hypersensitivity
than visual inspection of challenge site
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Table 3-9. Summarized Results from Studies Designed to Evaluate 

Glutaraldehyde-Induced Dermal Hypersensitivity
 
Reference/study
type and subjects Study design Results 
Stern et al. 1989
Dermal contact
hypersensitivity study
in female guinea pigs
(6/group)
Stern et al. 1989
Dermal contact
hypersensitivity study
in female mice 
(8/group)
Stern et al. 1989
Dermal contact
hypersensitivity study
in female mice 
(8/group)
Induction:  dermal application of 3%
glutaraldehyde to the shaved left side of
back on each of 14 consecutive days,
followed by 14 days of rest
Challenge:  dermal application of 10%
glutaraldehyde to the shaved left side of
back and left ear, visual evaluation at
24 and 48 hours postchallenge 
application, radioassay of tissue biopsies
from left and right lumbar regions and 
left and right ear taken at 48 hours
postchallenge 
Study included vehicle (olive oil:acetone 
1:4) and positive control groups
Induction:  dermal application of 0.3, 1,
or 3% glutaraldehyde to the ventral side 
on each of 5 or 14 consecutive days,
followed by 4 days of rest
Challenge:  dermal application of 10%
glutaraldehyde to the left ear, radioassay
of biopsied ear collected 24 hours
postchallenge
Study included negative, vehicle (olive 
oil:acetone 1:4), and positive control
groups
Induction:  dermal application of 0.3, 1,
or 3% glutaraldehyde to the upper dorsal
side on each of 5 consecutive days,
followed by 7 days of rest
Challenge:  Dermal application of 10%
glutaraldehyde to the left ear, radioassay
of biopsied ears and dorsal skin 
collected 48 hours postchallenge
Study included negative, vehicle (olive 
oil:acetone 1:4), and positive control
groups
Results of visual inspection:
glutaraldehyde induced contact
hypersensitivity response at 24 and 
48 hours postchallenge 
Results of radioassay:  contact
hypersensitivity response in the lumbar
tissue (but not ear tissue)
No evidence of a contact
hypersensitivity response
Contact hypersensitivity response at all
dose levels of glutaraldehyde 
administered during induction, more 
evident in ear tissues than dorsal skin 
tissues
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Table 3-9. Summarized Results from Studies Designed to Evaluate 

Glutaraldehyde-Induced Dermal Hypersensitivity
 
Reference/study
type and subjects Study design Results 
Descotes 1988 Induction:  two applications (2 days Significantly increased mean ear
apart) of 1% glutaraldehyde (in complete thickness
Mouse ear Freund’s adjuvant) to the ear
sensitization assay; Challenge:  Application of 10%
18 female BALB/c glutaraldehyde to the ear on day 9 and 
mice measurement of ear thickness
immediately following application and 
24 hours later
Azadi et al. 2004 Induction:  application of 0.1, 0.75, or Significantly increased ear thickness at
2.5% glutaraldehyde (in dimethyl 30 minutes postchallenge in group 
Mouse ear swelling formamide) to the ear on 3 consecutive administered 2.5% glutaraldehyde
test; female BALB/c days; ear thickness measured prior to during induction; delayed-type 
mice (8/group) challenge hypersensitivity response (at 48 hours
postchallenge application) in mice 
Challenge:  application of 2.5% administered 0.1 or 0.75%
glutaraldehyde to the ear; ear thickness glutaraldehyde during induction
measured at 30 minutes and 24 and
48 hours postchallenge application
Azadi et al. 2004 Application of 0.1, 0.75, or 2.5% Significantly increased lymphocyte 
glutaraldehyde (in dimethyl formamide) proliferation in cervical draining lymph 
Local lymph node to the ear on 3 consecutive days nodes of mice treated with 0.75 or 2.5%
assay; female CBA glutaraldehyde; significantly increased 
and BALB/c mice Study included vehicle and positive percentage of B200+ cells at all
controls glutaraldehyde dose levels; significantly
increased total serum IgE at highest
dose
Hilton et al. 1998 Application of 0.25, 0.5, 1, 2.5, or 5% Glutaraldehyde induces concentration­
glutaraldehyde (in acetone or dimethyl related significant increase in lymph 
Local lymph node formamide) to each ear daily for node cell proliferative activity at all but
assay; female CBA/ca 3 consecutive days, followed by the lowest concentration (0.25%)
mice (4/group) intravenous injection of 3H-methyl
thymidine on day 5 and sacrifice 5 hours
later for harvest of draining auricular
lymph nodes
Study included vehicle controls
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The potential for glutaraldehyde to induce dermal contact hypersensitivity in laboratory animals has been
evaluated in several studies; results are mixed (Table 3-9).  Some studies reported evidence of
glutaraldehyde-induced contact hypersensitivity (Azadi et al. 2004; Descotes 1988; Hilton et al. 1998;
Stern et al. 1989).  No evidence of glutaraldehyde-induced contact hypersensitivity was observed in
another study (BASF 2013).
Two studies evaluated the potential for glutaraldehyde-induced hypersensitivity following dermal
exposure, as indicated by increases in serum IgE. A 4-fold increase in serum IgE was reported for mice 
receiving dermal application of 25% glutaraldehyde (in acetone), followed 1 week later by 12.5%
glutaraldehyde applied to the ear (Ballantyne 1995).  In another study designed to assess total IgE
antibody production following dermal exposure to glutaraldehyde and other chemicals, female BALB/c
mice received two dermal administrations (7 days apart) for total application of 0–9.38 mg glutaraldehyde
in acetone:water (50:50) or 18.75 mg aqueous glutaraldehyde on the shaved flank (first application) and 
dorsal ear (second application) (Potter and Wederbrand 1995).  Analysis of serum collected 14 days
following the initial dermal application revealed significantly increased total IgE (approximately 4-fold 
greater than controls) at the total glutaraldehyde dose of 9.38 mg, but no significant increase at the
18.75 mg dose level.  The difference in responses may have been related to the inclusion of acetone as a 
solvent for the 0–9.38 mg dose levels; however, an acetone vehicle control group was not mentioned in 
the study report.
No studies were located regarding the following effects associated with dermal exposure of humans or
animals to glutaraldehyde:
3.2.3.4  Neurological Effects 
3.2.3.5  Reproductive Effects
3.2.3.6  Developmental Effects 
3.2.3.7  Cancer
3.2.4 Other Routes of Exposure 
Glutaraldehyde has been widely implicated as the cause of colitis and diarrhea following endoscopy or
sigmoidoscopy procedures, the likely result of contact irritation (e.g., Ahishali et al. 2009; Birnbaum et al. 
1995; Dolce et al. 1995; Durante et al. 1992; Fukunaga and Khatibi 2000; Hanson et al. 1998; Rozen et al. 
1994; Shih et al. 2011; Stein et al. 2001; West et al. 1995).
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3.3  GENOTOXICITY
The potential genotoxicity of glutaraldehyde has been assessed in a variety of in vitro and in vivo test 
systems; available results are summarized in Tables 3-10 and 3-11, respectively.
Glutaraldehyde did not induce mutations in Salmonella typhimurium strains TA98, TA1535, TA1537, or
TA1538 either with or without exogenous metabolic activation (Haworth et al. 1983; NTP 1993, 1999; 
Sakagami et al. 1988a, 1988b; Sasaki and Endo 1978; Slesinski et al. 1983; Union Carbide Chem & Plas
Co. 1991ii; Vergnes and Ballantyne 2002).  Glutaraldehyde was also nonmutagenic in a mixture of
S. typhimurium strains TA7001, TA7002, TA7003, TA7004, TA7005, and TA7006 (equal proportions) in 
the absence of exogenous metabolic activation (Kamber et al. 2009).  Positive results were obtained in
most assays using S. typhimurium strains TA102, TA104, TA2638, BA-9, and BA-13 in the absence of
exogenous metabolic activation; most of these assays did not include test results in the presence of
exogenous metabolic activation (Dillon et al. 1998; Jung et al. 1992; Levin et al. 1982; Marnett et al. 
1985; NTP 1993, 1999; Ruiz-Rubio et al. 1985; Watanabe et al. 1998; Wilcox et al. 1990).
Mixed responses were obtained in gene mutation assays using S. typhimurium strain TA100.  Mutations
were not induced in the presence or absence of exogenous metabolic activation in several of these assays 
(Sakagami et al. 1988a, 1988b; Sasaki and Endo 1978; Slesinski et al. 1983).  A weakly positive result
was obtained in the presence (but not the absence) of exogenous metabolic activation in one study
(Vergnes and Ballantyne 2002).  Results varied among performing laboratories as well.  In similarly
designed assays both in the presence and absence of exogenous metabolic activation, negative results 
were obtained in one laboratory, weakly positive results in another laboratory, and clearly positive results
in a third laboratory (results from one or more of these laboratories available in Dillon et al. 1998;
Haworth et al. 1983; and NTP 1993, 1999).
Gene mutation assays using Escherichia coli provided mixed results as well; the assays were performed
in the absence of exogenous metabolic activation.  Glutaraldehyde induced mutations in E. coli strain
WP2 uvrA (pKM101), but not strain WP2 (pKM101) in one set of assays (Wilcox et al. 1990), but
induced mutations in both strains in another set of assays (Watanabe et al. 1998).  Glutaraldehyde did not
induce mutations in E. coli strain WP2 uvrA in yet another assay (Hemminki et al. 1980).
Glutaraldehyde induced gene mutations in human TK6 lymphoblasts (St. Clair et al. 1991) and in the
mouse lymphoma cell line (L5178Y) (McGregor et al. 1988) in the absence of exogenous metabolic 
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Table 3-10. Genotoxicity of Glutaraldehyde In Vitro
Results
With Without
Species/test system End point activation activation Reference
Prokaryotic organisms:
Salmonella typhimurium Gene mutation – – Slesinski et al. 1983
TA100
S. typhimurium TA100 Gene mutation – – Sasaki and Endo 

1978
 
S. typhimurium TA100 Gene mutation –a –a Haworth et al. 1983;
NTP 1993, 1999
S. typhimurium TA100 Gene mutation (+)b (+)b Haworth et al. 1983;
NTP 1993, 1999
S. typhimurium TA100 Gene mutation +c +c Dillon et al. 1998; NTP
1993, 1999
S. typhimurium TA100 Gene mutation (+) – Vergnes and 

Ballantyne 2002
 
S. typhimurium TA100 Gene mutation – – Sakagami et al.
 
1988a, 1988b
 
S. typhimurium TA98 Gene mutation –a,b –a,b Haworth et al. 1983;
NTP 1993, 1999
S. typhimurium TA98 Gene mutation – – Sakagami et al. 1988b
S. typhimurium TA98 Gene mutation – – Sasaki and Endo 

1978
 
S. typhimurium TA98 Gene mutation – – Slesinski et al. 1983
S. typhimurium TA98 Gene mutation – – Union Carbide Chem
& Plas Co. 1991ii
S. typhimurium TA98 Gene mutation – – Vergnes and 

Ballantyne 2002
 
S. typhimurium TA1535, Gene mutation – – Slesinski et al. 1983
TA1537, TA1538
S. typhimurium TA1535, Gene mutation – – Union Carbide Chem
TA1537, TA1538 & Plas Co. 1991ii
S. typhimurium TA1535, Gene mutation – – Vergnes and 

TA1537, TA1538 Ballantyne 2002
 
–a,b –a,b S. typhimurium TA1535, Gene mutation Haworth et al. 1983;
TA1537 NTP 1993, 1999
S. typhimurium TA102 Gene mutation No data + Wilcox et al. 1990
S. typhimurium TA102 Gene mutation No data +d Jung et al. 1992
S. typhimurium TA102 Gene mutation No data – Levin et al. 1982
S. typhimurium TA102, Gene mutation (+)c (+)c Dillon et al. 1998; NTP
TA104 1993, 1999
S. typhimurium TA102, Gene mutation No data + Marnett et al. 1985
 
TA104
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Table 3-10. Genotoxicity of Glutaraldehyde In Vitro
Results
With Without
Species/test system End point activation activation Reference
S. typhimurium TA2638 Gene mutation No data + Levin et al. 1982
 
S. typhimurium TA102, Gene mutation – + Watanabe et al. 1998
 
TA2638
 
S. typhimurium BA-9 Gene mutation No data + Ruiz-Rubio et al. 1985
 
S. typhimurium TA7001, Gene mutation No data – Kamber et al. 2009
 
TA7002, TA7003,
 
TA7004, TA7005,
 
TA7006 (mixture of equal
 
proportions)
 
S. typhimurium BA-13 Gene mutation No data + Ruiz-Rubio et al. 1985
 
Escherichia coli WP2 Gene mutation No data – Wilcox et al. 1990
 
(pKM101)
 
E. coli WP2 uvrA Gene mutation No data + Wilcox et al. 1990
 
(pKM101)
 
E. coli WP2 (pKM101); Gene mutation No data + Watanabe et al. 1998
WP2 uvrA (pKM101)
E. coli WP2 uvrA Gene mutation No data – Hemminki et al. 1980
S. typhimurium DNA damage/repair + + Sakagami et al. 1988a
TA1535/pSK1002 (umu test)
E. coli WP2 uvrA ZA12 DNA damage/repair No data + Nunoshiba et al. 1991
E. coli WP2 uvrA CM561 DNA damage/repair No data + Nunoshiba et al. 1991
E. coli PQ37 DNA damage/repair – – Von der Hude et al.
(SOS chromotest) 1988
Bacillus subtilis M-45 DNA damage/repair + + Sakagami et al. 1988b
(rec-), H-17 (rec+) (liquid rec assay)
E. coli WP2 uvrA ZA60 DNA damage/repair No data + Nunoshiba et al. 1991
Eukaryotic organisms:
Mammalian cells:
Human TK6 Gene mutation No data + St. Clair et al. 1991
lymphoblasts
Mouse lymphoma cell Gene mutation No data + McGregor et al. 1988;
line (L5178Y) NTP 1993, 1999
Chinese hamster ovary Gene mutation – – Vergnes and 
cells Ballantyne 2002
Chinese hamster ovary Gene mutation – – Slesinski et al. 1983
cells
Chinese hamster ovary Gene mutation – – Union Carbide Chem
cells & Plas Co. 1991gg
Chinese hamster ovary Gene mutation – – Union Carbide Chem
cells & Plas Co. 1991hh
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Table 3-10. Genotoxicity of Glutaraldehyde In Vitro
Results
With Without
Species/test system End point activation activation Reference
Chinese hamster ovary Chromosomal – – Union Carbide Chem
cells aberrations & Plas Co. 1991jj
Chinese hamster ovary Chromosomal – – Vergnes and 
cells aberrations Ballantyne 2002
Chinese hamster ovary Chromosomal – +e Galloway et al. 1985;
cells aberrations NTP 1993, 1999
Chinese hamster ovary Chromosomal – –f Galloway et al. 1985;
cells aberrations NTP 1993, 1999
Chinese hamster ovary Chromosomal (+)g (+)h Tsai et al. 2000
cells aberrations
Chinese hamster ovary Sister chromatid – – Slesinski et al. 1983
cells exchange
Chinese hamster ovary Sister chromatid – – Union Carbide Chem
cells exchange & Plas Co. 1991gg
Chinese hamster ovary Sister chromatid +i +i Galloway et al. 1985;
cells exchange NTP 1993, 1999
Chinese hamster V79 Sister chromatid No data + Speit et al. 2008
lung fibroblasts exchange
Chinese hamster V79 Micronuclei – – Tsai et al. 2000
lung fibroblasts
Chinese hamster ovary Micronuclei No data + Speit et al. 2008
cells
Chinese hamster V79 DNA damage No data – Speit et al. 2008
lung fibroblasts
Human lung epithelial DNA double-strand No data +/– Vock et al. 1999
carcinoma cells (A549) breaks
Rat primary DNA strand breaks No data – Kuchenmeister et al.
hepatocytes 1998
Human TK6 DNA-protein No data + St. Clair et al. 1991
lymphoblasts cross-links
Rat primary Unscheduled DNA No data + St. Clair et al. 1991
hepatocytes synthesis
Rat primary Unscheduled DNA No data – Slesinski et al. 1983
hepatocytes synthesis
Rat primary Unscheduled DNA No data – Union Carbide Chem
hepatocytes synthesis & Plas Co 1991gg
Syrian hamster embryo Unscheduled DNA – – Zeiger et al. 2005
cells synthesis
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Table 3-10. Genotoxicity of Glutaraldehyde In Vitro
Results
With Without
Species/test system End point activation activation Reference
Syrian hamster embryo Cell transformation No data – Yamaguchi and 
cells Tsutsui 2003
aStudy performed at Case Western Reserve University.
 
bStudy performed at EG&G Mason Research Institute.
 
cStudy performed at Inveresk Research International.
 
dPositive results at two of three laboratories, a weakly positive result at the other laboratory.
 
eStudy performed at Columbia University.
 
fStudy performed at Litton Bionetics, Inc.
 
g1.8-fold increase relative to negative control.
 
h1.6-fold increase relative to negative control.
 
iPositive results at two separate laboratories (Columbia University and Litton Bionetics, Inc.).
 
– = negative result; + = positive result; +/– = inconclusive result; (+) = weakly positive result;
DNA = deoxyribonucleic acid
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Table 3-11. Genotoxicity of Glutaraldehyde In Vivo
Species/test system End point Results Reference
Rat (bone marrow) Chromosomal aberrations – Confidential 1987a
Rat (bone marrow) Chromosomal aberrations – Vergnes and Ballantyne 
2002
Mouse (bone marrow) Chromosomal aberrations +a NTP 1999
Mouse (peripheral blood) Micronucleus formation – Vergnes and Ballantyne 
2002
Mouse (peripheral blood) Micronucleus formation –b NTP 1999
Mouse (bone marrow) Micronucleus formation (+)c NTP 1999
Mouse (bone marrow) Micronucleus formation –d NTP 1999
Rat (testis) DNA cross links – Confidential 1987b
Rat (testis) DNA strand breaks – Confidential 1987c
Rat (hepatocytes) Unscheduled DNA synthesis – Mirsalis et al. 1989
Mouse (sperm cells) Dominant lethality – NTP 1993, 1999
Drosophila Sex-linked recessive lethal – Yoon et al. 1985; Zimmering 
mutations et al. 1989
aNegative result at 17 hours posttreatment, but positive results at 36 hours posttreatment.

bRepeated inhalation exposure of male and female mice for 13 weeks at glutaraldehyde concentrations up to 

0.5 ppm.
 
cSingle intraperitoneal injection.
 
dThree daily intraperitoneal injections, two trials.
 
– = negative result; + = positive result; –/+ = equivocal result; (+) = weakly positive result; DNA = deoxyribonucleic
 
acid
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activation.  Glutaraldehyde did not induce gene mutations in several assays using Chinese hamster ovary
cells in both the presence and absence of exogenous metabolic activation (Slesinski et al. 1983; Union 
Carbide Chem & Plas Co. 1991gg, 1991hh).
Assays designed to evaluate potential for glutaraldehyde to induce DNA damage/repair provided mostly
positive results.  Positive results were obtained for S. typhimurium strain TA1535/pSK1002 in the umu
test both in the presence and absence of exogenous metabolic activation (Sakagami et al. 1988b), E. coli
strains WP2 uvrA ZA12, WP2 uvrA ZA60, and WP2 uvrA CM561 in the absence of exogenous metabolic
activation (Nunoshiba et al. 1991), and in a liquid rec assay using Bacillus subtilis strains M-45 (rec -) and 
H-17 (rec+) in both the presence and absence of exogenous metabolic activation (Sakagami et al. 1988a).  
Glutaraldehyde did not induce DNA damage/repair in an assay using E. coli strain PQ37 in the presence 
of exogenous metabolic activation (von der Hude et al. 1988). Glutaraldehyde did not induce DNA strand 
breaks in Chinese hamster V79 lung fibroblasts (Speit et al. 2008) or rat primary hepatocytes 
(Kuchenmeister et al. 1998) in the absence of exogenous metabolic activation.  Inconclusive results were 
obtained for glutaraldehyde-induced DNA double-strand breaks in human lung epithelial carcinoma cells 
(A549) (Vock et al. 1999).
DNA-protein cross-links were noted in human TK6 lymphoblasts exposed to glutaraldehyde (St. Clair et
al. 1991).  Glutaraldehyde induced unscheduled DNA synthesis in rat primary hepatocytes in one assay
(St. Clair et al. 1991), but not in two other assays (Slesinski et al. 1983; Union Carbide Chem & Plas Co. 
1991gg).  In Syrian hamster embryo cells, glutaraldehyde did not induce unscheduled DNA synthesis
either in the presence or absence of exogenous metabolic activation (Zeiger et al. 2005), or cell
transformation in the absence of exogenous metabolic activation (Yamaguchi and Tsutsui 2003).
In assays that assessed the potential for glutaraldehyde to induce chromosomal aberrations in Chinese
hamster ovary cells, two assays were negative in both the presence and absence of exogenous metabolic 
activation (Union Carbide Chem & Plas Co. 1991jj; Vergnes and Ballantyne 2002).  In a third study that
included assays in two separate laboratories, the results in the absence of exogenous metabolic activation
were positive in one laboratory and negative in the other laboratory; both laboratories reported weakly
positive results in the presence of exogenous metabolic activation (Galloway et al. 1985).  In assays of
Chinese hamster ovary cells for glutaraldehyde-induced sister chromatid exchange, negative (Slesinski et
al. 1983; Union Carbide Chem & Plas Co. 1991gg) and positive (Galloway et al. 1985) or weakly positive
(Tsai et al. 2000) results were obtained both in the presence and absence of exogenous metabolic 
activation.  Glutaraldehyde induced sister chromatid exchange and micronuclei in Chinese hamster V79 
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lung fibroblasts in the absence of exogenous metabolic activation (Speit et al. 2008), but did not induce
micronuclei in Chinese hamster ovary cells in the presence or absence of exogenous metabolic activation
(Tsai et al. 2000).
The potential for glutaraldehyde to act as a genotoxic agent has been assessed in a number of in vivo
assays as well; results are mostly negative.  Glutaraldehyde did not induce chromosomal aberrations in
bone marrow cells (type not specified) from male and female Sprague-Dawley rats treated by gavage
once at 140–200 mg/kg or repeatedly at 20–28 mg/kg/day (Confidential 1987a), or polychromatophils
from bone marrow of other male and female Sprague-Dawley rats treated by single gavage at 7.5– 
60 mg/kg in another study (Vergnes and Ballantyne 2002).  Negative results were obtained in one trial of
male B6C3F1 mice treated with glutaraldehyde by intraperitoneal injection at 15–60 mg/kg and assessed
for chromosomal aberrations in the bone marrow at 17 hours postinjection; positive results were obtained 
in two other trials at 50 and/or 60 mg/kg with assessment at 36 hours postinjection (NTP 1999).
Glutaraldehyde did not induce micronucleus formation in the peripheral blood of male or female Swiss-
Webster mice following gavage administration at 40–125 mg/kg (Vergnes and Ballantyne 2002) or male 
B6C3F1 mice repeatedly exposed to glutaraldehyde vapor at 0.0625–0.5 ppm for 13 weeks (NTP 1999).  
A positive result for micronucleus formation was obtained in assessment of bone marrow from male 
B6C3F1 mice administered single intraperitoneal injection of glutaraldehyde at 15, 50, or 60 mg/kg (but
not at 30 mg/kg); however, negative results were obtained in a similar protocol that included 3 daily
intraperitoneal injections at 5–20 mg/kg/day (NTP 1999).
Evaluation of DNA from testes of Sprague-Dawley rats administered glutaraldehyde by single gavage at
18–55 mg/kg or five daily doses at 9–28 mg/kg/day revealed no evidence of treatment-related cross links 
or strand breaks (Confidential 1987b, 1987c).  Glutaraldehyde did not induce unscheduled DNA synthesis
in hepatocytes from male Fischer-344 rats treated by gavage once at 30–600 mg/kg (Mirsalis et al. 1989),
dominant lethality following gavage treatment of male JCL-ICR mice with 30 or 60 mg glutaraldehyde/kg 
and mating with untreated females for 6 weeks (NTP 1993, 1999), or sex-linked recessive lethal 
mutations in Drosophila (Yoon et al. 1985; Zimmering et al. 1989).
In summary, the available in vitro data suggest that glutaraldehyde is weakly mutagenic in bacteria and
mammalian cell lines. Varibility in test protocol among the various mutagenicity assays may be 
responsible for at least some of the variability in results. There is some evidence for glutaraldehyde­
induced chromosomal aberrations, sister chromatid exchange, and micronuclei in mammalian cells
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systems.  Glutaraldehyde does not appear to cause DNA damage or cell transformation in mammalian cell
systems.  Mostly negative results were obtained in assays for glutaraldehyde-induced unscheduled DNA 
synthesis in mammalian cell systems. Available in vivo data do not generally provide support for a
genotoxic role for glutaraldehyde (five studies reported negative results, one study reported a positive 
result, and another study reported a weakly positive result); however, data are limited. Glutaraldehyde
did not induce DNA cross-links or strand breaks, unscheduled DNA synthesis, or dominant lethality in 
rats and/or mice, or sex-linked recessive lethal mutations in Drosophila.  Negative or equivocal/weakly
positive results were reported from assays of glutaraldehyde-induced chromosomal aberrations and
micronuclei in mouse bone marrow.
3.4  TOXICOKINETICS
3.4.1 Absorption 
3.4.1.1  Inhalation Exposure 
Information regarding absorption via the inhalation route is limited to observations of systemic effects 
such as toxic hepatitis in mice following inhalation of glutaraldehyde for 24 hours at a reported
concentration of 0.133 mg/L (Varpela et al. 1971). No quantitative data were located regarding
absorption of inhaled glutaraldehyde.
3.4.1.2  Oral Exposure
No human data were located regarding absorption following oral exposure to glutaraldehyde.
Following gavage administration of radiolabeled glutaraldehyde to male Fischer rats at a mean dose of
68.5 mg/kg (Union Carbide Chem & Plas Co. 1991ff), radioactivity was detected in expired 14CO2 and 
urine, indicating that gastrointestinal absorption of glutaraldehyde and/or its metabolites occurs.  No
quantitative data were located regarding absorption following oral exposure of animals to glutaraldehyde.
3.4.1.3  Dermal Exposure 
In a material balance study, male and female Fischer 344 rats received aqueous 14C-glutaraldehyde to 12– 
15% of the total body surface under occluded conditions for 24 hours at concentrations resulting in 
estimated doses of up to 63 mg/kg to males and up to102 mg/kg to females (McKelvey et al. 1992).  
Based on recovery of radioactivity from skin and dressing, application materials and cage washings,
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expired 14CO2, urine, feces, and carcass, percutaneous absorption of glutaraldehyde and/or its metabolites 
was estimated to have been 4–9% of the administered dose.  Similar administration of 14C-glutaraldehyde
to male and female New Zealand white rabbits resulted in percutaneous absorption of approximately 33– 
53% of an administered 60 mg/kg dose.
In a pharmacokinetic study performed on rats and rabbits under conditions similar to those employed in 
the material balance study, calculated dermal absorption rate constants ranged from 0.2 to 2 per hour
(McKelvey et al. 1992).  Absorption was greater in the rabbits than the rats; estimates of dermal
absorption in the pharmacokinetic study were less than those estimated in the material balance study.
A material balance study assessed dermal penetration of 14C-glutaraldehyde through 1-inch disks of skin 
taken from rats, mice, guinea pigs, rabbits, and humans (women undergoing reconstructive
mammoplasty) (Ballantyne 1995; Frantz et al. 1993).  At the highest dose level (7.5% glutaraldehyde), 
estimated dermal penetration of the administered dose was 0.2% for the human skin compared to 0.7% for 
the animal species (range of 0.05% for the female rat skin to 1.73% for the male mouse skin).  Among the
laboratory animal species, absorption rates ranged from 0.804 mg/cm2/hour for the male rat skin to
2.510 mg/cm2/hour for the female rabbit skin; the absorption rate for the human skin was 
1.581 mg/cm2/hour. The results for the in vitro rat skin sample compare to the in vivo results from
McKelvey et al. (1992) when normalizing for total treated skin surface area (1.77 cm2 for the in vitro rat
skin sample compared to 144 cm2 for the treated area in the in vivo study).
Reifenrath et al. (1985) investigated the in vitro percutaneous penetration of 10% aqueous glutaraldehyde
through isolated human thin stratum corneum (chest and abdomen), abdominal epidermis, and thick
stratum corneum (blister tops from soles) during 1 hour postapplication.  Penetration of the applied dose
measured 2.8–4.4% for the epidermis and 3.3–13.8% for the thin stratum corneum; there was no 
indication of penetration through the thick stratum corneum.
3.4.1.4  Other Routes of Exposure
Based on the use of glutaraldehyde as a fixative in human root canal preparations, the absorption of
glutaraldehyde from canine and incisor pulpotomy sites was assessed in dogs (Myers et al. 1986).  
Pulpotomy sites received a cotton pellet containing 5.6 µCi of 14C-glutaraldehyde (as a 2.5% aqueous
solution) for 5 minutes.  Based on measurements of blood, urine, and expired air for 90 minutes following
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removal of the pellet and assessment of radioactivity in tissues, it was determined that approximately 3%
of the dose had been absorbed from the site.
3.4.2 Distribution 
In animal studies involving administration of radiolabeled glutaraldehyde, the proportion of radioactivity
in various tissues varied according to route of exposure.
3.4.2.1  Inhalation Exposure 
Information regarding distribution following inhalation exposure to glutaraldehyde is limited to the
observation of toxic hepatitis in mice following inhalation of glutaraldehyde for 24 hours at a reported
concentration of 0.133 mg/L, which indicates that systemic distribution of parent compound and/or its
metabolites occurs (Varpela et al. 1971).
3.4.2.2  Oral Exposure
No information was located regarding distribution following oral exposure of humans to glutaraldehyde.
Results of one animal study indicate that glutaraldehyde and/or its metabolites are distributed 
systemically following oral exposure.  At 48 hours following gavage administration of 14C-glutaraldehyde
to male Fischer rats at a mean dose of 68.5 mg/kg (Union Carbide Chem & Plas Co. 1991ff), an average
of 22% of the administered radioactivity was recovered in the carcass. Mean concentrations or
radioactivity were 58 µg glutaraldehyde/g wet tissue in the stomach, 21µg/g in the kidney, 19 µg/g in the
esophagus, 8 µg/g in the liver, 7 µg/g in the spleen, and 5 µg/g in the trachea, 5 µg/g in blood cells, and 
4 µg/g in lungs.  Lesser amounts were detected in bladder, brain, fat, heart, muscle, plasma, and testis.
3.4.2.3  Dermal Exposure 
No information was located regarding distribution following dermal exposure of humans to 
glutaraldehyde.
Male and female Fischer 344 rats and New Zealand white rabbits received dermal application of aqueous 
14C-glutaraldehyde under occluded conditions for 24 hours (McKelvey et al. 1992).  Of the absorbed 
radioactivity (4–9 and 33–53% of the administered dose for rats and rabbits, respectively), the highest
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concentrations of radioactivity were in found in bladder, bone marrow, and kidney of the male rats; lymph 
node, trachea, and kidney of the female rats; urinary bladder, kidney, pancreas, spleen, and salivary gland 
of the male rabbits; and blood cells, kidney, liver, lung, and spleen of the female rabbits. Smaller
concentrations were observed in a wide variety of other tissues and organs.
3.4.2.4  Other Routes of Exposure
Male and female Fischer 344 rats and New Zealand white rabbits received aqueous 14C-glutaraldehyde 
via intravenous injection (McKelvey et al. 1992).  At 24 hours postinjection, approximately 3–7 and 4– 
12% of the administered dose was recovered in tissues of the rats and rabbits, respectively.  The highest
concentrations of radioactivity were in blood cells and certain well-perfused tissues (spleen, lung, liver, 
kidney, and bone marrow); lesser concentrations were observed in a wide variety of other tissues and
organs.
Groups of rats were infused (intravenously) with 10 µCi of 14C-glutaraldehyde over a 1-minute period and 
assessed for up to 3 days postinfusion for the distribution of radioactivity between plasma and blood cells
(Ranly and Horn 1990).  During the postinfusion period, the ratio of red blood cell to plasma radioactivity
varied between 2 and 3.  The higher content in the cellular fraction was indicative of incorporation into 
red blood cells.  During the 3-day postinfusion period, a 6-fold reduction was observed for radioactivity in
the red blood cells and plasma, indicating similarity in elimination rates.  Ranly et al. (1990) infused rats
(intravenously) with 14C-glutaraldehyde, followed by sacrifice at 5 or 60 minutes postinfusion to assess
the cyctolic, membrane, and nuclear fractions of radioactivity in liver cells.  Significant radioactivity was
associated with cytosol and membrane fractions, but not nuclear fractions.
Canine and incisor pulpotomy sites of dogs received a cotton pellet containing 5.6 µCi of
14C-glutaraldehyde (as a 2.5% aqueous solution) for 5 minutes (Myers et al. 1986).  Examination of
tissues extracted at sacrifice 90 minutes following the glutaraldehyde treatment revealed that muscle
contained approximately 50% of the absorbed dose (3% of the applied dose), with 12% in red blood cells 
and lesser amounts (in descending order) in plasma, liver, lung, kidney, heart, and spleen.  A tissue-to­
plasma ratio of 2.21 for red blood cells suggested some degree of binding; tissue-to-plasma ratios for
other tissues were lower, indicating little or no binding affinity.
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3.4.3 Metabolism
Beauchamp et al. (1992) reviewed available data regarding the pharmacokinetics of glutaraldehyde and 
other aldehydes.  Based on results from in vivo studies and in vitro assays, Beauchamp et al. (1992)
proposed the metabolic pathway for glutaraldehyde shown in Figure 3-4.  According to the metabolic
scheme, glutaraldehyde undergoes oxidation to form glutaric γ-semialdehyde (step 1), which is oxidized 
to glutaric acid (step 2).  Synthesis of a coenzyme A (CoA) thioester, by a thiokinase reaction or transfer
of CoA from succinyl CoA catalyzed by a thiophorase, results in further metabolism to glutaryl CoA (step 
3), followed by reduction to glutaconyl CoA by glutaryl CoA dehydrogenase (step 4), production of
crotonyl CoA via decarboxylation which results in the release of CO2 (step 5), hydration to β-hydroxy­
butyryl CoA by enoyl CoA hydratase (step 6), conversion to acetyl CoA (step 7), and oxidation to CO2 
(step 8).  Results of in vitro assays suggest the involvement of NAD+ and FAD+ electron transport
systems in reduction reactions.
In an in vitro assay of 14C-glutaraldehyde-incubated rat liver cells, glutaraldehyde was metabolized to
14CO2 (Ranly et al. 1990).  However, no significant radioactivity was detected in isolated nucleic acids.
In another in vitro assay that assessed the production of 14CO2 by 14C-glutaraldehyde-treated rat red blood 
cells, uptake of radioactivity by red blood cells was approximately 20% of the dose.  However, the red 
blood cells did not appear to metabolize the glutaraldehyde as demonstrated by similarly low amounts of
14CO2 among intact and hemolyzed red blood cells (Ranly and Horn 1990).  Similar assessment using
intact and denatured liver tissue resulted in an 18-fold higher production of 14CO2 in the intact liver tissue
compared to that of denatured liver tissue and intact and hemolyzed red blood cells.
3.4.4 Elimination and Excretion 
In animal studies involving administration of radiolabeled glutaraldehyde, the proportion of radioactivity
in urine and feces varied according to route of exposure.
3.4.4.1  Inhalation Exposure 
No information was located regarding elimination or excretion in humans or animals following inhalation 
exposure to glutaraldehyde.
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Figure 3-4.  Proposed Metabolic Scheme for Glutaraldehyde
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3.4.4.2 Oral Exposure
Following gavage administration of 14C-glutaraldehyde to four male Fischer rats at a mean dose of
68.5 mg/kg (Union Carbide Chem & Plas Co. 1991ff), an average of 35% of the administered 
radioactivity was collected in the feces during 48 hours posttreatment.  Lesser amounts of radioactivity
were observed in the urine and expired 14CO2 (6 and 21% of the administered radioactivity, respectively).  
Of the expired 14CO2, 60% was excreted in the first 6 hours, and 92% was excreted in the first 24 hours.
The identity of specific radioactive urinary and fecal compounds was not determined.
3.4.4.3  Dermal Exposure 
No information was located regarding elimination or excretion in humans following dermal exposure to 
glutaraldehyde.
Male and female Fischer 344 rats received aqueous 14C-glutaraldehyde dermally under occluded 
conditions for 24 hours at concentrations resulting in estimated doses of up to 63–102 mg/kg (McKelvey 
et al. 1992).  Up to 3% of the administered radioactivity was recovered in the urine and lesser amounts in 
expired 14CO2.  Anion exchange chromatographic analysis of urine revealed two major fractions 
comprising 28–41% and 9–14%, respectively, of the urinary radioactivity, and one minor fraction 
comprising 3–5% of the urinary radioactivity.  The chemical composition of the fractions was not
determined.  For the rats, residual urinary radioactivity was 40–64% of the total urinary radioactivity.
Similar administration of 14C-glutaraldehyde to male and female New Zealand white rabbits resulted in
elimination of 2–12% and 2–17% of the administered dose in the urine and expired 14CO2, respectively.
Anion exchange chromatographic analysis of the rabbit urine revealed peaks similar to those obtained
from the rat urine, with the exception of a double peak for one of the fractions in the rabbit urine.  Major
fractions represented 11–25%, and 25–46% and 10–29% (double-peak fraction) of the urinary 
radioactivity; the minor fraction accounted for 7–9% of the urinary radioactivity.  For the rabbits, residual
urinary radioactivity was 2–13% of the total urinary radioactivity.
3.4.4.4  Other Routes of Exposure
Male and female Fischer 344 rats received aqueous 14C-glutaraldehyde via intravenous injection 
(McKelvey et al. 1992).  At 24 hours postinjection, approximately 7–12% of the administered dose had 
been recovered in the urine, 2.5–4.5% in the feces, and 64–78% in expired 14CO2. Approximately 24– 
***DRAFT FOR PUBLIC COMMENT***
   
 
    
 
 
 
  
 
   
  
  
 
    
 
   
  
 
    
 
   
     
    
  
 
    
 
  
  
    
   
   
   
  
     
 
  
    
 
 
 
 
  
97GLUTARALDEHYDE
3. HEALTH EFFECTS
33%, 10–29%, and 3–6% of the urinary radioactivity was associated with three separate urinary fractions.  
The chemical composition of the fractions was not determined; residual urinary radioactivity was 28–53%
of the total urinary radioactivity.  Following similar administration of 14C-glutaraldehyde to male and 
female New Zealand white rabbits, approximately 15.5–28%, 0.2–1.5%, and 30–71% of the administered 
dose were recovered in the urine, feces, and expired 14CO2, respectively.  Urinary fractions represented
10–19%, 26–44%, and12–20% (double-peak fraction), and 11–16% of the urinary radioactivity.  For the
rabbits, residual urinary radioactivity was 5–16% of the total urinary radioactivity.
Following intravenous infusion of rats with 10 µCi of 14C-glutaraldehyde, approximately 14% of the dose
was collected in the urine during the first hour postinfusion and 29% during the first 6 hours (Ranly and 
Horn 1990).  After 3 days, urinary excretion of radioactivity had decreased to approximately 0.2%/hour.  
Chromatographic analysis of urinary contents indicated that only 3% of the dose was excreted as parent
compound.  Specific urinary metabolites of glutaraldehyde were not identified.
Canine and incisor pulpotomy sites of dogs received a cotton pellet containing 5.6 µCi of
14C-glutaraldehyde (as a 2.5% aqueous solution) for 5 minutes (Myers et al. 1986).  During 90 minutes
posttreatment, radioactivity in urine, feces, and expired air was assessed.  Dogs were then sacrificed for
assessment of radioactivity in tissues.  Approximately 3% of the applied dose was absorbed.
Approximately 8% of the absorbed dose was excreted in the urine, another 3.6% in the expired air, and 
0.6% in the feces (biliary excretion).
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985). Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target
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tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species. The biological basis of
PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these
solutions.  
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty. The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste
sites) based on the results of studies where doses were higher or were administered in different species.
Figure 3-5 shows a conceptualized representation of a PBPK model.
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Figure 3-5.  Conceptual Representation of a Physiologically Based
 
Pharmacokinetic (PBPK) Model for a

Hypothetical Chemical Substance
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Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source:  adapted from Krishnan and Andersen 1994
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If PBPK models for glutaraldehyde exist, the overall results and individual models are discussed in this
section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species 
extrapolations.
PBPK models for glutaraldehyde were not located.
3.5  MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms
No information was located regarding pharmacokinetic mechanisms for glutaraldehyde.
3.5.2 Mechanisms of Toxicity
Aldehydes as a group are reactive chemicals with a highly electronegative oxygen atom and less 
electronegative atoms of carbon(s), and hence have a substantial dipole moment.  The carbonyl atom is
the electrophilic site of these types of molecules, making it react easily with nucleophilic sites on cell
membranes and in body tissues and fluids such as the amino groups in protein and DNA.  The
effectiveness of glutaraldehyde as a tanning agent for leather, tissue fixative for microscopy, and biocide 
is attributed to its propensity to react with and cross-link proteins (Peters and Richards 1977).  These 
molecular properties also contribute to portal-of-entry irritant and cytotoxic effects of glutaraldehyde,
although the precise mechanisms for these effects are not known. No information was located regarding
possible mechanisms of action for glutaraldehyde-induced dermal sensitization.
3.5.3 Animal-to-Human Extrapolations 
Major targets of glutaraldehyde toxicity (portal-of-entry irritation) are common to laboratory animals and 
humans.  Available animal data implicate the kidney as a target of toxicity following oral administration
of glutaraldehyde; it is therefore assumed that the kidney is a potential target of toxicity in humans,
although no human data were located to support this assumption.  No other information was located to 
indicate major species-specific differences in glutaraldehyde-induced health effects.
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3.6 HAZARD IDENTIFICATION AND MINIMAL RISK LEVELS 
3.6.1 Hazard Identification
Systematic review of available human and animal studies that assessed potential health effects associated
with inhalation, oral, and dermal/ocular exposure to glutaraldehyde resulted in determinations that
glutaraldehyde acts as a contact irritant at relatively low exposure levels, causing upper respiratory tract
irritation via the inhalation exposure route, gastrointestinal irritation via the oral exposure route, and 
dermal and ocular irritation upon contact with skin and eyes.  Available animal data implicate the kidney
as a target of glutaraldehyde toxicity via the oral route of exposure. Hazard identification conclusions for
glutaraldehyde, resulting from systematic review of available human and animal data, are presented in
Appendix B and are summarized as follows:
•	 Glutaraldehyde is known to cause irritation of the upper respiratory tract, based on a high level of
evidence from human and animal studies.
•	 Oral exposure to glutaraldehyde is presumed to cause adverse gastrointestinal effects in humans,
based on a high level of evidence from animal studies; human data are lacking.
•	 Direct contact between glutaraldehyde and skin is presumed to cause irritative effects in humans, 
based on a low level of evidence from human and high level of evidence from animal studies.
•	 Direct contact between glutaraldehyde and eyes is presumed to cause irritative effects in humans,
based a moderate level of evidence from human studies and high level of evidence from animal
studies.  
•	 Glutaraldehyde is presumed to cause adverse renal effects in humans, based on a high level of
evidence from animal studies that employed inhalation or oral exposure; human data are lacking.
As discussed below, MRLs for glutaraldehyde were derived based on the most sensitive effects from
available high quality animal studies.
3.6.2 Minimal Risk Levels (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for glutaraldehyde.  
An MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure. MRLs are based on
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for
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acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate
methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of
significant human exposure improve, these MRLs will be revised.
3.6.2.1  Inhalation MRLs
Acute-Duration. Limited quantitative human data are available. The glutaraldehyde odor threshold in
humans was determined to be in the range of 0.0003 ppm based on multiple 5-second exposures; a similar
exposure scenario resulted in a threshold of 0.47 ppm for the perception of an effect on nasal tissue (Cain 
et al. 2007).  Within a group of 50 female subjects exposed to air only or glutaraldehyde vapor at 0.035, 
0.050, 0.075, or 0.100 ppm for 15-minute intervals, the cumulative proportion of subjects who achieved 
50% correct detection of glutaraldehyde (self-reported perception of nasal sensation) ranged from <5% at
the glutaraldehyde concentration of 0.035 ppm to slightly more than 50% at 0.1 ppm (Cain et al. 2007).
The threshold of sensory irritation of glutaraldehyde vapor was assessed in five male and four female
subjects who had not been regularly exposed to glutaraldehyde vapor (Union Carbide Corp. 1976).  The
subjects were exposed for 2 minutes/day on 3 consecutive days to vapor from an activated (alkaline)
CIDEX solution (2% aqueous glutaraldehyde) and on a 4th day to glutaraldehyde vapor from an 
unactivated (acidic) solution.  Based on self-reported perception of sensory irritation (most frequently
nasal irritation; ocular irritation at relatively higher exposure levels), the human sensory irritation
threshold was approximately 0.237–0.245 ppm glutaraldehyde from the activated solution and 0.255 ppm 
for glutaraldehyde from the unactivated solution.  Case reports are available regarding glutaraldehyde­
induced occupational asthma (Chan-Yeung et al. 1993; Corrado et al. 1986; Cullinan et al. 1992; Di
Stefano et al. 1999; Gannon et al. 1995; Ong et al. 2004; Quirce et al. 1999; Trigg et al. 1992);
glutaraldehyde challenge concentrations on the order of 0.068–0.075 mg/m3 (0.016–0.018 ppm) induced 
hypersensitivity responses in some cases.
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Depressed body weight gain and actual body weight loss have been observed in laboratory animals
exposed to glutaraldehyde vapor.  Single exposure of male and female rats to glutaraldehyde vapor for
4 hours at analytical concentrations in the range of 9.1–43.5 ppm resulted in 35–42% depressed body
weight gain during 14 days of postexposure observation (Union Carbide Corp. 1992l).  Repeated 6-hour
exposures of male and female rats to glutaraldehyde vapor (5 days/week for 11 days) resulted in 33–41%
depressed body weight gain at 0.2 ppm glutaraldehyde and 21–22% body weight loss at 0.63 ppm (Union 
Carbide Corp 1992e).
The occurrence of histopathologic nasal lesions was selected as the critical effect for deriving an acute-
duration inhalation MRL for glutaraldehyde because the lesions clearly represent an adverse effect and
they occurred in the range of the lowest exposure concentrations employed in available acute-duration 
inhalation studies.  In the study of Union Carbide Corp (1992d), rhinitis and mild atrophy of the olfactory
mucosa were observed in male and female F344 rats exposed to glutaraldehyde vapor at 3.1 ppm for
6 hours/day for 9 exposures in 11 days; at an exposure level of 1.1 ppm, males (but not females) exhibited 
rhinitis and mild squamous metaplasia of the olfactory mucosa.  This study identified a no-observed­
adverse-effect level (NOAEL) of 0.3 ppm and a lowest-observed-adverse-effect level (LOAEL) of
1.1 ppm for nasal lesions in the male rats.  Zissu et al. (1994) observed histopathological lesions in the
respiratory epithelium of the septum and naso- and maxilloturbinates of male Swiss OF1 mice exposed to
glutaraldehyde vapor for 5 hours/day on 4 consecutive days at 0.3 ppm (the lowest concentration tested);
the severity of glutaraldehyde-induced nasal lesions increased with increasing exposure concentration. 
This study did not identify a NOAEL.  In a study designed to evaluate the time course of glutaraldehyde­
induced nasal lesions (Gross et al. 1994; NTP 1993), male and female F344 rats and B6C3F1 mice were
exposed to glutaraldehyde vapor for 6 hours/day for 1 or 4 days, or 6 or 13 weeks at glutaraldehyde vapor
concentrations of 0.0625, 0.125, 0.250, 0.5, or 1 ppm.  Exposure-related increased incidences of rats and
mice exhibiting selected nasal lesions were observed following exposure to glutaraldehyde vapor at
0.250 ppm 6 hours/day for as little as 1 or 4 days; there were no apparent exposure-related effects on
nasal lesion incidences at 0.125 ppm.  This study identified a NOAEL of 0.125 ppm and the lowest
LOAEL (0.25 ppm for histopathological nasal lesions) among the acute-duration inhalation studies and 
was therefore selected as the principal study for derivation of an acute-duration inhalation MRL for
glutaraldehyde.  Benchmark dose (BMD) analysis of nasal lesion incidences is precluded by the small
numbers of animals (n=5/sex) evaluated after 1 and 4 days of exposures.  Combining the data for males 
and females within an animal species is not considered appropriate due to uncertainty regarding gender-
specific sensitivity to glutaraldehyde-induced nasal lesions and slight gender differences in exposure
concentrations resulting in significantly increased incidences of particular nasal lesion types.  The
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NOAEL of 0.125 ppm and LOAEL of 0.25 ppm for histopathologic nasal lesions (subepithelial
neutrophils) in male F344 rats exposed to glutaraldehyde vapor for a single 6-hour period (Gross et al.
1994; NTP 1993) serve as the basis for deriving an acute-duration inhalation MRL for glutaraldehyde.  
The NOAEL of 0.125 ppm was duration-adjusted to simulate a 24-hour exposure (0.125 ppm x 6 hour/24 
hour = NOAELADJ of 0.031 ppm) and converted to a human equivalent concentration (HEC; NOAELHEC 
= 0.003 ppm) according to EPA (1994) cross-species dosimetric methodology for a category 1 gas where 
inhalation exposure-related effects occur within the extrathoracic region of the respiratory tract (the nasal
cavity in the case of glutaraldehyde).  A total uncertainty factor of 3 (1 for extrapolation from animals to 
humans using dosimetric adjustment and 3 for sensitive individuals) was applied and resulted in an acute-
duration inhalation MRL of 0.001 ppm (1x10-3 ppm).  An uncertainty factor of 1 (rather than the default
10) for extrapolation from animals to humans is justified because: (1) the dosimetric adjustment accounts 
for differences between rats and humans regarding respiratory tract kinetics, and (2) the critical effect
(nasal irritation) is the result of the propensity of glutaraldehyde to react with and cross-link cell 
membrane proteins (Peters and Richards 1977), a mechanism of action common to laboratory animals and 
humans. The uncertainty factor for sensitive individuals consists of a pharmacokinetic contribution 
(default of 3) and a pharmacodynamic contribution (default of 3).  The propensity of glutaraldehyde to 
react with and cross-link cell membrane proteins at the portal of entry is not expected to vary
significantly.  The critical effect (nasal lesions) is independent of glutaraldehyde absorption, distribution, 
metabolism, and elimination kinetics. Therefore, an uncertainty factor of 1 for intraspecies 
pharmacokinetics is justified.  A default uncertainty factor of 3 for intraspecies pharmacodynamics is 
retained in the absence of empirical data to suggest otherwise. Refer to Appendix A for more detailed 
information regarding derivation of the acute-duration inhalation MRL for glutaraldehyde.
Intermediate-Duration. No adequate exposure-response data are available for humans exposed to
glutaraldehyde by the inhalation route.
Exposure-related effects on body weight were observed in rats repeatedly exposed to glutaraldehyde
vapor at 0.9–1.6 ppm for periods of 16 days to 13 weeks (NTP 1993; Zissu et al. 1994); as much as 41– 
42% lower final mean body weight was noted in male and female rats exposed at 1.6 ppm, 6 hours/day
for 12 exposures in 16 days.  However, the body weight effects may be secondary to effects on the
respiratory tract, which appears to be the critical target of glutaraldehyde toxicity following repeated
inhalation exposures for 2–13 weeks.  Concentration-related increased incidence and severity of clinical
signs of respiratory irritation and histopathologic nasal lesions (exfoliation, inflammation, hyperplasia, 
and ulceration of nasal squamous epithelium; granulocytes and necrosis in nasal passages; laryngeal
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squamous metaplasia; necrosis in nasal nares) have been reported at exposure levels as low as 0.0625– 
1.6 ppm (Gross et al. 1994; NTP 1993, 1999; Union Carbide Corp. 1992f; van Birgelen et al. 2000; Zissu 
et al. 1998).  Histopathologic nasal lesions were sometimes noted at exposure levels lower than those
resulting in overt clinical signs of respiratory tract irritation.  In general, glutaraldehyde-induced 
histopathologic respiratory tract lesions were confined to the anterior nasal cavity and were not observed 
in lower respiratory tract regions.  However, in one study that assessed the lung, but not extrapulmonary
respiratory tract tissues, morphological changes were observed in pulmonary epithelium of male rats 
exposed to glutaraldehyde vapor at 0.1 ppm, 6 hours/day, 5 days/week for 4 weeks (Halatek et al. 2003).
Inflammation in the nasal vestibule/anterior nares of the female mice was identified as the most sensitive 
effect and was observed at the lowest exposure level tested (0.0625 ppm).  In a similarly-designed 
histopathology time-course study that evaluated the progression of nasal lesions for up to 13 weeks 
(5/species/sex/exposure group/time point) (Gross et al. 1994; NTP 1993), neutrophilic infiltration into 
intra- and subepithelial regions of the nasal vestibule of female mice was identified as the most sensitive 
effect and was observed at the lowest exposure level tested (0.0625 ppm).  The neutrophilic infiltration 
was consistent with inflammation in the core study, thus providing support to the findings of the core
study.  The incidence data for inflammation in the nasal vestibule/anterior nares of the B6C3F1 female
mice from the core study (NTP 1993) were selected to serve as the basis for deriving the intermediate-
duration inhalation MRL for glutaraldehyde.  All dichotomous models in the Benchmark Dose Modeling
Software (BMDS, Version 2.2) were fit to the incidence data for female B6C3F1 mice with inflammation 
in the nasal vestibule/anterior nares following exposure to glutaraldehyde vapor 6 hours/day, 5 days/week
for 13 weeks (NTP 1993). A 10% change from control incidence was selected as the benchmark response 
(BMR).  The resulting 95% lower confidence limit on the maximum likelihood estimate of the exposure
concentration associated with the selected benchmark response (BMCL10) of 0.0034 ppm was adjusted to 
simulate a continuous exposure scenario (0.0034 ppm x 6 hour/24 hours x 5 days/7 days = BMCL10ADJ of
0.0006 ppm).  Derivation of a HEC based on the BMCL10ADJ of 0.0006 ppm was performed according to 
EPA (1994) cross-species dosimetric methodology for a category 1 gas where inhalation exposure-related
effects occur within the extrathoracic region of the respiratory tract (the nasal cavity in the case of
glutaraldehyde), resulting in a BMCL10HEC of 0.00008 ppm (8x10-5 ppm).  A total uncertainty factor of
3 (1 for extrapolation from animals to humans using dosimetric adjustment and 3 for human variability)
was applied, resulting in an intermediate-duration inhalation MRL of 0.00003 ppm (3.0x10-5 ppm).  An
uncertainty factor of 1 (rather than the default 10) for extrapolation from animals to humans is justified 
because: (1) the dosimetric adjustment accounts for differences between rats and humans regarding
respiratory tract kinetics, and (2) the critical effect (nasal irritation) is the result of the propensity of
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glutaraldehyde to react with and cross-link cell membrane proteins (Peters and Richards 1977), a
mechanism of action common to laboratory animals and humans. The uncertainty factor for sensitive 
individuals consists of a pharmacokinetic contribution (default of 3) and a pharmacodynamic contribution 
(default of 3). The propensity of glutaraldehyde to react with and cross-link cell membrane proteins at the
portal of entry is not expected to vary significantly.  The critical effect (nasal lesions) is independent of
glutaraldehyde absorption, distribution, metabolism, and elimination kinetics.  Therefore, an uncertainty 
factor of 1 for intraspecies pharmacokinetics is justified. A default uncertainty factor of 3 for intraspecies 
pharmacodynamics is retained in the absence of empirical data to suggest otherwise. Refer to
Appendix A for more detailed information regarding derivation of the intermediate-duration inhalation 
MRL for glutaraldehyde.
Chronic-Duration. No chronic-duration inhalation MRL was derived for glutaraldehyde. Available
human data are inadequate to serve as a basis for a chronic-duration inhalation MRL for glutaraldehyde.  
Occupational exposure to glutaraldehyde has been commonly associated with symptoms of respiratory
tract irritation, particularly in medical facilities where glutaraldehyde is used as a disinfectant (e.g.,
Jachuck et al. 1989; NIOSH 1987a, 1987b; Norbäck 1988; Pisaniello et al. 1997; Vyas et al. 2000;
Waldron 1992; Waters et al. 2003).  Case reports of some workers exposed to glutaraldehyde during
disinfection processes provide some evidence of glutaraldehyde-induced respiratory hypersensitivity
(Chan-Yeung et al. 1993; Corrado et al. 1986; Cullinan et al. 1992; Di Stefano et al. 1999; Gannon et al. 
1995; Ong et al. 2004; Quirce et al. 1999; Trigg et al. 1992).  In controlled-exposure studies, individuals
with diagnosed glutaraldehyde-induced asthma were evaluated for responses to glutaraldehyde challenge 
exposure (Palczyński et al. 2001, 2005).  Other studies found no evidence of glutaraldehyde-induced 
respiratory sensitization among various groups of hospital workers with exposure to glutaraldehyde (Vyas 
et al. 2000; Waldron 1992; Waters et al. 2003) or employees at a glutaraldehyde production facility (Teta 
et al. 1995).  However, the available human data do not include quantitative exposure-response
information that could potentially serve as a basis for MRL derivation.
Quantitative animal data are available regarding the effects of chronic-duration inhalation exposure to 
glutaraldehyde.  In studies performed for the NTP, male and female F344/N rats (50/sex/group) were
exposed whole-body to glutaraldehyde vapor at target concentrations of 0, 0.25, 0.5, or 0.75 ppm for
6 hours/day, 5 days/week for 2 years; male and female B6C3F1 mice (50/sex/ group) were similarly
exposed at 0, 0.0625, 0.12, or 0.25 ppm (NTP 1999; van Birgelen et al. 2000).  These studies also 
identified the nasal cavity of the rats and mice as the most sensitive target of glutaraldehyde toxicity and
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identified a LOAEL of 0.0625 ppm (the lowest exposure concentration tested) for hyaline degeneration in 
the respiratory epithelium of the female mice.
To derive a potential chronic-duration inhalation MRL for glutaraldehyde, a NOAEL/LOAEL approach 
was explored based on hyaline degeneration in the respiratory epithelium of the female B6C3F1 mice 
because none of the dichotomous models in the Benchmark Dose Modeling Software (Version 2.2)
provided adequate fit to the data.  Conversion from intermittent exposure to a continuous exposure
scenario and calculation of a HEC resulted in a LOAELHEC of 0.0022 ppm.  Application of a total
uncertainty factor of 30 (10 for extrapolation from a LOAEL to a NOAEL, 1 for extrapolation from
animals to humans using dosimetric adjustment, and 3 for sensitive individuals) to the LOAELHEC of
0.0022 ppm resulted in a potential chronic-duration inhalation MRL of 0.00007 ppm (7.0x10-5 ppm).  An
uncertainty factor of 1 (rather than the default 10) for extrapolation from animals to humans is justified 
because: (1) the dosimetric adjustment accounts for differences between rats and humans regarding
respiratory tract kinetics, and (2) the critical effect (nasal irritation) is the result of the propensity of
glutaraldehyde to react with and cross-link cell membrane proteins (Peters and Richards 1977), a
mechanism of action common to laboratory animals and humans. The uncertainty factor for sensitive 
individuals consists of a pharmacokinetic contribution (default of 3) and a pharmacodynamic contribution 
(default of 3). The propensity of glutaraldehyde to react with and cross-link cell membrane proteins at the
portal of entry is not expected to vary significantly; thus, an uncertainty factor of 1 for intraspecies
pharmacokinetics is justified.  A default uncertainty factor of 3 for intraspecies pharmacodynamics is 
retained in the absence of empirical data to suggest otherwise. Using a BMD approach and a BMR of
10% change from control incidence for potential derivation of a chronic-duration inhalation MRL based 
on other nasal lesion incidence data from the male and female rats (squamous epithelial hyperplasia,
inflammation) and female mice (respiratory epithelial squamous metaplasia), the lowest BMCL10 was 
0.025 ppm for squamous epithelial inflammation in the female rats (multistage 1-degree model).
Conversion from intermittent exposure to a continuous exposure scenario and calculation of a HEC
resulted in a BMCL10HEC of 0.0007 ppm. Application of a total uncertainty factor of 3 (1 for extrapolation
from animals to humans using dosimetric adjustment and 3 for sensitive individuals) to the BMCL10HEC of
0.0007 ppm resulted in a potential chronic-duration inhalation MRL of 0.0002 ppm (2.0x10-4 ppm).
The potential chronic-duration inhalation MRL of 0.00007 ppm (7.0x10-5 ppm) using a NOAEL/LOAEL
approach for hyaline degeneration in the respiratory epithelium of the female B6C3F1 mice is
approximately 3-fold lower than the potential chronic-duration inhalation MRL of 0.0002 ppm
(2.0x10-4 ppm) from the most sensitive effect identified using a benchmark approach (BMCL10 of
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0.025 ppm for squamous metaplasia in the respiratory epithelium of the F344/N female rats.  However, 
the lowest chronic-duration inhalation MRL of 0.00007 ppm (7.0x10-5 ppm) is 2.3-fold higher than the
intermediate-duration inhalation MRL of 0.00003 ppm (3x10-5 ppm) for inflammation in the nasal
vestibule/anterior nares of the B6C3F1 female mice. As a conservative approach, the intermediate-
duration inhalation MRL of 0.00003 ppm (3x10-5 ppm) is considered to be protective of chronic-duration 
inhalation exposure to glutaraldehyde.
3.6.2.2 Oral MRLs
No human data are available to serve as a basis for deriving oral MRLs for glutaraldehyde.  Animal
studies employed gavage or drinking water exposure.  Gastrointestinal irritation was commonly observed 
following bolus gavage dosing; the gastrointestinal tract was less sensitive to glutaraldehyde ingested
from the drinking water. It is not likely that humans would inadvertently ingest glutaraldehyde in a bolus
dose; therefore, it is not appropriate to derive oral MRLs based on gastrointestinal irritation in animals 
administered glutaraldehyde by bolus dosing.  Humans are not likely to be exposed to toxicologically­
significant amounts of glutaraldehyde via the drinking water or diet.  However, oral MRLs designed to be
protective of possible human consumption of glutaraldehyde-contaminated food or water can be derived 
based on results of animal studies.
Acute-Duration. No acute-duration oral MRL was derived for glutaraldehyde. Gross pathologic 
evidence of glutaraldehyde-induced irritation in the lungs was observed following single gavage
administration of aqueous glutaraldehyde to rats and mice at doses ≥100 and ≥17 mg/kg, respectively
(Ballantyne 1995; Union Carbide Chem & Plas Co. 1992; Union Carbide Corp. 1992i).  The respiratory
effects are likely the result of aspiration of glutaraldehyde from the stomach.
Significantly depressed mean maternal body weight gain (57% less than controls) was observed in rat
dams administered aqueous glutaraldehyde at 50 mg/kg/day during gestation days (GDs) 6–15 (Ema et al. 
1992).  As much as 19% mean maternal body weight loss was reported in pregnant rabbits administered 
aqueous glutaraldehyde by gavage during GDs 7–19 at 22.5 mg/kg/day (BASF Corp. 1991a).  No
treatment-related effects on body weight were seen in male or female rats administered glutaraldehyde in
the drinking water for 14 days at concentrations resulting in doses as high as 100–105 mg
glutaraldehyde/kg/day (Union Carbide Chem & Plas Co. 1991o).
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Developmental end points have been assessed in rats and rabbits following oral exposure of maternal
animals during gestation.  There was no evidence of glutaraldehyde-induced reproductive or
developmental effects following gavage administration of glutaraldehyde at doses as high as 50– 
68 mg/kg/day during GDs 6–15 (BASF Corp. 1991c; Ema et al. 1992), rats exposed via the drinking
water at doses as high as 51 mg/kg/day during GDs 6–16 (BASF Corp. 1990l, 1991b), rabbits
administered gavage doses as high as 25 mg/kg/day during GDs 7–19 (BASF Corp. 1990m), or rabbits
exposed via the drinking water at doses as high as 23 mg/kg/day during GDs 7–20 (BASF Corp. 1991c).  
Gavage treatment of pregnant rabbits at 22.5 mg/kg/day resulted in effects that included decreased gravid
uterine weight (93% less than controls), decreased number of does with fetuses (1/15 versus 15/15 in 
controls), increased number of does with 100% resorptions (9/15 versus 0/15 in controls), increased 
postimplantation loss (94% versus 14% in controls), and markedly reduced mean placental and fetal body
weights (BASF Corp. 1991a).  However, the 22.5 mg/kg/day dose level was maternally toxic, resulting in
death (5/15 does) and actual body weight loss among survivors.  Significantly lower mean live fetal body
weights (6–9% less than controls) were noted at a gavage dose level of 100 mg/kg/day, a dose that
resulted in the death of 5/26 pregnant rats (Ema et al. 1992).
Pathologic evidence of glutaraldehyde-induced gastrointestinal irritation was observed following
administration of aqueous glutaraldehyde by single gavage at sublethal and lethal doses to rats and mice 
(Ballantyne 1995; Union Carbide Chem & Plas Co. 1991t, 1991z, 1992; Union Carbide Corp. 1992a, 
1992c, 1992i).  Clinical signs of gastrointestinal disturbances (lack of fecal production, diarrhea, and 
bleeding) were noted in pregnant rabbits administered glutaraldehyde by gavage at 22.5 mg/kg/day during
GDs 7–19 (BASF Corp. 1991a).  Upper alimentary mucosal irritation was reported for dogs receiving
glutaraldehyde from the drinking water for 14 days at 7–10 mg/kg/day (Union Carbide Chem & Plas Co. 
1991dd).
Based on available animal data, results of a 14-day oral study in dogs (Union Carbide Chem & Plas Co 
1991dd) suggest that the gastrointestinal tract is the most sensitive target of glutaraldehyde toxicity via
the oral exposure route.  In the study, beagle dogs (2/sex/group) were administered glutaraldehyde (50%
w/w aqueous solution) in the drinking water (corrected for percent active ingredient) for 14 days at
concentrations of 0, 150, or 250 ppm (author-estimated glutaraldehyde doses of 0, 7, and 14 mg/kg/day, 
respectively, for the males and 0, 10, and 13 mg/kg/day, respectively, for the females).  There were no 
treatment-related effects regarding clinical signs, body weight, food consumption, clinical chemistry, 
urinalysis, or necropsy findings.  Decreased water consumption was noted in the 250 ppm male and 
female dogs (approximately 30–45% less than controls).  One of two 250 ppm female dogs exhibited 
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moderate increases in erythrocyte count, hemoglobin, hematocrit, sodium, and chloride; these findings
may have been related to mild dehydration.  There were no treatment-related organ weight changes.
Histopathologic evaluations revealed some evidence of mucosal irritation (glossitis and esophagitis) in the
glutaraldehyde-exposed dogs, which was more prominent in the males.  The available Toxic Substances 
Control Act Test Submissions (TSCATS) study summary did not indicate whether the mucosal irritation 
occurred at both exposure levels; furthermore, insufficient numbers of dogs (2/gender/dose) were used to 
provide meaningful quantitative analysis of the data.
Intermediate-Duration. No intermediate-duration oral MRL was derived for glutaraldehyde.  
Available information regarding the effects of intermediate-duration oral exposure of animals to 
glutaraldehyde is limited.  There were no indications of glutaraldehyde-induced respiratory effects in rats
or mice receiving glutaraldehyde from the drinking water for 16 days or 13 weeks at doses as high as 
100–120 mg/kg/day (rats) and 200–328 mg/kg/day (mice) (Union Carbide Chem & Plas Co. 1991r,
1991v, 1991w).  Vomiting was noted in male and female dogs receiving glutaraldehyde from the drinking
water for 13 weeks at approximately 10 mg/kg/day; there was no indication of glutaraldehyde treatment-
related vomiting in low-dose (ca. 3 mg/kg/day) dogs (Union Carbide Chem & Plas Co. 1991ee).  No 
treatment-related histopathological or hematological effects were observed in studies of rats, mice, or
dogs receiving glutaraldehyde from the drinking water for 2–13 weeks at doses as high as 100–120, 200– 
328, and 13–15 mg/kg/day, respectively (Union Carbide Chem & Plas Co. 1991o, 1991r, 1991v, 1991w, 
1991ee).  Approximately 12% decreased mean relative kidney weight (in the absence of histopathologic
renal lesions) was reported in female rats receiving glutaraldehyde from the drinking water for 16 days at
328 mg/kg/day; kidney weight was not affected in male rats similarly treated at up to 257 mg/kg/day
(Union Carbide Chem & Plas Co. 1991v).  No treatment-related effects on body weight were seen in male
or female rats administered glutaraldehyde in the drinking water for 13 weeks at concentrations resulting
in doses as high as 25–35 mg/kg/day; at 100–120 mg/kg/day, depressed body weight gain in male and 
female rats was the likely result of decreased water and food consumption (Union Carbide Chem & Plas
Co. 1991r).  In other 13-week drinking water studies, no signs of treatment-related body weight effects 
were seen among male and female mice at glutaraldehyde doses as high as 200–233 mg/kg/day (Union 
Carbide Chem & Plas Co. 1991w) or male or female dogs at doses as high as 14–15 mg/kg/day (Union 
Carbide Chem & Plas Co. 1991ee).  There were no signs of ocular effects in rats, mice, or dogs receiving
glutaraldehyde from the drinking water for 13 weeks at doses as high as 100–120, 257–327, and 14– 
15 mg/kg/day, respectively (Union Carbide Chem & Plas Co. 1991r, 1991v, 1991ee).
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In a 2-generation oral study, groups of F0 rats were exposed to glutaraldehyde in the drinking water at
concentrations resulting in average glutaraldehyde doses of 0, 4.25, 17.5, or 69.07 mg/kg/day for the
males and 0, 6.68, 28.28, or 98.37 mg/kg/day for the females; doses to similarly-treated F1 parental rats
were 0, 4.53, 21.95, or 71.08 mg/kg/day for the males and 0, 6.72, 29.57, and 99.56 mg/kg/day for the
females (Neeper-Bradley and Ballantyne 2000).  Significantly depressed mean pup body weight per litter
was noted for high-dose F1 pups at postpartum days 21 and 28 (5–11% lower than controls); mean pup 
body weight gain per litter was 14–19% less than that of controls during lactation days 14–28.  
Significantly depressed mean pup body weight per litter was noted for high-dose F2 pups at postpartum
days 21 and 28 (7–13% lower than controls); for lactation days 14–21 and 21–28, mean pup body weight
gain per litter was 17–27% less than that of controls.  There were no treatment-related effects on other
developmental indices.
Available animal data indicate that the gastrointestinal tract of the dog is the most sensitive target of
glutaraldehyde toxicity following intermediate-duration oral exposure.  Beagle dogs (4/sex/group; age not
specified) were administered glutaraldehyde (50% w/w aqueous solution) in the drinking water (corrected
for percent active ingredient) for 13 weeks at concentrations of 0, 50, 150, or 250 ppm (author-calculated
glutaraldehyde doses of 0, 3.3, 9.6, and 14.1 mg/kg/day, respectively, for the males and 0, 3.2, 9.9, and 
15.1 mg/kg/day, respectively, for the females) (Union Carbide Chem & Plas Co. 1991ee).  Increased 
incidences of intermittent vomiting (fluid and food-like) were observed in the 150 and 250 ppm groups
compared to controls and 50 ppm groups.  The increased incidences of vomiting are considered to be
related to acute irritant properties of glutaraldehyde on the gastric mucosa.  The magnitude of body
weight changes was reported to be small and without evidence of a clear dose-response. Mean relative 
kidney weight of the 250 ppm exposure group of female dogs was significantly greater than controls.  The
increased relative kidney weight in the 250 ppm group of female dogs was not considered biologically
significant in the absence of evidence of exposure-related changes in urinalysis or renal histopathology.  
There were no apparent exposure-related effects regarding hematology or serum chemistry, or results of
gross and histopathologic examinations. Results from the 13-week dog study (Union Carbide Chem &
Plas Co. 1991ee) are considered inadequate for the purpose of MRL derivation due to the lack of
quantitative information in the available study report.
Chronic-Duration. Two chronic-duration oral toxicity animal studies are available for
glutaraldehyde.  In one study (Confidential 2002; BASF 2013), Wistar rats (50/sex/group) were
administered glutaraldehyde (50.5% active ingredient) in the drinking water for up to 24 months at
concentrations of 0, 100, 500, or 2,000 ppm (approximate daily glutaraldehyde intakes of 0, 3, 16, and 60 
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mg/kg/day, respectively, for the males and 0, 5, 24, and 88 mg/kg/day, respectively, for the females).
Increased incidences of nonneoplastic lesions were observed at the 2,000 ppm exposure level and 
involved the larynx (squamous metaplasia in males [18/50 versus 0/50 controls] and females [30/50 
versus 0/50 controls]) and trachea (squamous metaplasia in males [4/50 versus 0/50 controls] and females 
[11/50 versus 0/50 controls]).  In addition, significant trends for increasing incidence with increasing
glutaraldehyde concentration were noted for diffuse metaplasia in the larynx of male and female rats,
focal metaplasia in the larynx of females, focal squamous metaplasia in the trachea of males and females,
and diffuse metaplasia in the trachea of females.  Metaplasia was nearly always accompanied by
accumulation of keratin detritus in the laryngeal and/or tracheal lumen.  Some high-dose rats with
laryngeal/tracheal metaplasia also exhibited foreign body granulomas in the lung and/or inflammation in
the tracheal lumen. Significantly increased incidence of erosion/ulceration was noted in the glandular
stomach of 2,000-ppm females.  Purulent inflammation in the nasal cavity was seen in three males and six
females of the highest exposure level. The 2-year oral toxicity study of glutaraldehyde in Wistar rats 
(Confidential 2002; BASF 2013) identified NOAELs of 16 and 24 mg glutaraldehyde/kg/day for males
and females, respectively, and LOAELs of 60 and 88 mg glutaraldehyde/kg/day for males and females,
respectively, based on increased incidences of nonneoplastic laryngeal and tracheal lesions in males and 
females and increased incidence of erosion/ulceration in the glandular stomach of females.
In the other 2-year oral toxicity study (van Miller et al. 2002), Fischer 344 rats (100/sex/group) were
administered glutaraldehyde (50.0–51.3% w/w aqueous solution) in the drinking water at concentrations
of 0, 50, 250, or 1,000 ppm for 52 weeks (first interim sacrifice of 10/sex/group), 78 weeks (second 
interim sacrifice of 10/sex/group), or up to 2 years (main group).  Author-reported average glutaraldehyde
doses were 0, 4, 17, and 64 mg/kg/day, respectively, for the males and 0, 6, 25, and 86 mg/kg/day,
respectively, for the females. Treatment-related effects included slightly depressed body weight and 
lesions of the stomach.  The depressions in body weight were typically <10% in magnitude.  Gross
pathology revealed gastric irritation (multifocal color change, mucosal thickening, nodules, and ulceration 
affecting primarily the nonglandular mucosa) in 250- and 1,000-ppm male and female rats at 52-, 78-, and 
104-week sacrifice (prevalences of 30, 10–20, and 10%, respectively) and in animals that died prior to 
scheduled sacrifice (prevalence of 40%).  Histopathology revealed significantly increased incidences of
1,000-ppm male and female rats with mucosal hyperplasia in the stomach at terminal sacrifice (males:
7/51 versus 1/56 controls; females 7/56 versus 1/62 controls), but not at 52- or 78-week interim sacrifices.
Incidences of this lesion at the lower dose levels were not significantly different from those of controls.  
This study identified NOAELs of 4 and 6 mg/kg/day for the male and female rats, respectively, and
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LOAELs of 17 and 25 mg/kg/day for male and female rats, respectively, for gastric irritation (multifocal
color change, mucosal thickening, nodules, and ulceration affecting primarily the nonglandular mucosa).
The LOAEL of 17 mg/kg/day for gastric irritation in the male F344 rats (van Miller et al. 2002) is the 
lowest identified LOAEL from the 2-year studies and is associated with a NOAEL of 4 mg/kg/day.  A
chronic-duration oral MRL for glutaraldehyde based on the results of the 2-year study in F344 rats can be
derived using the NOAEL of 4 mg/kg/day as the point of departure.  Application of a total uncertainty
factor of 30 (10 for extrapolation from animals to humans and 3 for human variability) results in a
chronic-duration oral MRL of 0.1 mg/kg/day.  The uncertainty factor for human variability consists of a 
pharmacokinetic contribution (default of 3) and a pharmacodynamic contribution (default of 3). The
propensity of glutaraldehyde to react with and cross-link cell membrane proteins at the portal of entry is 
not expected to vary significantly; thus, an uncertainty factor of 1 for intraspecies pharmacokinetics is 
justified.  A default uncertainty factor of 3 for intraspecies pharmacodynamics is retained in the absence 
of empirical data to suggest otherwise. The chronic-duration oral MRL of 0.1 mg/kg/day is considered
protective for acute- and intermediate-duration oral exposure to glutaraldehyde as well.
3.7 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to
convey the fact that effects caused by such chemicals may not necessarily be adverse. Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens
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(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial,
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
No studies were located regarding endocrine disruption in humans or animals after exposure to
glutaraldehyde.
No in vitro studies were located regarding endocrine disruption of glutaraldehyde.
3.8 CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed.
Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are
critical periods of structural and functional development during both prenatal and postnatal life, and a
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage
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may not be evident until a later stage of development.  There are often differences in pharmacokinetics
and metabolism between children and adults.  For example, absorption may be different in neonates
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek
1966; Widdowson and Dickerson 1964).  The fetus/infant has an immature (developing) blood-brain 
barrier that past literature has often described as being leaky and poorly intact (Costa et al. 2004).
However, current evidence suggests that the blood-brain barrier is anatomically and physically intact at 
this stage of development, and the restrictive intracellular junctions that exist at the blood-CNS interface 
are fully formed, intact, and functionally effective (Saunders et al. 2008, 2012).
However, during development of the blood-brain barrier, there are differences between fetuses/infants and
adults which are toxicologically important. These differences mainly involve variations in physiological
transport systems that form during development (Ek et al. 2012).  These transport mechanisms (influx and 
efflux) play an important role in the movement of amino acids and other vital substances across the
blood-brain barrier in the developing brain; these transport mechanisms are far more active in the 
developing brain than in the adult.  Because many drugs or potential toxins may be transported into the 
brain using these same transport mechanisms—the developing brain may be rendered more vulnerable
than the adult.  Thus, concern regarding possible involvement of the blood-brain barrier with enhanced 
susceptibility of the developing brain to toxins is valid.  It is important to note however, that this potential
selective vulnerability of the developing brain is associated with essential normal physiological
mechanisms; and not because of an absence or deficiency of anatomical/physical barrier mechanisms.
The presence of these unique transport systems in the developing brain of the fetus/infant is intriguing; as 
it raises a very important toxicological question as to whether these mechanisms provide protection for
the developing brain or render it more vulnerable to toxic injury.  Each case of chemical exposure should
be assessed on a case-by-case basis.  Research continues into the function and structure of the blood-brain 
barrier in early life (Kearns et al. 2003; Saunders et al. 2012; Scheuplein et al. 2002).
Many xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of
growth and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and
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Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
No information was located to suggest age-related differences in glutaraldehyde toxicity.
3.9 BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment
of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta.  However, several
factors can confound the use and interpretation of biomarkers of exposure.  The body burden of a
substance may be the result of exposures from more than one source. The substance being measured may
be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from
exposure to several different aromatic compounds).  Depending on the properties of the substance (e.g., 
biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and 
all of its metabolites may have left the body by the time samples can be taken.  It may be difficult to
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identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids
(e.g., essential mineral nutrients such as copper, zinc, and selenium).
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung
capacity.  Note that these markers are not often substance specific. They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts).
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.
3.9.1  Biomarkers Used to Identify or Quantify Exposure to Glutaraldehyde
No information was located regarding glutaraldehyde-specific biomarkers of exposure, although detection 
of glutaraldehyde in tissue samples or body fluids could serve as confirmation of exposure to 
glutaraldehyde.
3.9.2  Biomarkers Used to Characterize Effects Caused by Glutaraldehyde
No information was located regarding glutaraldehyde-specific biomarkers of effects.
3.10 INTERACTIONS WITH OTHER CHEMICALS
No information was located regarding interactions of glutaraldehyde with other chemicals.
3.11 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to glutaraldehyde than will most 
persons exposed to the same level of glutaraldehyde in the environment.  Reasons may include genetic
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  
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These parameters result in reduced detoxification or excretion of glutaraldehyde, or compromised 
function of organs affected by glutaraldehyde.  Populations who are at greater risk due to their unusually
high exposure to glutaraldehyde are discussed in Section 6.7, Populations with Potentially High 
Exposures.
Available information regarding potential differences in susceptibility to glutaraldehyde toxicity is 
limited.  Some glutaraldehyde-exposed individuals exhibit dermal sensitization (Bardazzi et al. 1986;
Cusano and Luciano 1993; di Prima et al. 1988; Fowler 1989; Hamann et al. 2003; Hansen 1983a, 1983b;
Jordan et al. 1972; Kanerva et al. 2000; Kiec-Swierczynska and Krecisz 2001; Kiec-Swierczynska et al.
2001; Kucenic and Belsito 2002; Maibach 1975; Nethercott et al. 1988; Nettis et al. 2002; Ravis et al.
2003; Sanderson and Cronin 1968; Shaffer and Belsito 2000; Stingeni et al. 1995; Tam et al. 1989).  
Underlying factors contributing to the dermal sensitization of some people, but not others, have not been
elucidated.
3.12 METHODS FOR REDUCING TOXIC EFFECTS 
This section describes clinical practice and research concerning methods for reducing toxic effects of
exposure to glutaraldehyde.  However, because some of the treatments discussed may be experimental
and unproven, this section should not be used as a guide for treatment of exposures to glutaraldehyde.  
When specific exposures have occurred, poison control centers and medical toxicologists should be
consulted for medical advice.  The following texts provide specific information about treatment following
exposures to glutaraldehyde:  
Caraccio TR, McGuigan MA.  2004. Formaldehyde and glutaraldehyde.  In:  Dart RC, ed.  Medical
toxicology.  3rd ed.  Philadelphia, PA:  Lippincott Williams & Williams, 1246-1250.
Leikin JB, Paloucek FP, eds.  2002.  Poisoning and toxicology handbook.  3rd ed.  Hudson, OH:  Lexi-
Comp, Inc., 625-626.
Greenberg MI.  2002. Healthcare workers.  In: Goldfrank LR, Howland MA, Flomenbaum NE, et al., 
eds.  Goldfrank’s toxicological emergencies.  7th ed.  New York, NY: McGraw-Hill, 1677-1678.
3.12.1  Reducing Peak Absorption Following Exposure 
There are no known methods for reducing absorption of glutaraldehyde following exposure. The
following recommendations were extracted from the texts listed above. Glutaraldehyde reacts rapidly 
with tissues at the portal-of-entry.  Prompt removal from the source of exposure is indicated.  For
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inhalation exposure, move to fresh air; administer humidified oxygen if necessary.  Bronchospasm should 
be treated with standard treatment such as beta-2 agonists.  Severe inhalation exposures may require
hospitalization for observation and treatment.  For dermal and/or ocular exposure, irrigate the exposed 
area with copious amounts of water.  For oral exposure, observe for signs of gastrointestinal effects such
as hemorrhage, ulceration, and perforation.  In cases involving ingestion of large amounts of
glutaraldehyde, central nervous system depression and hypotension may be indicated.  In the absence of
respiratory compromise, one text indicated that ingested glutaraldehyde may be diluted with water
(Caraccio and McGuigan 2004). However, Ballantyne and Jordan (2001) indicated that dilution with 
water following ingestion of glutaraldehyde solutions might enhance the acute toxicity of glutaraldehyde, 
based on observations that acute oral LD50 values in laboratory animals decreased with increasing dilution 
down to approximately 1% glutaraldehyde when oral intake was expressed as absolute amount of
glutaraldehyde per body weight.  Therefore, dilution with water may or may not be advisable, depending
on the initial concentration of ingested glutaraldehyde solution. Emesis is contraindicated due to possible 
caustic injury or central nervous system depression.  Activated charcoal should not be administered due to 
risk of emesis.
3.12.2  Reducing Body Burden
No information was located regarding methods to reduce the body burden of absorbed glutaraldehyde.
3.12.3  Interfering with the Mechanism of Action for Toxic Effects
No information was located regarding methods to interfere with the mechanism of action for toxic effects 
of glutaraldehyde.
3.13 ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of glutaraldehyde is available. Where adequate information is
not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure 
the initiation of a program of research designed to determine the health effects (and techniques for
developing methods to determine such health effects) of glutaraldehyde.
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The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.13.1  Existing Information on Health Effects of Glutaraldehyde
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to
glutaraldehyde are summarized in Figure 3-6. The purpose of this figure is to illustrate the existing
information concerning the health effects of glutaraldehyde. Each dot in the figure indicates that one or
more studies provide information associated with that particular effect. The dot does not necessarily
imply anything about the quality of the study or studies, nor should missing information in this figure be
interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature.
3.13.2  Identification of Data Needs 
Acute-Duration Exposure. Data are available regarding perception of odor and nasal irritation 
following acute-duration exposure of volunteers to glutaraldehyde vapor (Cain et al. 2007; Union Carbide
Corp 1976).  In one controlled human study, repeated occlusive dermal applications of a 0.5%
glutaraldehyde solution resulted in application site erythematous responses in 7/109 volunteers and 
another 9/109 volunteers exhibited questionable responses; similar treatment with 0.1 or 0.2%
glutaraldehyde solutions resulted in only three positive results (Union Carbide Corp. 1966).  See the
section on Epidemiological and Human Dosimetry Studies for a summary of available information
regarding occupational exposure to glutaraldehyde.
Sufficient animal data are available regarding the effects of acute-duration inhalation exposure to 
glutaraldehyde; effects include mortalities at concentrations as low as 1.6 ppm (Zissu et al. 1994) and 
clinical signs of respiratory tract irritation and histopathologic nasal lesions at concentrations as low as 
0.2–2.6 ppm (Ballantyne 1995; Gross et al. 1994; NTP 1993; Union Carbide Corp. 1992d, 1992e, 1992l;
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Figure 3-6.  Existing Information on Health Effects of Glutaraldehyde
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Zissu et al. 1994).  Glutaraldehyde-induced histopathologic nasal lesions in rats (Gross et al. 1994; NTP
1993) serve as the critical effect for deriving an acute-duration inhalation MRL for glutaraldehyde.  One
study found no evidence of glutaraldehyde-induced respiratory sensitization as assessed by the LLNA
(van Triel et al. 2011).  Other effects in animals acutely exposed to glutaraldehyde vapor include
depressed body weight gain and actual body weight loss (Union Carbide Corp. 1992e, 1992l).
The acute oral lethality of glutaraldehyde has been adequately evaluated in laboratory animals using a
variety of aqueous dilutions (Ballantyne 1995; BASF Corp. 1990j; Union Carbide Chem & Plas Co. 
1992; Union Carbide Corp. 1992b, 1992i).  Evaluations of glutaraldehyde dilution on acute lethality in
male and female rats and mice indicate greater lethality at dilutions in the range of 1–15% compared to 
more concentrated solutions (Ballantyne 1995; Union Carbide Chem & Plas Co. 1991l; Union Carbide
Corp. 1992i).  Maternal deaths were reported from daily gavage administration of glutaraldehyde to rats
and rabbits during gestation (BASF Corp. 1991a; Ema et al. 1992).  Sublethal effects observed in 
laboratory animals acutely exposed to glutaraldehyde via the oral route include pathologic evidence of
glutaraldehyde-induced gastrointestinal irritation (Ballantyne 1995; BASF Corp. 1991a; Union Carbide
Chem & Plas Co. 1991t, 1991z, 1991dd, 1992; Union Carbide Corp. 1992a, 1992c, 1992i) and depressed
body weight gain or actual body weight loss (BASF Corp. 1991a; Ema et al. 1992; Union Carbide Chem
& Plas Co. 1991v). Available animal data indicate that the gastrointestinal tract in the dog may represent
the most sensitive target of glutaraldehyde toxicity via the oral exposure route (Union Carbide Chem &
Plas Co 1991dd). However, the available study summary lacked sufficient study details to provide
meaningful quantitative analysis of the data. Therefore, no acute-duration oral MRL was derived for
glutaraldehyde.
The acute lethality of glutaraldehyde in dermally-exposed animals has been adequately evaluated
(Ballantyne 1995; Ballantyne and Jordan 2001; BASF Corp. 1990i; Union Carbide Chem & Plas Co. 
1991k, 1991q; Union Carbide Chem & Plas Co. 1991y; Union Carbide Corp. 1992a, 1992b).
Glutaraldehyde-induced contact dermal irritation has been observed in numerous animal studies that
employed acute-duration exposure (Union Carbide Chem & Plas Co. 1991y; Union Carbide Corp. 1992a, 
1992b, 1992c). Signs of immunological effects following dermal induction and challenge exposure to 
glutaraldehyde include increased mean ear thickness in mice (Azadi et al. 2004; Descotes 1988) and
increased lymphocyte proliferation and serum IgE (Azadi et al. 2004; Ballantyne 1995; Hilton et al. 1998;
Potter and Wederbrand 1995). Ocular irritation has been reported in laboratory animals following ocular
instillation of glutaraldehyde solutions (Ballantyne 1995; Union Carbide Corp. 1992a, 1992b, 1992c;
Union Carbide Chem & Plas Co. 1991k; 1991y); ocular irritation has also been observed in animals 
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exposed to airborne glutaraldehyde (Hoechst Celanese Corp. 1981; Union Carbide Chem & Plas Co. 
1991p, 1991x; Union Carbide Corp. 1992e).
Available animal data adequately characterize the hazard of acute-duration exposure to glutaraldehyde via
inhalation and dermal routes. Additional animal studies do not appear necessary, but an animal study
could be designed to quantitatively assess the sublethal acute oral toxicity of glutaraldehyde in order to
provide an adequate basis for deriving an acute-duration oral MRL for glutaraldehyde.  Glutaraldehyde­
exposed humans should be monitored for signs of glutaraldehyde-induced ocular irritation, nasal lesions,
dermal sensitization, and respiratory sensitization.
Intermediate-Duration Exposure. Available data regarding the effects of intermediate-duration 
exposure of humans to glutaraldehyde are limited to controlled studies of volunteers designed to assess 
the dermal sensitization potential of glutaraldehyde.  In one study, 1/109 subjects exhibited evidence of
glutaraldehyde-induced dermal sensitization following repeated dermal applications during induction and 
subsequent dermal challenge (Union Carbide Corp. 1980).  There was no evidence of dermal irritation or
sensitization among another group of 21 volunteers following induction and challenge via repeated
dermal applications (Union Carbide Corp. 1966). See the section on Epidemiological and Human 
Dosimetry Studies for a summary of available information regarding occupational exposure to
glutaraldehyde.
Intermediate-duration inhalation exposure of rats and mice resulted in clinical signs and histopathologic
evidence of respiratory tract irritation (Gross et al. 1994; NTP 1993; Union Carbide Corp. 1992f; Zissu et
al. 1998).  Glutaraldehyde-induced histopathologic nasal lesions in rats (Gross et al. 1994; NTP 1993)
represent an appropriate critical effect from which to derive an intermediate-duration inhalation MRL for
glutaraldehyde. There was no evidence of glutaraldehyde-induced respiratory sensitization in a study of
guinea pigs repeatedly exposed to glutaraldehyde vapor followed by repeated challenge exposures
(Werley et al. 1995).
Depressed body weight gain was reported in male and female rats receiving glutaraldehyde from the 
drinking water for 13 weeks; however, the effect was the likely result of decreased water and food
consumption (Union Carbide Chem & Plas Co. 1991r). Vomiting was noted in dogs receiving
glutaraldehyde from the drinking water for 13 weeks (Union Carbide Chem & Plas Co. 1991ee). 
Available data suggest that dogs may be particularly sensitive to gastrointestinal irritation following oral 
exposure to glutaraldehyde.  However, the only available study summary lacked sufficient study details to 
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provide meaningful quantitative analysis of the data. Therefore, no intermediate-duration oral MRL was
derived for glutaraldehyde.
Increased serum IgE was noted in mice receiving a dermal application of glutaraldehyde followed by a 
challenge application to the ear (Ballantyne 1995).  A questionable response was observed in a similar
study (Potter and Wederbrand 1995).
Studies in animals adequately characterize the hazards of intermediate-duration exposure to 
glutaraldehyde via inhalation.  Additional animal studies are needed to quantitatively assess the 
intermediate-duration oral toxicity of glutaraldehyde in the most sensitive animal species in order to 
provide an adequate basis for deriving an acute-duration oral MRL for glutaraldehyde.  A well-designed 
intermediate-duration dermal toxicity study in animals is needed to adequately characterize the hazard of
repeated dermal exposure to glutaraldehyde.
Chronic-Duration Exposure and Cancer. See the section on Epidemiological and Human 
Dosimetry Studies for a summary of available information regarding occupational exposure to
glutaraldehyde.
Concentration-related increased incidence and severity of histopathologic nasal lesions were noted in rats
and mice repeatedly exposed to glutaraldehyde vapor for up to 2 years, (NTP 1999; van Birgelen et al. 
2000; Zissu et al. 1998); approximately 10% lower mean body weights were reported in the male and 
female rats (NTP 1999; van Birgelen et al. 2000).  In rats administered glutaraldehyde in the drinking
water for up to 2 years, significantly increased incidences of nonneoplastic lesions were noted in the
larynx and trachea (Confidential 2002).
Limited data are available regarding the carcinogenicity of glutaraldehyde in humans.  Teta et al. (1995)
found no evidence of increased mortality from cancer (total malignant neoplasms) within a group of
186 workers assigned to glutaraldehyde production or drumming from 1959 to 1992 at a West Virginia
facility when compared to the general U.S. population.  A total of 4 cancer deaths were observed 
compared to 6.1 expected (SMR=0.065; 95% CI: 0.2, 1.7).  The cancer SMR was lower for those who 
worked ≥5 years in the units.  Follow-up of this cohort resulted in no evidence for increased cancer rates 
for respiratory cancers or leukemia (Collins et al. 2006).
***DRAFT FOR PUBLIC COMMENT***
   
 
    
 
 
     
 
 
    
      
     
 
  
 
   
     
    
   
   
     
    
      
       
   
    
 
 
 
     
     
    
 
     
 
  
  
 
 
 
 
 
  
125GLUTARALDEHYDE
3. HEALTH EFFECTS
NTP determined that there was “no evidence of carcinogenic activity” of glutaraldehyde in male or
female F344/N rats exposed to glutaraldehyde vapor at 250, 500, or 750 ppb or male or female B6C3F1 
mice exposed to 62.5, 125, or 250 ppb for up to 2 years (NTP 1999).  This determination was based on 
the lack of treatment-related increased incidences of neoplastic lesions in any organ or tissue from the rats 
or mice.  van Miller et al. (2002) reported significantly increased incidences of LGLL in spleens and
livers of female (but not male) rats administered glutaraldehyde in the drinking water for up to 2 years at
concentrations of 50, 250, or 1,000 ppm (calculated doses in the range of 4–64 mg/kg/day for the males
and 6–86 mg/kg/day for the females) (van Miller et al. 2002). Due to high background and variable
incidences of LGLL in the Fischer 344 rat, statistical significance only in the female rats, and lack of a 
clear dose response, the study authors indicated that the biological significance of the LGLL findings was 
unclear and suggested that the statistical significance among the glutaraldehyde-treated female rats might
possibly have been a result of an abnormally low incidence of LGLL in the control females. Upon 
evaluation of the study results by a Cancer Assessment Review Committee for the U.S. EPA (EPA 2006), 
it was determined that the incidences of LGLL were either all within the historical range of three studies 
from the testing laboratory (19–35%) or the NTP historical control database (14–52%).  The Committee
did not consider the statistically increased incidences of LGLL in the female F344 rats to be treatment
related because: (1) LGLL is a common and highly variable spontaneous neoplasm in F344 rats;
(2) incidences were within the range of available historical control data; and (3) no significantly increased
incidences of LGLL or any other tumors were seen in the male rats of this drinking water study (van 
Miller et al. 2002), in male or female F344 rats or B6C3F1 mice exposed to glutaraldehyde vapor by
inhalation for 2 years (NTP 1999), or Wistar rats exposed via the drinking water for 2 years (Confidential 
2002).
Studies in animals adequately characterize the hazards of chronic-duration exposure to glutaraldehyde via
the inhalation route and confirm glutaraldehyde-induced nasal lesions as the most sensitive noncancer
effect following shorter-term inhalation exposure scenarios. Intermediate-duration inhalation studies
employed more exposure levels than chronic-duration inhalation studies, resulting in a slightly more
sensitive point of departure.  Therefore, the intermediate-duration inhalation MRL is considered 
protective of chronic-duration inhalation exposure as well. Additional chronic-duration inhalation studies
in animals do not appear necessary.  Additional information is needed regarding the chronic toxicity and 
carcinogenicity of glutaraldehyde using oral exposure in animals; noncancer results might serve as a basis 
for deriving a chronic-duration oral MRL for glutaraldehyde.
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Genotoxicity. Available in vitro data suggest that glutaraldehyde may be weakly mutagenic in 
bacteria strains and mammalian cell lines, based on both negative (Haworth et al. 1983; Hemminki et al.
1980; Levin et al. 1982; NTP 1993, 1999; Sakagami et al. 1988a, 1988b; Sasaki and Endo 1978; Slesinski
et al. 1983; Vergnes and Ballantyne 2002; Union Carbide Chem & Plas Co. 1991gg, 1991hh, 1991ii; 
Wilcox et al. 1990) and positive results (Dillon et al. 1998; Haworth et al. 1983; Jung et al. 1992; Kamber
et al. 2009; Levin et al. 1982; Marnett et al. 1985; NTP 1993, 1999; Ruiz-Rubio et al. 1985; Vergnes and 
Ballantyne 2002; Watanabe et al. 1998; Wilcox et al. 1990). There is some evidence for glutaraldehyde­
induced chromosomal aberrations, sister chromatid exchange, and micronuclei in mammalian cells
systems (Galloway et al. 1985; NTP 1993, 1999; Speit et al. 2008; Tsai et al. 2000).  Glutaraldehyde does
not appear to cause DNA damage or cell transformation in mammalian cell systems (Speit et al. 2008; 
Yamaguchi and Tsutsui 2003). Mostly negative results were obtained in assays for glutaraldehyde­
induced unscheduled DNA synthesis in mammalian cell systems (Slesinski et al. 1983; St. Clair et al.
1991; Union Carbide Chem & Plas Co 1991gg; Zeiger et al. 2005). Available in vivo data do not
generally provide support for a genotoxic role for glutaraldehyde; however, data are limited.
Glutaraldehyde did not induce DNA cross links and strand breaks, unscheduled DNA synthesis, or
dominant lethality in rats and/or mice, or sex-linked recessive lethal mutations in Drosophila
(Confidential 1987b, 1987c; Mirsalis et al. 1989; NTP 1993, 1999; Yoon et al. 1985; Zimmering et al.
1989).  Negative or equivocal/weakly positive results were reported from assays of glutaraldehyde­
induced chromosomal aberrations and micronuclei in mouse bone marrow (Confidential 1987a; NTP
1999; Vergnes and Ballantyne 2002).
Additional in vivo genotoxicity studies are needed to adequately assess the genotoxic potential of
glutaraldehyde, particularly studies designed to support or refute the evidence of glutaraldehyde-induced 
chromosomal aberrations and micronuclei in mouse bone marrow cells (NTP 1999).
Reproductive Toxicity. Limited human data are available. Glutaraldehyde exposure did not appear
to affect rates of spontaneous abortion among employees at Finnish hospitals compared to control
workers at the same hospitals who were not occupationally exposed to sterilizing agents for the years
1973–1979 (Hemminki et al. 1982, 1985). However, the studies included relatively small numbers of
spontaneous abortion cases (178 in one study and 217 in another study).
In a well-designed 2-generation reproductive/developmental toxicity study of male and female CD rats 
administered glutaraldehyde in the drinking water, there were no treatment-related effects on fertility and
no histopathological evidence of effects on reproductive organs or tissues (Neeper-Bradley and 
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Ballantyne 2000).  There was no evidence of glutaraldehyde-induced effects on selected
reproductive/developmental end points including numbers of corpora lutea, implantation sites, dead 
implantations, early and late resorptions, or live or dead fetuses, or on gross fetal anomalies at oral doses 
that did not result in severe maternal toxicity (BASF Corp. 1990l, 1990m, 1991a, 1991b, 1991c, Ema et
al. 1992). Sperm morphology and vaginal cytology evaluations in rats and mice repeatedly exposed to 
glutaraldehyde vapor for 13 weeks revealed no convincing evidence of exposure-related adverse 
reproductive effects (NTP 1993). No increased incidences of nonneoplastic mammary gland lesions were
found in histopathologic evaluations following 2 years of repeated exposure of rats and mice to
glutaraldehyde vapor (NTP 1999; van Birgelen et al. 2000).
Although human data are limited, available animal data do not suggest a reproductive toxicity hazard for 
glutaraldehyde.  Additional animal studies are not necessary. Glutaraldehyde-exposed workers should be
monitored for potential reproductive effects.
Developmental Toxicity. Available information regarding potential for glutaraldehyde-induced 
developmental effects in humans is limited to results of a study that included nurses employed in selected
departments at Finnish hospitals between 1973 and 1979 with 46 documented cases of mothers with a 
malformed child and controls consisting of nurses with normal births and matched by age and 
employment facility (Hemminki et al. 1985).  The cases and controls had the potential for exposure to 
anesthetic gases, cytostatic drugs, and other hazardous substances including glutaraldehyde.  One result of
the study was the observation that similar proportions of cases with a malformed child and normal birth 
controls had been exposed to glutaraldehyde (34/164 or 20.7% for cases and 88/464; 19.0% for controls).
These results suggest that glutaraldehyde was not likely a causal factor in the malformations, although the 
small numbers of study subjects precludes any definitive conclusions.
Developmental end points have been assessed in rats and rabbits following oral exposure of maternal
animals during gestation.  There was no evidence of glutaraldehyde-induced effects on reproductive/ 
developmental indices including numbers of corpora lutea, implantation sites, dead implantations, early
and late resorptions, or live or dead fetuses, or on gross fetal anomalies at doses that did not result in
severe maternal toxicity (BASF Corp. 1990l, 1990m, 1991a, 1991b, 1991c; Ema et al. 1992).
In a 2-generation oral study, F1 and F2 pups of maternal rats receiving glutaraldehyde from the drinking
water exhibited significantly depressed body weight and body weight gain during postpartum days 14–28, 
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likely a result of taste aversion to the glutaraldehyde-treated drinking water during weaning (Neeper-
Bradley and Ballantyne 2000). There were no treatment-related effects on other developmental indices.
Although human data are limited, available animal data do not suggest a developmental toxicity hazard
for glutaraldehyde.  Additional animal studies are not necessary. Glutaraldehyde-exposed workers should 
be monitored for potential developmental toxicity.
Immunotoxicity. Numerous reports are available in which dermal patch testing of glutaraldehyde 
elicited positive results; these results were obtained for individuals in a variety of occupational settings
where glutaraldehyde is used as a germicide (e.g., Bardazzi et al. 1986; Cusano and Luciano 1993; di
Prima et al. 1988; Fowler 1989; Hamann et al. 2003; Hansen 1983a, 1983b; Jordan et al. 1972; Kanerva
et al. 2000; Kiec-Swierczynska and Krecisz 2001; Kiec-Swierczynska et al. 2001; Kucenic and Belsito 
2002; Maibach 1975; Nethercott et al. 1988; Nettis et al. 2002; Ravis et al. 2003; Sanderson and Cronin 
1968; Shaffer and Belsito 2000; Stingeni et al. 1995; Tam et al. 1989). In one study designed to assess 
the dermal sensitization potential of glutaraldehyde in volunteers, repeated dermal applications of
glutaraldehyde followed by challenge application resulted in little evidence of glutaraldehyde-induced 
dermal sensitization (Union Carbide Corp. 1966, 1980).
All groups of mice and the guinea pigs that received dermal applications of 3% glutaraldehyde during 
induction exhibited visual and radioassay evidence of application-site hypersensitivity upon challenge
(Stern et al. 1989). Increased ear thickness was reported in mice following induction and challenge with 
topical doses of glutaraldehyde (Azadi et al. 2004; Descotes 1988).  Repeated dermal applications of
glutaraldehyde to the ear of mice resulted in lymphocyte proliferation (Azadi et al. 2004; Hilton et al. 
1998). A 4-fold increase in serum IgE was reported for mice receiving dermal application of 25%
glutaraldehyde followed by 12.5% glutaraldehyde applied to the ear (Ballantyne 1995).  Potter and 
Wederbrand (1995) reported significantly increased total serum IgE in female BALB/c mice receiving
dermal administrations of glutaraldehyde (9.38 mg) on the shaved flank (first application) and dorsal ear
(second application), but a higher induction dose (18.75 mg aqueous glutaraldehyde) elicited no increase
in total serum IgE. One study found no evidence of glutaraldehyde-induced dermal sensitization in 
guinea pigs (BASF 2013).
Case reports of some workers exposed to glutaraldehyde during disinfection processes provide some 
evidence of glutaraldehyde-induced respiratory hypersensitivity (Chan-Yeung et al. 1993; Corrado et al. 
1986; Cullinan et al. 1992; Di Stefano et al. 1999; Gannon et al. 1995; Ong et al. 2004; Quirce et al. 1999;
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Trigg et al. 1992).  Surveys of hospital workers in other studies found no evidence of glutaraldehyde­
induced respiratory sensitization (Vyas et al. 2000; Waldron 1992; Waters et al. 2003).  There were no 
indications of glutaraldehyde-induced respiratory sensitization within a group of 218 workers employed at
a glutaraldehyde production facility for an average of 3.8 years at TWA glutaraldehyde concentrations 
generally in the range of 0.04–0.08 ppm, but as high as 1.02 ppm during the year 1982 (Teta et al. 1995).
In one controlled study of health workers with diagnoses of glutaraldehyde-induced occupational asthma
and rhinitis, nonexposed atopic subjects with perennial asthma and rhinitis, and nonexposed healthy
subjects, glutaraldehyde challenge resulted in significantly increased eosinophil numbers and percentage 
and significantly increased concentrations of albumin, eosinophil cation protein, and mast-cell tryptase in
the nasal lavage fluid among those glutaraldehyde-exposed workers with diagnoses of glutaraldehyde­
induced occupational asthma and rhinitis (Palczyński et al. 2001). In a similarly-designed study that 
evaluated BALF components and Clara cell protein concentration in serum and BALF before and after
glutaraldehyde inhalation challenge, postchallenge evaluation revealed significantly lower Clara cell
protein levels in BALF and serum at 24 hours postchallenge and significant increases in proportions of
eosinophils, basophils, and lymphocytes in BALF of the glutaraldehyde-sensitized asthmatics (Palczyński
et al. 2005). 
Limited information is available regarding the potential for inhaled glutaraldehyde to cause 
immunological effects in laboratory animals.  There was no evidence of glutaraldehyde-induced 
respiratory sensitization among male Dunkin-Hartley guinea pigs exposed to glutaraldehyde vapor during 
induction and challenge phases (Werley et al. 1995).  In another study, repeated exposure of BALB/c
mice to glutaraldehyde vapor or aerosols resulted in clinical signs of respiratory tract irritation, but no 
evidence of glutaraldehyde-induced respiratory sensitization as assessed by the local lymph node assay
(van Triel et al. 2011).
The potential immunotoxicity of glutaraldehyde has not been adequately assessed; additional human and 
animal data are needed. Glutaraldehyde-exposed humans should continue to be monitored for dermal and 
respiratory hypersensivity. Additional animal studies should be designed to further assess the potential
for glutaraldehyde-induced hypersensitivity, particularly for the inhalation route of exposure.
Neurotoxicity. Information regarding neurological effects in humans exposed to glutaraldehyde is
limited to reports of increased incidences of self-reported headaches among occupationally-exposed 
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workers during disinfection processes in which glutaraldehyde was used (e.g., Guthua et al. 2001;
Norbäck 1988; Pisaniello et al. 1997; Waters et al. 2003).
Impaired righting reflex was noted in rats exposed to glutaraldehyde vapor for 4 hours; decreased motor
activity was observed during 14 days of postexposure observation (Union Carbide Corp. 1992l). There
were no clinical signs of neurotoxicity in male or female rats or mice repeatedly exposed to 
glutaraldehyde vapor for 13 weeks (NTP 1993) or rats or mice similarly exposed for up to 2 years (NTP
1999). 
Katagiri et al. (2011) measured neurotransmitter levels in various brain regions of the rat following nose-
only repeated exposure to glutaraldehyde vapor for 4 weeks.  In the medulla oblongata (the only region in 
which glutaraldehyde exposure-related changes were found), significantly lower mean 5-hydroxyindole­
acetic acid content was observed at glutaraldehyde vapor concentrations of 50–200 ppb.  Dopamine
content was significantly lower at concentrations of 100 and 200 ppm.
Workers exposed to glutaraldehyde vapor during disinfection processes should continue to be monitored 
for signs of neurological effects. A data need exists for a well-designed neurotoxicity study to assess
neurological and neuroendocrine effects in glutaraldehyde-exposed animals.  However, because no 
neurological health effects were observed at concentrations below which nasal lesions were observed, the
MRL developed on the basis of nasal lesions should be protective for glutaraldehyde-induced 
neurological effects.
Epidemiological and Human Dosimetry Studies. Occupational exposure to glutaraldehyde has
been commonly associated with symptoms of respiratory tract irritation, dermal irritation, ocular
irritation, and headaches, particularly in medical facilities where glutaraldehyde is used as a disinfectant 
(e.g., Bardazzi et al. 1986; Calder et al. 1992; Cusano and Luciano 1993; di Prima et al. 1988; Fowler
1989; Guthua et al. 2001; Hamann et al. 2003; Hansen 1983a, 1983b; Jachuck et al. 1989; Jordan et al. 
1972; Kanerva et al. 2000; Kiec-Swierczynska and Krecisz 2001; Kiec-Swierczynska et al. 2001; Kucenic 
and Belsito 2002; Maibach 1975; Nethercott et al. 1988; Nettis et al. 2002; NIOSH 1987a, 1987b; 
Norbäck 1988; Pisaniello et al. 1997; Ravis et al. 2003; Sanderson and Cronin 1968; Shaffer and Belsito 
2000; Stingeni et al. 1995; Tam et al. 1989; Vyas et al. 2000; Waldron 1992; Waters et al. 2003).  In 
occupational settings where personal or workplace air sampling was performed, self-reported respiratory
tract symptoms following short-term exposures occurred at concentrations as low as 0.012–0.17 ppm
(NIOSH 1987a, 1987b; Norbäck 1988; Pisaniello et al. 1997; Vyas et al. 2000).  There is some evidence 
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of glutaraldehyde-induced respiratory hypersensitivity in workers exposed to glutaraldehyde during
disinfection processes (Chan-Yeung et al. 1993; Corrado et al. 1986; Cullinan et al. 1992; Di Stefano et
al. 1999; Gannon et al. 1995; Ong et al. 2004; Quirce et al. 1999; Trigg et al. 1992); hypersensitivity
responses were elicited by challenge exposures as low as 0.016–0.018 ppm. Information regarding acute-
duration oral exposure of humans is limited to two case reports of respiratory distress, severe metabolic 
acidosis, and death in one case following intentional ingestion of biocides consisting of glutaraldehyde
and other substances (Perera et al. 2008; Simonenko et al. 2009).  
Glutaraldehyde-induced irritative effects have been fairly well documented among humans exposed in
occupational settings.  However, where potential for human exposure to glutaraldehyde exists, additional
data are needed and should include quantitative evaluation of glutaraldehyde-induced symptoms and 
accurate monitoring of exposure levels to facilitate evaluation of exposure-response relationships.  If
possible, human studies should include examination of nasal tissue for glutaraldehyde-induced nasal
lesions.
Biomarkers of Exposure and Effect.
Exposure. No information was located regarding glutaraldehyde-specific biomarkers of exposure.  It is
not likely that stable glutaraldehyde-specific biomarkers of exposure could be identified because absorbed 
glutaraldehyde is rapidly metabolized.
Effect. No information was located regarding glutaraldehyde-specific biomarkers of effects. Classical
portal-of-entry irritant effects caused by glutaraldehyde may result from exposure to other highly reactive
substances as well.  It is not likely that glutaraldehyde-specific biomarkers of effect would be identified.
Absorption, Distribution, Metabolism, and Excretion. No information was located regarding 
absorption, distribution, metabolism, or excretion of glutaraldehyde or its metabolites following
inhalation, oral, or dermal exposure of humans.  Limited animal data indicate that glutaraldehyde and/or
its metabolites can be absorbed following inhalation exposure (Varpela et al. 1971), oral exposure (Union 
Carbide Chem & Plas Co. 1991ff), and dermal exposure (McKelvey et al. 1992).  Rates of dermal
absorption have been estimated based on results of a pharmacokinetic study of rats and rabbits and
material balance study in rats (McKelvey et al. 1992).  Dermal penetration has been measured across
glutaraldehyde-treated skin samples from rats, mice, guinea pigs, rabbits, and humans (Frantz et al. 1993;
Reifenrath et al. 1985).  Results of animal studies indicate wide systemic distribution following oral or
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dermal absorption (McKelvey et al. 1992; Union Carbide Chem & Plas Co. 1991ff). A metabolic 
pathway for glutaraldehyde has been proposed based on available results from in vivo studies and in vitro
assays (Beauchamp et al. 1992; see Figure 3-4).  Limited information is available regarding elimination
and excretion following exposure to glutaraldehyde.  Following gavage administration of
14C-glutaraldehyde to four male Fischer rats at a mean dose of 86.5 mg/kg (Union Carbide Chem & Plas
Co. 1991ff), an average of 35% of the administered radioactivity was collected in the feces during
48 hours posttreatment.  Lesser amounts of radioactivity were observed in the urine and expired 14CO2 
(6 and 21% of the administered radioactivity, respectively). The identity of specific radioactive urinary
and fecal compounds was not determined.  Following dermal exposure to 14C-glutaraldehyde, up to 3% of
the administered radioactivity was recovered in the urine and lesser amounts in expired 14CO2. Anion 
exchange chromatographic analysis of urine revealed two major fractions and one minor fraction.  The
chemical composition of the fractions was not determined.  Similar administration of 14C-glutaraldehyde
to male and female New Zealand white rabbits resulted in elimination of 2–12 and 2–17% of the
administered dose in the urine and expired 14CO2, respectively.
Glutaraldehyde pharmacokinetics have been assessed to some extent in animals. However, a data need 
exists for additional pharmacokinetic studies in animals to provide support to the proposed metabolic
pathways for glutaraldehyde, identify major urinary metabolites, and possibly shed light on mechanisms
of action for glutaraldehyde.
Comparative Toxicokinetics. Limited information is available regarding species-specific 
differences in glutaraldehyde toxicokinetics. Percutaneous absorption of glutaraldehyde and/or its
metabolites was greater in rabbits than rats (McKelvey et al. 1992). In vitro assessment of dermal
penetration indicated somewhat greater penetration in skin from rats, mice, guinea pigs, and rabbits than 
human skin samples (Frantz et al. 1993).  No information was located regarding species-specific 
differences in distribution or metabolism.  Following dermal exposure to glutaraldehyde, the excretion of
glutaraldehyde and/or its metabolites in the urine was greater in rabbits than rats; fecal excretion was 
greater in rats than rabbits (McKelvey et al. 1992).
Portal-of-entry irritation has been identified as the most prominent (and most sensitive) effect of
glutaraldehyde toxicity; therefore, large differences in response across species are not anticipated and
additional studies in comparative toxicity are not identified as a data need at this time.
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Methods for Reducing Toxic Effects. There are no known methods for reducing absorption or
body burden of glutaraldehyde following exposure.  Glutaraldehyde reacts rapidly with tissues at the
portal-of-entry.  Prompt removal from the source of exposure is indicated.  No information was located 
regarding methods to interfere with mechanisms of action for toxic effects of glutaraldehyde. It is not 
likely that additional studies would identify appropriate methods for reducing the toxic effects of
glutaraldehyde; therefore, no data need is identified at this time.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above.
No information was located to suggest age-related differences in glutaraldehyde toxicity.  Because the 
most prominent effects of exposure to glutaraldehyde are portal-of-entry irritant effects, it is expected that 
effects in children would be similar to those observed in adults and laboratory animals.  Additional
studies that assess potential age-related differences in susceptibility to glutaraldehyde toxicity do not 
appear necessary.
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:
Exposures of Children.
3.13.3  Ongoing Studies 
No ongoing studies were identified in the National Institutes of Health (NIH) Research Portfolio Online
Reporting Tools (RePORTER 2014).
***DRAFT FOR PUBLIC COMMENT***
   
 
    
 
 
 
 
 
 
 
 
  
134GLUTARALDEHYDE
3. HEALTH EFFECTS
This page is intentionally blank.
***DRAFT FOR PUBLIC COMMENT***
   
 
 
 
 
 
 
   
 
  
   
 
  
 
   
 
   
  
   
 
 
 
 
 
  
135GLUTARALDEHYDE
4. CHEMICAL AND PHYSICAL INFORMATION
4.1  CHEMICAL IDENTITY
Glutaraldehyde is an aldehyde commonly used as a disinfectant (EPA 2007).  Information regarding the
chemical identity of glutaraldehyde is located in Table 4-1.  Glutaraldehyde is typically prepared as an 
aqueous solution in which it may exist in various forms depending upon the pH, concentration, and 
temperature of the solution.
4.2  PHYSICAL AND CHEMICAL PROPERTIES 
Glutaraldehyde is a colorless, oily liquid with a pungent odor (EPA 2007; HSDB 2011).  It is soluble in 
water and incompatible with strong oxidizers and strong bases (NIOSH 2011).  Information regarding the
physical and chemical properties of glutaraldehyde is located in Table 4-2.
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Table 4-1.  Chemical Identity of Glutaraldehyde
Characteristic Information
Chemical name	 Glutaraldehyde
Synonym(s)	 Pentanedial; glutaral; glutardialdehyde; glutaric dialdehyde; 1,5-pentanedial;
1,3-diformylpropane; glutaric aldehyde; glutaric acid dialdehyde; glutarol;
gluteraldehyde; potentiated acid glutaraldehyde; aldehyd glutarowy (Polish);
glutaraldehyd (Czech); glutaralum (INN-Latin); Sporicidin; 4-01-00-03659 (Beilstein 
Handbook Reference); BRN 0605390; CCRIS 3800; Caswell No. 468; EINECS
203-856-5; EPA Pesticide Chemical Code 043901; NSC 13392;
UNII-T3C89M417Na,b 
Registered trade 	 Ucardine; Nuosept 95; Cidex, component of; Odix, component of; Aldesen;
name(s)	 Alhydex; Glutaralum; Hospex; NCI-C55425; Sonacide; Coldcide-25 Microbiocide 
Concentrate; GKN-O Microbiocide Concentrate; Ucarcide 250b,c,d 
Chemical formula	 C5H8O2
Chemical structurea	 O O 
H H 
Identification numbers:
CAS Registry 111-30-8
NIOSH RTECS MA2450000e 
EPA Hazardous No data
Waste
OHM/TADS No data
DOT/UN/NA/IMDG UN 2810e 
HSDB 949
NCI No data
aChemIDplus 2013.
bHSDB 2011. 
cMcEntee 2000.
dEPA 2007.
eNIOSH 2011.
CAS = Chemical Abstracts Services; CIS = Chemical Information System; DOT/UN/NA/IMDG = Department of
Transportation/United Nations/North America/International Maritime Dangerous Goods Code; EPA = Environmental
Protection Agency; HSDB = Hazardous Substance Data Bank; NCI = National Cancer Institute; NIOSH = National
Institute for Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data 
System; RTECS = Registry of Toxic Effects of Chemical Substances
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Table 4-2.  Physical and Chemical Properties of Glutaraldehyde
Property
Molecular weight (g/mol) 100.11a 
Color Colorless liquid; oilyb 
Physical state Liquida 
Melting point -14°Cc 
Boiling point 188°C (decomposes)c 
Density 0.72c 
Odor Sharp and pungenta 
Odor threshold:
Water No data
Air 0.0003 ppm; 0.47 ppm for perception of effect on nasal tissued 
Taste No data
Solubility:
Water 51.3 g/La 
Other solvents Miscible with acetone and isopropanol; methylene 
chloride = 36 g/L; ethyl acetate = 30 g/L; toluene = 4.4 g/L;
n-hexane = 0.096 g/Le; soluble in alcoholc 
Partition coefficients:
Log Kow -0.33b 
Log Koc 120–500b 
Vapor pressure at 25°C 17 mm Hg at 20°Cc 
OH radical rate constant 2.38x10-11 cm3/molecule-second at 25°Cb 
Henry's law constant at 25°C 2.4x10-8 atm-m3/mol at 25°C (estimated)b 
Autoignition temperature No data
Flashpoint Not applicablec 
Flammability limits at 25°C Non-flammablec 
Incompatibilities Strong oxidizers, strong bases; alkaline solutions of
glutaraldehyde (i.e., activated glutaraldehyde) react with 
alcohol, ketones, amines, hydrazines, and proteinsf 
Conversion factors (25°C and 1 atm) 1 mg/L=245 ppm; 1 ppm=4.1 mg/m3b 
Explosive limits No data
aEPA 2007.
 
bHSDB 2011.
 
cLewis 2007
 
dCain et al. 2007.
 
eBallantyne and Jordan 2001.
 
fNIOSH 2011.
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5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1  PRODUCTION
No information is available in the TRI database on facilities that manufacture or process glutaraldehyde
because this chemical is not required to be reported under Section 313 of the Emergency Planning and 
Community Right-to-Know Act (Title III of the Superfund Amendments and Reauthorization Act of
1986) (EPA 2005).
Glutaraldehyde, one of the most important commercial dialdehydes (Kohlpaintner et al. 2013), is
produced by either the gas-phase oxidation of cyclopentene or by a Diels-Alder reaction.  In the Diels-
Alder reaction, the reaction of acrolein and methyl vinyl ether in a 1:1 ratio results in 3,4-dihydro­
2-methoxy-2H-pyran (CAS No. 4454-05-1), which undergoes acidic hydrolysis to yield glutaraldehyde 
and alkanol (HSDB 2011; Kohlpaintner et al. 2013). Both reactions utilize a multistage extraction with
water to recover the glutaraldehyde (Kohlpaintner et al. 2013).
Glutaraldehyde is supplied as a 50% biological solution as well as 4, 15, 25, and 45% solutions (EPA
2007; Lewis 2007).  It is also available as its bis(sodium bisulfate) adduct (Kohlpaintner et al. 2013). The 
anhydrous form of glutaraldehyde is unstable and therefore not commercially available (Arntz et al. 2012;
EPA 2007).
5.2  IMPORT/EXPORT
Although glutaraldehyde may be imported to the United States from Germany (HSDB 2011; IPCS 1998), 
actual import volumes were not available.  However, it is classified as a High Production Volume (HPV)
chemical; HPV chemicals are those chemicals produced or imported to the United States in volumes
>1 million pounds (HSDB 2011).  Historically, international import volumes of glutaraldehyde are as
follows:  Australia, over 100 tons/year; Sweden, approximately 165 tons/year; Denmark, approximately
50 tons/year; France, greater than 1,000 tons/year; United Kingdom, several hundred tons/year; and 
Canada, between 33 and 333 tons/year.  Additionally, Norway imports approximately 12,700 tons/year of
glutaraldehyde-containing products (IPCS 1998). More recent data were not located.
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5.3  USE 
Glutaraldehyde is often used in industrial, laboratory, agricultural, and medical settings (Ballantyne and 
Jordan 2001; EPA 2007).  It has numerous uses, including: disinfection and sterilization; leather tanning; 
chemical intermediate; industrial antimicrobial agent and pesticide (algaecide, bacteriocide, and
fungicide); biological tissue fixative; protein and polyhydroxy material cross-linked; x-ray processing;
embalming fluid; printing industry preservative; poultry house fogging and other agricultural sanitization;
as a materials preservative; intermediate for adhesives, sealants, and pharmaceuticals; and in the paper
and textile industries (Borchers 2012; EPA 2007; HSDB 2011; IPCS 1998; Kohlpaintner et al. 2013;
Lewis 2007).  Former uses of glutaraldehyde include cooling tower applications, macrofoulant control, 
and sterilization of critical medical equipment that would be in contact with bodily fluids (i.e., 
hemodialysis tubing and dental instruments) (EPA 2007; HSDB 2011).
Glutaraldehyde is often used as a disinfectant for hospital, medical, and dental facilities (EPA 2007).  One 
of the primary uses is for the cold sterilization of medical and dental equipment that cannot be heat
sterilized, such as endoscopes or bronchoscopes (Ballantyne and Jordan 2001; Borchers 2012; IPCS 
1998; Uhr et al. 2013).  Glutaraldehyde can be used to sterilize instruments against a wide spectrum of
biocidal activity (both Gram-positive and Gram-negative bacteria, spores, and viruses).  Glutaraldehyde is
most effective for sterilization around pH 8; however, at this pH, it tends to polymerize.  Therefore, it is
supplied as a stable, acidic solution (pH 3.0–4.5) and activated by an alkaline buffer (i.e., sodium
bicarbonate) to pH 7.8–8.0 (Ballantyne and Jordan 2001; IPCS 1998; Uhr et al. 2013).  A 1 or 2% 
aqueous solution is typically utilized for these applications (Ballantyne and Jordan 2001; IPCS 1998).  
Glutaraldehyde is also used in x-ray developing solutions as a cross-linking agent to minimize drying
time (IPCS 1998).
Glutaraldehyde is often used in industrial settings.  In oil and gas recovery and pipeline activities, as well
as industrial water treatment, glutaraldehyde may be used as a biocide (API 2015; Arntz et al. 2012; IPCS
1998; Kohlpaintner et al. 2013; McCurdy 2011).  Glutaraldehyde is used in a variety of applications for
the oil industry, such as in oil storage tanks, water floods, drilling and packer fluids, gas pipe and well
systems, and hydrofracturing equipment to prevent growth of sulfate reducing bacteria that contributes to 
metal corrosion.  Glutaraldehyde can also be found in water-based lubricants for conveyors, air washer
and industrial scrubbing systems, cooling and process water systems, and sugar beet mills and water
systems. In the paper industry, it may be used as a biocide in process water systems, pigments, fillers,
and coatings (EPA 2007; IPCS 1998).  It is also used in both the paper and textile industries to improve
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the wet strength as well as the stability of fibers (Kohlpaintner et al. 2013).  Metalworking fluids may also 
contain glutaraldehyde as an antimicrobial agent (McEntee 2000).  In the leather tanning industry, 0.5– 
2% solutions of glutaraldehyde may be used for leather softening and to help resist mold, water, and 
alkalis (IPCS 1998).
Agriculturally, glutaraldehyde is used in poultry houses for egg sanitation, cleaning of hatcheries and 
processing facilities, in animal housing, and for sanitizing farm equipment and other hard surfaces (EPA
2007; IPCS 1998).  Typical cleaning solutions contain 0.1–0.3% glutaraldehyde and are sprayed, washed, 
or foamed onto surfaces.  A 400 ppm solution of glutaraldehyde can be used with automated equipment
for fogging.  Egg shells are sanitized with 750 ppm glutaraldehyde solutions.  In aquaculture, 
glutaraldehyde may be used to help control viruses (IPCS 1998). 
In the laboratory, glutaraldehyde is used to cross-link with proteins (Chotani et al. 2012; IPCS 1998).  In 
aqueous solutions, it will partially polymerize, resulting in oligomers (IPCS 1998).  It is also used as a
bifunctional coupling reagent to bind antibodies to enzymes (Wulff and Henniger 2012) and as a
biological tissue fixative (IPCS 1998; Winslow 2003), as well as for the polymerization of pyridoxylated 
human hemoglobin (Winslow 2003).
The distribution of glutaraldehyde in end-use products for Australia includes:  55% for cold disinfectant
for health care settings; 20% for x-ray film processing; 10% for water treatment; 5% for animal housing
disinfecting; 5% for tanning of leather; and 5% other (i.e., toilet disinfection, microscopy, aquaculture, 
and air duct disinfection).  In France, the distribution is as follows: 50% for disinfection, 40% for
photographic uses, 5% for the leather industry, and 5% for the paper industry.  Norwegian usage of
glutaraldehyde is primarily for industrial cleaning agents (80%), followed by 14% in photocopying
developers.  The United Kingdom primarily uses glutaraldehyde for cold disinfectant applications and as
a biocide in off-shore oil processes (IPCS 1998).  Distribution of use was not available for the United 
States.
There are limited direct consumer uses of glutaraldehyde, although it may be present in paints and 
laundry detergents as a slimicide (EPA 2007; HSDB 2011).  It is used to sanitize hard surfaces in areas
that the general population may encounter (EPA 2007).  It may also be present as a preservative in non-
aerosol cosmetics in the European market at concentrations <0.1% (IPCS 1998; McEntee 2000).  Use of
glutaraldehyde as a pesticide for food use is prohibited (EPA 2013g).  Glutaraldehyde may have been
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used for the topical treatment of warts (i.e., plantar warts) (HSDB 2011), although it is generally not used 
on skin (Siebert and Harke 2012).
Counterfeit products advertised as glutaraldehyde, but containing substitutes such as formaldehyde and/or
other aldehydes, may be found in some markets (McGinley 2012).  Toxicity profiles of such products
may be significantly different from that of genuine glutaraldehyde; counterfeit products may also be
difficult to distinguish from genuine glutaraldehyde without the assistance of sophisticated analytical
procedures.
5.4  DISPOSAL
Glutaraldehyde is considered toxic to fish, aquatic invertebrates, oysters, and shrimp and should not be
discharged to water bodies (EPA 2007; IPCS 2000; NIOSH 2000).  It is subject to requirements under the
National Pollution Discharge Elimination System (NPDES) (EPA 2007).
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6. POTENTIAL FOR HUMAN EXPOSURE
6.1  OVERVIEW
Glutaraldehyde is used as a biocide in medical, industrial, agricultural, oil and natural gas industry, and 
laboratory settings (Ballantyne and Jordan 2001; EPA 2007).  It can be released to the environment
through various means.  It may enter indoor air from its uses as a disinfectant, in x-ray development, and 
from paints and laundry detergents that used it as a slimicide (EPA 2007; HSDB 2011; Rietz 1985;
Sekine et al. 2005).  Glutaraldehyde can also enter the atmosphere from oil and gas operations, industrial
water treatment processes, poultry house fogging, and vehicle emissions (Arntz et al. 2012; EPA 2007;
HSDB 2011; IPCS 1998; Kohlpaintner et al. 2013).
Releases to water generally occur as a result of waste water disposal from hospitals, textile and paper
industries, industrial water treatment processes, cooling water systems, leather tanning, and oil and gas 
operations (Arntz et al. 2012; EPA 2007; IPCS 1998; Kohlpaintner et al. 2013).  Glutaraldehyde solutions
are often disposed of as sewage, from which residues can be released to water following sewage treatment
processes (IPCS 1998).  Disposal of cold disinfectant solutions from hospitals is the major source of
glutaraldehyde to surface waters (Emmanuel et al. 2005; IPCS 1998; Jolibois et al. 2002).
When in the environment, glutaraldehyde is generally in the aquatic phase.  Glutaraldehyde degrades
rapidly under both aerobic and anaerobic conditions in water and under aerobic conditions in soil (EPA
2007; Leung 2001).  It is considered to be rather mobile in soils (HSDB 2011).  Glutaraldehyde does not
bioaccumulate in aquatic organisms, and is not thought to present a significant risk to aquatic or terrestrial
compartments (HSDB 2011; IPCS 1998).  Glutaraldehyde solutions are most stable under acidic to 
neutral conditions (Ballantyne and Jordan 2001; EPA 2007; IPCS 1998; Smith and Wang 2006; Uhr et al.
2013).  Higher pH levels can cause it to polymerize over time (Smith and Wang 2006).
Glutaraldehyde has been identified in both indoor and outdoor air samples (Ban-Weiss et al. 2008; HSDB
2011; NICNAS 1994; Rietz 1985; Sekine et al. 2005).  The majority of the atmospheric monitoring has
been done in hospitals and dental clinics where glutaraldehyde is used for sterilization. The highest
airborne concentrations generally occur near the source of sterilization equipment, although the effects are
often mitigated by proper ventilation and handling techniques (Rietz 1985).  Concentrations of
glutaraldehyde in wastewater have been measured, primarily for waste streams originating from hospitals 
where glutaraldehyde solutions are regularly disposed of as sewage (Jolibois et al. 2002).
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Exposure to glutaraldehyde is primarily through inhalation (Smith and Wang 2006), although dermal
contact and ingestion may also occur (NIOSH 2000, 2011).  The general public is generally not exposed 
to glutaraldehyde, as it is primarily used in industrial or medical applications (EPA 2007; IPCS 1998).  
People may be exposed in medical facilities or other areas where glutaraldehyde solutions are used for
cleaning, and from paint and laundry detergents that contain glutaraldehyde (EPA 2007; IPCS 1998).  
There is a slight potential for glutaraldehyde residues to contaminate food sources due to its use as a 
disinfectant in animal housing (EPA 2007).  The primary occupational exposure to glutaraldehyde occurs
when products are used in medical and dental applications for disinfecting purposes or x-ray processing
(EPA 2007; HSDB 2011; IPCS 1998; NICNAS 1994; Smith and Wang 2006).  Operating room nurses, 
radiographers, x-ray technicians, and cleaning staff have the highest potential for glutaraldehyde exposure
(Smith and Wang 2006).  However, occupational exposure may also occur as a result of paper
manufacturing, oil and gas operations, animal house fogging and cleaning, metalworking, and other
industrial processes where glutaraldehyde is used or produced (EPA 2007; IPCS 1998).
6.2  RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing
facilities are required to report information to the TRI only if they employ 10 or more full-time
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces,
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI
chemical in a calendar year (EPA 2005).
6.2.1 Air
There is no information on releases of glutaraldehyde to the atmosphere from manufacturing and 
processing facilities because these releases are not required to be reported (EPA 2005).
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Glutaraldehyde may be released to indoor air from its used as a disinfectant (EPA 2007; Rietz 1985).  
Glutaraldehyde is used in hospitals and dental clinics as a disinfectant as well as in the process of
developing x-rays, where it has been identified in air samples (Rietz 1985; Sekine et al. 2005).  Releases
to air can also occur from the use of paints and detergents that contain glutaraldehyde as a slimicide (EPA
2007; HSDB 2011).  Levels of glutaraldehyde in indoor air can typically be controlled with proper use
and ventilation practices (Rietz 1985). 
Releases of glutaraldehyde to outdoor air can occur from its use as a biocide in oil and gas recovery and 
pipeline operations, as well as industrial water treatment (Arntz et al. 2012; IPCS 1998; Kohlpaintner et
al. 2013).  Poultry house fogging can also release glutaraldehyde to the air (EPA 2007; IPCS 1998).  
Glutaraldehyde can also be released to air from vehicle emissions (HSDB 2011).  As might be expected, 
medium and heavy duty diesel trucks were found to contribute more glutaraldehyde to the atmosphere
than light-duty vehicles (HSDB 2011).
6.2.2  Water
There is no information on releases of glutaraldehyde to the water from manufacturing and processing
facilities because these releases are not required to be reported (EPA 2005).
Glutaraldehyde may be released to water as a result of its many commercial and industrial uses, including
applications as a biocide in industrial water treatment processes, textile and paper industries, cooling and 
process water systems, oil and gas operations (including hydrofracturing processes), x-ray processing, and 
leather tanning (API 2015; Arntz et al. 2012; EPA 2007; IPCS 1998; Kohlpaintner et al. 2013; McCurdy
2011).  Waste solutions of glutaraldehyde are typically poured down the drain and thus enter sewage
treatment facilities. Treated sewage effluent is then released to surface waters, allowing glutaraldehyde 
residues to enter the aquatic environment (IPCS 1998).
The use of glutaraldehyde in disinfectants can result in significant release of glutaraldehyde to surface 
waters (Emmanuel et al. 2005; EPA 2007; IPCS 1998; Jolibois et al. 2002; Sano et al. 2005).  In 
particular, disinfectants from facilities such as from hospitals are discharged to waste water, often in large 
quantities, which can then enter water resources where they may present a risk to aquatic organisms 
(Emmanuel et al. 2005; Jolibois et al. 2002).  Its use as a cold disinfectant in hospitals, particularly in 
metropolitan areas, results in large quantities of glutaraldehyde being released to sewage, and it was 
found that these solutions may retain at least 50% of their biocidal activity (IPCS 1998).  Australian data
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indicate that the primary release of glutaraldehyde to the environment arises from its use as a cold
sterilant, which is released to sewage.  Assuming that 75% of the 50 tonnes per year of glutaraldehyde
used for cold sterilization is disposed of in sewage in a worst-case scenario, the average daily Australian
discharge of glutaraldehyde would be 100 kg, resulting in a wastewater concentration of approximately
40 µg/L (IPCS 1998).
Jolibois et al. (2002) predicted that the glutaraldehyde concentration in hospital waste water is 0.50 mg/L, 
due to disinfecting solutions being released to aquatic environments after use.  However, upon 
measurement of glutaraldehyde concentrations at Rouen University Hospital, it was discovered that peak
glutaraldehyde concentrations in waste water were around 8 times higher than predicted.  The hospital
uses approximately 10 m3 (10,000 L) of glutaraldehyde-containing solutions per year, containing
approximately 365 kg of glutaraldehyde.  Measured glutaraldehyde concentrations in the hospital waste 
water were typically around or below the predicted concentration of 0.5 mg/L, with the exception of one
sample, where the glutaraldehyde concentration was 3.72 mg/L.  This sample was found to correlate to
when disinfecting solutions were replaced within the hospital, and the remaining solution from the
previous week was discarded (Jolibois et al. 2002).
Waste water originating in hospitals can contain hundreds of hazardous chemicals (Emmanuel et al.
2005).  Interactions between these chemicals can have additional consequences in the environment, such 
as the combination of glutaraldehyde from disinfectants with surfactants, chemicals commonly contained
in detergents (Emmanuel et al. 2005).  A study of the release of glutaraldehyde from waste water to water
resources determined that it is acutely toxic on aquatic organisms (Emmanuel et al. 2005).  It may be 
considered moderately toxic to aquatic organisms and highly toxic to algae (Jolibois et al. 2002), although 
it appears that in many situations, dilution mitigates the risk to the aquatic environment (IPCS 1998).  The
risk to the aquatic environment, particularly algae, may be higher during periods of drought (IPCS 1998).  
Additionally, biodegradation and reaction with proteinaceous constituents of raw sewage may help to
mitigate glutaraldehyde concentrations in waste water (IPCS 1998).
Smaller volumes and concentrations of glutaraldehyde are typically used in applications other than cold 
sterilization.  X-ray film processing may not present a significant hazard to the aquatic environment as 
glutaraldehyde reacts with sulfites in the process.  For cooling water discharge, Australian data indicate 
that glutaraldehyde is released to sewage at maximum concentrations of 250 mg/L.  Leather tanning is 
expected to result in discharge of 1–3% of the original amount glutaraldehyde, which may then react with 
dissolved proteins in the effluent from the tannery.  As animal housing typically results in release to the 
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atmosphere through spraying, it is not expected to contribute significantly to aquatic glutaraldehyde
contamination.  In Sweden, waste water emanating from paper mills can contain glutaraldehyde at
concentrations of 6 mg/L (IPCS 1998).
Glutaraldehyde has been investigated for use as a biocide in ballast water treatment for both marine and
freshwater systems (U.S. Coast Guard 2004).  In this capacity, there is a significant likelihood of release
to water (Sano et al. 2005).  A study of biocides for ballast water noted that after treatment, some residual
glutaraldehyde could remain in water (U.S. Coast Guard 2004).  Despite its release potential,
glutaraldehyde appears to be an effective biocidal treatment against a wide range of organisms for this 
application (U.S. Coast Guard 2004).  It was noted that glutaraldehyde is a Class D substance under the
Merchant Shipping Regulations (Control of Pollution by Noxious Liquid Substances in Bulk), Schedule I 
(1987) for Great Britain, under which discharge into the sea is prohibited and discharge of residual
mixtures is subject to restrictions. Glutaraldehyde is also regulated under OSHA (U.S. Coast Guard
2004).  Regardless, since it was found to have relatively quick half-life in water (<2 days) and has limited 
regulatory concerns, the study found that glutaraldehyde has a potential for use in ballast water treatment
(U.S. Coast Guard 2004), and can thus enter the aquatic environment.  
6.2.3 Soil 
There is no information on releases of glutaraldehyde to the soil from manufacturing and processing
facilities because these releases are not required to be reported (EPA 2005).
Glutaraldehyde use in disinfectants could result in release to soils and sediments (EPA 2007; IPCS 1998)
through release of waste water that may leach into surrounding soils.  Likewise, glutaraldehyde could 
potentially be released to soil as a result of industrial uses, including industrial water treatment processes,
paper and textile industries, cooling and process water systems, and oil and gas recovery operations
(Arntz et al. 2012; EPA 2007; IPCS 1998; Kohlpaintner et al. 2013).  However, as glutaraldehyde is a
hydrophilic compound, biodegrades in soil, and does not bioaccumulate, it does not appear to present a
risk to the terrestrial environment (IPCS 1998).
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6.3  ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
In the environment, glutaraldehyde is expected to partition to water, due to small air/water and soil/water
partition coefficients.  It degrades under both aerobic and anaerobic conditions in water and under aerobic
conditions in soil (EPA 2007).  Due to the limited persistence in air, soil, and water, significant transport
of glutaraldehyde is not expected (IPCS 1998).  If glutaraldehyde is present in soil and sediments,
however, it is not expected to significantly adsorb (Emmanuel et al. 2005; HSDB 2011), but could 
potentially be mobile.  A study was performed to determine the adsorption and desorption potential of
glutaraldehyde in various soil types.  Aqueous solutions of glutaraldehyde in 0.01 M calcium chloride at
concentrations of 0.51, 1.0, 2.5, 5.0, and 10.3 g/L were used to determine measured Koc values in different
soil types.  Koc values of glutaraldehyde in sandy loam, silty clay loam, silt loam, loamy sand, and 
sediment were determined to be 210, 500, 340, 460, and 120, respectively.  These results indicate that
glutaraldehyde has a moderate to high mobility in soil, and will therefore not adsorb strongly (HSDB
2011).  In particular, glutaraldehyde has a high mobility in sandy soil, but a more moderate mobility in 
sandy loam, silt loam, silty clay loam, and loamy sandy soils (EPA 2007).  Based on an estimate Henry’s
Law constant of 2.4x10-8 atm-m3/mole, glutaraldehyde is not expected to volatilize from water surfaces
(HSDB 2011).  It also has a low likelihood of volatilizing from either moist or dry soil (HSDB 2011).
6.3.2 Transformation and Degradation
Glutaraldehyde is a hydrophilic compound and is considered to be readily biodegradable in both water
and soil (EPA 2007; HSDB 2011; IPCS 1998; Jolibois et al. 2002; Leung 2001).  It is not expected to 
bioaccumulate in aquatic organisms at an appreciable rate (HSDB 2011; IPCS 1998), based on an 
estimate bioconcentration factor (BCF) value of 3.2 (HSDB 2011).  The risk to aquatic organisms is
thought to be low under typical, non-drought conditions and there are no appreciable risks to the
terrestrial environment from release of glutaraldehyde (IPCS 1998).
Glutaraldehyde is stable under acidic to neutral conditions (EPA 2007).  The anhydrous form of
glutaraldehyde is unstable, and therefore, it is only available commercially as a solution (Arntz et al.
2012; EPA 2007; Lewis 2007). While glutaraldehyde is stable in light, it oxidizes in the presence of air
(Smith and Wang 2006).  Additionally, increasing temperature and pH results in decreased stability for
aqueous glutaraldehyde solutions (Smith and Wang 2006).  While glutaraldehyde solutions are stable at
acidic pH, they are only useful as disinfectants at alkaline pH levels (Thomas and Russell 1974).
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Glutaraldehyde tends to polymerize around pH 8–9, which coincides with the pH where it is most
effective as a disinfectant. It is, therefore, supplied as a stable, acidic solution of pH 3.0–4.5 and must be
activated by an alkaline buffer such as sodium bicarbonate to pH 7.8–8.9 before use (Ballantyne and 
Jordan 2001; IPCS 1998; Smith and Wang 2006; Uhr et al. 2013).  Dilute glutaraldehyde solutions (1– 
2%) are typically used for disinfecting, but they tend to polymerize with time, resulting in a solution 
containing limited aldehyde radicals and consequently reduced antibacterial function.  Glutaraldehyde 
solutions must, therefore, be prepared fresh on a regular basis (Smith and Wang 2006).
6.3.2.1  Air
Small amounts of glutaraldehyde that volatilize to air (for example, from water cooling tower drift due to
its use as a biocide in cooling systems) will not likely persist in the atmosphere.  It is degraded in the
atmosphere by reaction with photochemically-produced hydroxyl radicals.  For this reaction, it has an 
estimated half-life in air of 16 hours.  As glutaraldehyde has an experimental first-order rate constant of
0.0035/day for the photolysis of aqueous solutions, it may be susceptible to direct photolysis by sunlight 
(HSDB 2011; IPCS 1998).  Additionally, glutaraldehyde is hydrophillic and will be removed from the
atmosphere by wet deposition (IPCS 1998).
6.3.2.2  Water
Glutaraldehyde is expected to quickly decompose in water (Emmanuel et al. 2005; EPA 2007; IPCS
1998; Leung 2001; U.S. Coast Guard 2004), and has been classified as readily biodegradable in
freshwater, as determined by the Organization for Economic Cooperation and Development (OECD)
301D (Closed Bottle) method, with the potential for degradation in marine environments.  Glutaraldehyde
present at 100 mg/L, achieved 59% of its theoretical biochemical oxygen demand (BOD) using an 
activated sludge inoculum and the modified MITI (OECD 301C) test (HSDB 2011).
A study performed using a river water-sediment system found that glutaraldehyde degraded rapidly under
both aerobic and anaerobic conditions.  In this system, glutaraldehyde was found to partition primarily to 
the water phase, with a pseudo-first-order half-life of 10.6 hours under aerobic conditions and 7.7 hours
under anaerobic conditions (Leung 2001). Glutaraldehyde was stable in sterilized control samples
maintained at pH 5 and 7 for 31 days; however, at pH 9, 30% was degraded, primarily to a cyclicized 
dimer of glutaraldehyde, 3-formyl-6-hydroxy-2-cyclohexene-1-propanal.  Extrapolated half-lives for
abiotic degradation of 508, 102, and 46 days at pH 5, 7, and 9, respectively were calculated.  Under
aerobic conditions, glutaraldehyde was found to degrade to glutaric acid and subsequently carbon dioxide, 
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whereas under anaerobic conditions, it was degraded into 5-hydroxypentanal followed by 1,5-pentanediol
(Leung 2001).  A second study from the EPA Registration Eligibility Decision (RED) document for
glutaraldehyde reported hydrolysis half-lives at 25°C of 628, 394, and 63.8 days at pH 5, 7, and 9, 
respectively (EPA 2007). At 70°C, hydrolysis of glutaraldehyde proceeds more rapidly with half-lives
of 53, 6.5, and 0.23 days at pH levels of 5, 7, and 9, respectively.  Glutaraldehyde was also
photolytically degraded to a small degree in natural sunlight at 25°C.  The half-life was calculated to be 
195 days.  A buffered, aqueous solution at pH 5 was used in the experiment (EPA 2007).
Since glutaraldehyde is a biocide, it is toxic to many aquatic organisms (Emmanuel et al. 2005; NIOSH
2000).  However, Emmanuel et al. (2005) concluded that glutaraldehyde release in hospital waste water at
typical concentrations ranging from 0.50 to 3.72 mg/L would not likely pose a threat to beneficial bacteria 
in waste water treatment processes (Emmanuel et al. 2005).  Glutaraldehyde present at 100 mg/L, 
achieved 59% of its theoretical BOD using an activated sludge inoculum and the modified MITI (OECD
301C) test (HSDB 2011).
Contamination of groundwater and surface waters by glutaraldehyde is unlikely due to rapid 
biodegradation potential and dilution in surface waters (EPA 2007; IPCS 1998).  Degradation of
glutaraldehyde in sewage treatment plants, where it reacts with proteins in the effluent, is expected to help 
mitigate release to water (IPCS 1998).  Dilution may also have a significant effect on glutaraldehyde 
concentrations in water.  Studies at a Canadian paper mill and a de-inking plant showed rapid reductions
in glutaraldehyde concentrations in white water effluent (water that is removed from paper-processing
systems during formation of paper sheets, filtered, and reused within several seconds or minutes to reduce
the need for fresh water).  After 6 hours, the glutaraldehyde concentration in white water effluent from the
paper mill was reduced from 51 to 4 mg/L.  At the de-inking plant, glutaraldehyde concentrations in 
effluent was reduced from 56 to 5 mg/L in 7 hours.  The study concluded that dilution was a contributing
factor in decreasing the glutaraldehyde concentrations (IPCS 1998).
6.3.2.3  Sediment and Soil
Glutaraldehyde does not appear to present any appreciable risks when released to the terrestrial
environment due to its adsorption coefficients, tendency to partition to water, and biodegradation 
potential.  It is expected to have limited persistence in soil (EPA 2007; IPCS 1998).
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When present in soil and sediments, it is not expected to adsorb significantly and will have a moderate to
high mobility (Emmanuel et al. 2005; EPA 2007; HSDB 2011), based on measured Koc values ranging 
from 120 to 500 (HSDB 2011).  The high mobility indicates that glutaraldehyde may not be present in 
significant quantities in soil.  It has been found to rapidly degrade in soils under aerobic conditions (EPA
2007).  Leung (2001) found that glutaraldehyde was metabolized rapidly under both aerobic and 
anaerobic condition in a water-sediment system.
6.3.2.4  Other Media
No information was located regarding the transformation and degradation of glutaraldehyde in other
media.
6.4  LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to glutaraldehyde depends in part on the
reliability of supporting analytical data from environmental samples and biological specimens.
Concentrations of glutaraldehyde in unpolluted atmospheres and in pristine surface waters are often so 
low as to be near the limits of current analytical methods.  In reviewing data on glutaraldehyde levels 
monitored or estimated in the environment, it should also be noted that the amount of chemical identified 
analytically is not necessarily equivalent to the amount that is bioavailable. The analytical methods 
available for monitoring glutaraldehyde in a variety of environmental media are detailed in Chapter 7.
6.4.1 Air
Glutaraldehyde was found to be released to air from vehicle emissions.  Measurements taken in a San
Francisco Bay area highway tunnel during the summers of 2001 and 2006 found mean emission factors
from light-duty vehicles of 0.13 and 0.06 mg glutaraldehyde/kg gasoline, respectively.  Glutaraldehyde 
was not detected in samples from 1999.  Medium- and heavy-duty diesel trucks were found to emit more
glutaraldehyde to the atmosphere than light-duty vehicles; in 2006, a mean emission factor of 0.55 mg
glutaraldehyde/kg diesel was measured in the tunnel (Ban-Weiss et al. 2008). Light-duty vehicles and 
medium/heavy-duty diesel trucks passed through separate bores of the tunnel.
Sampling was performed at three Danish hospitals and a dental clinic to determine the concentrations of
glutaraldehyde in air in facilities where it is used for disinfection of endoscopes and in the development of
x-rays.  Air samples obtained over 15–25-minute time periods found concentrations of glutaraldehyde
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ranging from <0.080 to 0.500 mg/m3 (<0.02–0.12 ppm) of air. Levels in the hospital settings were higher
than those in the dental clinic, where glutaraldehyde is primarily used for x-ray development.  In the
hospital samples, the highest levels of airborne glutaraldehyde were found in the surgical department.  
According to the authors, the low glutaraldehyde concentrations found in these facilities are likely a result
of proper handling and ventilation practices (Rietz 1985).
A dental clinic in Kanagawa, Japan that utilizes a glutaraldehyde solution for equipment sterilization was 
monitored for airborne glutaraldehyde concentrations.  Eight-hour samples were collected using a passive 
sampler when the dental clinic was closed, such that the wind speeds during sampling were constant.
Samples were obtained at 1.2 m above the floor, at the typical breathing height of a Japanese adult.
Indoor air concentrations ranged from not detectable to 16 ppb.  The highest concentrations were located
in the examination room, nearest the sterilizer, whereas glutaraldehyde was not detectable in the waiting
room (Sekine et al. 2005).
Australian studies of glutaraldehyde in air during cold disinfection practices found that concentrations
rarely exceeded 0.1 ppm when proper ventilation procedures were followed (NICNAS 1994).  Monitoring
of Australian hospitals near endoscopy areas where glutaraldehyde was used in 1–2% solutions, using
both personal and area monitoring equipment, found air concentrations ranging from 0 to 0.49 ppm, while
operating room measurements ranged from 0 to 0.9 ppm.  Monitoring at dental facilities resulted in air
concentrations ranging from 0.007 to 0.022 ppm.  Other hospitals were found to have personal
glutaraldehyde monitoring air concentrations up to 0.6 ppm and area monitoring concentrations of up to 
0.3 ppm (NICNAS 1994).  Air concentrations of glutaraldehyde in areas where x-ray film is processed
were generally <0.2 ppm in Australia.  The air concentrations ranged from 0 to 0.4 ppm (NICNAS 1994).  
In an Australian chicken farm, air concentrations were found to be 0.007 ppm when an egg collector
sprayed 0.1–0.3% glutaraldehyde solutions (NICNAS 1994).
6.4.2 Water
Glutaraldehyde has been detected in waste water originating from hospitals.  Measurements of
glutaraldehyde concentrations in wastewater from Rouen University Hospital were typically around or
below 0.5 mg/L, with the exception of a peak concentration of 3.72 mg/L, which coincided with a weekly
disposal of disinfecting solutions (Jolibois et al. 2002).
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6.4.3 Sediment and Soil
Monitoring data for glutaraldehyde in soil and sediment were not available.
6.4.4 Other Environmental Media 
No information regarding glutaraldehyde concentrations in other environmental media was located.
6.5  GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Primary exposure to glutaraldehyde occurs through inhalation (Smith and Wang 2006), although dermal
contact and ingestion may also occur (NIOSH 2000, 2011).  Exposure of the general population may be
minimal, however, as glutaraldehyde is primarily used in industrial or medical applications (EPA 2007;
IPCS 1998).  Consumer applications of glutaraldehyde, such as use in cosmetics, are thought to present
low concern to the general population.  While unlikely, exposure to the general population could occur in 
health care settings where cleaning agents containing glutaraldehyde are used, primarily in the case of a 
spill or inadequate rinsing of surfaces; following drift from cooling water towers used in water treatment; 
from air duct fogging disinfection if proper ventilation procedures are not followed; via household items
(i.e., laundry detergents or paints) that use glutaraldehyde as a preservative (e.g., slimicide); or from
various sources in the papermaking process (EPA 2007; IPCS 1998).  Because glutaraldehyde is used in
oil and gas recovery operations (including hydrofracturing processes), there is potential for exposure
among workers and among the general population living in areas surrounding such operations. Although 
glutaraldehyde is used as a disinfectant for poultry/livestock equipment and processing premises, because
it degrades so rapidly, the potential for glutaraldehyde residues to contaminate food sources is very slight.
People using masking kits which contain glutaraldehyde for the purpose of defeating potentially positive
drug tests may also be exposed to this substance from inhalation or dermal routes (Wu et al. 1994).  
Patients undergoing selected medical procedures may inadvertently be exposed.  For example, 
glutaraldehyde has been widely implicated as the cause of colitis and diarrhea following endoscopy or
sigmoidoscopy procedures, the likely result of contact irritation (e.g., Ahishali et al. 2009; Birnbaum et al. 
1995; Dolce et al. 1995; Durante et al. 1992; Fukunaga and Khatibi 2000; Hanson et al. 1998; Rozen et al. 
1994; Shih et al. 2011; Stein et al. 2001; West et al. 1995).
Occupational exposure may occur during processes which use or produce glutaraldehyde, particularly
when proper ventilation is not used or when products are sprayed (IPCS 1998).  This may result from the
addition of glutaraldehyde to industrial processes; paper manufacture; aluminum rolling; oil and gas 
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drilling; x-ray film processing; fogging and spraying for disinfecting purposes; pesticidal applications
such as cleaning of animal and poultry cages; and cleaning of medical and dental facilities and equipment
(EPA 2007; IPCS 1998).
The primary occupational exposure to glutaraldehyde appears to be inhalation and dermal contact from
use in medical and dental applications (EPA 2007; HSDB 2011; IPCS 1998; NICNAS 1994; Smith and 
Wang 2006). Total exposure depends on the frequency and duration of contact as well as environmental
glutaraldehyde concentrations and the use of personal protective equipment (Rietz 1985; Smith and Wang
2006).  Medical equipment and dental equipment, such as endoscopes and operating room instruments, 
are often disinfected using glutaraldehyde solutions at higher concentrations (as high as 2% active 
ingredient) than used in pesticidal applications (e.g., 0.25% active ingredient for egg sanitation) (EPA
2007).  Between 5 and 10% of health care workers are reported to be exposed to glutaraldehyde (Cohen 
and Patton 2006).  Operating room nurses, radiographers, x-ray technicians, and cleaners tend to have the 
highest health-care related occupational exposure rates (Smith and Wang 2006). Health care workers 
utilizing cold sterilization procedures and x-ray film processing methods may be exposed to 
glutaraldehyde concentrations ranging from 0.13 to 2% (HSDB 2011).  Air concentrations of
glutaraldehyde during disinfection of medical equipment were found to range between <0.5 and 570 ppb, 
depending on the usage, ventilation, and other conditions.  Disinfection via manual methods produced 
higher air concentrations than automated disinfection processes (EPA 2007).  Disinfection of dental
equipment using a 2% solution over 5 and 6 minutes resulted in glutaraldehyde air concentrations of
540 and <160 ppb, respectively (EPA 2007).  The American Conference of Governmental Industrial
Hygienists (ACGIH) threshold limit value (TLV) for glutaraldehyde exposure is 0.05 ppm (Cohen and 
Patton 2006).
Inhalation is a primary pathway of exposure to personnel in facilities where glutaraldehyde is used or
produced.  At various glutaraldehyde manufacturing and formulation facilities, glutaraldehyde air
concentrations were measured at <10–340 ppb over 15-minute sampling intervals (EPA 2007).  Paper
manufacturing processes, including application of adhesives, pigments, and fillers, and addition of
glutaraldehyde as a slimicide to paper mill process water, can result in exposure. Paper mills using a 50%
solution had glutaraldehyde air concentrations ranging from not detectable to 130 ppb over 30–60 minutes
(EPA 2007).  In a latex plant where a 45% glutaraldehyde solution was used, air concentrations of 27 ppb 
were observed over a 15-minute time period (EPA 2007).
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During aluminum milling processes, air concentrations were found to range from not detectable to 
180 ppb (EPA 2007).  At a drilling field utilizing a glutaraldehyde-containing product, Aldacide G, air
concentrations of 20–120 ppb were measured (EPA 2007).
Glutaraldehyde can be used for spraying and fogging disinfection at poultry houses.  Inhalation exposure
can occur when personnel enter the facility following application.  At various poultry hatcheries and 
houses, air concentrations of glutaraldehyde ranged from not detectable to 1,060 ppb for 500 and 
1,000 ppm solutions with sampling periods ranging from 10 to 60 minutes (EPA 2007).  Air
concentrations following manual spraying of a 2% solution in a chicken facility, sampled over
15 minutes, ranged from 20 to 120 ppb (EPA 2007).  Fogging with a 3% glutaraldehyde solution has also 
been tested for disinfection following SARS outbreaks (EPA 2007).
Glutaraldehyde exposure may also result from the use of metal working fluids, in cooling tower
applications, and during painting processes (EPA 2007).  Air concentrations measured while 45%
glutaraldehyde-containing metal working fluids were transferred between containers were found to range
from <71 to <290 ppb over 16- and 22-minute sample durations, respectively (EPA 2007).  Dermal
exposure to glutaraldehyde from metalworking fluids could also occur, but is not thought to be a major
concern (EPA 2007).  Transfer of a 45% solution for a cooling tower application over a 5-minute period
resulted in an air concentration of <660 ppb glutaraldehyde (EPA 2007).  Around a paint spray booth at
an automobile manufacturing plant, a 30-minute sample found air concentrations of glutaraldehyde
ranging from not detectable to 158 ppb (EPA 2007).
6.6  EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.8, Children’s Susceptibility.
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
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sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
Exposure of children to glutaraldehyde is expected to be minimal, as glutaraldehyde is primarily used in
industrial and medical applications (EPA 2007; IPCS 1998).  It may be possible for children to be
exposed to glutaraldehyde residues and vapor in medical facilities, particularly those where improper
ventilation exists, or by exposure to paint fumes and household products (i.e., laundry detergent)
containing glutaraldehyde (EPA 2007; IPCS 1998). Because glutaraldehyde is used in oil and gas 
recovery operations (including hydrofracturing processes), there is potential for exposure among children 
living in areas surrounding such operations. The potential for exposure to glutaraldehyde through ingestion
of dust and soil is expected to be low based on the low potential for soil adsorption and the high rate of degradation.
Glutaraldehyde has not been detected in breast milk.
6.7  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
The highest glutaraldehyde exposure rates appear to affect personnel working in medical and dental
facilities where glutaraldehyde is used as a disinfecting agent (EPA 2007; HSDB 2011; IPCS 1998).
Significant exposure may also occur among workers involved in oil and gas recovery operations, although 
limited information is available regarding exposure levels within such operations.
6.8  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of glutaraldehyde is available. Where adequate information is
not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of
research designed to determine the health effects (and techniques for developing methods to determine
such health effects) of glutaraldehyde.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
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6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The physical and chemical properties of glutaraldehyde are 
general well understood and have been discussed in Chapter 4 (Table 4-2).  There are no significant data
needs.
Production, Import/Export, Use, Release, and Disposal. According to the Emergency
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this
information for 2011, became available in November of 2012. This database is updated yearly and should
provide a list of industrial production facilities and emissions.
Methods of manufacturing and uses of glutaraldehyde are available and have been discussed in Chapter 5.
However, import and export volumes were not available.  Additional information concerning import and 
export, release, and disposal of glutaraldehyde is needed.
Environmental Fate. Data suggest that glutaraldehyde is rapidly degradable in air, water, and soil
(EPA 2007; HSDB 2011; IPCS 1998; Leung 2001).  Additional data do not appear necessary at this time.
Bioavailability from Environmental Media. No data exist regarding glutaraldehyde bioavailability
from environmental media such as soil or drinking water.  However, glutaraldehyde is known to rapidly
biodegrade in soil and water (EPA 2007; Leung 2001); thus, it is not expected to be bioavailable from
these sources.
Food Chain Bioaccumulation. Glutaraldehyde is not expected to bioconcentrate due to its ability
to be degraded in the environment (HSDB 2011; IPCS 1998).  Therefore, bioaccumulation through the
food chain is expected to be low (IPCS 1998).  No data needs are identified.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of
glutaraldehyde in contaminated media at hazardous waste sites are needed so that the information
obtained on levels of glutaraldehyde in the environment can be used in combination with the known body
burden of glutaraldehyde to assess the potential risk of adverse health effects in populations living in the 
vicinity of hazardous waste sites. Data regarding ambient levels in the environment, particularly near oil
and gas recovery operations, would be useful to assess the potential risk to the general population.
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Exposure Levels in Humans. Exposure to glutaraldehyde can occur primarily through inhalation 
and dermal contact with solutions containing glutaraldehyde, such as disinfectants (EPA 2007; IPCS 
1998; Smith and Wang 2006).  Inhalation and dermal exposures are fairly well understood.  However,
there is a possibility of exposure through food sources, where animal housing is cleaned with
glutaraldehyde solutions. Additional information concerning exposure through ingestion would be useful.
Because glutaraldehyde is used in oil and gas recovery operations (including hydrofracturing processes)
and pipeline installations, information regarding exposure levels among the workers and among the
general population in areas surrounding such operations would be useful.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. Children may be exposed to glutaraldehyde through the same routes as
adults.  However, as occupational settings such as hospitals are the major source of glutaraldehyde 
exposure, children may not be exposed to detrimental levels of glutaraldehyde.  Additional information 
concerning exposure of children to glutaraldehyde is needed.
Child health data needs relating to susceptibility are discussed in Section 3.13.2, Identification of Data
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for glutaraldehyde were located.  This substance is not
currently one of the compounds for which a sub-registry has been established in the National Exposure 
Registry.  The substance will be considered in the future when chemical selection is made for sub-
registries to be established.  The information that is amassed in the National Exposure Registry facilitates 
the epidemiological research needed to assess adverse health outcomes that may be related to exposure to 
this substance.
6.8.2 Ongoing Studies 
No ongoing environmental fate studies for glutaraldehyde were identified using identified in the NIH 
Research Portfolio Online Reporting Tools (RePORTER 2014).  
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7. ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that are available for detecting,
measuring, and/or monitoring glutaraldehyde, its metabolites, and other biomarkers of exposure and 
effect to glutaraldehyde.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the 
intention is to identify well-established methods that are used as the standard methods of analysis.  Many
of the analytical methods used for environmental samples are the methods approved by federal agencies 
and organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).
Other methods presented in this chapter are those that are approved by groups such as the Association of
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).
Additionally, analytical methods are included that modify previously used methods to obtain lower
detection limits and/or to improve accuracy and precision.
7.1  BIOLOGICAL MATERIALS
Analytical methods to quantify glutaraldehyde in biological materials are not readily available since the
determination of glutaraldehyde in biological matrices is confounded by its reactivity with amine and 
other functional groups of proteins and enzymes.  It is this property that has led to its widespread use as a
cross-linking agent for proteins.  Furthermore, in vivo and in vitro studies using laboratory animals
suggest that glutaraldehyde is rapidly metabolized in the body.  The proposed metabolic pathway of
glutaraldehyde has been summarized in Section 3.4.3 (Metabolism) of this profile.  Glutaraldehyde can be
detected in urine samples by reaction with diethyl thiobarbituric acid in a potassium phosphate buffer
solution and measuring the fluorescence of the resultant complex (Wu et al. 1994).  This method was
discussed in the context of glutaraldehyde’s use as a masking agent in which it is added to adulterated
urine samples in order to cause false negatives during enzyme immunoassay drug testing rather than as a 
screening method for exposure to this substance.
Stable-isotope dilution assays involving conventional electron-impact ionization and gas 
chromatography-mass spectrometry (GS-MS) have been developed to detect and quantify levels of
glutaric acid (a metabolite of glutaraldehyde) and other substances in body fluids (Baric et al. 1999;
Shigematsu et al. 2005).  In the method described by Shigematsu et al. (2005), ethylacetate was used to
extract glutaric acid from a mixture containing serum or cerebrospinal fluid, sodium chloride,
hydrochloric acid, and known amounts of radiolabeled glutaric acid and 3-hydroxyglutaric acid.  Glutaric
acid was extracted from urine samples (mixed with creatinine and radiolabeled glutaric acid and
3-hydroxyglutaric acid) by incubation with urease and deproteinization using methanol.  The limit of
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quantification for glutaric acid in aqueous solution was 0.0019 nmol/mL using QP5050 GC-MS and 
0.057 nmol/mL using SSQ710 GC-MS; percent recovery was in the range of 83–86%.
7.2  ENVIRONMENTAL SAMPLES 
Atmospheric glutaraldehyde concentrations can be determined by a number of methods.  Some methods
include thermal desorption/gas chromatographic analysis; OSHA method 64: high performance liquid 
chromatographic (HPLC) analysis; NIOSH method 2531; silica gel adsorption/gas chromatographic (GC)
analysis; alumina adsorption/gas chromatographic analysis; colorimetric determination using 3-methyl­
2-benzothiazolinone hydrazone (MBTH); and direct-reading instruments (NICNAS 1994).  These
methods are summarized in Table 7-1.
In the thermal desorption/GC method, air sampled by a pump is passed through an adsorption tube
containing Tenax-GC.  The tube is connected to the GC, which is fitted with a flame ionization detector
(FID), and the sample is thermally desorbed and separated with temperature programming over
approximately 15 minutes (NICNAS 1994).
With the OSHA method 64, samples collected by a pump on 37-mm glass fiber filters are treated with a 
5% solution of dinitrophenyl-hydrazine hydrochloride (DNPH), followed by desorption using acetonitrile.  
The solution is injected into the HPLC, which uses a ultra-violet (UV) absorption detector.  For this
method, the detection limit has been reported as approximately 0.1 µg and 18 µg/m3 (HSDB 2011;
NICNAS 1994).
A similar HPLC method was also utilized by Sekine et al. (2005) to determine glutaraldehyde
concentrations.  A passive sampler packed with DNPH was used to collect glutaraldehyde samples in air,
eluted with 10 mL of acetonitrile, and concentrations of glutaraldehyde were determined using HPLC.  
The HPLC utilized a Shimadzu LC-6A pump with an SPD-6A UV-visible detector and the following
conditions; a 4.6x150 mm, 5 µm, Inertsil ODS-80A column; a 60/40 acetonitrile/distilled water eluent at 
1.5 mL/minute; detection at 360 nm; and an injection volume of 20 µL.  The limit of detection was
1.2 ppb of glutaraldehyde for 8-hour sampling (3 times the HPLC baseline noise); the limit of quantitation
was 3.9 ppb of glutaraldehyde (10 times the HPLC baseline noise).
Wellons et al. (1998) utilized a method based on OSHA method 64, whereby glutaraldehyde was also
measured as a DNPH derivative.  A 37 mm filter cassette with DNPH pre-coated AE glass fiber filters 
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Table 7-1. Analytical Methods for Determining Glutaraldehyde in Environmental
 
Samples
 
Sample Sample Percent
matrix Preparation method Analytical method detection limit recovery Reference
Air	 Drawing air through sampling 
tubes containing Amberlite 
XAD-2 with DNPH
Air	 Passive sampler containing
DNPH; elution with acetonitrile
Air	 Cassette with DNPH; desorbed 
with acetonitrile
Air	 Passive badge sampler with 
DNPH; desorbed with 
acetonitrile
Air	 Air sampled by pump passed 
through adsorption tube
containing Tenax-GC
Air	 Sample on 37 mm glass fiber
filter treated with 5% DNPH
hydrochloride; desorbed in 
acetonitrile
Air	 Sample on XAD-2 tube treated 
with DNPH hydrochloride
Air	 Samples on adsorption tubes
filled with silica gel; desorbed in 
acetone
Air	 Samples in adsorption tubes
packed with silica gel;
desorbed in acetone
Air	 Samples on adsorption tubes
packed with alumina; desorbed 
with phosphate buffer
Air	 Samples drawn through 
impingers containing distilled 
water
Air	 Direct reading instrument
Air Diffusive sampler filter with
DNPH; washed with acetonitrile
UV 
spectrophotometer
HPLC
HPLC with UV
detector at 355 nm
HPLC with UV
detector at 355 nm
GC with FID
HPLC with UV
absorption
GC with FID
GC with FID
GC with FID
GC with Tenax-GC 
column, FID
Colorimetric
analysis with MBTH
Fuel cell sensor;
glutaraldehyde 
catalytically oxidized 
to produce electrical
response
HPLC
0.02 mg/m3 for
3-L air sample
1.2 ppb for
8-hour sample
0.27 µg/ 
sample;
0.004 ppm for
15-minute 
sample
0.006 µg/ 
sample;
0.016 ppm for
15-minute 
sample
0.1 µg or
18 µg/m3 
0.3 and 1 µg
0.02 ppm
0.29 µg/ 
sample;
0.005 ppm for
15-L sample
0.05–5 ppm v/v 
or 0.03–4 ppm
0.03 mg/m3 
Rietz 1985
Sekine et al.
2005
Wellons et
al. 1998
Wellons et
al. 1998
NICNAS
1994
NICNAS
1994
NICNAS
1994
NICNAS
1994
Wellons et
al. 1998
NICNAS
1994
NICNAS
1994
NICNAS
1994;
Wellons et
al. 1998
Lindahl and 
Levin 1995
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Table 7-1. Analytical Methods for Determining Glutaraldehyde in Environmental
 
Samples
 
Sample 
matrix Preparation method Analytical method
Sample 
detection limit
Percent
recovery Reference
Water Diluted 25% glutaraldehyde
solutions prepared in methanol
Spectrophotometer
with absorbance at
480 nm
1 mg/L Jolibois et
al. 2002
Water Diluted 25% glutaraldehyde
solutions prepared in methanol
GC/MS Jolibois et
al. 2002
Aqueous
solutions
Titration with 0.5 N
hydroxylamine 
hydrochloride
10–50%
glutaraldehyde 
solutions
NICNAS
1994
Aqueous
solutions
Water sample added to MBTH Absorbance at
605 or 610 nm
0.5–10 ppm
glutaraldehyde 
solutions
NICNAS
1994
Aqueous
solutions
Sodium bisulfide added to 
water sample
Titrated with 
standardized 
sulfuric acid
25–5,000 ppm
glutaraldehyde 
solutions
NICNAS
1994
Aqueous
solutions
Water sample GC with Tenax-GC 
or Porapak PS
column, FID
1–2,500 ppm
w/v
glutaraldehyde 
solutions
NICNAS
1994
DNPH = 2,4-dinitrophenylhydrazine; FID = flame ionization detector; GC = gas chromatography; HPLC = high 
performance liquid chromatography; MBTH = 3-methyl-2-benzothiazolinone hydrazine; UV = ultraviolet
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was used with high-volume personal sample pumps at 1 L/minute to collect 15-minute air samples.  The 
filter cassettes were capped and frozen until analysis, whereby each section was desorbed in 2 mL
acetonitrile, with a desorption efficiency of nearly 100%.  Solutions were analyzed with HPLC using a
UV detector at 355 nm.  A lower limit of quantitation of 0.27 µg/sample, or 0.004 ppm for a 15-minute
sample was attained, with percent recoveries of 105 and 96% after 17 days ambient temperature and 
16 days -20 ºC storage, respectively (Wellons et al. 1998).  Similarly, Wellons et al. (1998) also tested a
passive badge sampler, containing a filter impregnated with DNPH that has a sampling rate of
5.88 mL/minute.  Badges were exposed to air for 15 minutes, then capped.  Glutaraldehyde was desorbed
with 1 mL acetonitrile and the same HPLC method was utilized.  The method was found to have a lower
limit of quantification of 0.006 µg/sample, or 0.016 ppm for 15 minutes (Wellons et al. 1998).  
The NIOSH method 2531 utilizes a sample collected on washed XAD-2 tubes that are then treated with 
dinitrophenyl-hydrazine hydrochloride.  Samples are analyzed with GC using FID.  The detection limit of
this method has been reported at both 0.3 and 1 µg (HSDB 2011; NICNAS 1994).
Similarly, Rietz (1985) determined glutaraldehyde concentrations in air by passing known volumes of air
through sampling tubes that contained Amberlite XAD-2 that were coated with DNPH as the adsorption
material.  As the experiment was designed to sample glutaraldehyde as well as formaldehyde and
acrolein, acetonitrile was used to elute the resulting hydrazones and the compounds were then separated 
using an RP C-18 column.  The chemicals were identified using a UV spectrophotometer at a wavelength 
of 365 nm.  For a 3-L air sample, the limit of detection for glutaraldehyde was determined to be
0.02 mg/m3 of air with a 95% confidence level. This method was determined to be acceptable for
glutaraldehyde concentrations ranging from 0.04 to 2.1 mg/m3 of air (Rietz 1985).
A diffusive sampler was used to determine the glutaraldehyde concentrations in air by Lindahl and Levin 
(1995).  The sampler utilized a 20x45 mm filter coated impregnated with DNPH, placed in a
60x30x5-mm polypropylene housing unit along with a 2.9-mm thick screen. The samples were analyzed
by eluting the glutaraldehyde-DNPH from the filter with 2.0 or 3.0 mL acetonitrile by shaking for
1 minute and injecting 10 µL samples into the HPLC.  The HPLC consisted of two Waters M-6000 A 
pumps with a Waters M-710 B autosampler and Shimadzu absorbance detector. The detection limit was
determined to be approximately 0.03 mg/m3 for 15-minute samples (Lindahl and Levin 1995).
In the silica gel adsorption/GC analysis method, samples are obtained by a pump on adsorption tubes that
are filled with silica gel. The sample is then desorbed with acetone and the solution is injected into a GC
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using FID.  For 15-minute exposure samples of a 30-L air sample, the detection limit has been reported as 
0.02 ppm (NICNAS 1994).
This method of direct measurement of glutaraldehyde in air was evaluated by Wellons et al. (1998).  A
70x6 mm (OD) glass tube was packed with silica gel.  High-volume personal sample pumps drew air
through the tubes at 1 L/minute for 15 minutes.  Tubes were then capped and frozen until analysis, where
the glutaraldehyde was desorbed with 1 mL of acetone.  Glutaraldehyde concentrations were determined 
by GC using an FID.  Losses of 4 and 7% glutaraldehyde occurred from freezing for 14 and 21 days, 
respectively.  A detection limit of 0.29 µg/sample, or 0.005 ppm for a 15-L sample, was attained (Wellons 
et al. 1998).
Alumina adsorption/GC analysis is accomplished using air samples obtained with a pump.  The samples 
are collected on adsorption tubes packed with alumina.  Samples are then desorbed with a phosphate
buffer solution and injected into a GC that has a Tenax-GC column and FID installed (NICNAS 1994).
Glutaraldehyde concentrations in air can also be evaluated by colorimetric determination using 3-methyl­
2-benzothiazolinone hydrazone (MBTH).  Air samples containing are drawn through impingers that
contain distilled water, such as with a reciprocating air pump with flow rates up to 1 L/minute.
Glutaraldehyde absorbs into the water, due to its soluble nature, and concentrations can then be
determined using colorimetric analysis with MBTH solution.  This method may be problematic if other
aldehydes and ketones are present (NICNAS 1994).
A direct-reading instrument known as the Lion Glutaraldemeter is commercially available for the 
determination of glutaraldehyde concentrations in air.  Air samples of 10 mL are drawn in with a self-
contained sample pump, and response times are approximately 60 seconds.  A fuel cell sensor in the
meter causes glutaraldehyde to go through catalytic oxidation, producing an electrical response, which is 
proportional to the amount of glutaraldehyde in the air.  This method has a reported detection limit of
0.05–5 ppm v/v, although this was also reported as 0.03–4 ppm.  The instrument may give erroneous
readings if alcohols and other aldehydes are present, although the manufacturer offers an optional filter
which removes phenol interference and corrects for alcohol interference (NICNAS 1994; Wellons et al. 
1998).
Methods have also been developed to determine glutaraldehyde concentrations in water and aqueous
solutions.  For high levels of glutaraldehyde in aqueous solutions (i.e., solutions of 10–50%), the standard 
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method involves titration with 0.5 N hydroxylamine hydrochloride.  To determine glutaraldehyde
concentrations at lower levels, the following methods may be used: colorimetric determination using
MBTH; titration after reaction with sodium bisulfite, and GC analysis. These methods are summarized in
Table 7-1.  
Colorimetric determination of glutaraldehyde in water is performed by adding the sample to a solution of
MBTH and measuring the absorbance at 605 or 610 nm.  While the presence of other ketones or
aldehydes may interfere, this method is usable for glutaraldehyde concentrations of 0.5–10 ppm in water
(NICNAS 1994).
Jolibois et al. (2002) examined glutaraldehyde concentrations in hospital waste water. The study utilized
a variation on the spectrophotometric method, whereby standard solutions of a diluted 25% commercial
glutaraldehyde solution were prepared in methanol.  A coloring reagent mixture of 40 µL of 5% aqueous
phenol solution and 10 mL of 70% perchloric acid was prepared.  The experiment was performed by
adding 100 µL of the methanolic sample to 1 mL of the reagent.  After a 15-minute time period for color
development, the absorbance was measured on a spectrophotometer at 480 nm.  A detection limit of
1 mg/L was obtained.  The method was verified by analyzing the methanolic eluates by GC/mass 
spectrometry (MS) using a Varian 3900 GC with a Saturn 2100 detector, splitless injector (230°C), and 
CP-SIL 8CB-MS fused silica column (30 m by 0.25 mm ID) with a 1 µL injection volume and helium as
the carrier gas (Jolibois et al. 2002).
Glutaraldehyde concentrations in water can also be determined using a titration technique.  Sodium
bisulfide is added to the water sample to react with the carbonyl groups.  The solution is then titrated with 
standardized sulfuric acid. This method may be used for glutaraldehyde solutions ranging from 25 to 
5,000 ppm, but interference by ketones and other aldehydes, as well as acids and bases in the sample, may
be an issue (NICNAS 1994).
In GC analysis of glutaraldehyde in water, the sample is injected into a GC equipped with a Tenax-GC or
Porapak PS column and a flame ionization detector.  This method can detect glutaraldehyde
concentrations ranging from 1 to 2,500 ppm w/v (NICNAS 1994).
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7.3  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of glutaraldehyde is available. Where adequate information is
not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of glutaraldehyde. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.
Methods are available to detect glutaric acid (a metabolite of glutaraldehyde) in bodily fluids.  Such
methods could be applied to detect and quantify glutaraldehyde metabolites in urine and/or serum of
glutaraldehyde-exposed workers, although environmental exposure to low levels of glutaraldehyde might
not warrant this type of biomonitoring.
Exposure.  Additional information concerning procedures to determine glutaraldehyde exposures in 
biological materials is needed.
Effect. Information concerning procedures to determine the effect of glutaraldehyde in biological
materials is needed.
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media.
Methods are available to detect glutaraldehyde in air and water at levels that may be a concern for health.  
No methods for determining glutaraldehyde concentrations in soil were located, but it is unlikely that this
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would be an important environmental medium for glutaraldehyde as it is rapidly degraded in soil,
possibly by bacteria.
7.3.2 Ongoing Studies 
No ongoing analytical studies for glutaraldehyde were identified in the NIH Research Portfolio Online 
Reporting Tools (RePORTER 2014).  
***DRAFT FOR PUBLIC COMMENT***
   
 
  
 
 
 
 
 
 
 
 
  
168GLUTARALDEHYDE
7.  ANALYTICAL METHODS
This page is intentionally blank.
***DRAFT FOR PUBLIC COMMENT***
   
 
 
 
 
 
 
   
 
   
 
     
  
   
    
    
   
   
       
    
 
    
  
    
    
    
   
      
 
 
      
    
     
 
 
     
        
 
    
 
 
 
 
  
169GLUTARALDEHYDE
8. REGULATIONS, ADVISORIES, AND GUIDELINES
 
MRLs are substance specific estimates, which are intended to serve as screening levels, are used by
ATSDR health assessors and other responders to identify contaminants and potential health effects that
may be of concern at hazardous waste sites.
An MRL of 0.001 ppm (1x10-3 ppm) has been derived for acute-duration inhalation exposure (≤14 days)
to glutaraldehyde.  The MRL is based on a NOAEL of 0.125 ppm and a LOAEL of 0.25 ppm for
histopathological nasal lesions in male F344 rats exposed to glutaraldehyde vapor for a single 6-hour
period (Gross et al. 1994; NTP 1993).  The NOAEL of 0.125 ppm was duration-adjusted to simulate a
24-hour exposure (0.125 ppm x 6 hours/24 hours = NOAELADJ of 0.031 ppm) and converted to a HEC
(NOAELHEC = 0.003 ppm) according to EPA (1994) cross-species dosimetric methodology for a category
1 gas where inhalation exposure-related effects occur within the extrathoracic region of the respiratory
tract.  A total uncertainty factor of 3 (1 for extrapolation from animals to humans using dosimetric
adjustment and 3 for sensitive individuals) was applied.
An MRL of 0.00003 ppm (3.0x10-5 ppm) has been derived for intermediate-duration inhalation exposure
(15–364 days) to glutaraldehyde.  BMD analysis was applied to incidence data for female B6C3F1 mice 
with inflammation in the nasal vestibule/anterior nares following exposure to glutaraldehyde vapor
6 hours/day, 5 days/week for 13 weeks (NTP 1993).  A 10% change from control incidence was selected
as the BMR. The resulting 95% lower confidence limit on the maximum likelihood estimate of the 
exposure concentration associated with the selected BMR (BMCL10) of 0.0034 ppm was adjusted to 
simulate a continuous exposure scenario (0.0034 ppm x 6 hours/24 hours x 5 days/7 days = BMCL10ADJ of
0.0006 ppm).  Derivation of a HEC based on the BMCL10ADJ of 0.0006 ppm was performed according to 
EPA (1994) cross-species dosimetric methodology for a category 1 gas where inhalation exposure-related
effects occur within the extrathoracic region of the respiratory tract (the nasal cavity in the case of
glutaraldehyde), resulting in a BMCL10HEC of 0.00008 ppm (8x10-5 ppm).  A total uncertainty factor of
3 (1 for extrapolation from animals to humans using dosimetric adjustment and 3 for human variability)
was applied.
An MRL of 0.1 mg/kg/day has been derived for chronic-duration oral exposure (365 days or more) to 
glutaraldehyde.  The MRL is based on a NOAEL of 4 mg/kg/day and a LOAEL of 17 mg/kg/day for
gastric irritation (multifocal color change, mucosal thickening, nodules, and ulceration affecting primarily
the nonglandular mucosa) in male F344 rats administered glutaraldehyde in the drinking water for 2 years
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(van Miller et al. 2002). The NOAEL of 4 mg/kg/day was divided by a total uncertainty factor of
30 (10 for extrapolation from animals to humans and 3 for human variability).
IARC has not classified glutaraldehyde as to its carcinogenicity (IARC 2013). The World Health
Organization (WHO) has not established any air quality or drinking water guidelines for glutaraldehyde
(WHO 2010, 2011).
OSHA has not established any enforceable standards for glutaraldehyde (OSHA 2013a), although NIOSH
and ACGIH have recommended a ceiling limit of 0.2 ppm that should not be exceeded at any time
(ACGIH 2013; NIOSH 2011).
The American Industrial Hygiene Association (AIHA) and the Department of Energy (DOE) have
established identical values for responding to potential releases of airborne glutaraldehyde for use in 
community emergency planning. The values established by AIHA (2011) and the DOE (2012) are the 
Emergency Response Planning Guidelines (ERPGs-1, -2, -3) and Protective Active Criteria (PAC-1, -2, 
and -3), respectively. These values (0.2, 1, and 5 ppm) represent increasing severity of effects (mild, 
irreversible, and life-threatening, respectively) for a 1-hour exposure.
EPA and NTP have not classified glutaraldehyde as a carcinogen. The EPA has not derived an oral
reference dose (RfD) or an inhalation reference concentration (RfC) for glutaraldehyde (IRIS 2013). 
ACGIH (2013) has classified glutaraldehyde as an A4 carcinogen (not classifiable as a human 
carcinogen).
Under the Toxic Substances Control Act (TSCA), glutaraldehyde is on the list of chemicals that
manufacturers and importers must report for each plant site at which they manufactured or imported
glutaraldehyde during the reporting period specified (EPA 2012i, 2012j).
The international and national regulations, advisories, and guidelines regarding glutaraldehyde in air, 
water, and other media are summarized in Table 8-1.  
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1. Regulations, Advisories, and Guidelines Applicable to Glutaraldehyde
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification No data IARC 2013
WHO Air quality guidelines No data WHO 2010
Drinking water quality guidelines No data WHO 2011
NATIONAL
Regulations and 
Guidelines:
a. Air
ACGIH TLV STEL (ceiling)a 0.05 ppm ACGIH 2013
AIHA ERPG-1b,c 0.2 ppm AIHA 2011
ERPG-2 1 ppm
ERPG-3 5 ppm
DOE PAC-1d 0.2 ppm DOE 2012
PAC-2 1 ppm
PAC-3 5 ppm
EPA AEGLs No data EPA 2013a
Second AEGL chemical priority list No data EPA 2013b
Hazardous air pollutant No data EPA 2013c
42 USC 7412
NAAQS No data EPA 2013f
NIOSH REL (ceiling TWA)e 0.2 ppm NIOSH 2011
IDLH No data
OSHA PEL (8-hour TWA) for general industry No data OSHA 2013a
29 CFR 1910.1000,
Table Z-1
Highly hazardous chemicals No data OSHA 2013b
29 CFR 1910.119,
Appendix A
b. Water
EPA Designated as hazardous substances in 
accordance with Section 311(b)(2)(A) of
the Clean Water Act
No data EPA 2012a
40 CFR 116.4
Drinking water contaminant candidate 
list
No data EPA 2009a
74 FR 51850
Drinking water standards and health 
advisories
No data EPA 2012b
National primary drinking water
standards
No data EPA 2009b
National recommended water quality
criteria
No data EPA 2009c
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1. Regulations, Advisories, and Guidelines Applicable to Glutaraldehyde
Agency Description Information Reference
NATIONAL (cont.)
EPA Reportable quantities of hazardous No data EPA 2012d
substances designated pursuant to 40 CFR 117.3
Section 311 of the Clean Water Act
c. Food
FDA EAFUSf Yes FDA 2013
d. Other
ACGIH Carcinogenicity classification A4g ACGIH 2013
EPA Carcinogenicity classification No data IRIS 2013
RfC No data
RfD No data
Identification and listing of hazardous No data EPA 2012c
waste 40 CFR 261,
Appendix VIII
Inert pesticide ingredients in pesticide Yes EPA 2013d
products approved for nonfood use only
Master Testing List No data EPA 2013e
RCRA waste minimization PBT priority No data EPA 1998e
chemical list 63 FR 60332
Standards for owners and operators of No data EPA 2012e
hazardous waste TSD facilities; 40 CFR 264,
groundwater monitoring list Appendix IX
Superfund, emergency planning, and 
community right-to-know
Designated CERCLA hazardous No data EPA 2012f
substance and reportable quantity 40 CFR 302.4
Effective date of toxic chemical No data EPA 2012h
release reporting 40 CFR 372.65
Extremely hazardous substances No data EPA 2012g
and its threshold planning quantity 40 CFR 355,
Appendix A
TSCA chemical lists and reporting EPA 2012i
periods 40 CFR 712.30
Effective date 09/30/1991
Reporting date 11/27/1991
TSCA health and safety data reporting EPA 2012j
40 CFR 716.120Effective date 09/30/1991
Reporting date 06/30/1998
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1. Regulations, Advisories, and Guidelines Applicable to Glutaraldehyde
Agency Description Information Reference
NATIONAL (cont.)
NTP Carcinogenicity classification No data NTP 2014
aBased on upper respiratory tract, skin, and eye irritation and central nervous system impairment. Potential for 

glutaraldehyde to produce dermal sensitization. The TLV-STEL is a 15-minute TWA exposure that should not be 

exceeded at any time during an 8-hour workday.
 
bERPG-1:  maximum airborne concentration below which it is believed that nearly all individuals could be exposed for
 
up to 1 hour without experiencing other than mild transient adverse health effects or perceiving a clearly defined,
 
objectionable odor; ERPG-2: maximum airborne concentration below which it is believed that nearly all individuals
 
could be exposed for up to 1 hour without experiencing or developing irreversible or other serious health effects or
 
symptoms which could impair an individual's ability to take protective action; ERPG-3:  maximum airborne 

concentration below which it is believed that nearly all individuals could be exposed for up to 1 hour without
 
experiencing or developing life-threatening health effects (AIHA 2011).
 
cOdor should be detectable near ERPG-1.
 
dPAC-1:  mild, transient health effects; PAC-2:  irreversible or other serious health effects that could impair the ability
 
to take protective action; PAC-3:  life-threatening health effects (DOE 2012).
 
eTesting has not been completed to determine the carcinogenicity of glutaraldehyde; however, the limited studies to 

date indicate that this substance has chemical reactivity and mutagenicity similar to acetaldehyde and 

malonaldehyde, therefore, NIOSH recommends that careful consideration should be given to reducing exposures to 

glutaraldehyde (NIOSH 2011).

fThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 

additives or listed or affirmed as GRAS.
 
gA4: not classifiable as a human carcinogen
 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;
 
AIHA = American Industrial Hygiene Association; CERCLA = Comprehensive Environmental Response,
 
Compensation, and Liability Act; CFR = Code of Federal Regulations; DOE = Department of Energy;
 
EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection Agency;
 
ERPG = emergency response planning guidelines; FDA = Food and Drug Administration; FR = Federal Register;
 
GRAS = generally recognized as safe; IARC = International Agency for Research on Cancer; IDLH = immediately
 
dangerous to life or health; IRIS = Integrated Risk Information System; NAAQS = National Ambient Air Quality
 
Standards; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program; 

OSHA = Occupational Safety and Health Administration; PAC = protective action criteria; PBT = persistent,
 
bioaccumulative, and toxic; PEL = permissible exposure limit; RCRA = Resource Conservation and Recovery Act;
 
REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose;
 
STEL = short-term exposure limit; TLV = threshold limit value; TSCA = Toxic Substances Control Act;
 
TSD = treatment, storage, and disposal; TWA = time-weighted average; USC = United States Code; WHO = World
 
Health Organization
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms
at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or
exposure. These may suggest potential topics for scientific research, but are not actual research studies.
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Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or
irreversible health effects.
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.
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Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of individuals in a population who develop a specified condition to the total
number of individuals in that population who could have developed that condition in a specified time
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors. The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.
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Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no
statistically or biologically significant increases in frequency or severity of adverse effects seen between
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based
and physiologically-based.  A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end
points.  These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments
representing organs or tissue groups with realistic weights and blood flows. These models require a 
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variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Prospective Study—A type of cohort study in which the pertinent observations are made on events
occurring after the start of the study.  A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a
professional judgment of the entire database on the chemical. The RfDs are not applicable to
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
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Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or
inherited characteristic that is associated with an increased occurrence of disease or other health-related
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes
continually.  No more than four excursions are allowed per day, and there must be at least 60 minutes
between exposure periods.  The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour
workday or 40-hour workweek.
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system.
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APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach. They are below levels that might cause adverse health effects in the people most sensitive to
such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method
suitable for this route of exposure.  MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that
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are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Human Health Sciences, expert panel peer reviews, and agency-wide MRL
Workgroup reviews, with participation from other federal agencies and comments from the public.  They
are subject to change as new information becomes available concomitant with updating the toxicological
profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels.
For additional information regarding MRLs, please contact the Division of Toxicology and Human 
Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop 
F-57, Atlanta, Georgia 30329-4027.
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A-3GLUTARALDEHYDE
APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Glutaraldehyde
CAS Numbers: 111-30-8
Date: December 2015
Profile Status: Draft for Public Comment
Route: [x] Inhalation   [ ] Oral
Duration: [x] Acute  [ ] Intermediate   [ ] Chronic
Graph Key: 13
Species: Rat
Minimal Risk Level: 0.001 [ ] mg/kg/day  [x] ppm
References:
Gross EA, Mellick PW, Kari FW, et al.  1994.  Histopathology and cell replication responses in the
respiratory tract of rats and mice exposed by inhalation to glutaraldehyde for up to 13 weeks.  Fundam
Appl Toxicol 23(3):348-362.
NTP.  1993.  NTP Technical report on toxicity studies of glutaraldehyde (CAS No. 111-30-8)
administered by inhalation to F344/N tats and B6C3F1 mice.  Research Triangle Park, NC:  National
Toxicology Program, U.S. Department of Health and Human Services.  25. NIH Publication 93-3348, 
Number 25.
Experimental design: In a study designed to evaluate the time course of glutaraldehyde-induced nasal
lesions, male and female F344 rats and B6C3F1 mice were exposed to glutaraldehyde vapor for
6 hours/day for 1 or 4 days, or 6 or 13 weeks at glutaraldehyde vapor concentrations of 0.0625, 0.125, 
0.250, 0.5, or 1 ppm and sacrificed for evaluation of exposure-related nasal lesions.
Effect noted in study and corresponding doses: Exposure-related increased incidences of rats and mice 
exhibiting selected nasal lesions were observed following exposure to glutaraldehyde vapor at 0.250 ppm
6 hours per day for as little as 1 or 4 days; there were no apparent exposure-related effects on nasal lesion
incidences at 0.125 ppm (Table A-1). This study identified a NOAEL of 0.125 ppm, and the lowest
LOAEL (0.25 ppm for histopathological nasal lesions) among the acute-duration inhalation studies and 
was therefore selected as the principal study for derivation of an acute-duration inhalation MRL for
glutaraldehyde.
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APPENDIX A
Table A-1.  Incidences of Male and Female F344 Rats and B6C3F1 Mice with
 
Selected Histopathologic Nasal Lesions Following Exposure to
 
Glutaraldehyde Vapor 6 Hours/Day for 1 or 4 Daysa
 
Species
Exposure 
level 
Squamous
exfoliation
Intraepithelial
neutrophils
Subepithelial 
neutrophils
Epithelial 
erosions
(gender) (ppm) 1 day 4 days 1 day 4 days 1 day 4 days 1 day 4 days
Rat (male) 0 0/5 0/5 0/5 0/5 0/5 1/5 (0.2)b 0/5 0/5
0.0625 1/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5
0.125 0/4 0/5 0/4 0/5 0/4 2/5 (0.4) 0/4 0/5
0.250 1/5 0/5 1/5 (0.4) 0/5 3/5 (0.8) 1/5 (0.2) 1/5 1/5
0.500 3/5 3/5 2/5 (0.4) 5/5 (1.4) 5/5 (1.8) 5/5 (1.6) 5/5 2/5
1.00 5/5 5/5 5/5(1.2) 5/5 (2.6) 5/5 (2.6) 5/5 (3.4) 5/5 5/5
0.250 2/5 3/5 0/5 2/5 (0.4) 1/5 (0.2) 4/5 (1.4) 0/4 2/5
0.500 3/5 5/5 2/5 (0.6) 5/5 (2.2) 5/5 (2.4) 5/5 (2.8) 4/5 3/5
1.00 4/5 5/5 4/5 (1.0) 5/5 (3.4) 5/5 (2.8) 5/5 (3.8) 5/5 5/5
0.250 0/5 4/5 0/5 1/5 (0.2) 1/5 (0.2) 2/5 (0.4) 0/5 0/5
0.500 4/5 2/5 1/5 (0.2) 4/5 (1.8) 2/5 (0.4) 4/5 (1.8) 1/5 1/5
1.00 5/5 5/5 5/5 (1.0) 5/5 (2.8) 5/5 (1.6) 5/5 (3.2) 2/5 2/5
0.250 0/5 2/5 0/5 1/5 (0.4) 0/5 1/5 (0.4) 0/5 0/5
0.500 5/5 5/5 0/5 5/5 (1.0) 2/5 (0.4) 5/5 (1.6) 0/5 0/5
1.00 4/5 5/5 1/5 (0.4) 4/5 (0.8) 3/5 (1.2) 5/5 (2.0) 1/5 2/5
Rat (female) 0 0/5 0/5 0/5 1/5 (0.2) 0/5 2/5 (0.4) 0/5 0/5
0.0625 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5
0.125 0/5 0/5 0/5 0/5 1/5 (0.4) 0/5 1/5 0/5
Mouse 0 0/5 0/5 1/5 (0.2) 0/5 1/5 (0.2) 0/5 0/5 0/5
(male) 0.0625 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5
0.125 0/5 0/5 1/5 (0.2) 0/5 1/5 (0.2) 0/5 0/5 0/5
Mouse 0 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5
(female) 0.0625 0/5 0/5 0/5 1/5 (0.2) 0/5 0/5 0/5 0/5
0.125 0/5 0/5 0/5 0/5 1/5 (0.2) 0/5 0/5 0/5
aGray shaded cells suggest a toxicologically significant increased incidence from controls.
 
bSeverity (in parentheses) is the mean for all animals in a group where: 0 = no lesion; 1 = minimal; 2 = mild;
 
3 = moderate; and 4 = marked.
 
Sources:  Gross et al. 1994; NTP 1993
Dose and end point used for MRL derivation: 0.125 ppm (adjusted for continuous exposure and 
converted to a human equivalent concentration resulting in a NOAELHEC of 0.003 ppm)
[x] NOAEL   [ ] LOAEL
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[x]  1 for extrapolation from animals to humans using dosimetric conversion
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A-5GLUTARALDEHYDE
APPENDIX A
[x]  3 for human variability
An uncertainty factor of 1 (rather than the default 10) for extrapolation from animals to humans is
justified because: (1) the dosimetric adjustment accounts for differences between rats and humans 
regarding respiratory tract kinetics, and (2) the critical effect (nasal irritation) is the result of the 
propensity of glutaraldehyde to react with and cross-link cell membrane proteins (Peters and Richards 
1977), a mechanism of action common to laboratory animals and humans.  The uncertainty factor for 
human variability consists of a pharmacokinetic contribution (default of 3) and a pharmacodynamic
contribution (default of 3). The propensity of glutaraldehyde to react with and cross-link cell membrane 
proteins at the portal of entry is not expected to vary significantly.  The critical effect (nasal lesions) is 
independent of glutaraldehyde absorption, distribution, metabolism, and elimination kinetics. Therefore,
an uncertainty factor of 1 for intraspecies pharmacokinetics is justified.  A default uncertainty factor of 3 
for intraspecies pharmacodynamics is retained in the absence of empirical data to suggest otherwise.
Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
Derivation of a HEC based on the NOAELADJ was performed according to EPA (1994) cross-species 
dosimetric methodology for a category 1 gas where inhalation exposure-related effects occur within the
extrathoracic region of the respiratory tract (the nasal cavity in the case of glutaraldehyde) using the 
following equation:
RGDRET = (VE/SAET)A / (VE/SAET)H [equation 4-18 in EPA 1994]
where:
RGDR = ratio of the regional gas dose in animals to that of humans
VE = minute volume (cm3/minute)
SA = surface area (cm2)
ET = extrathoracic
A = animal
H = human
EPA-reported SAET values for rats (15 cm2) and humans (200 cm2) were taken from Table 4-4 of EPA
(1994).  Minute volumes were taken from Table 1-4 of EPA (1988) in which they were presented as
m3/day (0.14 m3/day = 97.2 cm3/minute for subchronic exposure of the female F344 rat).  Subchronic
values were used because the rats were approximately 6–7 weeks old at the initiation of exposures.  
According to EPA (1994), the default minute volume for humans is 13,800 cm3/minute.  Therefore:
RGDRET (rat) = (97.2 mL/minute/15 cm2) / (13,800 mL/minute/200 cm2) = 6.48/69 = 0.0939
The human equivalent NOAEL was calculated according to the following equation:
NOAEL[HEC] = NOAEL[ADJ] x RGDRET (rat) = 0.031 ppm x 0.0939 = 0.003 ppm (3x10-3 ppm)
Was a conversion used from intermittent to continuous exposure? The 6-hour exposure was converted to 
a continuous exposure scenario by multiplying the 6-hour NOAEL of 0.125 ppm by 6 hours/24 hours, 
resulting in a NOAELADJ of 0.031 ppm. The adjustment to account for continuous exposure scenarios is
necessary because nasal lesions were observed in glutaraldehyde-exposed rats and mice at lower exposure 
levels following 6 or 13 weeks of repeated 6-hour exposures than those eliciting nasal lesions following a
single 6-hour exposure or repeated 6-hour exposures on 4 consecutive days.
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APPENDIX A
Other additional studies or pertinent information that lend support to this MRL: In a study of Union 
Carbide Corp (1992d), rhinitis and mild atrophy of the olfactory mucosa were observed in male and 
female F344 rats exposed to glutaraldehyde vapor at 3.1 ppm for 6 hours/day for 9 exposures in 11 days;
at an exposure level of 1.1 ppm, males (but not females) exhibited rhinitis and mild squamous metaplasia 
of the olfactory mucosa.  This study identified a NOAEL of 0.3 ppm and a LOAEL of 1.1 ppm for nasal
lesions in the male rats.  Zissu et al. (1994) observed histopathological lesions in the respiratory
epithelium of septum and naso- and maxilloturbinates of male Swiss OF1 mice exposed to glutaraldehyde
vapor for 5 hours/day on 4 consecutive days at 0.3 ppm (the lowest concentration tested); the severity of
glutaraldehyde-induced nasal lesions increased with increasing exposure concentration.  This study did 
not identify a NOAEL.
Agency Contacts (Chemical Managers): Sharon Wilbur, M.A.
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A-7GLUTARALDEHYDE
APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Glutaraldehyde
CAS Numbers: 111-30-8
Date: December 2015
Profile Status: Draft for Public Comment
Route: [x] Inhalation   [ ] Oral
Duration: [ ] Acute [x] Intermediate   [ ] Chronic
Graph Key: 37
Species: Mouse
Minimal Risk Level: 0.00003 [ ] mg/kg/day  [x] ppm
References:
Gross EA, Mellick PW, Kari FW, et al.  1994.  Histopathology and cell replication responses in the
respiratory tract of rats and mice exposed by inhalation to glutaraldehyde for up to 13 weeks.  Fundam
Appl Toxicol 23(3):348-362.
NTP.  1993.  NTP Technical report on toxicity studies of glutaraldehyde (CAS No. 111-30-8)
administered by inhalation to F344/N rats and B6C3F1 mice.  Research Triangle Park, NC:  National
Toxicology Program, U.S. Department of Health and Human Services.  25. NIH Publication 93-3348, 
Number 25.
Experimental design: Groups of male and female B6C3F1 mice (10/sex/group) were exposed to 
glutaraldehyde vapor for 6 hours/day, 5 days/week, for 13 weeks at concentrations of 0, 0.0625, 0.125, 
0.25, 0.5, or 1.0 ppm and evaluated for survival, clinical signs, body weight, selected organ and tissue 
weights, and gross and histopathology (particularly the nasal cavity).
Effect noted in study and corresponding doses: Concentration-related increased incidence and severity of
clinical signs of respiratory irritation and histopathologic nasal lesions (exfoliation, inflammation, 
hyperplasia, and ulceration of nasal squamous epithelium; granulocytes and necrosis in nasal passages;
laryngeal squamous metaplasia; necrosis in nasal nares) were reported. Histopathologic nasal lesions 
were sometimes noted at exposure levels lower than those resulting in overt clinical signs of respiratory
tract irritation.  In general, glutaraldehyde-induced histopathologic respiratory tract lesions were confined 
to the anterior nasal cavity and were not observed in lower respiratory tract regions.  Incidence data for
selected nonneoplastic nasal lesions in the male and female B6C3F1 mice are presented in Table A-2.  
The incidence data for inflammation in the nasal vestibule/anterior nares of the B6C3F1 female mice 
from the core study (NTP 1993) were selected to serve as the basis for deriving an intermediate-duration 
inhalation MRL for glutaraldehyde because this lesion exhibited the lowest effect level (0.0625 ppm).  All
dichotomous models in the BMDS (Version 2.2) were fit to the incidence data for inflammation in the
nasal vestibule/anterior nares of the female mice; the highest exposure group was dropped because the 
incidence of inflammation in this group was not reported (the study authors stated that “inflammation was
a component of ‘squamous exfoliation’ and not diagnosed separately when the latter was present”).  A
BMR of 10% extra risk was applied. The results of the BMD analysis are summarized in Table A-3.
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Table A-2.  Incidences of Male and Female B6C3F1 Mice Exhibiting 

Selected Histopathologic Lesions Following Exposure to 

Glutaraldehyde Vapor 6 Hours/Day, 5 Days/Week for
 
13 Weeks in the Core Study of NTP (1993)a
 
Exposure level (ppm)
0 0.0625 0.125 0.250 0.500 1.000
Males
Nasal passages/turbinates
Respiratory epithelium
Inflammation 0 0 0 0 0 4(1.0)b
Squamous metaplasia 0 0 0 0 0 1 (1.2)
Nasal vestibule/anterior nares
Squamous exfoliation 0 0 0 1 (1.0) 2 (1.0) 9 (2.8)c
Inflammation 0 0 0 0 7 (1.1)c 0d 
Erosion 0 0 0 1 (1.0) 1 (1.0) 0 
Larynx
Squamous metaplasia 0 0 0 0 0 7 (1.6)c
Necrosis 0 0 0 0 0 2 (1.0)
Females
Nasal passages/turbinates
Respiratory epithelium
Inflammation 0 0 0 0 1 (1.0) 7 (1.4) c
Squamous metaplasia 0 0 0 0 0 3 (1.0)
Nasal vestibule/anterior nares
Squamous exfoliation 0 0 0 1 (1.0) 2 (2.5) 10 (2.8)c
Inflammatione 0 5 (1.0)b 8 (2.0)c 8 (1.6)c 8 (2.5)c 0d 
Erosion 0 0 1 (1.0) 0 0 0 
Larynx
Squamous metaplasia 0 0 0 0 0 10 (1.6)c
Necrosis 0 0 0 0 0 2 (1.0)
aIncidence is the number of core-study animals with lesions for groups of 10 animals.  Average severity (in
 
parentheses) is based on the number of animals with lesions: 1 = minimal, 2 = mild, 3 = moderate, and 4 = marked.

bSignificantly different from control incidence according to Fisher’s exact test (p<0.05).
 
cSignificantly different from control incidence according to Fisher’s exact test (p<0.01).

dInflammation was a component of “squamous exfoliation” and not diagnosed separately when the latter was
 
present.
 
eGray-shaded cells depict the lesion incidence data that were subjected to benchmark dose (BMD) analysis.
 
Source: NTP 1993
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Table A-3.  Results from BMD Analysis of Incidences of Female B6C3F1 Mice
 
Exhibiting Inflammation in the Nasal Vestibular/Anterior Nares
 
Following Exposure to Glutaraldehyde Vapor 6 Hours/Day,
 
5 Days/Week for 13 Weeks
 
χ2 Scaled residualsb 
Goodness Dose Dose 
Model DF χ2 
of fit
p-valuea 
below
BMC
above 
BMC AIC
Overall 
largest
BMC10 
(ppm)
BMCL10 
(ppm)
Gammac 4 10.75 0.03 0.00 1.12 -2.67 53.34
Logistic
LogLogisticd,e 
3
4
10.88
1.63
0.01
0.80
-2.20
0.00
0.52
-0.09
-2.20
-0.98
61.44
47.40 0.0065 0.0034
LogProbitd 4 8.81 0.07 0.00 0.85 -2.60 51.54
Multistage (1-degree)f 4 10.75 0.03 0.00 0.12 -2.67 53.34
Multistage (2-degree)f 4 10.75 0.03 0.00 1.12 -2.67 53.34
Multistage (3-degree)f 4 10.75 0.03 0.00 1.12 -2.67 53.34
Multistage (4-degree)f 4 10.75 0.03 0.00 1.12 -2.67 53.34
Probit 3 10.99 0.01 -2.26 0.50 -2.26 61.92
Weibullc 4 10.75 0.03 0.00 1.12 -2.67 53.34
aValues <0.1 fail to meet conventional goodness-of-fit criteria.
 
bScaled residuals at doses immediately below and above the BMD; also the largest residual at any dose.
 
cPower restricted to ≥1.
dSlope restricted to ≥1.
eSelected model.  The LogLogistic model was the only model providing adequate fit to the data.
fBetas restricted to ≥0.
AIC = Akaike Information Criterion; BMC = benchmark concentration; BMCL = 95% lower confidence limit on the 
BMC (subscripts denote benchmark response: i.e., 10 = dose associated with 10% extra risk); BMD = maximum 
likelihood estimate of the dose associated with the selected benchmark response; DF = degree of freedom
The Gamma, Logistic, LogProbit, Multistage, Probit, and Weibull models failed to meet conventional
goodness-of-fit criteria because their χ2 p-values were <0.1.  The LogLogistic model provided adequate fit
to the data (χ2 p-value = 0.80, largest scaled residual -0.98), a BMC10 of 0.0065 ppm, and a BMCL10 of
0.0034 ppm.  Figure A-1 plots predicted incidences of the female mice exhibiting inflammation in the 
nasal vestibule/nares from the LogLogistic model and observed incidence values from data in Table A-3.
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A-10GLUTARALDEHYDE
APPENDIX A
Figure A-1.  Predicted and Observed Incidence of Female Mice Exhibiting 
Inflammation in the Nasal Vestibular/Anterior Nares Following Exposure
to Glutaraldehyde Vapor 6 Hours/Day, 5 Days/Week for 13 Weeks.*
*BMC and BMCL are associated with a 10% extra risk change from control
0
0.2
0.4
0.6
0.8
1
0 0.1 0.2 0.3 0.4 0.5
Fraction Affected
Exposure concentration (ppm)
LogLogistic Model with 0.95 Confidence Level
BMCL BMC
LogLogistic
Dose and end point used for MRL derivation: BMCL10 of 0.0034 ppm.  
[ ] NOAEL   [ ] LOAEL
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[x]  1 for extrapolation from animals to humans using dosimetric conversion
[x]  3 for human variability
An uncertainty factor of 1 (rather than the default 10) for extrapolation from animals to humans is
justified because: (1) the dosimetric adjustment accounts for differences between rats and humans 
regarding respiratory tract kinetics, and (2) the critical effect (nasal irritation) is the result of the 
propensity of glutaraldehyde to react with and cross-link cell membrane proteins (Peters and Richards 
1977), a mechanism of action common to laboratory animals and humans.  The uncertainty factor for
human variability consists of a pharmacokinetic contribution (default of 3) and a pharmacodynamic
contribution (default of 3). The propensity of glutaraldehyde to react with and cross-link cell membrane 
proteins at the portal of entry is not expected to vary significantly.  The critical effect (nasal lesions) is 
independent of glutaraldehyde absorption, distribution, metabolism, and elimination kinetics. Therefore,
an uncertainty factor of 1 for intraspecies pharmacokinetics is justified.  A default uncertainty factor of 3
for intraspecies pharmacodynamics is retained in the absence of empirical data to suggest otherwise.
Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.
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If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
Derivation of a human equivalent concentration (HEC) based on the BMCLADJ was performed according
to EPA (1994) cross-species dosimetric methodology for a category 1 gas where inhalation exposure-
related effects occur within the extrathoracic region of the respiratory tract (the nasal cavity in the case of
glutaraldehyde) using the following equation:
RGDRET = (VE/SAET)A / (VE/SAET)H [equation 4-18 in EPA 1994]
where:
RGDR = ratio of the regional gas dose in animals to that of humans
VE = minute volume (cm3/minute)
SA = surface area (cm2)
ET = extrathoracic
A = animal
H = human
EPA-reported SAET values for mice (3 cm2) and humans (200 cm2) were taken from Table 4-4 of EPA
(1994).  Minute volumes were taken from Table 1-4 of EPA (1988) in which they were presented as
m3/day (0.04 m3/day = 27.8 cm3/minute for subchronic exposure of the female B6C3F1 mouse).  
According to EPA (1994), the default minute volume for humans is 13,800 cm3/minute.  Therefore:
RGDRET (mouse) = (27.8 mL/minutes/3 cm2) / (13,800 mL/minutes/200 cm2) = 9.27/69 = 0.134
The human equivalent BMCL10 was calculated according to the following equation:
BMCL10HEC = BMCL10ADJ x RGDRET (mouse) = 0.0006 ppm x 0.134 = 0.00008 ppm (8x10-5 ppm)
Was a conversion used from intermittent to continuous exposure? The 6-hour/day, 5 days/week exposure
was converted to a continuous exposure scenario by multiplying the BMCL10 of 0.0034 ppm by
6 hours/24 hours and 5 days/7 days, resulting in a BMCL10ADJ of 0.0006 ppm.
The adjustment to account for continuous exposure scenarios is necessary because nasal lesions were 
observed in glutaraldehyde-exposed rats and mice at lower exposure levels following 6 or 13 weeks of
repeated 6-hour exposures than those eliciting nasal lesions following a single 6-hour exposure or
repeated 6-hour exposures on 4 consecutive days.
Other additional studies or pertinent information that lend support to this MRL: The principal study
(Gross et al. 1994; NTP 1993) included groups of male and female F344/N rats exposed to glutaraldehyde 
vapor for 6 hours/day, 5 days/week, for 13 weeks at 0.0625, 0.125, 0.250, 0.5, or 1 ppm as well.  Nasal
lesions similar to those observed in the mice were also noted in the rats (see Table A-4).  In a similarly-
designed histopathology time-course study that evaluated the progression of nasal lesions for up to 13 
weeks (5/species/sex/exposure group/time point) (Gross et al. 1994; NTP 1993), neutrophilic infiltration 
into intra- and subepithelial regions of the nasal vestibule of female mice was identified as the most
sensitive effect and was observed at the lowest exposure level tested (0.0625 ppm) (see Table A-5).  The
neutrophilic infiltration was consistent with inflammation in the core study, thus providing support to the
findings of the core study.
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Table A-4.  Incidences of Male and Female F344/N Rats Exhibiting
 
Selected Histopathologic Nasal Lesions Following Exposure to

Glutaraldehyde Vapor 6 Hours/Day, 5 Days/Week for 13 Weeks 

in the Core Study of NTP (1993)a
 
Exposure level (ppm)
0 0.0625 0.125 0.250 0.500 1.000
Males
Respiratory epithelium
Nasoturbinates/septum
Hyperplasia 0 0 0 0 0 7 (1.7)b
Hyperplasia, goblet cell 0 0 0 1 (1.0) 3 (1.0) 9 (1.4)b
Squamous metaplasia 0 0 0 0 0 5 (2.0)c
Inflammation 0 0 0 0 0 7 (1.0)b
Lateral wall
Hyperplasia 0 0 1 (1.0) 0 4 (1.0)c 7 (1.7)b
Squamous metaplasia 0 0 0 0 1 (1.0) 7 (2.5)b
Olfactory epithelium
Degeneration 0 0 0 0 0 1 (2.0)
Nasal vestibule/anterior nares
Squamous exfoliation 0 0 0 1(1.0) 4 (1.0)c 9 (1.1)b
Inflammation 0 1 (1.0) 0 0 0 3 (1.0)
Females
Respiratory epithelium
Nasoturbinates/septum
Hyperplasia 0 0 0 0 0 4 (1.7)c
Hyperplasia, goblet cell 0 0 0 0 0 8 (1.2)b
Squamous metaplasia 0 0 0 0 0 5 (1.4)c
Inflammation 0 0 0 1 (1.0) 0 5 (1.2)c
Lateral wall
Hyperplasia 0 0 0 1 (2.0) 2 (1.0) 8 (1.6)b
Squamous metaplasia 0 0 0 1 (3.0) 0 8 (2.0)b
Olfactory epithelium
Degeneration 0 0 0 0 0 2 (1.5)
Nasal vestibule/anterior nares
Squamous exfoliation 0 0 0 3 (1.3) 7 (1.1)b 9 (1.7)b
Inflammation 1 (1.0) 0 0 0 0 0
Erosion 0 0 0 0 1 (1.0) 2 (2.0)
aIncidence is the number of core-study animals with lesions for groups of 10 animals.  Average severity (in
 
parentheses) is based on the number of animals with lesions: 1 = minimal, 2 = mild, 3 = moderate, and 4 = marked.

bSignificantly different from control incidence according to Fisher’s exact test (p<0.01).
 
cSignificantly different from control incidence according to Fisher’s exact test (p<0.05).
 
Source: NTP 1993
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 Table A-5.  Incidences of Male and Female F344/N Rats and B6C3F1 Mice
 
 Exhibiting Selected Histopathologic Lesions in the Nasal
 
   Vestibule Following Exposure to Glutaraldehyde Vapor
 
      6 Hours/Day, 5 Days/Week For 13 Weeks in the  

 
 Histopathology Time-Course Studya
 
  0
 Exposure level (ppm)
 0.0625  0.125  0.250  0.500  1.000
Male rat 
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils 
Epithelial erosions 
Squamous metaplasia 
 Female rat
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils 
Epithelial erosions 
Squamous metaplasia 
 Male mouse
Squamous exfoliation 
Intraepithelial neutrophils 
Subepithelial neutrophils 
Epithelial erosions 
Squamous metaplasia 
 Female mouse
Squamous exfoliation 
Intraepithelial neutrophils 
 
 0
5 (1.2)b  
5 (1.0) 
 1  
1 (0.2) 
 0
1 (0.2) 
2 (0.4) 
 0
 0
 0
 0
 0
 0
 0
 0
 0
 
 0
3 (0.8) 
4 (1.0) 
 1
 0
 0
 0
 0
 0
 0
 0
 0
1 (0.2) 
 0
 0
 0
4 (2.0) 
 
 0
5 (1.0) 
5 (1.2) 
 0
 0
 0
1 (0.4) 
1 (0.8) 
 0
 0
 0
1 (0.2) 
2 (0.8) 
 0
 0
 0
5 (2.4) 
 
 2
5 (1.2) 
5 (1.6) 
 1
 0
 0
3 (1.0) 
3 (1.0) 
 0
 0
 3
4 (1.6) 
5 (2.2) 
 1
 0
 0
5 (3.2) 
 
 2
4 (1.2) 
5 (1.4) 
 1
5 (2.0) 
 2
2 (0.8) 
4 (1.8) 
 0
3 (1.2) 
 1
5 (2.6) 
5 (2.8) 
 3
1 (0.2) 
1/4 
4/4 (2.8) 
 
 2
5 (1.6) 
5 (2.0) 
 1
5 (3.0) 
 4
4 (1.4) 
4 (2.0) 
 1
5 (2.6) 
–c  
 –
 –
 –
 –
 –
 –
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5 (2.0 5 (2.8) 5 (3.2) 4/4 (2.8)Subepithelial neutrophils 2 (0.4) –
Epithelial erosions 0 0 0 0 0/4 –
Squamous metaplasia 0 0 0 0 1/4 (0.5) –
aGray shaded cells suggest a toxicologically significant increased incidence from controls.

bIncidence is the number of animals with lesions for groups of five animals unless a denominator is given.  Severity
 
(in parentheses) was averaged for five animals/group where:  0 = no lesion, 1 = minimal, 2 = mild, 3 = moderate, and 

4 = marked.

cNot evaluated, all animals died.
 
Sources: Gross et al. 1994; NTP 1993
Agency Contacts (Chemical Managers): Sharon Wilbur, M.A.
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MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Glutaraldehyde
CAS Numbers: 111-30-8
Date: December 2015
Profile Status: Draft for Public Comment
Route: [ ] Inhalation   [x] Oral
Duration: [ ] Acute   [ ] Intermediate   [x] Chronic
Graph Key: 46
Species: Rat
Minimal Risk Level: 0.1 [x] mg/kg/day   [ ] ppm
Reference: van Miller JP, Hermansky SJ, Losco PE, et al.  2002.  Chronic toxicity and oncogenicity
study with glutaraldehyde dosed in the drinking water of Fischer 344 rats.  Toxicology 175(1-3):177-189.
Experimental design: In a 2-year chronic toxicity and oncogenicity study, Fischer 344 rats 
(100/sex/group) were administered glutaraldehyde (50.0–51.3% w/w aqueous solution) in the drinking
water at concentrations of 0, 50, 250, or 1,000 ppm for 52 weeks (first interim sacrifice of 10/sex/group), 
78 weeks (second interim sacrifice of 10/sex/group), or up to 104 weeks (main group).  Author-reported 
average glutaraldehyde doses were 0, 4, 17, and 64 mg/kg/day, respectively, for the males and 0, 6, 25,
and 86 mg/kg/day, respectively, for the females.  Animals were observed for survival, clinical signs, body
weight, and food and water consumption.  Eyes were examined by indirect ophthalmoscopy before the
start of dosing and after weeks 52, 78, and 104.  Hematology and serum chemistry evaluations were
performed at weeks 12, 26, 52, 78, and 104 (10 rats/sex/group).  Urine was collected from 10 
rats/sex/group during weeks 12, 25, 51, 77, and 103 for urinalysis.  All surviving rats were sacrificed at
week 104.  At sacrifice, liver, kidneys, brain, heart, adrenal glands, and testes were removed and weighed.
Comprehensive gross and histopathologic examinations were performed on all animals.
Effect noted in study and corresponding doses: Treatment-related effects included slightly depressed
body weight and lesions of the stomach.  The depressions in body weight were typically <10% in 
magnitude.  Gross pathology revealed gastric irritation (multifocal color change, mucosal thickening,
nodules, and ulceration affecting primarily the nonglandular mucosa) in 250- and 1,000-ppm male and 
female rats at 52-, 78-, and 104-week sacrifice (prevalences of 30, 10–20, and 10%, respectively) and in 
animals that died prior to scheduled sacrifice (prevalence of 40%).  Histopathology revealed significantly
increased incidences of 1,000-ppm male and female rats with mucosal hyperplasia in the stomach at
terminal sacrifice (males: 7/51 versus 1/56 controls; females 7/56 versus 1/62 controls), but not at 52- or
78-week interim sacrifices.  Incidences of this lesion at the lower dose levels were not significantly
different from those of controls.  This study identified NOAELs of 4 and 6 mg/kg/day for the male and 
female rats, respectively, and LOAELs of 17 and 25 mg/kg/day for male and female rats, respectively, for
gastric irritation (multifocal color change, mucosal thickening, nodules, and ulceration affecting primarily
the nonglandular mucosa).
Dose and end point used for MRL derivation: 4 mg/kg/day
[x] NOAEL   [ ] LOAEL
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[x]  10 for extrapolation from animals to humans
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[x]  3 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not
applicable.
Was a conversion used from intermittent to continuous exposure? No.
Other additional studies or pertinent information that lend support to this MRL: Wistar rats 
(50/sex/group) were administered glutaraldehyde (50.5% active ingredient) in the drinking water for up to 
24 months at concentrations of 0, 100, 500, or 2,000 ppm (approximate daily glutaraldehyde intakes of 0, 
3, 16, and 60 mg/kg/day, respectively, for the males and 0, 5, 24, and 88 mg/kg/day, respectively, for the
females) (BASF 2013; Confidential 2002).  Increased incidences of non-neoplastic lesions were observed 
at the 2,000 ppm exposure level and involved the larynx (squamous metaplasia in males [18/50 versus 
0/50 controls] and females [30/50 versus 0/50 controls]) and trachea (squamous metaplasia in males [4/50 
versus 0/50 controls] and females [11/50 versus 0/50 controls]).  In addition, significant trends for
increasing incidence with increasing glutaraldehyde concentration were noted for diffuse metaplasia in 
the larynx of male and female rats, focal metaplasia in the larynx of females, focal squamous metaplasia
in the trachea of males and females, and diffuse metaplasia in the trachea of females.  Metaplasia was 
nearly always accompanied by accumulation of keratin detritus in the laryngeal and/or tracheal lumen.
Some high-dose rats with laryngeal/tracheal metaplasia also exhibited foreign body granulomas in the 
lung and/or inflammation in the tracheal lumen. Significantly increased incidence of erosion/ulceration 
was noted in the glandular stomach of 2,000-ppm females. Purulent inflammation in the nasal cavity was
seen in three males and six females of the highest exposure level.
Agency Contacts (Chemical Managers): Sharon Wilbur, M.A.
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B-1GLUTARALDEHYDE
APPENDIX B.  FRAMEWORK FOR ATSDR’S SYSTEMATIC REVIEW OF 

HEALTH EFFECTS DATA FOR GLUTARALDEHYDE
 
To increase the transparency of ATSDR’s process of identifying, evaluating, synthesizing, and 
interpreting the scientific evidence on the health effects associated with exposure to glutaraldehyde,
ATSDR utilized a slight modification of NTP’s Office of Health Assessment and Translation (OHAT)
systematic review methodology (NTP 2013a; Rooney et al. 2014).  ATSDR’s framework is an eight-step
process for systematic review with the goal of identifying the potential health hazards of exposure to
glutaraldehyde:
• Step 1.  Problem Formulation
• Step 2.  Literature Search and Screen for Health Effects Studies
• Step 3.  Extract Data from Health Effects Studies
• Step 4.  Identify Potential Health Effect Outcomes of Concern
• Step 5.  Assess the Risk of Bias for Individual Studies
• Step 6.  Rate the Confidence in the Body of Evidence for Each Relevant Outcome
• Step 7. Translate Confidence Rating into Level of Evidence of Health Effects
• Step 8.  Integrate Evidence to Develop Hazard Identification Conclusions
B.1 PROBLEM FORMULATION
The objective of the toxicological profile and this systematic review was to identify the potential health
hazards associated with inhalation, oral, or dermal/ocular exposure to glutaraldehyde.  The inclusion 
criteria used to identify relevant studies examining the health effects of glutaraldehyde are presented in
Table B-1. 
Data from human and laboratory animal studies were considered relevant for addressing this objective.
Human studies were divided into two broad categories:  observational epidemiology studies and 
controlled exposure studies.  The observational epidemiology studies were further divided:  cohort studies
(retrospective and prospective studies), population studies (with individual data or aggregate data), and 
case-control studies.
B.2 LITERATURE SEARCH AND SCREEN FOR HEALTH EFFECTS STUDIES
A literature search and screen was conducted to identify studies examining the health effects of
glutaraldehyde.  Studies for other sections of the toxicological profile were also identified in the literature
search and screen step.  Although these studies were not included in the systematic review process, the 
results of some studies (e.g., mechanistic studies, toxicokinetic studies) were considered in the final steps 
of the systematic review. ATSDR primarily focused on peer-reviewed articles without publication date or
language restrictions.  Non-peer-reviewed studies that were considered relevant to the assessment of the 
health effects of glutaraldehyde have undergone peer review by at least three ATSDR-selected experts 
who have been screened for conflict of interest.
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Table B-1.  Inclusion Criteria for the Literature Search and Screen
Species
Human
Laboratory mammals
Route of exposure
Inhalation
Oral
Dermal (or ocular)
Parenteral (these studies will be considered supporting data)
Health outcome
Death
Systemic effects
Respiratory effects
 
Cardiovascular effects
 
Gastrointestinal effects
 
Hematological effects
 
Musculoskeletal effects
 
Hepatic effects
 
Renal effects
 
Endocrine effects
 
Dermal effects
 
Ocular effects
 
Body weight effects
 
Metabolic effects
 
Other systemic effects
 
Immunological effects
 
Neurological effects
 
Reproductive effects
 
Developmental effects
 
Cancer
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B.2.1 Literature Search
The following databases were searched, without date restrictions, in January 2013:
• PubMed 
• National Library of Medicine’s TOXLINE
• Scientist and Technical Information Network’s TOXCENTER
• National Pesticide Information Retrieval System (NPIRS)
• Toxic Substances Control Act Test Submissions (TSCATS) and TSCATS2
Review articles were identified and used for the purpose of providing background information and 
identifying additional references.  ATSDR also identified reports from the grey literature, which included 
unpublished research reports, technical reports from government agencies, conference proceedings and
abstracts, and theses and dissertations.
The search strategy used the chemical name, CAS number (i.e., 111-30-8), synonyms, and Medical
Subject Headings (MeSH) terms for glutaraldehyde.  A total of 5,197 records were identified and 
imported into EndNote (version 5).  After the identification and removal of 1,850 duplicates by
EndNote, the remaining 3,337 records were moved to the literature screening step.
B.2.2 Literature Screening
A two-step process was used to screen the literature search to identify relevant studies examining the 
health effects of glutaraldehyde:
• Title and Abstract Screen
• Full Text Screen
Title and Abstract Screen. Within the Endnote library, titles and abstracts were screened manually for
relevance.  Studies that were considered relevant were moved to the second step of the literature 
screening process.  Studies were excluded when the title and abstract clearly indicated that the study did
not meet the inclusion criteria (Table B-1).  In the Title and Abstract Screen step, 3,337 records were
reviewed; 291 studies were considered relevant to Chapter 3 of the toxicological profile and were moved 
to the next step in the process.
Full Text Screen. The second step in the literature screening process was a full text review of individual
studies considered relevant in the Title and Abstract Screen step.  Each study was reviewed to determine 
whether it met the inclusion criteria; however, the quality of the studies was not evaluated at this step of
the process.  Of the 291 studies undergoing Full Text Screen, 118 studies did not meet the inclusion 
criteria; some of the excluded studies were used as background information on toxicokinetics or
mechanisms of action or were relevant to other sections of the toxicological profile.  
A summary of the results of the literature search and screening is presented in Figure B-1.
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Figure B-1. Literature Search and Screen for Glutaraldehyde Health Effect Studies
Number of records identified
PubMed
1,257
TOXLINE
1,044
TOXCENTER
402
NPIRS
2,381
TSCATS/TSCATS2
113
Total number of records: 5,187
Duplicates found and removed: 1,850
Number of records screened: 3,337
Number of records excluded as not relevant for
Chapter 3 of the toxicological profile: 3,046
Number of articles screened: 291
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Number of studies for qualitative review: 173
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B.3 EXTRACT DATA FROM HEALTH EFFECTS STUDIES
Relevant data extracted from the individual studies selected for inclusion in the systematic review were 
collected in customized data forms in Distiller.  A summary of the type of data extracted from each study
is presented in Table B-2.  For references that included more than one experiment or species, data
extraction records were created for each experiment or species.
A summary of the extracted data for each study is presented in the Supplemental Document for
Glutaraldehyde and overviews of the results of the inhalation, oral, and dermal exposure studies are
presented in Section 3.2 of the profile and in the Levels Significant Exposures tables in Section 3.2 of the
profile (Tables 3-1, 3-7, and 3-8, respectively).
B.4 IDENTIFY POTENTIAL HEALTH EFFECT OUTCOMES OF CONCERN 
Overviews of the potential health effect outcomes for glutaraldehyde identified in human and animal
studies are presented in Tables B-3 and B-4, respectively.  The available human studies examined a 
limited number of end points and reported respiratory, dermal, and ocular effects.  Animal studies
examined a number of end points following inhalation, oral, and dermal/ocular exposure.  These studies
reported respiratory, gastrointestinal, hematological, renal, dermal, ocular, body weight, and
developmental effects. The hematological effects that were observed in one intermediate-duration 
inhalation exposure animal study were considered to be secondary to the nasal effects or were of
questionable toxicological relevance due to the small magnitude of change.  The body weight effects were 
not considered a primary effect and were likely secondary to the morbidity associated with the 
respiratory, gastrointestinal, or dermal effects.  Similarly, the developmental effects appear to be
secondary to maternal lethality (inhalation study) or taste aversion to glutaraldehyde-containing water.  
Thus, the available human and animal studies identify five potential health outcomes for glutaraldehyde:
respiratory, gastrointestinal, renal, dermal, and ocular effects; the evidence streams for these outcomes 
were continued through Steps 5–8 of the systematic review.  Animal studies have examined other
potential end points, but did not find effects. For example, 16 animal studies examined the liver, but none
of the studies reported an adverse effect. In the absence of human studies examining these potential
outcomes, these data were considered inadequate for assessing the human hazard potential and were not
continued through the systematic review process.
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Table B-2.  Data Extracted From Individual Studies
Citation
Chemical form
Route of exposure (e.g., inhalation, oral, dermal)
Specific route (e.g., gavage in oil, drinking water)
Species
Strain
Exposure duration category (e.g., acute, intermediate, chronic)
Exposure duration
Frequency of exposure (e.g., 6 hours/day, 5 days/week)
Exposure length
Number of animals or subjects per sex per group 
Dose/exposure levels
Parameters monitored
Description of the study design and method
Summary of calculations used to estimate doses (if applicable)
Summary of the study results
Reviewer’s comments on the study
Outcome summary (one entry for each examined outcome)
No-observed-adverse-effect level (NOAEL) value
 
Lowest-observed-adverse-effect level (LOAEL) value
 
Effect observed at the LOAEL value
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Table B-3.  Overview of the Health Outcomes for Glutaraldehyde Evaluated In Human Studies
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Inhalation studies
Cohort 6
5-9 ≥10
5-9 ≥10
6
Case control
 
Population
 
3
Controlled exposure 3
Oral studies
Cohort
Case control
Population
Controlled exposure
Dermal studies
Cohort
Case control
Population
2 1Controlled Exposure 2 1
Number of studies examining end point 0 1 2 3 4
 
Number of studies reporting outcome 0 1 2 3 4
 
***DRAFT FOR PUBLIC COMMENT***
   
 
  
 
 
 
    
 
   
 
 
 
  
 
 
 
  
 
   
 
 
 
 
  
 
 
 
               
                                     
                                     
                                     
                
                                     
                                     
                                     
                
                                     
                                     
                                     
                 
                
 
 
 
 
  
B-8GLUTARALDEHYDE
APPENDIX B
Table B-4.  Overview of the Health Outcomes for Glutaraldehyde Evaluated in Experimental Animal Studies
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2
0
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0
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0
2
0
2
0
2
1
2
0
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0
Oral studies
0 1 0 0 3 0 1 0 0
1Chronic-duration 1
2
2
1
0
1
0
1
0
1
1
Dermal studies
Acute-duration 7
5
5
1
1
Intermediate-duration
Chronic-duration
Number of studies examining end point 0 1 2 3 4
Number of studies reporting outcome 0 1 2 3 4
Systemic effects
11
11
8
Acute-duration 7 1 7 6 9 77 0 0 2 1 0
Intermediate-duration 3 1 4 3 4 3 5 1 1
7
5-9 ≥10
5-9 ≥10
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B.5 ASSESS THE RISK OF BIAS FOR INDIVIDUAL STUDIES
B.5.1 Risk of Bias Assessment
The risk of bias of individual studies was assessed using OHAT’s risk of bias questions (Rooney et al.
2014) and guidance for assessing risk of bias (NTP 2013b).  The risk of bias questions for observational
epidemiology studies, human-controlled exposure studies, and animal experimental studies are presented
in Tables B-5, B-6, and B-7, respectively.  Each risk of bias question was answered on a four-point scale:
• Definitely low risk of bias (++)
• Probably low risk of bias (+)
• Probably high risk of bias (-)
• Definitely high risk of bias (– –)
In general, “definitely low risk of bias” or “definitely high risk of bias” were used if the question could be
answered with information explicitly stated in the study report.  If the response to the question could be
inferred, then “probably low risk of bias” or “probably high risk of bias” responses were typically used.
Table B-5.  Risk of Bias Questionnaire for Observational Epidemiology Studies
Selection bias
Were the comparison groups appropriate?
Confounding bias
Did the study design or analysis account for important confounding and modifying variables?
Did researchers adjust or control for other exposures that are anticipated to bias results?
Performance bias
Did researchers adhere to the study protocol?
Attrition/exclusion bias
Were outcome data complete without attrition or exclusion from analysis?
Detection bias
Were the outcome assessors blinded to study group or exposure level?
 
Were the confounding variables assessed consistently across groups using valid and reliable 

measures?
 
Is there confidence in the exposure characterization?
 
Is there confidence in outcome assessment?
 
Selective reporting bias
Were all measured outcomes reported?
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Table B-6. Risk of Bias Questionnaire for Human-Controlled Exposure Studies
Selection bias
Was administered dose or exposure level adequately randomized?
 
Was the allocation to study groups adequately concealed?
 
Confounding bias
Did the study design or analysis account for important confounding and modifying variables?
Did researchers adjust or control for other exposures that are anticipated to bias results?
Performance bias
Did researchers adhere to the study protocol?
 
Were the research personnel and human subjects blinded to the study group during the study?
 
Attrition/exclusion bias
Were outcome data complete without attrition or exclusion from analysis?
Detection bias
Were the outcome assessors blinded to study group or exposure level?
 
Were the confounding variables assessed consistently across groups using valid and reliable 

measures?
 
Is there confidence in the exposure characterization?
 
Is there confidence in outcome assessment?
 
Selective reporting bias
Were all measured outcomes reported?
Table B-7.  Risk of Bias Questionnaire for Experimental Animal Studies
Selection bias
Was administered dose or exposure level adequately randomized?
 
Was the allocation to study groups adequately concealed?
 
Confounding bias
Did the study design or analysis account for important confounding and modifying variables?
Did researchers adjust or control for other exposures that are anticipated to bias results?
Performance bias
Were experimental conditions identical across study groups?
 
Did researchers adhere to the study protocol?
 
Were the research personnel blinded to the study group during the study?
 
Attrition/exclusion bias
Were outcome data complete without attrition or exclusion from analysis?
Detection bias
Were the outcome assessors blinded to study group or exposure level? 

Were the confounding variables assessed consistently across groups using valid and reliable 

measures?
 
Is there confidence in the exposure characterization?
 
Is there confidence in outcome assessment?
 
Selective reporting bias
Were all measured outcomes reported? 
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After the risk of bias questionnaires were completed for the health effects studies, the studies were 
assigned to one of three risk of bias tiers based on the responses to the key questions listed below and the 
responses to the remaining questions. 
•	 Is there confidence in the exposure characterization? (only relevant for observational studies)
•	 Is there confidence in the outcome assessment? 
•	 Does the study design or analysis account for important confounding and modifying variables? 
(only relevant for observational studies)
First Tier. Studies placed in the first tier received ratings of “definitely low” or “probably low” risk of
bias on the key questions AND received a rating of “definitely low” or “probably low” risk of bias on the
responses to at least 50% of the other applicable questions.
Second Tier. A study was placed in the second tier if it did not meet the criteria for the first or third tiers.
Third Tier. Studies placed in the third tier received ratings of “definitely high” or “probably high” risk of
bias for the key questions AND received a rating of “definitely high” or “probably high” risk of bias on 
the response to at least 50% of the other applicable questions.
The results of the risk of bias assessment for the different types of glutaraldehyde health effects studies 
(observational epidemiology, human experimental, and animal experimental studies) are presented in
Tables B-8, B-9, and B-10, respectively.
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Table B-8.  Summary of Risk of Bias Assessment for Glutaraldehyde—Observational Epidemiology Studies
Risk of bias criteria and ratings
Selective 
Selection Performance Attrition / reporting 
bias Confounding bias bias exclusion bias Detection bias bias
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e 
th
e 
ou
tc
om
e 
as
se
ss
or
s 
bl
in
de
d 
to
 s
tu
dy
 g
ro
up
 o
r e
xp
os
ur
e 
le
ve
l?
W
er
e 
th
e 
co
nf
ou
nd
in
g 
va
ria
bl
es
as
se
ss
ed
 c
on
si
st
en
tly
 a
cr
os
s 
gr
ou
ps
us
in
g 
va
lid
 a
nd
 re
lia
bl
e 
m
ea
su
re
s?
Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
ex
po
su
re
 
ch
ar
ac
te
riz
at
io
n?
Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
ou
tc
om
e 
as
se
ss
m
en
t?
W
er
e 
al
l m
ea
su
re
d 
ou
tc
om
es
re
po
rte
d?
 
R
is
k 
of
 b
ia
s 
tie
r 
Reference
Outcome:  Respiratory effects
Cross-sectional cohort studies
NIOSH 1987a na – – + + + na + + + Second
NIOSH 1987b na – – + + + na + + + Second
Pisaniello et al. 1997 + – – + + + na + + + Second
Vyas et al. 2000 + – – + + + na + + + Second
Waters et al. 2003 + – – + + + na + + + Second
Cohort studies
Norbäck 1988 + + – + + + na + + + First
++ = definitely low risk of bias; + = probably low risk of bias; – = probably high risk of bias; – – = definitely high risk of bias; na = not applicable
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APPENDIX B
Table B-9.  Summary of Risk of Bias Assessment for Glutaraldehyde—Human-Controlled Exposure Studies
Risk of bias criteria and ratings
Attrition/ Selective 
Performance exclusion reporting 
Selection bias Confounding bias bias bias Detection bias bias
W
as
 a
dm
in
is
te
re
d 
do
se
 o
r e
xp
os
ur
e
le
ve
l a
de
qu
at
el
y 
ra
nd
om
iz
ed
?
W
as
 th
e 
al
lo
ca
tio
n 
to
 s
tu
dy
 g
ro
up
s
ad
eq
ua
te
ly
 c
on
ce
al
ed
?
D
id
 th
e 
st
ud
y 
de
si
gn
 o
r a
na
ly
si
s
ac
co
un
t f
or
 im
po
rta
nt
 c
on
fo
un
di
ng
 
an
d 
m
od
ify
in
g 
va
ria
bl
es
?
D
id
 re
se
ar
ch
er
s 
ad
ju
st
 o
r c
on
tro
l f
or
ot
he
r e
xp
os
ur
es
 th
at
 a
re
 a
nt
ic
ip
at
ed
 
to
 b
ia
s 
re
su
lts
?
D
id
 re
se
ar
ch
er
s 
ad
he
re
 to
 th
e 
st
ud
y
pr
ot
oc
ol
?
W
er
e 
th
e 
re
se
ar
ch
 p
er
so
nn
el
 b
lin
de
d 
to
 th
e 
st
ud
y 
gr
ou
p 
du
rin
g 
th
e 
st
ud
y?
W
er
e 
ou
tc
om
e 
da
ta
 c
om
pl
et
e 
w
ith
ou
t
at
tri
tio
n 
or
 e
xc
lu
si
on
 fr
om
 a
na
ly
si
s?
W
er
e 
th
e 
ou
tc
om
e 
as
se
ss
or
s 
bl
in
de
d 
to
 s
tu
dy
 g
ro
up
 o
r e
xp
os
ur
e 
le
ve
l?
W
er
e 
th
e 
co
nf
ou
nd
in
g 
va
ria
bl
es
as
se
ss
ed
 c
on
si
st
en
tly
 a
cr
os
s 
gr
ou
ps
us
in
g 
va
lid
 a
nd
 re
lia
bl
e 
m
ea
su
re
s?
Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
ex
po
su
re
 
ch
ar
ac
te
riz
at
io
n?
Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
ou
tc
om
e 
as
se
ss
m
en
t?
W
er
e 
al
l m
ea
su
re
d 
ou
tc
om
es
re
po
rte
d?
 
R
is
k 
of
 b
ia
s 
tie
r 
Reference
Outcome:  Respiratory effects
Inhalation acute exposure
Union Carbide Corp.
1976
+ na + + + + ++ na na + + + First
Cain et al. 2007 + na + + + + ++ na na + + + First
1966 
Union Carbide Corp.
1980 
+ + + + + + + + + + + + First
++
Outcome:  Dermal effects
Dermal acute exposure
Union Carbide Corp. + + + + + + + + + + + + First
Outcome:  Ocular effects
Ocular acute exposure
Cain et al. 2007 + na + + + + na na + + + First
++ = definitely low risk of bias; + = probably low risk of bias; – = probably high risk of bias; – – = definitely high risk of bias; na = not applicable
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APPENDIX B
Table B-10.  Summary of Risk of Bias Assessment for Glutaraldehyde—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 
Selection bias Confounding bias Performance bias bias Detection bias bias
W
as
 a
dm
in
is
te
re
d 
do
se
 o
r e
xp
os
ur
e
le
ve
l a
de
qu
at
el
y 
ra
nd
om
iz
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?
W
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e 
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to
 s
tu
dy
 g
ro
up
s
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eq
ua
te
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 c
on
ce
al
ed
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D
id
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st
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y 
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si
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na
ly
si
s 
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co
un
t
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m
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nt
 c
on
fo
un
di
ng
 a
nd
 m
od
ify
in
g 
va
ria
bl
es
?
D
id
 re
se
ar
ch
er
s 
ad
ju
st
 o
r c
on
tro
l f
or
ot
he
r e
xp
os
ur
es
 th
at
 a
re
 a
nt
ic
ip
at
ed
 to
 
bi
as
 re
su
lts
?
W
er
e 
ex
pe
rim
en
ta
l c
on
di
tio
ns
 id
en
tic
al
ac
ro
ss
 s
tu
dy
 g
ro
up
s?
D
id
 re
se
ar
ch
er
s 
ad
he
re
 to
 th
e 
st
ud
y
pr
ot
oc
ol
?
W
er
e 
th
e 
re
se
ar
ch
 p
er
so
nn
el
 b
lin
de
d 
to
 
th
e 
st
ud
y 
gr
ou
p 
du
rin
g 
th
e 
st
ud
y?
W
er
e 
ou
tc
om
e 
da
ta
 c
om
pl
et
e 
w
ith
ou
t
at
tri
tio
n 
or
 e
xc
lu
si
on
 fr
om
 a
na
ly
si
s?
W
er
e 
th
e 
ou
tc
om
e 
as
se
ss
or
s 
bl
in
de
d 
to
 
st
ud
y 
gr
ou
p 
or
 e
xp
os
ur
e 
le
ve
l?
W
er
e 
th
e 
co
nf
ou
nd
in
g 
va
ria
bl
es
as
se
ss
ed
 c
on
si
st
en
tly
 a
cr
os
s 
gr
ou
ps
us
in
g 
va
lid
 a
nd
 re
lia
bl
e 
m
ea
su
re
s?
Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
ex
po
su
re
 
ch
ar
ac
te
riz
at
io
n?
Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
ou
tc
om
e 
as
se
ss
m
en
t?
W
er
e 
al
l m
ea
su
re
d 
ou
tc
om
es
 re
po
rte
d?
Reference
Outcome: Respiratory effects
Inhalation acute exposure
R
is
k 
of
 b
ia
s 
tie
r 
Werley et al. 1995
 
(mouse)
 
Werley et al. 1995
 
(guinea pig)
 
Gross et al. 1994 

(rat)
 
Gross et al. 1994 

(mouse)
 
Gross et al. 1994 

(rat)
 
Gross et al. 1994 

(mouse)
 
Zissu et al. 1994 

(mouse)
 
+ + + + ++ + + + + + ++ ++ +
+ + + + + + + + + + ++ ++ ++
+ + + + ++ ++ + ++ + + ++ ++ ++
+ + + + ++ ++ + ++ + + ++ ++ ++
+ + + + ++ ++ + ++ + + ++ ++ ++
+ + + + ++ ++ + ++ + + ++ ++ ++
+ + + + + + + + + na ++ ++ +
First
First
First
First
First
First
First
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Table B-10.  Summary of Risk of Bias Assessment for Glutaraldehyde—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 
Selection bias Confounding bias Performance bias bias Detection bias bias
W
as
 a
dm
in
is
te
re
d 
do
se
 o
r e
xp
os
ur
e
le
ve
l a
de
qu
at
el
y 
ra
nd
om
iz
ed
?
W
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e 
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ca
tio
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to
 s
tu
dy
 g
ro
up
s
ad
eq
ua
te
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 c
on
ce
al
ed
?
D
id
 th
e 
st
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y 
de
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na
ly
si
s 
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co
un
t
fo
r i
m
po
rta
nt
 c
on
fo
un
di
ng
 a
nd
 m
od
ify
in
g 
va
ria
bl
es
?
D
id
 re
se
ar
ch
er
s 
ad
ju
st
 o
r c
on
tro
l f
or
ot
he
r e
xp
os
ur
es
 th
at
 a
re
 a
nt
ic
ip
at
ed
 to
 
bi
as
 re
su
lts
?
W
er
e 
ex
pe
rim
en
ta
l c
on
di
tio
ns
 id
en
tic
al
ac
ro
ss
 s
tu
dy
 g
ro
up
s?
D
id
 re
se
ar
ch
er
s 
ad
he
re
 to
 th
e 
st
ud
y
pr
ot
oc
ol
?
W
er
e 
th
e 
re
se
ar
ch
 p
er
so
nn
el
 b
lin
de
d 
to
 
th
e 
st
ud
y 
gr
ou
p 
du
rin
g 
th
e 
st
ud
y?
W
er
e 
ou
tc
om
e 
da
ta
 c
om
pl
et
e 
w
ith
ou
t
at
tri
tio
n 
or
 e
xc
lu
si
on
 fr
om
 a
na
ly
si
s?
W
er
e 
th
e 
ou
tc
om
e 
as
se
ss
or
s 
bl
in
de
d 
to
 
st
ud
y 
gr
ou
p 
or
 e
xp
os
ur
e 
le
ve
l?
W
er
e 
th
e 
co
nf
ou
nd
in
g 
va
ria
bl
es
as
se
ss
ed
 c
on
si
st
en
tly
 a
cr
os
s 
gr
ou
ps
us
in
g 
va
lid
 a
nd
 re
lia
bl
e 
m
ea
su
re
s?
Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
ex
po
su
re
 
ch
ar
ac
te
riz
at
io
n?
Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
ou
tc
om
e 
as
se
ss
m
en
t?
W
er
e 
al
l m
ea
su
re
d 
ou
tc
om
es
 re
po
rte
d?
R
is
k 
of
 b
ia
s 
tie
r 
Reference
Zissu et al. 1994 
(mouse)
Union Carbide Corp.
1992l (rat)
Union Carbide Corp.
1992d (rat)
Union Carbide Corp.
1992e (rat)
+ + + + + + + + + na ++ ++ +
++ + + + + + + + + + ++ + ++
++ + + + + + + ++ + + ++ ++ ++
+ + + + + + + + + + + + +
+ + + + ++ ++ + ++ + + ++ ++ ++
+ + + + ++ ++ + ++ + + ++ ++ ++
+ + + + ++ ++ + ++ + + ++ ++ ++
+ + + + ++ ++ + ++ + + ++ ++ ++
+ + + + ++ ++ + ++ + + ++ ++ ++
First
First
First
First
Inhalation intermediate exposure
Gross et al. 1994 

(rat)
 
Gross et al. 1994 

(mouse)
 
Gross et al. 1994 

(rat)
 
Gross et al. 1994 

(mouse)
 
NTP 1993 (mouse)
 
First
First
First
First
First
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Table B-10.  Summary of Risk of Bias Assessment for Glutaraldehyde—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 
Selection bias Confounding bias Performance bias bias Detection bias bias
D
id
 th
e 
st
ud
y 
de
si
gn
 o
r a
na
ly
si
s 
ac
co
un
t
fo
r i
m
po
rta
nt
 c
on
fo
un
di
ng
 a
nd
 m
od
ify
in
g 
va
ria
bl
es
?
D
id
 re
se
ar
ch
er
s 
ad
ju
st
 o
r c
on
tro
l f
or
ot
he
r e
xp
os
ur
es
 th
at
 a
re
 a
nt
ic
ip
at
ed
 to
 
bi
as
 re
su
lts
?
W
er
e 
ex
pe
rim
en
ta
l c
on
di
tio
ns
 id
en
tic
al
ac
ro
ss
 s
tu
dy
 g
ro
up
s?
D
id
 re
se
ar
ch
er
s 
ad
he
re
 to
 th
e 
st
ud
y
pr
ot
oc
ol
?
W
er
e 
th
e 
re
se
ar
ch
 p
er
so
nn
el
 b
lin
de
d 
to
 
th
e 
st
ud
y 
gr
ou
p 
du
rin
g 
th
e 
st
ud
y?
W
er
e 
th
e 
ou
tc
om
e 
as
se
ss
or
s 
bl
in
de
d 
to
 
st
ud
y 
gr
ou
p 
or
 e
xp
os
ur
e 
le
ve
l?
W
er
e 
th
e 
co
nf
ou
nd
in
g 
va
ria
bl
es
as
se
ss
ed
 c
on
si
st
en
tly
 a
cr
os
s 
gr
ou
ps
us
in
g 
va
lid
 a
nd
 re
lia
bl
e 
m
ea
su
re
s?
Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
ex
po
su
re
 
ch
ar
ac
te
riz
at
io
n?
Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
ou
tc
om
e 
as
se
ss
m
en
t?
W
er
e 
al
l m
ea
su
re
d 
ou
tc
om
es
 re
po
rte
d?
W
as
 a
dm
in
is
te
re
d 
do
se
 o
r e
xp
os
ur
e
le
ve
l a
de
qu
at
el
y 
ra
nd
om
iz
ed
?
W
as
 th
e 
al
lo
ca
tio
n 
to
 s
tu
dy
 g
ro
up
s
ad
eq
ua
te
ly
 c
on
ce
al
ed
?
W
er
e 
ou
tc
om
e 
da
ta
 c
om
pl
et
e 
w
ith
ou
t
at
tri
tio
n 
or
 e
xc
lu
si
on
 fr
om
 a
na
ly
si
s?
R
is
k 
of
 b
ia
s 
tie
r 
NTP 1993 (rat) + + + + + + +
Reference
++ ++ ++ ++ ++ ++
+ + + + ++ ++ + ++ + + ++ ++ ++
+ + + + ++ ++ + ++ + + ++ ++ ++
++ + + + + + + ++ + + ++ ++ ++
++ + + + + ++ + ++ + + ++ ++ ++
++ + + + + ++ + ++ + + ++ ++ ++
++ + + + + ++ + ++ + + ++ ++ ++
++ + + + + ++ + ++ + + ++ ++ ++
First
NTP 1993 (mouse) First
NTP 1993 (rat) First
Union Carbide Corp. First
1992f (rat)
Inhalation chronic exposure
NTP 1999; van 

Birgelen et al. 2000 

(rat)
 
NTP 1999 (rat)
 
NTP 1999; van 

Birgelen et al. 2000 

(mouse)
 
NTP 1999 (mouse)
 
First
First
First
First
Outcome:  Gastrointestinal effects
Oral acute exposure
BASF Corp. 1990l + + + + + + + + + + + + + First
(rat)
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Table B-10.  Summary of Risk of Bias Assessment for Glutaraldehyde—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 
Selection bias Confounding bias Performance bias bias Detection bias bias
W
as
 a
dm
in
is
te
re
d 
do
se
 o
r e
xp
os
ur
e
le
ve
l a
de
qu
at
el
y 
ra
nd
om
iz
ed
?
W
as
 th
e 
al
lo
ca
tio
n 
to
 s
tu
dy
 g
ro
up
s
ad
eq
ua
te
ly
 c
on
ce
al
ed
?
D
id
 th
e 
st
ud
y 
de
si
gn
 o
r a
na
ly
si
s 
ac
co
un
t
fo
r i
m
po
rta
nt
 c
on
fo
un
di
ng
 a
nd
 m
od
ify
in
g 
va
ria
bl
es
?
D
id
 re
se
ar
ch
er
s 
ad
ju
st
 o
r c
on
tro
l f
or
ot
he
r e
xp
os
ur
es
 th
at
 a
re
 a
nt
ic
ip
at
ed
 to
 
bi
as
 re
su
lts
?
W
er
e 
ex
pe
rim
en
ta
l c
on
di
tio
ns
 id
en
tic
al
ac
ro
ss
 s
tu
dy
 g
ro
up
s?
D
id
 re
se
ar
ch
er
s 
ad
he
re
 to
 th
e 
st
ud
y
pr
ot
oc
ol
?
W
er
e 
th
e 
re
se
ar
ch
 p
er
so
nn
el
 b
lin
de
d 
to
 
th
e 
st
ud
y 
gr
ou
p 
du
rin
g 
th
e 
st
ud
y?
W
er
e 
ou
tc
om
e 
da
ta
 c
om
pl
et
e 
w
ith
ou
t
at
tri
tio
n 
or
 e
xc
lu
si
on
 fr
om
 a
na
ly
si
s?
W
er
e 
th
e 
ou
tc
om
e 
as
se
ss
or
s 
bl
in
de
d 
to
 
st
ud
y 
gr
ou
p 
or
 e
xp
os
ur
e 
le
ve
l?
W
er
e 
th
e 
co
nf
ou
nd
in
g 
va
ria
bl
es
as
se
ss
ed
 c
on
si
st
en
tly
 a
cr
os
s 
gr
ou
ps
us
in
g 
va
lid
 a
nd
 re
lia
bl
e 
m
ea
su
re
s?
Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
ex
po
su
re
 
ch
ar
ac
te
riz
at
io
n?
Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
ou
tc
om
e 
as
se
ss
m
en
t?
W
er
e 
al
l m
ea
su
re
d 
ou
tc
om
es
 re
po
rte
d?
R
is
k 
of
 b
ia
s 
tie
r 
Reference
BASF Corp. 1990m
(rabbit)
BASF Corp. 1991a
(rabbit)
BASF Corp. 1991c
(rat)
Union Carbide 
Chem & Plas Co.
1992 (rat)
Union Carbide Corp.
1992a (rat)
Union Carbide Corp.
1992i (mouse)
Union Carbide
Chem & Plas Co.
1991dd (dog)
+ + + + + + + ++ + + + + +
+ + + + ++ ++ + ++ + + ++ ++ ++
+ + + + ++ ++ + + + + ++ ++ ++
+ + + + + + + + + + + + +
+ + + + + + + + + + ++ + +
+ + + + + + + + + + + + +
+ + + + + + + + + + + + +
First
First
First
First
First
First
First
Oral intermediate exposure
Union Carbide + + + + + + + + + + + + + First
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Table B-10.  Summary of Risk of Bias Assessment for Glutaraldehyde—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 
Selection bias Confounding bias Performance bias bias Detection bias bias
W
as
 a
dm
in
is
te
re
d 
do
se
 o
r e
xp
os
ur
e
le
ve
l a
de
qu
at
el
y 
ra
nd
om
iz
ed
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 c
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 c
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r c
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l c
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 b
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 c
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th
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or
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 c
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e 
ex
po
su
re
 
ch
ar
ac
te
riz
at
io
n?
Is
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W
er
e 
al
l m
ea
su
re
d 
ou
tc
om
es
 re
po
rte
d?
R
is
k 
of
 b
ia
s 
tie
r 
Reference
Chem & Plas Co.
1991ee (dog)
van Miller et al. 2002 
(rat)
+ + + + + ++ + ++ + na + + + First
NTP 1993 (rat) + + + + ++ ++ + ++ + + ++ ++ ++ First
NTP 1993 (mouse) + + + + ++ ++ + ++ + + ++ ++ ++ First
+ + + + + + + ++ + + + + +
+ + + + ++ ++ + + + + ++ ++ ++
+ + + + ++ ++ + + + + ++ ++ ++
Oral chronic exposure
Outcome:  Renal effects
Inhalation intermediate exposure
Oral acute exposure
BASF Corp. 1990l + + + + + + + + + + + + + First
(rat)
BASF Corp. 1990m First
(rabbit)
BASF Corp. 1991c First
(rat)
 
BASF Corp. 1991c
 First
(rabbit)
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Table B-10.  Summary of Risk of Bias Assessment for Glutaraldehyde—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 
Selection bias Confounding bias Performance bias bias Detection bias bias
D
id
 th
e 
st
ud
y 
de
si
gn
 o
r a
na
ly
si
s 
ac
co
un
t
fo
r i
m
po
rta
nt
 c
on
fo
un
di
ng
 a
nd
 m
od
ify
in
g 
va
ria
bl
es
?
D
id
 re
se
ar
ch
er
s 
ad
ju
st
 o
r c
on
tro
l f
or
ot
he
r e
xp
os
ur
es
 th
at
 a
re
 a
nt
ic
ip
at
ed
 to
 
bi
as
 re
su
lts
?
W
er
e 
ex
pe
rim
en
ta
l c
on
di
tio
ns
 id
en
tic
al
ac
ro
ss
 s
tu
dy
 g
ro
up
s?
D
id
 re
se
ar
ch
er
s 
ad
he
re
 to
 th
e 
st
ud
y
pr
ot
oc
ol
?
W
er
e 
th
e 
re
se
ar
ch
 p
er
so
nn
el
 b
lin
de
d 
to
 
th
e 
st
ud
y 
gr
ou
p 
du
rin
g 
th
e 
st
ud
y?
W
er
e 
ou
tc
om
e 
da
ta
 c
om
pl
et
e 
w
ith
ou
t
at
tri
tio
n 
or
 e
xc
lu
si
on
 fr
om
 a
na
ly
si
s?
W
er
e 
th
e 
ou
tc
om
e 
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se
ss
or
s 
bl
in
de
d 
to
 
st
ud
y 
gr
ou
p 
or
 e
xp
os
ur
e 
le
ve
l?
W
er
e 
th
e 
co
nf
ou
nd
in
g 
va
ria
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es
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se
ss
ed
 c
on
si
st
en
tly
 a
cr
os
s 
gr
ou
ps
us
in
g 
va
lid
 a
nd
 re
lia
bl
e 
m
ea
su
re
s?
Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
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po
su
re
 
ch
ar
ac
te
riz
at
io
n?
Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
ou
tc
om
e 
as
se
ss
m
en
t?
W
er
e 
al
l m
ea
su
re
d 
ou
tc
om
es
 re
po
rte
d?
W
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 a
dm
in
is
te
re
d 
do
se
 o
r e
xp
os
ur
e
le
ve
l a
de
qu
at
el
y 
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nd
om
iz
ed
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W
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 th
e 
al
lo
ca
tio
n 
to
 s
tu
dy
 g
ro
up
s
ad
eq
ua
te
ly
 c
on
ce
al
ed
?
R
is
k 
of
 b
ia
s 
tie
r 
Union Carbide + + + + + + + + + + + First
Chem & Plas Co.
1991f (rat)
Union Carbide 

Reference
++ ++
++ + + + + + + ++ + + ++ + +
++ + + + ++ ++ + ++ + + ++ + +
++ + + + ++ + + ++ + + ++ + +
+ + + + + + + + + + + + +
van Miller et al. 2002 
(rat)
+ + + + + ++ + ++ + na + + + First
First
 
Chem & Plas Co.
 
1991o (rat)
 
Oral intermediate exposure
Union Carbide 
Chem & Plas Co.
1991w (mouse)
Union Carbide 
Chem & Plas Co.
1991r (rat)
Union Carbide 
Chem & Plas Co.
1991ee (dog)
First
First
First
Oral chronic exposure
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Table B-10.  Summary of Risk of Bias Assessment for Glutaraldehyde—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 
Selection bias Confounding bias Performance bias bias Detection bias bias
Reference
Outcome:  Dermal effects
Dermal acute exposure
W
as
 a
dm
in
is
te
re
d 
do
se
 o
r e
xp
os
ur
e
le
ve
l a
de
qu
at
el
y 
ra
nd
om
iz
ed
?
W
as
 th
e 
al
lo
ca
tio
n 
to
 s
tu
dy
 g
ro
up
s
ad
eq
ua
te
ly
 c
on
ce
al
ed
?
D
id
 th
e 
st
ud
y 
de
si
gn
 o
r a
na
ly
si
s 
ac
co
un
t
fo
r i
m
po
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 c
on
fo
un
di
ng
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ify
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bl
es
?
D
id
 re
se
ar
ch
er
s 
ad
ju
st
 o
r c
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W
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e 
ex
pe
rim
en
ta
l c
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ns
 id
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ro
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 s
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dy
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ro
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D
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se
ar
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he
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 th
e 
st
ud
y
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ot
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?
W
er
e 
th
e 
re
se
ar
ch
 p
er
so
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 b
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to
 
th
e 
st
ud
y 
gr
ou
p 
du
rin
g 
th
e 
st
ud
y?
W
er
e 
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tc
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e 
da
ta
 c
om
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et
e 
w
ith
ou
t
at
tri
tio
n 
or
 e
xc
lu
si
on
 fr
om
 a
na
ly
si
s?
W
er
e 
th
e 
ou
tc
om
e 
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se
ss
or
s 
bl
in
de
d 
to
 
st
ud
y 
gr
ou
p 
or
 e
xp
os
ur
e 
le
ve
l?
W
er
e 
th
e 
co
nf
ou
nd
in
g 
va
ria
bl
es
as
se
ss
ed
 c
on
si
st
en
tly
 a
cr
os
s 
gr
ou
ps
us
in
g 
va
lid
 a
nd
 re
lia
bl
e 
m
ea
su
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Is
 th
er
e 
co
nf
id
en
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 in
 th
e 
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po
su
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ch
ar
ac
te
riz
at
io
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Is
 th
er
e 
co
nf
id
en
ce
 in
 th
e 
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tc
om
e 
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se
ss
m
en
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W
er
e 
al
l m
ea
su
re
d 
ou
tc
om
es
 re
po
rte
d?
R
is
k 
of
 b
ia
s 
tie
r 
Union Carbide 
Chem & Plas Co.
1991y (mouse)
Union Carbide 
Chem & Plas Co.
1991aa (rabbit)
Union Carbide Corp.
1992a (rabbit)
Union Carbide Corp.
1992b (rabbit)
Union Carbide Corp.
1992c (rabbit)
Union Carbide Corp.
1992h (rabbit)
Dermal intermediate exposure
++ + + + + + + + + + ++ + +
na na + + ++ ++ na ++ na na + + +
+ + + + + + + + + + ++ + +
+ + + + + + + + + + + + +
+ + + + + + + + + + + + +
na na + + na + na + na na + + +
Werley et al. 1996 + + + + + ++ + ++ + + ++ ++ ++ First
First
First
First
First
First
First
***DRAFT FOR PUBLIC COMMENT***
   
 
  
 
 
  
  
 
   
 
        
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
   
               
  
 
              
   
 
              
               
  
 
 
              
  
  
              
   
 
              
   
 
              
 
 
 
 
  
B-21GLUTARALDEHYDE
APPENDIX B
Table B-10.  Summary of Risk of Bias Assessment for Glutaraldehyde—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 
Selection bias Confounding bias Performance bias bias Detection bias bias
D
id
 th
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st
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r a
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 c
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r c
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l c
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 b
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e 
ou
tc
om
e 
as
se
ss
or
s 
bl
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 c
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e 
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ac
te
riz
at
io
n?
Is
 th
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e 
co
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id
en
ce
 in
 th
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tc
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e 
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se
ss
m
en
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W
er
e 
al
l m
ea
su
re
d 
ou
tc
om
es
 re
po
rte
d?
W
er
e 
ou
tc
om
e 
da
ta
 c
om
pl
et
e 
w
ith
ou
t
at
tri
tio
n 
or
 e
xc
lu
si
on
 fr
om
 a
na
ly
si
s?
W
as
 a
dm
in
is
te
re
d 
do
se
 o
r e
xp
os
ur
e
le
ve
l a
de
qu
at
el
y 
ra
nd
om
iz
ed
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W
as
 th
e 
al
lo
ca
tio
n 
to
 s
tu
dy
 g
ro
up
s
ad
eq
ua
te
ly
 c
on
ce
al
ed
?
R
is
k 
of
 b
ia
s 
tie
r 
Outcome:  Ocular effects
Inhalation acute exposure
Hoechst Celanese + First
Corp. 1981 (rat)
Union Carbide Corp.
Reference
++ + + + na + na ++ na na ++ ++
+ + + + + + + + + + + + +
na na na na na + na ++ na na ++ ++ ++
na na + + na + na + na na + + +
+ + + + + + + + + + ++ + +
+ + + + + + + + + + + + +
First
1992e (rat)
(rat)
Ocular Acute Exposure
Union Carbide 
Chem & Plas Co.
1991cc (rabbit)
Union Carbide 
Chem & Plas Co. 
1991k (rabbit)
Union Carbide Corp.
1992a (rabbit)
Union Carbide Corp.
1992b (rabbit)
First
First
First
First
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Table B-10.  Summary of Risk of Bias Assessment for Glutaraldehyde—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 
Selection bias Confounding bias Performance bias bias Detection bias bias
D
id
 th
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 c
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r c
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 re
su
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r e
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 c
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l c
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y
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W
er
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e 
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 b
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st
ud
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W
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e 
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 c
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w
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t
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or
 e
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lu
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na
ly
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W
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e 
th
e 
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om
e 
as
se
ss
or
s 
bl
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to
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or
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 c
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l m
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R
is
k 
of
 b
ia
s 
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r 
Reference
+ + + + + + + + + + + + + First
Union Carbide Corp.
1992c (rabbit)
++ = definitely low risk of bias; + = probably low risk of bias; – = probably high risk of bias; – – = definitely high risk of bias
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B.6 RATE THE CONFIDENCE IN THE BODY OF EVIDENCE FOR EACH RELEVANT
OUTCOME
Confidences in the bodies of human and animal evidence were evaluated independently for each potential
outcome.  ATSDR did not evaluate the confidence in the body of evidence for carcinogenicity; rather, the
Agency defaulted to the cancer weight-of-evidence assessment of other agencies including DHHS, EPA, 
and IARC.  The confidence in the body of evidence for an association or no association between exposure
to glutaraldehyde and a particular outcome was based on the strengths and weaknesses of individual
studies.  Four descriptors were used to describe the confidence in the body of evidence for effects or when
no effect was found:
•	 High confidence: the true effect is highly likely to be reflected in the apparent relationship
•	 Moderate confidence: the true effect may be reflected in the apparent relationship
•	 Low confidence: the true effect may be different from the apparent relationship
•	 Very low confidence: the true effect is highly likely to be different from the apparent
 
relationship
 
Confidence in the body of evidence for a particular outcome was rated for each type of study: case-
control, case series, cohort, population, human-controlled exposure, and experimental animal.  In the
absence of data to the contrary, data for a particular outcome were collapsed across animal species, routes 
of exposure, and exposure durations.  If species (or strain), route, or exposure duration differences were
noted, then the data were treated as separate outcomes.
B.6.1 Initial Confidence Rating
In ATSDR’s modification to the OHAT approach, the body of evidence for an association (or no 
association) between exposure to glutaraldehyde and a particular outcome was given an initial confidence
rating based on the key features of the individual studies examining that outcome.  The presence of these 
key features of study design was determined for individual studies using four “yes or no” questions in 
Distiller, which were customized for epidemiology or experimental animal study designs.  Separate 
questionnaires were completed for each outcome assessed in a study.  The key features for observational
epidemiology (cohort, population, and case-control) studies, human-controlled exposure studies, and 
experimental animal studies are presented in Tables B-11, B-12, and B-13, respectively. The initial 
confidence in the study was determined based on the number of key features present in the study design:
•	 High Initial Confidence: Studies in which the responses to the four questions were “yes”.
•	 Moderate Initial Confidence: Studies in which the responses to only three of the questions
were “yes”.
•	 Low Initial Confidence: Studies in which the responses to only two of the questions were “yes”.
•	 Very Low Initial Confidence: Studies in which the response to one or none of the questions
was “yes”.
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Table B-11. Key Features of Study Design for Observational Epidemiology
 
Studies
 
Exposure was experimentally controlled 
Exposure occurred prior to the outcome
Outcome was assessed on individual level rather than at the population level
A comparison group was used
Table B-12. Key Features of Study Design for Human-Controlled Exposure
 
Studies
 
A comparison group was used or the subjects served as their own control
A sufficient number of subjects were tested
Appropriate methods were used to measure outcomes (i.e., clinically-confirmed outcome versus self-
reported)
Appropriate statistical analyses was performed and reported or the data were reported in such a way to 
allow independent statistical analysis
Table B-13. Key Features of Study Design for Experimental Animal Studies
A concurrent control group was used
A sufficient number of animals per group were tested
Were appropriate parameters used to assess a potential adverse effect
Appropriate statistical analyses were performed and reported or the data were reported in such a way to 
allow independent statistical analysis
The presence or absence of the key features and the initial confidence levels for studies examining
respiratory, gastrointestinal, renal, dermal, and ocular effects observed in the observational epidemiology, 
human experimental, and animal experimental studies are presented in Tables B-14, B-15, and B-16, 
respectively.
A summary of the initial confidence ratings for each outcome is presented in Table B-17.  If individual
studies for a particular outcome and study type had different study quality ratings, then the highest
confidence rating for the group of studies was used to determine the initial confidence rating for the body 
of evidence; any exceptions were noted in Table B-17.
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Table B-14. Presence of Key Features of Study Design for Glutaraldehyde—
 
Observational Epidemiology Studies
 
Key features
C
on
tro
lle
d 
ex
po
su
re
E
xp
os
ur
e 
pr
io
r t
o 
ou
tc
om
e
O
ut
co
m
es
 a
ss
es
se
d 
on
 
an
 in
di
vi
du
al
 le
ve
l
C
om
pa
ris
on
 g
ro
up
Initial study 
confidenceReference
Outcome:  Respiratory effects
Cross-sectional cohort studies
NIOSH 1987a
NIOSH 1987b
Pisaniello et al. 1997
No Yes Yes No Low
No Yes Yes No Low
No Yes Yes Yes Moderate
No Yes Yes No
No Yes Yes Yes
Yes Yes Yes No Moderate
Yes Yes Yes No Moderate
No Yes Yes No Low
Cohort studies
Norbäck 1988 No Yes Yes Yes Moderate
Vyas et al. 2000 Low
Waters et al. 2003 Moderate
Table B-15. Presence of Key Features of Study Design for Glutaraldehyde—
 
Human-Controlled Exposure Studies
 
Key feature
C
on
cu
rre
nt
 c
on
tro
l g
ro
up
 
or
 s
el
f-c
on
tro
l
S
uf
fic
ie
nt
 n
um
be
r o
f
su
bj
ec
ts
 te
st
ed
A
pp
ro
pr
ia
te
 m
et
ho
ds
 to
 
m
ea
su
re
 o
ut
co
m
e
A
de
qu
at
e 
da
ta
 fo
r
st
at
is
tic
al
 a
na
ly
si
s
Initial study
confidenceReference
Outcome:  Respiratory effects
Inhalation acute exposure
Union Carbide Corp. 1976
Cain et al. 2007
Outcome:  Dermal effects
Dermal acute exposure
Union Carbide Corp. 1966 No Yes Yes No Low
Union Carbide Corp. 1980 
Outcome:  Ocular Effects
Ocular acute exposure
Cain et al. 2007 ModerateYes Yes Yes No
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Table B-16. Presence of Key Features of Study Design for Glutaraldehyde—
 
Experimental Animal Studies
 
Key feature
C
on
cu
rre
nt
 c
on
tro
l g
ro
up
S
uf
fic
ie
nt
 n
um
be
r o
f a
ni
m
al
s 
pe
r g
ro
up
A
pp
ro
pr
ia
te
 p
ar
am
et
er
s 
to
as
se
ss
 p
ot
en
tia
l e
ffe
ct
A
de
qu
at
e 
da
ta
 fo
r s
ta
tis
tic
al
an
al
ys
is
 
Initial study
confidenceReference
Outcome:  Respiratory effects
Inhalation acute exposure
Werley et al. 1995 (mouse) Yes No Yes Yes Moderate
Werley et al. 1995 (guinea pig)
Gross et al. 1994 (rat)
Gross et al. 1994 (mouse)
Gross et al. 1994 (rat)
Gross et al. 1994 (mouse)
Zissu et al. 1994 (mouse)
Zissu et al. 1994 (mouse)
Union Carbide Corp. 1992l (rat)
Union Carbide Corp. 1992d (rat)
Union Carbide Corp. 1992e (rat)
Inhalation intermediate exposure
Yes No Yes Yes
Yes No Yes Yes
Yes No Yes Yes
Yes No Yes Yes
Yes No Yes Yes
Yes Yes Yes Yes
Yes Yes Yes Yes
Yes Yes Yes Yes
Yes Yes Yes Yes
Yes Yes Yes Yes
Yes No Yes Yes
Yes No Yes Yes
Yes No Yes Yes
Yes No Yes Yes
Yes No Yes Yes
Yes Yes Yes Yes
Yes Yes Yes Yes
Yes Yes Yes No
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Moderate
Moderate
Moderate
Moderate
Moderate
High
High
High
High
High
Gross et al. 1994 (rat) Yes No Yes Yes Moderate
Moderate
Moderate
Moderate
Moderate
Moderate
High
High
Moderate
Gross et al. 1994 (mouse)
Gross et al. 1994 (rat)
Gross et al. 1994 (mouse)
NTP 1993 (mouse)
NTP 1993 (rat)
NTP 1993 (mouse)
NTP 1993 (rat)
Union Carbide Corp. 1992f (rat)
Inhalation chronic exposure
NTP 1999; van Birgelen et al. 2000 (rat)
NTP 1999 (rat)
NTP 1999; van Birgelen et al. 2000 (mouse)
NTP 1999 (mouse)
Outcome:  Gastrointestinal effects
Oral acute exposure
BASF Corp. 1990l (rat) Yes Yes Yes Yes High
BASF Corp. 1990m (rabbit)
BASF Corp. 1991a (rabbit)
BASF Corp. 1991c (rat)
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Table B-16. Presence of Key Features of Study Design for Glutaraldehyde—
 
Experimental Animal Studies
 
Key feature
C
on
cu
rre
nt
 c
on
tro
l g
ro
up
S
uf
fic
ie
nt
 n
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be
r o
f a
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m
al
s 
pe
r g
ro
up
A
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 p
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 p
ot
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tia
l e
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A
de
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at
e 
da
ta
 fo
r s
ta
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Initial study
confidenceReference
Union Carbide Chem & Plas Co. 1992 (rat)
Union Carbide Corp. 1992a (rat)
Union Carbide Corp. 1992i (mouse)
Union Carbide Chem & Plas Co. 1991dd (dog)
No No Yes No Very low
No No Yes No Very low
No No Yes Yes Low
Yes No Yes No Low
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes No Yes No Low
Yes Yes Yes No Moderate
Yes Yes Yes No Moderate
Yes Yes Yes No Moderate
Yes Yes Yes No Moderate
No No Yes No Very low
No No Yes No Very low
No No Yes No Very low
No No Yes No Very low
Oral intermediate exposure
Union Carbide Chem & Plas Co. 1991ee (dog) Yes Yes Yes No Moderate
Oral chronic exposure
van Miller et al. 2002 (rat) Yes Yes Yes Yes High
Outcome:  Renal effects
Inhalation intermediate exposure
NTP 1993 (rat)
NTP 1993 (mouse)
Oral acute exposure
BASF Corp. 1990l (rat) Yes Yes Yes Yes High
BASF Corp. 1990m (rabbit)
BASF Corp. 1991c (rat)
BASF Corp. 1991c (rabbit)
Union Carbide Chem & Plas Co. 1991f (rat)
Union Carbide Chem & Plas Co. 1991o (rat)
Oral intermediate exposure
Union Carbide Chem & Plas Co. 1991w (mouse)
Union Carbide Chem & Plas Co. 1991r (rat)
Union Carbide Chem & Plas Co. 1991ee (dog)
Oral chronic exposure
van Miller et al. 2002 (rat) Yes Yes Yes Yes High
Outcome:  Dermal effects
Dermal acute exposure
Union Carbide Chem & Plas Co. 1991y (mouse) Yes No Yes Yes Moderate
Union Carbide Chem & Plas Co. 1991aa (rabbit)
Union Carbide Corp. 1992a (rabbit)
Union Carbide Corp. 1992b (rabbit)
Union Carbide Corp. 1992c (rabbit)
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Table B-16. Presence of Key Features of Study Design for Glutaraldehyde—
 
Experimental Animal Studies
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Reference Initial studyconfidence
Union Carbide Corp. 1992h (rabbit) No No Yes No Very low
Dermal intermediate exposure
Werley et al. 1996 (rat) Yes Yes Yes Yes High
Outcome:  Ocular effects
Inhalation acute exposure
Hoechst Celanese Corp. 1981 (rat) No Yes Yes Yes Moderate
Yes Yes Yes Yes High
Union Carbide Chem & Plas Co. 1991cc (rabbit) No Yes Yes Yes Moderate
Union Carbide Chem & Plas Co. 1991k (rabbit) No No Yes No Very low
Union Carbide Corp. 1992a (rabbit) No No Yes No Very low
Union Carbide Corp. 1992b (rabbit) No No Yes No Very low
Union Carbide Corp. 1992c (rabbit) No No Yes No Very low
Union Carbide Corp. 1992e (rat)
Ocular acute exposure
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Table B-17.  Initial Confidence Rating for Glutaraldehyde Health Effects Studies
Initial study Initial confidence
confidence rating
Outcome:  Respiratory effects
Inhalation acute exposure
Human studies
Cross-sectional cohort studies
NIOSH 1987a Low
NIOSH 1987b Low Moderate
Pisaniello et al. 1997 Moderate
Cohort studies
Norbäck 1988 Moderate
Vyas et al. 2000 Low Moderate
Waters et al. 2003 Moderate
Controlled exposure
Union Carbide Corp. 1976
Cain et al. 2007
Moderate
Moderate
Moderate
Animal studies
Werley et al. 1995 (mouse) Moderate
Werley et al. 1995 (guinea pig) Moderate
Gross et al. 1994 (rat) Moderate
Gross et al. 1994 (mouse) Moderate
Gross et al. 1994 (rat) Moderate
Gross et al. 1994 (mouse)
Zissu et al. 1994 (mouse)
Moderate
High
High
Zissu et al. 1994 (mouse) High
Union Carbide Corp. 1992l (rat) High
Union Carbide Corp. 1992d (rat) High
Union Carbide Corp. 1992e (rat) High
Inhalation intermediate exposure
Gross et al. 1994 (rat) Moderate
Gross et al. 1994 (mouse) Moderate
Gross et al. 1994 (rat) Moderate
Gross et al. 1994 (mouse) Moderate
NTP 1993 (mouse) Moderate High
NTP 1993 (rat) Moderate
NTP 1993 (mouse) High
NTP 1993 (rat) High
Union Carbide Corp. 1992f (rat) Moderate
Inhalation chronic exposure
Animal studies
NTP 1999; van Birgelen et al. 2000 (rat)
NTP 1999 (rat)
High
High
High
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Table B-17.  Initial Confidence Rating for Glutaraldehyde Health Effects Studies
Initial study Initial confidence
confidence rating
NTP 1999; van Birgelen et al. 2000 (mouse) High
NTP 1999 (mouse) High
Outcome:  Gastrointestinal effects
Oral acute exposure
Animal studies
BASF Corp. 1990l (rat) High
BASF Corp. 1990m (rabbit) High
BASF Corp. 1991a (rabbit) High
BASF Corp. 1991c (rat)
Union Carbide Chem & Plas Co. 1992 (rat)
High
Very low
High
Union Carbide Corp. 1992a (rat) Very low
Union Carbide Corp. 1992i (mouse) Low
Union Carbide Chem & Plas Co. 1991dd (dog) Low
Oral intermediate exposure
Animal studies
Union Carbide Chem & Plas Co. 1991ee (dog) Moderate Moderate
Oral chronic exposure
Animal studies
van Miller et al. 2002 (rat) High High
Outcome:  Renal effects
Inhalation intermediate exposure
Animal studies
NTP 1993 (rat)
NTP 1993 (mouse)
High
High
High
Oral acute exposure
Animal studies
BASF Corp. 1990l (rat) High
BASF Corp. 1990m (rabbit) High
BASF Corp. 1991c (rat)
BASF Corp. 1991c (rabbit)
High
High
High
Union Carbide Chem & Plas Co. 1991f (rat) Low
Union Carbide Chem & Plas Co. 1991o (rat) Moderate
Oral intermediate exposure
Animal studies
Union Carbide Chem & Plas Co. 1991w (mouse) Moderate
Union Carbide Chem & Plas Co. 1991r (rat) Moderate Moderate
Union Carbide Chem & Plas Co. 1991ee (dog) Moderate
Oral chronic exposure
Animal studies
van Miller et al. 2002 (rat) High High
Outcome:  Dermal effects
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Table B-17.  Initial Confidence Rating for Glutaraldehyde Health Effects Studies
Initial study Initial confidence
confidence rating
Dermal acute exposure
Human studies
Controlled exposure
Union Carbide Corp. 1966 (irritation)
Union Carbide Corp. 1980 (irritation)
Low
Low
Low
Animal studies
Union Carbide Chem & Plas Co. 1991y (mouse) Moderate
Union Carbide Chem & Plas Co. 1991aa (rabbit) Very low
Union Carbide Corp. 1992a (rabbit) Very low Moderate
Union Carbide Corp. 1992b (rabbit) Very low 
Union Carbide Corp. 1992c (rabbit) Very low
Union Carbide Corp. 1992h (rabbit) Very low
Dermal intermediate exposure
Animal studies
Werley et al. 1996 (rat) High High
Outcome:  Ocular effects
Ocular acute exposure (airborne vapor)
Human studies
Controlled exposure
Cain et al. 2007 Moderate Moderate
Animal studies
Hoechst Celanese Corp. 1981 (rat)
Union Carbide Corp. 1992e (rat)
Moderate
High
High
Ocular acute exposure (ocular instillation)
Animal studies
Union Carbide Chem & Plas Co. 1991cc (rabbit) Moderate
Union Carbide Corp. 1992h (rat) Very low
Union Carbide Corp. 1992a (rabbit) Very low Moderate
Union Carbide Corp. 1992b (rabbit) Very low
Union Carbide Corp. 1992c (rabbit) Very low
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B.6.2 Adjustment of the Confidence Rating 
The initial confidence rating was then downgraded or upgraded depending on whether there were
substantial issues that would decrease or increase confidence in the body of evidence. The nine properties 
of the body of evidence that are considered are listed below. The summaries of the assessment of the 
confidence in the body of evidence for respiratory, gastrointestinal, renal, dermal, and ocular effects are 
presented in Table B-18. If the confidence ratings for a particular outcome were based on more than one 
type of human study, then the highest confidence rating was used for subsequent analyses.  An overview
of the confidence in the body of evidence for all health effects associated with glutaraldehyde exposure is 
presented in Table B-19.
Five properties of the body of evidence were considered to determine whether the confidence rating
should be downgraded:
•	 Risk of bias. Evaluation of whether there is substantial risk of bias across most of the studies 
examining the outcome.  This evaluation used the risk of bias tier groupings for individual studies
examining a particular outcome (Tables B-14, B-15, and B-16).  Below are the criteria used to
determine whether the initial confidence in the body of evidence for each outcome should be
downgraded for risk of bias:
o	 No downgrade if most studies are in the risk of bias first tier
o	 Downgrade one confidence level if most studies are in the risk of bias second tier
o	 Downgrade two confidence levels if most studies are in the risk of bias third tier
•	 Unexplained inconsistency. Evaluation of whether there is inconsistency or large variability in 
the magnitude or direction of estimates of effect across studies that cannot be explained.  Below
are the criteria used to determine whether the initial confidence in the body of evidence for each
outcome should be downgraded for unexplained inconsistency:
o	 No downgrade if there is little inconsistency across studies or if only one study evaluated 
the outcome
o	 Downgrade one confidence level if there is variability across studies in the magnitude or
direction of the effect
o	 Downgrade two confidence levels if there is substantial variability across studies in the 
magnitude or direct of the effect
•	 Indirectness. Evaluation of four factors that can affect the applicability, generalizability, and 
relevance of the studies:
o	 Relevance of the animal model to human health—unless otherwise indicated, studies in
rats, mice, and other mammalian species are considered relevant to humans 
o	 Directness of the end points to the primary health outcome—examples of secondary 
outcomes or nonspecific outcomes include organ weight in the absence of histopathology
or clinical chemistry findings in the absence of target tissue effects
o	 Nature of the exposure in human studies and route of administration in animal studies— 
inhalation, oral, and dermal exposure routes are considered relevant unless there are 
compelling data to the contrary
o	 Duration of treatment in animal studies and length of time between exposure and 
outcome assessment in animal and prospective human studies—this should be considered
on an outcome-specific basis
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Table B-18. Adjustments to the Initial Confidence in the Body of Evidence
Initial Adjustments to the initial confidence rating Final 
confidence confidence
Outcome:  Respiratory Effects
Cross-sectional cohort studies Moderate None Moderate
Cohort studies Moderate -1 for risk of bias:  studies in risk of bias second tier Low
Human controlled exposure studies Moderate +1 for consistency: threshold levels were consistent across studies High
Animal studies High None High
Outcome:  Gastrointestinal Effects
Animal studies High None High
Outcome:  Renal Effects
Animal studies High None High
Outcome:  Dermal Effects
Human controlled exposure studies Low None Low
Animal studies High None High
Outcome:  Ocular Effects
Human controlled exposure studies Moderate None Moderate
Animal studies High +1 consistency:  effects were consistently observed High
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Table B-19.  Confidence in the Body of Evidence for Glutaraldehyde
Confidence in body of evidence
Outcome Human studies Animal studies
Respiratory effects High High
Gastrointestinal effects No data High
Renal effects No data High
Dermal effects Low High
Ocular effects Moderate High
Below are the criteria used to determine whether the initial confidence in the body of evidence for
each outcome should be downgraded for indirectness:
o	 No downgrade if none of the factors are considered indirect
o	 Downgrade one confidence level if one of the factors is considered indirect
o	 Downgrade two confidence levels if two or more of the factors are considered indirect
•	 Imprecision. Evaluation of the narrowness of the effect size estimates and whether the studies 
have adequate statistical power.  Data are considered imprecise when the ratio of the upper to 
lower 95% CIs for most studies is ≥10 for tests of ratio measures (e.g., odds ratios) and ≥100 for
absolute measures (e.g., percent control response).  Adequate statistical power is determined if
the study can detect a potentially biologically meaningful difference between groups (20%
change from control response for categorical data or risk ratio of 1.5 for continuous data).  Below
are the criteria used to determine whether the initial confidence in the body of evidence for each 
outcome should be downgraded for imprecision:
o	 No downgrade if there are no serious imprecisions
o	 Downgrade one confidence level for serious imprecisions
o	 Downgrade two confidence levels for very serious imprecisions 
•	 Publication bias. Evaluation of the concern that studies with statistically significant results are
more likely to be published than studies without statistically significant results.
o	 Downgrade one level of confidence for cases where there is serious concern with
publication bias
Four properties of the body of evidence were considered to determine whether the confidence rating
should be upgraded:
• Large magnitude of effect. Evaluation of whether the magnitude of effect is sufficiently large
so that it is unlikely to have occurred as a result of bias from potential confounding factors.  
o	 Upgrade one confidence level if there is evidence of a large magnitude of effect in a few
studies, provided that the studies have an overall low risk of bias and there is no serious 
unexplained inconsistency among the studies of similar dose or exposure levels; 
confidence can also be upgraded if there is one study examining the outcome, provided 
that the study has an overall low risk of bias
•	 Dose response. Evaluation of the dose-response relationships measured within a study and 
across studies.  Below are the criteria used to determine whether the initial confidence in the body
of evidence for each outcome should be upgraded:
o Upgrade one confidence level for evidence of a monotonic dose-response gradient
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o	 Upgrade one confidence level for evidence of a non-monotonic dose-response gradient
where there is prior knowledge that supports a non-monotonic dose-response and a non-
monotonic dose-response gradient is observed across studies
•	 Plausible confounding or other residual biases. This factor primarily applies to human studies 
and is an evaluation of unmeasured determinants of an outcome such as residual bias towards the 
null (e.g., “healthy worker” effect) or residual bias suggesting a spurious effect (e.g., recall bias).
Below is the criterion used to determine whether the initial confidence in the body of evidence for
each outcome should be upgraded:
o	 Upgrade one confidence level for evidence that residual confounding or bias would 
underestimate an apparent association or treatment effect (i.e., bias toward the null) or
suggest a spurious effect when results suggest no effect
•	 Consistency in the body of evidence. Evaluation of consistency across animal models and 
species, consistency across independent studies of different human populations and exposure
scenarios, and consistency across human study types. Below is the criterion used to determine 
whether the initial confidence in the body of evidence for each outcome should be upgraded:
o Upgrade one confidence level if there is a high degree of consistency in the database
B.7 TRANSLATE CONFIDENCE RATING INTO LEVEL OF EVIDENCE OF HEALTH 
EFFECTS
In the seventh step of the systematic review of the health effects data for glutaraldehyde, the confidence in
the body of evidence for specific outcomes was translated to a level of evidence rating. The level of
evidence rating reflected the confidence in the body of evidence which was established in the sixth step of
the systematic review (Section B.6) and the direction of the effect (i.e., toxicity or no toxicity); route-
specific differences were noted. The level of evidence for health effects was rated on a five-point scale:  
•	 High level of evidence: High confidence in the body of evidence for an association between 
exposure to the substance and the health outcome
•	 Moderate level of evidence: Moderate confidence in the body of evidence for an association 
between exposure to the substance and the health outcome
•	 Low level of evidence: Low confidence in the body of evidence for an association between 
exposure to the substance and the health outcome
•	 Evidence of no health effect: High confidence in the body of evidence that exposure to the
substance is not associated with the health outcome
•	 Inadequate evidence: Low or moderate confidence in the body of evidence that exposure to the
substance is not associated with the health outcome
A summary of the level of evidence of health effects for glutaraldehyde is presented in Table B-20.
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Table B-20.  Level of Evidence of Health Effects for Glutaraldehyde
Outcome
Confidence in body
of evidence
Direction of health
effect
Level of evidence for
health effect
Human studies
Respiratory effects High Health effect
(inhalation only)
High
Gastrointestinal effects No data No data No data
Renal effects No data No data No data
Dermal effects Low Health effect Low
(dermal contact)
Ocular effects Moderate Health effect Moderate
(ocular contact)
Animal studies
Respiratory effects High Health effect
(inhalation only)
High
Gastrointestinal effects High Health effect
(oral only)
High
Renal effects High Health effect
(inhalation, oral)
High
Dermal effects High Health effect
(dermal contact)
High
Ocular effects High Health effect
(ocular contact)
High
B.8 INTEGRATE EVIDENCE TO DEVELOP HAZARD IDENTIFICATION CONCLUSIONS
The final step involved the integration of the evidence streams for the human studies and animal studies 
to allow for a determination of hazard identification conclusions.  For health effects, there were four
hazard identification conclusion categories:
• Known to be a hazard to humans
• Presumed to be a hazard to humans
• Suspected to be a hazard to humans
• Not classifiable as to the hazard to humans
The initial hazard identification was based on the highest level of evidence in the human studies and the 
level of evidence in the animal studies; if there were no data for one evidence stream (human or animal),
then the hazard identification was based on the one data stream (equivalent to treating the missing
evidence stream as having low level of evidence). The hazard identification scheme is presented in
Figure B-2 and described below.
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Figure B-2. Hazard Identification Scheme
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Low Moderate High
Level of evidence for health effects in animal studies
Known
Suspected Presumed
Not Classifiable Suspected Presumed
•	 Known: A health effect in this category would have:
o	 High level of evidence for health effects in human studies AND a high, moderate, or low
level of evidence in animal studies.
•	 Presumed: A health effect in this category would have:
o	 Moderate level of evidence in human studies AND high or moderate level of evidence in
animal studies OR
o	 Low level of evidence in human studies AND high level of evidence in animal studies
•	 Suspected: A health effect in this category would have:
o	 Moderate level of evidence in human studies AND low level of evidence in animal
studies OR
o	 Low level of evidence in human studies AND moderate level of evidence in animal
studies
•	 Not classifiable: A health effect in this category would have:
o	 Low level of evidence in human studies AND low level of evidence in animal studies
Other relevant data such as mechanistic or mode-of-action data were considered to raise or lower the level
of the hazard identification conclusion by providing information that supported or opposed biological
plausibility.
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Two hazard identification conclusions categories were used when the data indicated that there may be no 
health effect in humans:
• Not identified to be a hazard in humans
• Inadequate to determine hazard to humans
If the human level of evidence conclusion of no health effect was supported by the animal evidence of no 
health effect, then the hazard identification conclusion category of “not identified” was used.  If the
human or animal level of evidence was considered inadequate, then a hazard identification conclusion 
category of “inadequate” was used.  As with the hazard identification for health effects, the impact of
other relevant data was also considered for no health effect data.  
The hazard identification conclusions for glutaraldehyde are presented in Table B-21.
Table B-21.  Hazard Identification Conclusions for Glutaraldehyde
Outcome Hazard identification 
Respiratory effects Known health effect following inhalation exposure
Gastrointestinal effects Presumed health effect following oral exposure
Renal effects Presumed health effect
Dermal effects Presumed health effect following dermal exposure
Ocular effects Presumed health effect following ocular exposure
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Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended
audience is the general public, especially people living in the vicinity of a hazardous waste site or
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format.  The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight­
of-evidence discussions for human health end points by addressing the following questions:
1.	 What effects are known to occur in humans?
2.	 What effects observed in animals are likely to be of concern to humans?
3.	 What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not
meant to support regulatory action, but to acquaint health professionals with exposure levels at which
adverse health effects are not expected to occur in humans.
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MRLs should help physicians and public health officials determine the safety of a community living near
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational
exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.10, "Interactions with Other Substances,” and Section 3.11, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgment,
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR
cannot make this judgment or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used
in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure 
(LSE) tables.
Chapter 3
Health Effects
Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to
locate data for a specific exposure scenario. The LSE tables and figures should always be used in
conjunction with the text. All entries in these tables and figures represent studies that provide reliable,
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.
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LEGEND
See Sample LSE Table 3-1 (page C-6)
(1)	 Route of Exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each
route of exposure and will not, therefore, have all five of the tables and figures.
(2)	 Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.
In this example, an inhalation study of intermediate exposure duration is reported.  For quick
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3)	 Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4)	 Key to Figure. Each key number in the LSE table links study information to one or more data
points using the same key number in the corresponding LSE figure.  In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5)	 Species. The test species, whether animal or human, are identified in this column.  Chapter 2,
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL.
(6)	 Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al.
1981).
(7)	 System.  This column further defines the systemic effects. These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8)	 NOAEL.  A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
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(9)	 LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs.
(10)	 Reference.  The complete reference citation is given in Chapter 9 of the profile.
(11)	 CEL.  A CEL is the lowest exposure level associated with the onset of carcinogenesis in
experimental or epidemiologic studies.  CELs are always considered serious effects. The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing
measurable cancer increases.
(12)	 Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health
effects observed within the acute and intermediate exposure periods are illustrated.
(14)	 Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15)	 Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16)	 NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the
LSE table.
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(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q1*).
(19)	 Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.
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1
2
12
→	 Table 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation
LOAEL (effect)Exposure 
Less serious Serious (ppm)Key to 	 frequency/ NOAEL
(ppm)figurea Species duration System (ppm)	 Reference
→	 INTERMEDIATE EXPOSURE
5 6 7 8 9 10
3 → Systemic ↓
18 Rat
→4
CHRONIC EXPOSURE
Cancer
38 Rat
39 Rat
40 Mouse
↓ ↓ ↓
13 wk Resp 3b 
5 d/wk
6 hr/d
18 mo
5 d/wk
7 hr/d
89–104 wk
5 d/wk
6 hr/d
79–103 wk
5 d/wk
6 hr/d
↓
10 (hyperplasia)
11
↓
20	 (CEL, multiple
organs)
10	 (CEL, lung tumors,
nasal tumors)
10	 (CEL, lung tumors,
hemangiosarcomas)
↓
Nitschke et al. 1981
Wong et al. 1982
NTP 1982
NTP 1982
→	 a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).
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ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BALF bronchoalveolar lavage fluid
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMCx concentration that produces a X% change in response rate of an adverse effect
BMCLX 95% lower confidence limit on the BMCX 
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLX 95% lower confidence limit on the BMDX 
BMDS Benchmark Dose Software
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
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DOD Department of Defense
DOE Department of Energy
DOL Department of Labor
DOT Department of Transportation
DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register
FSH follicle stimulating hormone
g gram
GC gas chromatography
gd gestational day
GLC gas liquid chromatography
GPC gel permeation chromatography
HEC Human Equivalent Concentration
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization
IRIS Integrated Risk Information System
Kd adsorption ratio
kg kilogram
kkg metric ton
Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill
LDLo lethal dose, low
LDH lactic dehydrogenase
LH luteinizing hormone
LOAEL lowest-observed-adverse-effect level
LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
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m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie
MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor
MFO mixed function oxidase
mg milligram
mL milliliter
mm millimeter
mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System
NLM National Library of Medicine
nm nanometer
nmol nanomole
NOAEL no-observed-adverse-effect level
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
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OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell
REL recommended exposure level/limit
RfC reference concentration
RfD reference dose
RNA ribonucleic acid
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act
TWA time-weighted average
UF uncertainty factor
U.S. United States
USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
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WBC white blood cell
WHO World Health Organization
> greater than
≥ greater than or equal to
= equal to
< less than
≤ less than or equal to
% percent
α alpha
β beta
γ gamma
δ delta
μm micrometer
μg microgram
q1* cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result
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